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ABSTRACT 
 
This thesis describes a series of in vitro, animal and humans studies conducted with the aim 
of investigating the effect of polyphenol-rich green coffee bean extract (GCBE) and dark 
chocolate (DC) on biomarkers of glucose metabolism, lipid profile and blood pressure (BP) 
in overweight and obese individuals.   
 
Green coffee and Theobroma cacao bean extracts were found to be rich in polyphenols and 
to act as effective free radical scavenging compounds in vitro.  A potential role for GCBE in 
inhibiting pancreatic lipase was identified in vitro.  Preliminary human studies revealed a 
differential effect of GCBE and DC on fasting glucose, total cholesterol, BP and urinary 
glucocorticoids.  Accordingly, consumption of 200mg GCBE containing 90mg chlorogenic 
acid (CGA) twice daily for 14 days by healthy overweight and obese volunteers reduced 
systolic BP (P=0.043), urinary free cortisone (P=0.0015) and waist circumference (-0.78cm; 
P=0.013) but raised salivary cortisone (P=0.042) without significantly affecting capillary 
fasting glucose, total cholesterol or urinary antioxidant excretion (P>0.05).  The ability of 
CGA to differentially regulate cortisol metabolism was further highlighted in male C57BL6 
mice wherein daily administration of a diet containing 0.15% CGA for 17 days marginally 
increased cortisol in kidney (P=0.108; eta
2
=0.26) and reduced hepatic cortisol (P=0.219; 
eta
2
=0.14).  In the preliminary single-blind randomised cross-over DC study, 2-week 
consumption of 20g DC containing 500mg or 1000mg polyphenols by overweight and obese 
individuals produced equal reductions in capillary fasting glucose, systolic and diastolic BP. 
This was further confirmed by the long-term placebo-controlled trial wherein ingestion of 
20g DC (500mg polyphenols) for 4 weeks reduced fasting glucose (P=0.028), insulin 
resistance (P=0.005), systolic (P=0.020), diastolic BP (P=0.008) and improved insulin 
sensitivity (QUICKI, P=0.04; revised-QUICKI, P=0.026) and urinary antioxidant capacity 
(total phenolics, P=0.046; ferric-reducing capacity, P=0.048) without significantly affecting 
lipid profile (P>0.05).   A particular contribution of the main study is the finding that 
overweight and obese individuals respond more effectively to polyphenol-rich DC, 
compared to lean individuals, but more adversely to polyphenol-deficient placebo.  The latter 
was marked by the rise in fasting insulin, insulin resistance and salivary cortisol. 
 
In conclusion, this thesis supports a role for polyphenol-rich GCBE and DC in counteracting 
overweight and obesity-related complications.  The role of GCBE and CGA in modulating 
glucocorticoid metabolism emerges as a novel and potentially relevant field of research to 
the prevention of overweight and obesity-related complications.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: dark chocolate, green coffee bean extract, polyphenols, glucose, insulin, 
lipid, blood pressure, glucocorticoids, obesity 
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 1. General Introduction 
1.1. Background and structure of the thesis  
 
Over the last two decades, the emergence of the concept that plant-derived polyphenols act 
via various biochemical, physiological and endocrinological pathways to promote health and 
prevent chronic diseases has stimulated much interest in this field.  However, the diversity 
and complexity of these compounds implies that much remains to be elucidated concerning 
the mechanisms by which these compounds influence health.  With the rising obesity 
epidemic, improving our knowledge of the relation between diet and health is becoming 
increasingly ever more important.  This is especially evident when considering that obesity is 
associated with various metabolic abnormalities including insulin resistance, endothelium 
dysfunction and dyslipidaemia, which are in turn implicated in the development of diabetes, 
hypertension and cardiovascular disease.    
 
This thesis consists of five chapters.  Chapter 1 begins by providing an overview of the 
definition, classification, prevalence and consequences of obesity.  This step is crucial to 
highlighting the global burden of the overweight and obesity epidemic whilst emphasising 
the need to prevent overweight and obesity-related chronic conditions through appropriate 
dietary strategies and public health strategies aimed at promoting health in this high-risk 
population.  In section 1.3, the pathophysiology of obesity is examined. The role of insulin 
resistance as the centre of obesity-related complications is described (section 1.4-1.6).  The 
molecular and biochemical pathways underlying the association between insulin resistance, 
hypertension and dyslipidaemia are critically evaluated.  This provides the rationale for 
investigating the three main variables stated in the title of the thesis: glucoregulatory 
biomarkers, blood pressure and lipid profile.  Next in sections 1.7-1.9, the etiology of insulin 
resistance is discussed with specific reference to the role of free fatty acids (FFA)s, cortisol 
and oxidative stress in promoting obesity-related insulin resistance, three variables that are 
subsequently examined in the main study and which reflect potential mechanistic pathways 
that underlie insulin resistance and overweight and obesity-related hypertension and 
dyslipidaemia.  This discussion sets the scene for Section 1.10 which begins by defining and 
classifying polyphenols and moves towards examining the potential role of these powerful 
antioxidants in preventing type-II diabetes, hypertension and cardiovascular disease in 
overweight and obesity.  Particular attention is drawn to green coffee bean extract (GCBE) 
and dark chocolate (DC) as important dietary sources of polyphenols.  Conflicts and gaps in 
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the literature are indentified.  The main concepts discussed in Chapter 1 are then summarised 
and brought forward in section 1.120.   The hypothesis and overall aim of the PhD research 
are stated and specific rationale for each of the in vitro, animal and human studies are 
highlighted (Section 1.13).  In, Chapter 2 the general materials and methods used in this 
thesis are described.  The principles of the antioxidant and pancreatic lipase assays are 
highlighted and details are provided concerning the collaborative mice study that was 
conducted at the Queen‘s Medical Research Institute, Edinburgh, UK.  Section 2.3 then 
describes the preliminary GCBE and DC human studies and the main DC study.  The 
rationale behind the selected study designs are discussed and the strengths and limitations of 
such designs are pointed out.  A description of subjects sources and selection, inclusion and 
exclusion criteria is provided and the basis for selecting the GCBE and DC polyphenol doses 
is underlined.  The main findings of the thesis are then outlined in Chapter 3.  Chapter 4 
builds on these results by discussing the implications and the limitations of the studies and 
by providing directions for future research.  The overall findings of the thesis are then 
summarised in Chapter 5 and the conclusion stated. 
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1.2. Overweight and Obesity 
1.2.1 Definition 
Obesity can be defined as excess accumulation of body fat arising from a sustained or a 
periodic positive energy balance that is when energy intake exceeds energy expenditure 
(WHO, 2000).  The most common method of classifying overweight and obesity is based on 
Body Mass Index (BMI).  Accordingly, the World Health Organisation (WHO) classifies 
individuals with BMI 25-29.99 kg/m
2 
as overweight while individuals with BMI≥ 30 kg/m2 
are termed obese.  Obesity could also be categorized further into abdominal or peripheral 
obesity using waist circumference (WC) as a surrogate measure of body fat distribution (see 
section 2.11.4).  The importance of distinguishing between abdominal and peripheral obesity 
is discussed in section 2.11.4.  These standard WHO definitions will be adopted throughout 
this thesis, unless otherwise stated.      
 
1.2.2 Prevalence 
In recent years the prevalence of obesity has increased reaching epidemic levels.  
Worldwide, an estimated 1.6 billion adults are overweight and at least 400 million are obese 
(WHO, 2006).  These rates are predicted to increase reaching 2.3 billion overweight adults 
and 700 million obese by 2015 (WHO, 2006).  Britain is amongst the countries with highest 
prevalence of overweight and obesity in Western Europe
1
 with 65.7% of British men and 
61.9% of British women being categorised as overweight or obese (Figure 1.1).  These 
figures are closely reflected in the Scottish Heath Survey 2003 which demonstrates that 
65.4% of Scottish men and 59.7% of Scottish women are either overweight or obese 
(Bromley et al., 2005).   Interestingly, although men in Scotland are more likely to be 
overweight (43.0% vs. 33.8%), the prevalence of obesity (22.4% vs. 26.0%), morbid obesity 
(1.6% vs. 3.4%) or raised waist-to-hip ratio (WHR) and WC (28.8% and 28.0% vs. 37.1% 
and 38.9%) is higher amongst women in Scotland (Bromley et al., 2005).  This has several 
implications since abdominal fat distribution, characterised by raised WC and WHR, is 
known to be an independent risk factor for obesity-associated co-morbidities and mortality. 
 
 
 
                                                 
1
 Western Europe as defined by UN. 
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Figure 1.1 Prevalence of overweight and obesity in Western Europe (Ono et al., 2005). 
 
1.2.3 Health consequences 
Apart from being a major contributor to chronic disease burden and mortality, obesity- 
particularly abdominal obesity, is also closely related to the metabolic syndrome, a cluster of 
diseases that encompasses the following conditions (WHO, 2000): 
 Dyslipidaemia 
 Hypertension 
 Glucose intolerance and insulin resistance 
 Abdominal obesity 
 
Using analyses from 33 cohort studies and data from a number of international 
epidemiological studies such as the International study on Salt and Blood Pressure 
(INTERSALT) and the National Health and Nutrition Examination Survey (NHANES) III, 
James et al. (2004) estimated that the global burden of chronic diseases ascribed to excess 
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body weight were 58% for type II diabetes, 21% for ischemic heart disease and 39% for 
hypertension.  Based on this data, overweight and obesity were found to be accountable for 
2.5 million global annual deaths and 30 million disability-adjusted life years in 2000 (James 
et al., 2004).  In Scotland, obesity accounts for 500,000 cases of hypertension, 50,000 cases 
of coronary heart disease and over 30,000 cases of type II diabetes, amongst others (Grant et 
al., 2007) (Table 1.1) with substantial costs incurred by the National Health Service (Bourn, 
2001).   
 
Table 1.1 The estimated prevalence of obesity-related diseases and the estimated 
number of cases attributable to obesity in Scotland in 2003 (Grant et al., 2007). 
 
 
 
 
 
Table 1.2 provides estimates of the relative risk of developing chronic diseases as a result of 
obesity (Grant et al., 2007).  Taking in account these figures, the strong association between 
obesity and diabetes, hypertension and cardiovascular disease (CVD) and the continually 
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rising obesity epidemic, the need for implementing adequate public health strategies to 
prevent obesity and its associated complications is becoming ever-more important.  Notably, 
the WHO in its Global Strategy on Diet, Physical Activity and Health emphasises the need to 
render ‗healthier diet options more affordable and accessible‘ (Samuelson, 2004).  This 
emphasis stems from the recognition that in the absence of a supportive physical and 
economical environment, nutrition and health messages often fail to influence individuals 
‗dietary behaviour as a result of the persistent pressure to consume unhealthy diets‘ 
(Samuelson, 2004).  Wieringa et al. (2008) have identified nutritional factors and food 
product supply, particularly the quality of food products, as ‗prominent points of intervention 
for prevention strategies‘.  Although, Wieringa et al. (2008) argued a limited role for 
functional foods in preventing overweight and obesity as a result of their inability to tackle 
the underlying lifestyle risk factors, excess energy intake and physical inactivity, functional 
food may provide a cost-effective strategy in preventing overweight and obesity-associated 
co-morbidities and mortalities.  This is particularly true when considering that 90% of type II 
diabetics are obese (Kumanyika et al., 2002) and that in women, obesity is the third most 
powerful predictor of CVD (after age and blood pressure) and that women who are obese are 
12 times more likely to develop type II diabetes than women of a healthy weigh (Bourn, 
2001).  In order to understand how functional foods and polyphenols can influence 
overweight and obesity, it is important to explore the underlying pathophysiology of 
overweight and obesity and apply current knowledge in this field to the chemical and 
physiological properties of polyphenols. 
 
 
Table 1.2  Relative risk of chronic diseases in obese women and men (Grant et al., 
2007). 
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1.3. Pathophysiology: Insulin resistance as the centre of obesity-
associated complications 
Understanding the physiological abnormalities governing the current obesity epidemic is 
pivotal to the development of effective dietary approaches to deal with this complex multi-
factorial disease. This is particularly evident when considering the central role of obesity in 
the development of CVD and its ability to influence other CVD risk factors (Grundy, 2004) 
(Figure 1.2).   For decades, the association between insulin resistance, type II diabetes, 
hypertension and dyslipidaemia have been recognised. Reaven  (1988) proposed the term 
Syndrome X as a condition encompassing all of the above metabolic disturbances with 
insulin resistance forming the centre of these physiological abnormalities.  Surprisingly 
Reaven (1988) did not include obesity in their initial definition of Syndrome X and it was 
not until  1991 that Ferrannini and colleagues postulated that insulin  resistance is the 
underlying metabolic abnormality linking obesity with type II diabetes, hypertension and 
dyslipidaemia.  The concept of the metabolic syndrome as an insulin resistance syndrome 
was born. 
 
 
 
Figure 1.2 Obesity as the underlying risk factor of cardiovascular disease 
 
 
Insulin resistance is defined as reduced insulin action in peripheral tissues including skeletal 
muscle, adipose and liver (Caballero, 2003).  It is characterised by an exaggerated response 
to normal circulating levels of fasting glucose (Simoneau and Kelley, 1998) and has been 
suggested to be the main driving force behind the metabolic syndrome cluster (Reaven, 
1988).  However, insulin resistance is not a prerequisite feature of obesity since only 26% of 
the obese population exhibit this condition while the majority demonstrate insulin 
Obesity 
Hypertension 
Dyslipidaemia 
 Insulin resistance Cardiovascular disease 
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hypersecretion (Ferrannini et al., 1997). Similarly, more recent findings suggest that none of 
insulin resistance, fat mass or fat distribution are sole determinants of the risk of 
hypertension and CVD in obesity and that instead each factor contributes distinctively via a 
variety of metabolic pathways to form the metabolic syndrome cluster (Ferrannini et al., 
2007).  Nonetheless, consistent evidence still exists for the association between insulin 
resistance, type II diabetes, hypertension, atherosclerosis, and endothelium dysfunction with 
close associations being reported between insulin resistance and higher FFA, triglycerides 
(TG), low-density lipoprotein (LDL)-cholesterol and lower high-density lipoprotein (HDL)-
cholesterol, and between compensatory hyperinsulinaemia and higher fasting glucose and 
blood pressure (Ferrannini et al., 2007), as will be discussed in the following sections.   
 
1.4. Insulin and glucose metabolism 
Insulin is the chief regulator of glucose metabolism in the body.  Its actions are mediated via 
the insulin receptor (IR) which is widely distributed in both non-insulin sensitive tissues such 
as the central nervous system, in particular the brain where it helps control  glucose and 
energy metabolism body weight and food intake (Bruning et al., 2000; Bingham et al., 2002; 
Kyriaki., 2003), and in insulin target tissues such as the liver, skeletal muscle and adipose 
tissue where it acts to maintain glucose homeostasis in both the fed and fasting state (Saltiel 
and Khan, 2001).  In skeletal muscle and adipose tissue, insulin controls glucose uptake via 
enhanced translocation, docking and fusion of glucose transporter-4 (GLUT4) into plasma 
membranes (Saltiel and Khan, 2001).  This step is considered the rate-limiting step for 
glucose utilisation and glycogenolysis (Saltiel and Khan, 2001).  Storage of glucose in the 
form of glycogen is also initiated in skeletal muscle and in the form of TG in adipose tissue 
during the fasting and fed state (Klover and Mooney, 2003). In the liver, insulin assists in the 
regulation of numerous genes that control the synthesis of key enzymes involved in 
gluconeogenesis and glycogenolysis.  This ability to regulate gene expression by affecting 
gene transcription, mRNA stability and mRNA translation has been extensively reviewed 
and is considered one of the chief functions of insulin with over 100 genes being influenced 
by this hormone (Sutherland et al., 1998; O‘Brien et al., 2001; Foufelle and Ferre, 2002).  
Insulin can also directly influence the activity of gluconeogenic and glycogenic enzymes by 
controlling their phosphorylation state (see Saltiel and Khan, 2001). As such, Klover and 
Mooney (2003) have described insulin‘s hepatic activities as both acute (post-translational 
modification of key enzymes) and chronic (gene expression). 
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Together insulin‘s actions in skeletal muscle, adipose tissue and liver are directed towards 
maintaining glucose blood concentrations within a tight physiological range.  In obesity, 
defects in insulin‘s glucoregulatory functions result in disruption of the above metabolic 
processes leading to hyperglycaemia, hyperinsulinaemia and insulin resistance.  The 
following sections will focus on describing some of the molecular disturbances in  insulin‘s 
downstream signalling pathways seen in obesity and insulin resistant states and which help 
explain the link between insulin resistance and overweight and obesity-related diabetes, 
hypertension and dyslipidaemia. The role of FFAs in inducing hyperglycaemia and 
hyperinsulinaemia will also be highlight later in section 1.7.5.   
 
1.4.1 Insulin downstream signalling pathways 
As stated earlier, insulin‘s actions are mediated via the IR. Insulin binding to IR results in 
tyrosine phosphorylation of the β-subunit of IR which leads to conformational changes in IR 
and subsequently tyrosine phosphorylation of insulin receptor substrate (IRS) proteins and 
activation of two main downstream signalling pathways: the phosphatidylinositol 3-kinase 
(PI3K)–Akt/protein kinase B (PKB) pathway and the Ras–mitogen-activated protein kinase 
(MAPK) pathway (Saltiel and Khan, 2001; Taniguchi et al., 2006) (see Figure 1.3).  The 
former pathway controls insulin‘s metabolic functions while the second is involved in gene 
expression and together both these pathways play a role in cell growth and differentiation 
(Taniguchi et al., 2006) (Figure 1.3).  The activity of these pathways is generally regulated 
by secondary messengers known as  protein kinases.  Of relevance to this discussion are the 
protein kinases responsible for GLUT4 translocation and subsequent glucose uptake which 
include PI3K and its downstream effectors Akt/PKB and protein kinase C (PKC) 
(Vollenweider et al., 2002) (Figure 1.3). Akt/PKB and PKC are considered downstream 
effectors of PI3K because their activity depends on PI3K-induced activation of 
phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) which then promotes phosphoinositide-
dependent protein kinase-1 and -2 (PDK-1 and 2)-dependent Akt/PKB and PKC 
phosphorylation and activity at the level of plasma membrane (Alessi et al., 1997; Chou et 
al., 1998; Le Good et al., 1998; Bandyopadhyay et al., 1999a-b; Wick et al., 2000; 
Bandyopadhyay et al., 2005).  The complexity of this insulin signalling pathway has been 
recently described in an excellent review by Taniguchi et al. (2006) but overall, the result of 
such network of events is increased GLUT4 translocation to plasma membrane and enhanced 
glucose uptake in skeletal muscle and adipose tissue (Bandyopadhyay et al., 1999a-b; Hill et 
al., 1999; Wang et al., 1999; Braiman et al., 2001). Undoubtedly any dysfunctions in this 
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signalling network will result in diminished insulin-induced glucose disposal, hence insulin 
resistance.   
 
 
 
 
Figure 1.3 Schematic of insulin downstream signalling pathway showing the insulin 
receptor, the insulin receptor substrate (IRS) and the phosphatidylinositol 3-kinase 
(PI3K)-AKt/protein kinase B (PKB) pathway and Ras-mitogen activated protein kinase 
(MAPK) pathway  (Muniyappa et al., 2007). 
  
α-subunit of insulin receptor 
β-subunit of insulin receptor 
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1.4.2  Insulin downstream signalling in obesity 
Obesity is known to be associated with various defects in insulin downstream signalling in 
both skeletal muscle (Caro et al., 1987) and adipose tissue (Goodyear et al., 1995). However, 
inconsistencies still exist concerning the location of these defects within the insulin 
signalling pathway. To exemplify, Goodyear et al. (1995) has demonstrated that skeletal 
muscle biopsies from morbidly obese patients express a 35% diminishment in insulin-
stimulated receptor tyrosine phosphorylation, a 38% decrement in IRS-1 tyrosine 
phosphorylation and a 3.5-fold reduction in insulin-dependent IRS-1 PI3K activity compared 
to lean individuals. The density of IR, IRS-1 and the p85 subunit of PI3K, according to 
Goodyear et al. (1995), is also altered with obese individuals expressing only 55, 54, and 
64% of these components relatively to lean individuals. In contrast, skeletal muscle from 
obese glucose-intolerant patients exhibits impaired insulin-stimulated glucose uptake in the 
absence of any changes in IRS-1-dependent PI3K activation, or the protein expression of IR, 
IRS-1, IRS-2, the p85 regulatory subunit of PI3K, Akt, PKC-ζ/λ, GLUT1, or GLUT4 
(Vollenweider et al., 2002). In fact, it appears that in obese glucose-intolerant patients, 
defective insulin-stimulated glucose uptake in skeletal muscle is precipitated by a reduction 
in insulin-stimulated IRS-2 tyrosine phosphorylation, IRS-2–dependent PI3K and PKC-ζ/λ 
activation (Vollenweider et al., 2002).  To add to these controversies, more recent studies 
have reported that the activity of PI3K, PDK1 and Akt/PKB is unaltered in obesity and that 
the levels of PKCλ/ζ are comparable between lean and obese individuals (Kim et al., 1999; 
Kim et al., 2003).  At present, insufficient evidence exists to elaborate on the differences 
between the afore-mentioned findings.  However, it can be speculated that disturbances in 
insulin-signalling network are likely to differ depending on the degree of obesity or the 
extent and severity of insulin resistance.  Patients from Goodyear et al.‘s (1995) study had a 
BMI of 52.9±3.6 kg/m
2
 compared to the studies of Vollenweider et al. (2002) and Kim et al. 
(1999, 2003) wherein patients had a BMI of 32.5±1.6 kg/m
2
, 31±1.3 kg/m
2 
and 33.4±1.4 
kg/m
2
, respectively.  Similarly, patients from Vollenweider et al. (2002) were glucose-
intolerant whereas glucose tolerance was not tested in the other studies.  Additional support 
could be gained from findings that obese patients with established type II diabetes 
demonstrate more prominent defects in insulin signalling, and subsequently in insulin-
stimulated skeletal muscle glucose uptake, than either lean or obese non-type II diabetic 
patients (Kim et al., 1999).  This is further seen in that insulin-stimulated IRS-1 tyrosine 
phosphorylation and PI3K activity is 40–50% lower in obese type II diabetes patients 
compared to lean or obese individuals (Kim et al., 2003) and so is insulin induced IRS-2–
dependent PI3K activity (Kim et al., 1999).  Moreover, obese type II diabetes patients 
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demonstrate a 46% reduction in the expression of PKCλ/ζ which is then reflected in reduced 
PKCλ/ζ activity compared to lean and obese subjects (Kim et al., 2003).  These effects could 
be attributed to the fact that insulin resistance and the accompanying compensatory 
hyperinsulinaemia can impair insulin-stimulated skeletal muscle glucose uptake 
independently of obesity (Korsheninnikova et al., 2002).   
 
Regardless of these inconsistencies, it is now becoming increasingly recognised that the 
inability of insulin to stimulate glucose disposal could arise from defects in the expression of 
IRS protein domains, such as the p85 subunit, or in PKCλ/ζ activation.  Accordingly, insulin-
induced activation of PKCλ/ζ has been shown to be reduced by as much as 57% in obesity 
(Kim et al., 1999; Kim et al., 2003).  Kim et al. (2003) argues that a PI3K-independent 
mechanism is implicated in the aetiology of impaired insulin-induced PKCλ/ζ activation 
(Kim et al., 2003). Support for this concept could be derived from observations that the 
PKCζ isoform provokes GLUT4 translocation and glucose uptake in the absence of insulin 
(Braiman et al., 2001).   Farese et al. (2005) has also suggested that the mechanism 
accounting for impaired insulin-induced atypical protein kinase C (aPKC) activation in 
skeletal muscle could lie downstream of PI3K; for instance at the level of PIP3 (Sajan et al., 
2004; Farese et al., 2005). However, according to Kim et al.‘s (2003) the defect is possibly 
situated even further downstream of the insulin signalling network since PDK1 activity is not 
impaired in obesity.  
 
As described earlier, the p85 subunit is the regulatory subunit of IRS1. It mediates IRS1-
dependent stimulation of PI3K via its ability to stabilise and inhibit the catalytic activity of 
the p110 subunit of IRS1 (Yu et al., 1998a).  This effect occurs through the binding of the 
nSHS-linked iSH2 domain of p85 to p110α (Yu et al., 1998b).  In general, the balance 
between the p85 and the p110 subunits determines the extent of p100 activity (Brachmann et 
al., 2005).  In obesity, there is an excess expression of p85/55/50 (Bandyopadhyay et al., 
2005).  This enhanced P85/55/50 expression can inhibit p100 catalytic activity on lipid 
kinase PIP3 (Ueki et al., 2002) resulting in a negative correlation being present between 
P85/55/50 expression and insulin sensitivity (Bandyopadhyay et al., 2005).   Furthermore, 
p85 can interact with IRS1 in the cytosol producing large p85-IRS complexes that become 
docked in the cytosol and cannot be translocated to the plasma membrane, the site of PIP3 
production (Luo et al., 2005).   The consequence of such actions is reduced PI3K signalling 
even in the absence of a defect in insulin growth factor (IGF)-1 activation (Luo et al., 2005).  
Similar effects can be induced with overfeeding in women wherein increasing caloric intake 
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produces an increase in p85α expression in skeletal muscle, a fall in P110, a raised p85α to 
p110 ratio, and a reduction in PI3K activity, all of which is then reflected as reduced insulin 
sensitivity (Cornier et al., 2006). Deletion of all p85 isomers, on the other hand, in mice 
improves insulin sensitivity regardless of the degree of impairment in PI3K activity 
(Terauchi et al., 1999; Fruman et al., 2000; Mauvais-Jarvis et al., 2002). Overexpression of 
P85/55/50 is also accompanied with increased activity of the proinflammatory kinases: Jun 
N-terminal kinase-1 (JNK-1) and PKCƟ, which can act as alternative mechanisms by which 
p85 isomers impair insulin signalling (Bandyopadhyay et al., 2005). This could be illustrated 
in that these proinflammatory kinases stimulate serine/threonine phosphorylation of IRS-1/2 
while suppressing its tyrosine phosphorylation leading to suppression of IRS1 (Aguirre et 
al., 2000) and PI3K activity (Bandyopadhyay et al., 2005), hence diminished insulin-
stimulated glucose uptake (Itani et al., 2000).  In concurrence, endoplasmic reticulum stress, 
characterised by elevated levels of JNK, have recently emerged as a key pathological feature 
of impaired IR signalling in obesity (Ozcan et al., 2004).  
 
Defects in adipose tissue insulin regulation are also present in obesity.  These defects 
somehow resemble the abnormalities described in skeletal muscle.  This is because 
compared to lean individuals, insulin-induced glucose disposal and IR-dependent stimulation
 
of IRS-1, PI3K and aPKCs, but not PKB,
 
is reduced in adipose tissue of obese individuals 
(Sajan et al., 2004). The ability of PIP3 to activate aPKCs is also decreased (Sajan et al., 
2004).  Once type II diabetes develops further defects in IRS-1 expression and IRS-1–
dependent PI3K activity are observed in obesity (Rondinone et al., 1997). However the 
extent to which abnormalities in adipose tissue insulin signalling can directly contribute to 
whole-body insulin resistance remains speculative (Kahn and Flier, 2000).  To explain, 
consistent with the importance of insulin signalling in stimulating glucose uptake in 
adipocytes, in mice overexpression of GLUT4 in adipose tissue but not skeletal muscle is 
associated with improved fasting glucose and glucose tolerance. Whole-body glucose uptake 
and adipose tissue glucose disposal is also ameliorated under basal and insulin-stimulated 
conditions (Shepherd et al., 1993; Gnudi et al., 1996).  Paradoxally, knock-out of IR gene 
produces mice that are equally protected against obesity-induced glucose intolerance (Bluher 
et al., 2002).  Such anomalies could be explained by the fact that overexpression of GLUT4 
in adipose tissue, while enhancing glucose uptake into adipocytes, may reduce glucose 
supply to skeletal muscle forcing the latter to utilise fatty acids as a source of energy (Gnudi 
et al., 1995).  Moreover, according to Gnudi et al. (1995-1996), improvements in adipose 
tissue insulin sensitivity does not necessarily protect against high-fat diet induced insulin 
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resistance in skeletal muscle or liver (Gnudi et al., 1995; Gnudi et al., 1996).  Because of 
these inconsistencies, it is unsurprising that defects in insulin downstream signalling 
pathways in skeletal muscle are counted as the main driving force precipitating the 
development of systemic insulin resistance in obesity, especially when considering that 
glucose disposal in skeletal muscle accounts for 75% of glucose uptake in the body (Saltiel 
and Khan, 2001).     
 
In contrast to skeletal muscle and adipose tissue, hepatic insulin-induced aPKC activation 
appears to be preserved in type II diabetic non-obese Goto-Kakazaki rats and ob/ob-diabetic 
mice (Farese et al., 2005) or upregulated in obese (fa/fa) rats (Qu et al., 1999) while PKB 
activation is either maintained in non-diabetic high-fat fed mice or compromised in type-II 
diabetic non-obese Goto-Kakazaki rats and ob/ob-diabetic mice (Standaert et al., 2004). The 
cause of this differential aPKC activity between skeletal muscle, adipose tissue and liver is 
unknown, but could be postulated to involve tissue-specific differences in aPKC regulation 
by IRSs.  Accordingly, IRS1 is seen as the dominant IRS responsible for insulin-induced 
aPKC activation in skeletal muscle, while in adipose tissue aPKC is regulated by both IRS1 
and IRS2 and finally in the liver aPKC is controlled by IRS2 (Kido et al., 2000; Previs et al., 
2000; Farese et al., 2005) (Figure 1.4).  Regardless of these differences, hepatic changes in 
aPKC and PKB in combination with skeletal muscle and adipose tissue-induced systemic 
insulin resistance, are likely to further exacerbate the metabolic situation in obesity by 
promoting hyperglycaemia, dyslipidaemia and non-alcoholic steatohepatitis (Standaert et al., 
2004; Farese et al., 2005).  In particular, dyslipidaemia could be induced by the up 
regulatory effect of the sustained or heightened hepatic PKC activity on sterol regulatory 
element binding protein-1c (SREBP-1c) expression (see section 1.6.2).   
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Figure 1.4 Differential regulation of PKC by IRS-1/PI3K in skeletal muscle, by IRS-1/2/PI3K in adipose tissue and by IRS-2/PI3K in liver. 
Note the role of IRS-2/PI3K in lipogenesis and IRS-1/PI3K in glycogenolysis and gluconeogenesis (Farese et al., 2005).  
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1.4.3 Insulin’s vascular actions: role in glucose metabolism 
In addition to regulating IR signalling network, insulin can influence glucose metabolism 
through its vascular actions (Baron et al., 1995; Baron et al., 1996).  The molecular basis of 
these vasodilatory properties and the association between insulin resistance and endothelium 
dysfunction are well established and will be discussed in section 1.5.  Overall, these vascular 
actions are directed towards increasing blood flow to target tissues, in particular skeletal 
muscle, where the rise in surface exchange area permits insulin-dependent stimulation of IR 
downstream signalling and subsequently glucose uptake (Mather et al., 2000). Consistent 
with this obese subjects exhibit reduced forearm blood flow rate which is accompanied with 
delayed delivery of insulin into skeletal muscle interstitial fluid, (Sjostrand et al., 2002; 
Sjostrand et al., 2005), the site of skeletal muscle IR (Vincent et al., 2005).   
 
However, until recently, inconsistencies still existed concerning the extent to which insulin‘s 
vascular actions contribute to insulin-mediated glucose uptake.   This is because while some 
authors reported a significant relation between the rate of insulin-dependent skeletal muscle 
glucose disposal and the magnitude of flow dependent glucose uptake (Baron et al., 1995), 
several others failed to perceive any association between bulk flow and glucose uptake 
(Nuutila et al., 1996; Laine et al., 1998; Natali et al., 1998; Pitkanen et al., 1999).  These 
inconsistencies were reported despite the fact that insulin‘s vasodilatory actions helped 
explain one-third of insulin‘s effect on glucose uptake (Baron et al., 1995).  Subsequent 
investigation revealed that, apart from influencing large vessels, insulin can also affect the 
microvasculature by selectively redistributing blood flow from non-nutritive to nutritive 
vessels (Baron and Clark, 1997; Clark et al., 2003; Vincent et al., 2005; Newman et al., 
2007).  These findings were important because they implied that not all increases in bulk 
flow are associated with improved insulin-mediated glucose uptake since only nutritive 
vessels are capable of extracting nutrients such as glucose (Newman et al., 2001). This 
helped explained the earlier discrepancies as  most authors who failed to reach similar 
conclusion as Baron et al. (1995, 1996) used vasodilatory agents that increased blood flow 
into non-nutritive capillaries (Clark et al., 2003).  Importantly, it was observed that insulin-
stimulated microvascular recruitment (nutritive flow) and glucose uptake is nitric oxide 
(NO)-dependent (Vincent et al., 2003; Vincent et al., 2004).  This specificity was further 
reinforced by studies demonstrating that administration of methacholine, a NO vasodilator, 
improves forearm blood flow, capillary recruitment, glucose uptake and interstitial insulin 
concentrations
 
in obese individuals (Murdolo et al., 2008) while inhibition of NO by nitro-i.-
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arginine methyl ester offsets insulin-stimulated rise in total limb flow and microvascular 
recruitment resulting in a 40% reduction in glucose uptake (Vincent et al., 2003).   
 
Based on this evidence it could be summarised that insulin can potentially promote skeletal 
muscle glucose uptake through its ability to increase total limb flow and to selectively 
regulate microvascular perfusion.  However, much remains to be clarified as to the 
contribution of vasodilatation in each of these compartments in modulating insulin 
glucoregulatory function. This is because  compared to the large resistant vessels responsible 
for bulk flow, the microvasculature is  more sensitive to insulin since infusions of 
physiological concentrations of this hormone  increase microvascular recruitment and 
skeletal muscle perfusion before any changes in total limb flow are detected (Coggins et al., 
2001; Vincent et al., 2002) (see Section 1.5.3).  Moreover, it appears that capillary 
recruitment could occur independently of changes in blood flow (Steinberg et al., 1996; 
Rattigan et al., 1997) and that total blood flow is only a rate-limiting factor for skeletal 
muscle glucose uptake in insulin sensitive but not insulin-resistant subjects (Baron et al., 
2000).  Regardless of this, it remains to be stated that in obesity defects in insulin-mediated 
vascular function could still contribute to postprandial glucose intolerance (Baron et al., 
1990) which is one of the earliest defects observed in normal glucose tolerant patients who 
subsequently develop hyperglycaemia and type II diabetes (Pratley and Weyer et al., 2002).   
 
1.4.4 Physiological aspects of insulin resistance in obesity 
Under normal physiological conditions, 50-55% of glucose production is ascribed to 
gluconeogenesis following an overnight fast which is raised to 93±2% after 42h of fasting 
(Landau et al., 1996; Petersen et al., 1996).  The remaining whole body glucose release is 
ascribed to hepatic glycogenolysis (Petersen et al., 1996).  Glycogen synthesis in skeletal 
muscle, on the other hand, accounts for the largest proportion of whole-body glucose 
disposal and effectively all of non-oxidative glucose metabolism (Shulman et al., 1990).  
The balance between these processes helps maintain glucose homeostasis 
 
Generally, physiological concentrations of insulin suppress gluconeogenesis by 20% and 
completely abolish glycogenolysis (Gastaldelli et al., 2001).  In obesity, these processes are 
disturbed resulting in heightened hepatic gluconeogenesis and glycogenolysis (Muller et al., 
1997; Gastaldelli et al., 2000, 2004; Basu et al., 2005). Skeletal muscle glycogenolysis is 
also impaired in obesity (Damsbo et al.,1991) and the sum of these anomalies stimulates the 
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development of fasting hyperglycaemia (Gastaldelli et al., 2000, 2004).  In relation to 
gluconeogenesis, it is estimated that for every unit increase in BMI, a 0.9% rise in 
gluconeogenesis is produced.  The degree of overweight and obesity  and visceral obesity 
can also independently predict gluconeogenic flux (Gastaldelli et al., 2004) and the 
percentage contribution of gluconeogenesis to whole-body glucose production during fasting 
(Gastaldelli et al., 2000). This enhanced gluconeogenesis is attributed to enhanced influx of 
amino acids to the liver due to impaired insulin ability to inhibit post-absorptive protein 
catabolism (Chevalier et al., 2006).  Increased hepatic glycolytic and gluconeogenic 
enzymes activity is also implicated in enhanced gluconeogenesis and glycogenolysis seen in 
obesity (Seidman et al.,1970; Perez et al., 1998).   
 
In relation to glycogenolysis, impaired glucose storage in skeletal muscle of obese 
individuals is strongly correlated with defective insulin-stimulated glucose uptake (Hojland 
et al., 2009).  This effect occurs because glucose uptake constitutes the rate limiting step for 
glucose utilisation and glycogen synthesis, and this process is impaired in obesity as a 
consequence of the disturbances in insulin-stimulated downstream signalling described 
earlier.   Glycogen synthase activity is also severely compromised in obesity (Kim et al., 
1999; Golay et al., 2002; Damsbo et al., 1991) which is reflected in diminished non-
oxidative glucose metabolism (Golay et al., 2002; Damsbo et al., 1991).  In fact, defects in 
glycogen synthase constitute one of the most recognised and earliest defects observed in 
obese individuals (Golay et al., 2002; Damsbo et al.,1991). These defects have been recently 
attributed to failure of insulin to induce glycogen synthase phosphorylation, a process that 
activates glycogen synthase and promotes glycogen synthesis (Hojland et al., 2009).  
Although the insulin-dependent Akt/PKB transduction pathway is known to be implicated in 
the stimulation of glycogen synthase kinase, a serine/threonine kinase that regulates 
glycogen synthase phosphorylation and activation (Welsch and Proud, 1993; Cross et al., 
1995; Cohen, 1999), the extent of involvement of glycogen synthase kinase in obesity-
related insulin resistance remains to be clarified, since the activity of the Akt/PKB pathway 
is preserved in obesity (Kim et al., 1999).  
 
1.4.5 Insulin resistance and type II diabetes 
Insulin resistance precedes hyperglycaemia and hence is an important risk factor for the 
development of type II diabetes. It is one of the cardinal features of obesity and evidence 
from longitudinal studies suggests that in most cases disturbances in insulin-dependent non-
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oxidative glucose disposal, hence storage, and insulin-independent glucose uptake occur 
early during the transition from normglycaemia to glucose intolerance (Weyer et al., 1999; 
Martin et al., 1992) and almost a decade before the initial onset of type II diabetes (Martin et 
al., 1992).  In addition to defects in insulin action, abnormalities in insulin secretion and 
endogenous glucose output are involved in the pathogenesis of type II diabetes (Weyer et al., 
1999).   Each of these pathogenic factors contributes to the development of type II diabetes 
at different stages of the disease and is, in turn, influenced by excess adiposity (Figure 1.8; p. 
37).  In particular, impaired insulin activity, delayed insulin release following a meal and 
post-prandial hyperglycaemia form one of the earliest defects precipitating the rise in 
endogenous glucose production and clinical hyperglycaemia (Pratley and Weyer, 2001).  
Subsequently, identifying nutritional strategies that target these specific disturbances in 
insulin activity and secretion at early stages of disease development remain imperative to the 
long-term prevention of obesity-associated type II diabetes (Weyer et al., 1999; Pratley and 
Weyer, 2001; Pratley and Weyer, 2002), especially when considering that in recent years, the 
prevalence of type II diabetes has risen in equal proportion to the obesity epidemic with over 
190 million of people suffering from this chronic condition (WHO, 2009). 
 
In general, it is well documented that both insulin resistance (Haffner et al., 1990; Lillioja et 
al., 1993; Haffner et al., 1995) and obesity (Wang et al., 2005; Vazquez et al., 2007) are 
important predictors of type II diabetes.  However, it appears that regardless of the reciprocal 
relation between insulin action or secretion and obesity (Weyer et al., 2000a), excess 
adiposity, either characterised as abdominal adiposity or enlarged adipocytes,  remains an 
independent and in conjunction with insulin resistance an additive predictor of type II 
diabetes (Abbasi et al., 2002; Weyer et al., 2000b; Ferrannini et al., 2004).  The molecular 
basis for such relation could be obtained from the ectopic fat storage theory (see Section 
1.7.2) wherein dysfunctional mitochondrial β-oxidation and failure of fat cell to proliferate is 
closely linked to insulin resistance and type II diabetes (Heilbronn et al., 2004).  Importantly, 
however, it appears that hyperinsulinaemia can predict future weight gain and rise in WHR 
(Odeleye et al., 1997; Gould et al., 1999;) possibly as a result of insulin‘s ability to regulate 
lipolysis (Section 1.6.4). This could be further illustrated in that individuals who progress to 
type II diabetes experience greater weight gain than non-progressors  (Weyer et al., 1999) 
while  treatment with insulin simultaneously improves glycaemia  and weight control in 
obese type II diabetics (Ratner et al., 2002; Hollander et al., 2003; Hollander et al., 2004).  
Likewise, in a prospective 5-year follow-up study, Chen et al. (1995) reported that defects in 
insulin secretion often precede visceral obesity in some type II diabetes progressors which 
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may imply that a vicious circle of cause and effect exits that contributes to the sustained 
glucose intolerance and hyperinsulinaemia that then lead to type II diabetes. The 
consequence of such association could lie in that dietary strategies aimed at reversing 
obesity-related insulin resistance and type II diabetes may also be central to managing body 
weight. 
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1.5. Insulin resistance, endothelium dysfunction and hypertension 
The complex relation between insulin resistance and hypertension is likely to involve several 
physiological mechanisms including insulin‘s effect on the sympathetic nervous system, the 
endocrine system and the vasculature (Figure 1.5).  
 
 
 
 
 
 
Figure 1.5 Contrasting insulin’s actions on cardiovascular system (Muniyappa et al., 
2007).  Note the effect of insulin on vasculature and hypothalamus wherein increased 
NO bioavailability and activation of sympathetic nervous system (SNS) lead to vascular 
relaxation.  By contrast, note the effect of insulin on heart and kidney.  Herein, 
enhanced cardiac contractility and sodium reabsorption raise blood pressure. These 
differential effects of insulin can be explained by the fact that insulin’s NO pathway 
predominates in vasculature while the activity of insulin MAPK pathway predominates 
in heart and kidney.  In obesity and the metabolic syndrome, the balance is shifted 
towards enhanced activity of MAPK pathway (see text).   
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In relation to the vasculature, recent studies have identified a selective insulin signalling 
pathway in the endothelium.   This selective pathway bears striking similarity to the insulin-
signalling pathways seen in skeletal muscle and adipose tissue, and has been shown, in fact, 
to express all the necessary components of insulin downstream signalling notably IRS, PI3K 
and Akt/PKB (Cleland and Connell, 2005; Kim et al., 2006). Interestingly, this pathway 
appears to play a key regulatory role in maintaining vascular function by controlling the 
production of NO. This has led several authors to conclude that defects in this signalling 
pathway could contribute to impairment in NO bioavailability, which is then reflected as 
abnormalities in vascular function, i.e. impaired capillary recruitment, and diminished limb 
blood flow (Cleland and Connell, 2005; Kim et al., 2006).  The following section describes 
these defects in relation to obesity-associated hypertension.   
 
1.5.1 Endothelium dysfunction 
The vascular endothelium consists of a group of cells that line the capillaries thereby 
separating the lumen of blood vessels from the vascular smooth muscle.  It acts as an 
endocrine organ, producing a variety of bioactive substances that help regulate vasomotor 
tone (Kumar and Clark, 2005).  Of particular importance is NO, a powerful vasodilator 
produced in the endothelium through the oxidation of L-arginine via the enzyme endothelial 
NO-synthase (eNOS) (Kumar and Clark, 2005).  In obesity, there is evidence of impaired 
endothelial dilation (Arkin et al., 2008, DeJongh et al., 2004) and diminished NO 
bioavailability (Mather et al., 2004). This diminished NO bioavailability and endothelium 
dysfunction appears to be linked to obesity via an imbalance between insulin‘s vasodilatory 
and vasoconstrictive actions (Jonk et al., 2007), as illustrated below. 
 
1.5.2 Insulin’s downstream signalling pathways: relevance to vascular 
endothelium 
As part of its glucoregulatory function, insulin helps increase capillary recruitment and blood 
flow, which as well as dilating the vessels allows for increased glucose uptake by skeletal 
muscle (Jonk et al., 2007).  This effect is achieved through insulin‘s ability to regulate 
vasodilation and vasoconstriction through two distinct and independent pathways, the 
Akt/PKB-dependent pathway and the MAPK-dependent pathway (Scherrer et al., 1994, 
Potenza et al., 2009) (Figure 1.6).  Insulin‘s net effect on vascular endothelium depends on 
the balance between these two pathways (Scherrer et al., 1994, Potenza et al., 2009). 
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In insulin resistance, there is a specific impairment in the Akt-signalling pathway while the 
activity of the MAPK-pathway remains preserved (Jonk et al., 2007).  Coupled with insulin 
hypersecretion as observed in obesity, this results in enhanced MAPK-signalling and 
diminished Akt-signalling which leads to an imbalance between the generation of NO and 
the secretion of endothelin-1, an endothelium-derived factor that opposes NO activity (Jonk 
et al., 2007).  The result is impaired insulin-induced vasodilation and enhanced insulin-
induced vasoconstriction.  This state is characteristic of endothelium dysfunction and is 
thought to be one of the earliest underlying pathophysiological abnormalities seen in 
hypertension.   
 
Much debate remains as to whether insulin resistance precedes and hence causes 
endothelium dysfunction or whether it is a mere complication of changes in microvascular 
circulation (Cleland and Connell, 2005).  Such uncertainties arise from the complex 
mechanisms and the common cellular and biochemical pathways shared by insulin resistance 
and endothelium dysfunction.  Nonetheless, what remains clear is that in obesity, a 
reciprocal relation exits between insulin resistance and endothelium dysfunction, which is 
eventually expressed in the form of vascular pathologies such as hypertension and 
atherosclerosis.  
 
 24 
 
 
Figure 1.6  Diagram showing effect of increased angiotensin-II and free fatty acid 
(FFA) production on the balance between insulin’s vasoconstrictive and vasodilatory 
actions (adapted from Jonk et al., 2007).  eNOS endothelial nitric oxide synthase, IRS 
insulin receptor substrate, NO nitric oxide, ROS reactive oxygen species. 
 
 
 
  
IRS-tyrosine 
Atk pathway 
eNOS 
NO 
MAPK 
pathway 
endothelin-1 
IRS-tyrosine-P 
angiotensin II and FFA  
vasodilation vasoconstriction 
Vascular smooth 
muscle cell 
 
ROS 
NAD(P)H 
oxidase 
NAD(P)H 
oxidase ROS 
peroxynitrite 
+ 
- 
+ 
Excess adipose tissue 
Endothelial cell 
insulin  
Insulin receptor 
 25 
In this respect, studies on spontaneously hypertensive rats provide an excellent model on 
how insulin resistance and endothelium dysfunction act through shared mechanisms to 
induce hypertension in obesity. Accordingly, these studies demonstrate that in spontaneously 
hypertensive rats, insulin resistance occurs concurrently with endothelium dysfunction 
(Potenza et al., 2005).  This, as described earlier is expressed in the form of impaired PI3K-
dependent NO production and enhanced MAPK-dependent endothelin-1 secretion.  
Importantly, these dysregulations in insulin‘s vascular actions and endothelium function 
become apparent at early stages of hypertension (LeNoble et al., 1990) and are even evident 
in  healthy offspring of patients with hypertension (Antonios et al., 2003).   
 
Interestingly, in spontaneously hypertensive rats, treatment with insulin-sensitizing drugs 
and anti-hypertensives such as metformin, pioglitazone, enalapril, or rosiglitazone, evokes 
simultaneous improvements in both plasma insulin levels and systolic blood pressure (SBP) 
(Verma et al., 1994; Grinsell et al., 2000; Potenza et al., 2006).  In the case of rosiglitazone 
and enalapril, this effect has been shown to occur as a result of re-established balance 
between insulin‘s vasodilatory and vasoconstrictive actions (Potenza et al., 2006).  Together 
these findings support the importance of controlling insulin resistance as a means of reducing 
the risk of hypertension (De Jongh et al., 2006). 
 
In humans, early studies investigating the relation between insulin and hypertension yielded 
conflicting results.  While studies using artificially-induced hyperinsulinaemia showed a 
beneficial effect on blood pressure (Gans et al., 1992), case-controlled (Welborn et al., 1966; 
Ferrannini et al., 1987) and prospective cross-sectional studies identified hyperinsulinaemia 
as an independent risk factor for hypertension (Skarfors et al., 1991; Lissner  et al., 1992; 
Zavaroni et al, 1994; Ferrannini et al., 1997) (also refer to review by Cleland and Connell, 
2005).  These inconsistencies could be explained by the fact that artificially induced 
hyperinsulinaemia could have promoted insulin‘s vasodilatory actions (Section 1.5.2).  
Conversely, in the observational cross-sectional studies, hyperinsulinaemia might have 
reflected a compensatory rise in insulin in response to insulin resistance, thereby pinpointing 
insulin resistance as an important contributor to hypertension (Section 1.7.5).  Indeed, 
several studies have shown strong correlation between insulin sensitivity and blood pressure 
(Welborn et al., 1966; Ferrannini et al., 1987; Serne et al., 1999).  This is further reinforced 
by the fact that hypertensives have lower insulin sensitivity values than normotensives 
(Serne et al., 1999) and that for every 10-unit increase in insulin resistance a 1.7 mm Hg and 
2.3 mm Hg rise in SBP and diastolic blood pressure (DBP) is observed (Ferrannini et al., 
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1997).  Interestingly, the relation between insulin resistance and elevated blood pressure 
appears to occur independently of BMI (Cleland and Connell, 2005), which is consistent 
with the concept of insulin resistance being the underlying factor linking obesity with 
elevated blood pressure.  The earlier sections have described the molecular basis of the 
imbalance in insulin‘s hemodynamic actions. The next question that arises is how do such 
defects are then expressed on physiological level? 
 
1.5.3 Insulin-induced capillary recruitment and blood flow 
Numerous studies have reported an inverse correlation between microvascular function and 
blood pressure in lean normotensives with or without familial predisposition to hypertension, 
in patients with borderline hypertension or hypertension, and in obese individuals (Serne et 
al, 1999, 2001; De Jongh et al., 2004a-b).  In particular, the work by Serne et al. (1999) 
showed that microvascular function is strongly related to both insulin sensitivity and blood 
pressure, which led the authors to conclude that microvascular dysfunction is the main 
mechanism linking insulin sensitivity to blood pressure.  Such findings were consistent with 
the concept of microvascular dysfunction as a cause of insulin resistance and hypertension 
(De Jongh et al., 2004a).   However, further investigations by the same group revealed that 
microvascular function is closely correlated with blood pressure and insulin's metabolic and 
vasodilatory actions (Serne et al., 2001). In fact, in addition to having impaired insulin 
sensitivity, hypertensives patients were found to exhibit reduced capillary recruitment, 
impaired acetylcholine-mediated vasodilatation, and diminished insulin-mediated 
vasodilatation (Serne et al., 2001). Notably, capillary recruitment after arterial occlusion was 
shown to correlate negatively with blood pressure but positively with insulin sensitivity and 
insulin-mediated vasodilatation, this relation persisting from normotensives through to 
hypertensives (Serne et al., 2001). Similar observations were reported with lean and obese 
individuals wherein capillary recruitment or NO-dependent vasodilation were found to 
correlate positively with insulin sensitivity but inversely with blood pressure (De Jongh et 
al., 2004a). Undoubtedly, such evidence implies that a primary defect in insulin‘s selective 
vascular transduction pathway is likely to govern the relation between insulin resistance and 
hypertension.  This could be further reinforced by Serne et al. (2002) latest work which 
showed that hyperinsulinaemia promotes vascular function by inducing both 
NO/endothelium-dependent and endothelium-independent vasodilation. The former finding 
is consistent with other studies showing stimulatory effects of insulin on acetylcholine, a 
known NO-dependent vasodilator (Steinberg et al., 1994, Taddei et al., 1995, Cardillo et al., 
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1998), although the second finding is in disagreement with De Jongh et al. (2004b) who 
observed no changes in sodium-nitroprusside, an endothelium-independent vasodilator, 
during hyperinsulinaemia.  Despite these inconsistencies, Serne et al. (2002) and others (De 
Jongh et al., 2004b) have repeatedly shown that hyperinsulinaemia can promote capillary 
recruitment and vasomotion, all of which reflects improved endothelial activity.  According 
to Kim et al. (2006), enhanced capillary recruitment is one of the first stages by which 
insulin improves vascular function and consequently blood pressure.  This stage is observed 
within 10 minutes of administration of intravenous insulin and appears to reach its maximal 
effect by 30 minutes.  Capillary recruitment is thought to be the more critical of the two 
stages since it permits the shift of blood flow from non-nutritive to nutritive blood vessels 
(Clark et al., 2003). Moreover, in the absence of an effect on blood flow, increased capillary 
recruitment following administration of physiological concentrations of insulin could still be 
observed (Coggins et al., 2001, Clark et al., 2003).  The second stage involves increased 
total limb blood flow which occurs several hours following initial administration of insulin.  
The stimulatory effect of insulin on blood flow was first documented by Laakso et al. (1990, 
1992) and their colleagues Baron et al. (1993).  Accordingly, physiological and supra-
physiological levels of insulin were shown to augment overall limb blood flow in a dose-
dependent (Laakso, 1990, 1992; Baron et al., 1993; De Jongh et al., 2004b) and NO-
dependent manner (Steinberg et al., 1994).  Based on this evidence, it could be postulated 
that insulin‘s vascular signalling pathway is central to the regulation of capillary recruitment 
and total blood flow, hence endothelium function, and that disturbances in insulin‘s 
hemodynamic actions such as observed in obesity will inevitably result in impaired vascular 
function and hypertension.  In line with this concept, several studies have demonstrated that, 
in obesity, insulin‘s ability to evoke skeletal muscle blood flow is impaired (Laakso et al., 
1990), and that compared to lean individuals, obese individuals have higher SBP, impaired 
insulin sensitivity, impaired capillary recruitment and endothelium-mediated vasodilation in 
both the basal state and during hyperinsulinaemia (De Jongh et al., 2004a).  
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1.6. Insulin resistance and dyslipidaemia 
Physiological relations between insulin resistance and lipid metabolism have been 
recognised for decades and are thought to play a key role in promoting CVD in insulin-
resistant states such as diabetes, obesity and the metabolic syndrome.  This could be 
illustrated by the fact that insulin resistant states often share dyslipidaemia as a common 
pathological feature (Lamarche and Mauger, 2005).  This dyslipidaemia is characterised by 
elevated plasma TG concentrations and reduced concentrations and size of HDL-cholesterol 
(Maclean et al., 2000; Garvey et al., 2003; Goff et al., 2005).  Notably, this phenotype  of 
elevated plasma TG and reduced HDL appears to be specific to insulin resistant states 
(Couillard et al., 2000).  The concentration of LDL-cholesterol is not necessarily augmented 
but, the number of the denser, smaller and more atherogenic LDL-cholesterol is increased in 
insulin-related dyslipidaemia (Maclean et al., 2000; Garvey et al., 2003; Goff et al., 2005).   
The consequence of such disturbances in lipid metabolism is reflected in the high incidence 
of CVD and mortality amongst these population subgroups. 
 
Such strong physiological associations between insulin resistance and dyslipidaemia could 
only arise as a consequence of a close and interlinked biochemical regulation of both glucose 
and lipid metabolism.  Insulin is recognised as one of the primary hormonal regulators of 
lipid metabolism.   It acts on various stages of lipid metabolism.  For instance, during the 
post-prandial state, insulin promotes the uptake of TG into adipose tissue by upregulating the 
activity of adipose tissue lipoprotein lipase (LPL) (Semenkovich et al., 1989; Panarotto et 
al., 2002).  It also promotes de novo lipogenesis wherein excess glucose is converted to fatty 
acids for storage as energy reserves in the white adipose tissue (Saltiel and Khan, 2001). 
Insulin also inhibits lipolysis and gluconeogenesis (Saltiel and Khan, 2001). 
 
1.6.1 Effect on triglyceride uptake 
LPL is an enzyme responsible for the hydrolysis of TG-rich lipoproteins postprandially in 
chylomircons and during fasting in very low density lipoproteins (VLDL) (Lamarche and 
Mauger, 2005).  Defects in its activity are closely linked to a rise in plasma TG levels 
(Tsutsumi, 2003).  In insulin resistant-states, there is a concomitant impairment in plasma 
LPL activity (Sumner et al., 2005) and  adipose tissue LPL expression which together are 
thought to induce postprandial triglyceridaemia as a result of reduced TG-rich lipoprotein 
uptake (Panarotto et al., 2002).  This is evident in that fasting insulin and insulin-mediated 
glucose uptake are strongly and inversely correlated with fasting plasma TG and VLDL 
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concentrations (Maheux et al., 1997; Ambrosch et al., 1998), but inversely with plasma LPL 
activity and adipose tissue LPL mRNA expression (Maheux et al., 1997).  Likewise, defects 
in LPL activity are also associated with a reduction in plasma HDL in insulin-resistant obese 
individuals (Tsutsumi, 2003) which explains the high TG/ low HDL dyslipidaemia seen in 
insulin resistance (James et al., 2003).  Recently, De Jongh et al. (2006) have also revealed 
that insulin can influence LPL activity indirectly via its effects on endothelium function.  
This is exemplified in the negative correlation seen between capillary recruitment and 
dyslipidaemia (De Jongh et al., 2006; IJzerman et al., 2006).  De Jongh et al. (2006) argues 
that such association can result from the loss of contact surface area between LPL and 
lipoproteins as a result of, reduced capillary recruitment, which then attenuates TG uptake 
leading to a rise in plasma TG and subsequent changes in HDL and LDL particles, as 
described later. 
 
1.6.2 Effect on triglyceride clearance and lipogenesis 
In addition to regulating TG uptake, insulin controls the clearance of  TG-rich chylomicrons 
and their remnants.  In this respect, insulin resistance has been shown to be associated with 
diminished LDL-receptor activity which is then expressed by the presence of high levels of 
apolipoprotein B-48 and apolipoprotein B-100 in the circulation (James et al., 2003).  
Attenuation of insulin resistance in obesity, on the other hand, is accompanied by improved 
LDL receptor binding and activity (James et al., 2003).  Hyperinsulinaemia and insulin 
resistance have also been documented to stimulate lipogenesis as evident by increased 
hepatic VLDL synthesis and secretion (Brown and Goldstein, 2008).    
 
The molecular basis of such effect has been hypothesised to include defects in post-receptor 
insulin signalling (Brown and Goldstein, 2008).  These abnormalities somehow resemble the 
disturbances in insulin‘s vascular actions (see Section 1.5.2) in that they occur as a 
consequence of an imbalance between two insulin-dependent pathways.  Accordingly 
hyperinsulinaemia is postulated to selectively downregulate insulin downstream signalling 
pathways, i.e. IRS/PI3K/protein kinase B/forkhead box O transcription factor 1 
(IRS/PI3K/Akt/FOXO1) while activating some poorly defined pathway that regulates 
hepatic SREBP1c expression and activity (Brown and Goldstein, 2008; Semple et al., 2009). 
SREBP-1c is a transcription factor found predominantly in the liver which stimulates 
lipogenesis (Shimano et al., 2007).  It is generally activated in the presence of excess energy 
intake where it acts to promote the storage of energy by the conversion of glucose to TG 
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(Shimano et al., 2007). Uncontrolled activation of hepatic SREBP-1c can cause 
hypertriglyceridaemia and synthesis of large TG-rich VLDL in the liver due to direct 
suppression of insulin signalling pathways and glycogen synthesis (Ide et al., 2004; Shimano 
et al., 2007) as well as by mediating the effect of insulin resistance on LDL-receptor (Kotzka 
et al., 2000). 
 
So far, much controversy exists concerning the IRS isomer that controls insulin signalling 
activation of STREBP1-c.  Kohjima et al. (2008) has shown that the expression of IRS1 but 
not IRS2, is positively correlated with the expression of SREBP-1c (Kohjima et al., 2008). 
However, the latter is in contrast to the findings of Semple et al. (2009) of an inverse relation 
between IRS-2 protein levels and SREBP transcription. Such discrepancy could be explained 
by the fact that in addition to regulating SREBP1-c, IRS-2 is, in itself, negatively influenced 
by SREBP1-c (Ide et al., 2004; Taniguchi et al., 2005; Shimano et al., 2007; Kohjima et al., 
2008).  Regardless of inconsistencies, most authors argue in favour of a primary role of IRS-
2/ Akt 1 signalling pathway in modulating  insulin‘s regulation of lipid metabolism (Farese 
et al., 2005; Taniguchi et al., 2005; Bouzakri et al., 2006).   IRS-1/ Akt 2, on the other hand, 
is thought to be more relevant to glucose metabolism (Taniguchi et al., 2005; Bouzakri et al., 
2006).  In this respect, Taniguchi et al. (2005) has demonstrated that reduced hepatic 
expression of IRS2 augments SREBP-c levels independently of insulin.  Moreover, Kohjima 
et al. (2008) has documented that IRS-2 is negatively correlated with Foxa2, another 
transcription factor involved in lipid metabolism and which promotes  β-oxidation.    As 
such, it may be that increased hepatic expression of IRS1 in conjunction with reduced 
expression of IRS2 act synergetically and via distinct pathways to augment SREBP-1c 
expression and consequently lipogenesis.  However, in obese insulin-resistant and 
hyperinsulinaemic states concurrent reductions in hepatic IRS-1 and IRS-2 are observed 
which argues against such concept (Anai et al., 1998, 1999).  In agreement with the specific 
functions of IRS1 and IRS 2 proposed by Kido et al. (2000) and Previs et al. (2000), 
Taniguchi et al. (2005) has shown  that rats expressing hepatic knock-outs of IRS-1 and IRS-
2 exhibit all the salient features of the metabolic syndrome including fasting hyperglycaemia, 
fasting hyperinsulinaemia, insulin resistance, glucose intolerance, dyslipidaemia amongst 
others.   Such observations undoubtedly mark a central role of defects in the IRS2 pathway 
in increasing hepatic SREBP1-c expression in insulin-resistant states.  Factors such as 
increased expression and activity of liver X receptor have also been shown to accelerate 
insulin‘s stimulatory effect on SREBP-1c transcription (Chen et al., 2004; Taniguchi et al., 
2005).  Interestingly, Kotzka et al. (2000) has identified STREBP-1 as a substrate for the 
 31 
MAPK signalling pathway, which when considering the unaltered MAPK activity seen in 
insulin resistance is likely to contribute to the activation of STREBP1-c.   
 
1.6.3 Consequences of impaired triglyceride uptake, clearance and 
lipogenesis on lipoprotein metabolism 
Impaired TG uptake and clearance and enhanced lipogenesis increase  plasma TG and total 
TG pool which precipitates the development of  TG-enriched HDL (Rashid et al., 2002a).  
Enrichment of HDL with TG occurs via upregulation of cholesteryl ester transfer protein 
(CETP), an enzyme that promotes the uptake of  TG from chylomicrons and VLDL to HDL 
(Matsuura et al., 2006; Yvan-Charvet et al., 2007).   A number of cell culture and human 
studies have demonstrated that insulin can downregulate the activity of CETP (Arii et al., 
1997; Kaser et al., 2001) but that in conditions of impaired insulin metabolism, such as type 
II diabetes, the ability of insulin to suppress CETP activity is hindered (Kaser et al., 2001).  
This when combined with enhanced hepatic lipase activity under insulin resistant conditions 
not only alters the composition HDL particles but also enhances the clearance of TG-
enriched HDL (Lamarche et al., 1998; Couillard et al., 2000; Rashid et al., 2003a-b).  This 
increased susceptibility of TG-enriched HDL to metabolic degradation, as measured by 
fractional catabolic rate of apoA-1, a marker of HDL clearance
 
(Nestle et al., 1987), was first 
documented by Lamarche et al. (1999), and subsequently reviewed by Rashid et al. (2002b).   
 
Besides generating an atherogenic profile and reducing HDL concentrations, insulin 
resistance can also alter the size and composition of HDL in a way that leads to the loss of 
HDL anti-atherogenic properties.  The genes that link insulin resistance with altered HDL-
particle size have been identified almost over a decade ago by Rainwater et al. (1997).  
Recent studies have elaborated further on the link between insulin resistance and HDL 
particle size by demonstrating that unregulated CETP activity stimulates the removal of 
esterified cholesterol from HDL (Matsuura et al., 2006; Yvan-Charvet et al., 2007).  This 
results in the formation of small, dense and dysfunctional HDL.  Inhibition of CETP, on the 
other hand, restores HDL‘s anti-atherogenic properties by preserving its large cholesterol 
ester-rich composition, which then reduces the risk of atherosclerosis by accelerating the 
uptake of free cholesterol from foam cells by HDL (Matsuura et al., 2006; Yvan-Charvet et 
al., 2007).  Likewise, insulin has been shown to regulate the activity of lecithin: cholesterol 
acyltransferase and phospholipid transfer protein, two enzymes that are involved in 
promoting HDL‘s reverse cholesterol transfer activity (Riemens et al., 1999).  This reverse 
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cholesterol transfer mechanism enables HDL to transfer cholesterol from peripheral cells to 
liver and accounts for HDL‘s anti-atherogenic effects (Riemens et al., 1999).  Although 
theoretically, enhanced lecithin: cholesterol acyltransferase and phospholipid transfer protein 
should be associated with increased reverse cholesterol transfer, hence improved anti-
atherogenic properties of HDL, in insulin-resistance increased activity of these enzymes is 
strongly linked to increased plasma TG concentrations (Riemens et al., 1999) and 
atherosclerosis (Schlitt et al., 2003).  In respect to phospholipid transfer protein, this effect 
have been explained by the ability of this enzyme to promote uptake of oxidised 
phospholipids by HDL, rendering the latter less protective against atherogensis (Schlitt et al., 
2003).  
 
It is noteworthy that in contrast to its ability to influence TG, VLDL and HDL, insulin has no 
direct effect on LDL.   Although changes in the size and density of LDL are observed in 
insulin resistant states, these effects are attributed to hypertriglyceridaemia which has been 
shown to predict 62% of variance in LDL size (Ambrosch et al., 1998) .  As a result, any link 
between LDL particle size and insulin resistance has been postulated to occur via the effect 
of insulin resistance on the metabolism of other lipoproteins (Ambrosch et al., 1998; 
Friedlander et al., 2000). 
 
1.6.4 Effect on lipolysis 
Insulin regulates both hormone sensitive lipase (HSL)-dependent and HSL-independent 
lipolysis.  With HSL-dependent lipolysis, insulin activates phosphodiesterase-3B 
(Rondinone et al., 2000) leading to increased degradation of protein kinase A (PKA)-
dependent cAMP (Degerman et al., 1998). Since raised cAMP levels are central to the 
activation of HSL, a reduction in their levels result in inhibition of HSL activity, hence a 
reduction in HSL-dependent lipolysis (Stralfors et al., 1984).  These molecular mechanisms 
have been reviewed in detail by Holm (2003) and  Jaworski et al. (2007). Likewise, insulin 
inhibits HSL-independent lipolysis, a key process involved in basal lipolysis, by 
downregulation of a novel lipolytic enzyme known as hepatic triglyceride lipase  (Kim et al., 
2006).  Remarkably, in obese insulin-resistant subjects, the expression of adipose 
triglyceride lipase and HSL is strongly and inversely correlated with insulin resistance and 
hyperinsulinaemia (Jocken et al., 2007).  This relation occurs independently of fat mass 
(Jocken et al., 2007).   
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In addition to these mechanisms, upregulation of STREBP1-c plays a critical role in 
controlling insulin-mediated suppression of fatty acid oxidation via negative feedback 
mechanisms involving IRS-2 (Taniguchi et al., 2005; Shimano et al., 2007; Kohjima et al., 
2008).  Together these disturbances in insulin-mediated lipolysis increase the storage of fat 
in adipose tissue leading to obesity (Nishino et al., 2007).   
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1.7. Etiology of insulin resistance in obesity 
1.7.1 The role of  circulating plasma free fatty acids 
Obesity is characterised by elevated plasma FFA levels (Ghanim et al., 2004), which occurs 
as a consequence of increased adipose tissue mass (Frayn, 2001), impaired post-prandial 
lipaemia (Frayn, 1998, 2002) and possibly high-fat diets (Schrauwen-Hinderling et al., 
2006).                         
 
To illustrate, it is generally agreed that fasting insulin levels are negatively correlated with 
efflux of FFA per unit adipose tissue (Karpe and Tan, 2005).  In obesity, although expression 
of HSL is diminished (Langin et al., 2005) and basal lipolysis is decreased (Steinberg et al., 
2007), the sum of FFA released per total adipose tissue mass is greater than in lean 
individuals (Flatt, 1972, Frayn et al., 2001).  When combined with impaired insulin-induced 
inhibition of lipolysis, this results in a continuous state of elevated circulating FFA (Langin, 
2006).  This is further exacerbated by the abnormal post-prandial lipaemia observed in 
obesity, particularly abdominal obesity (Mekki et al., 1999, van Hees et al., 2008).  To 
illustrate, following a meal, TG are transported as chylomicrons to adipose tissue and non-
adipose tissue, i.e. liver and skeletal muscle.  The proportion of TG deposited in the latter 
tissues is inversely related to the extent of TG ‗trapping‘ in adipose tissue (Sniderman et al., 
1998). In conditions such as obesity, delayed TG uptake from chylomicrons into adipose 
tissue (Kalant et al., 2000) and impaired chylomicrons remnant clearance (Martins and 
Redgrave, 2004), increase the availability of FFA to liver and skeletal muscle rendering them 
susceptible to lipid accumulation (Frayn, 2001, Kotronen and Yki-Järvinen, 2008), hence 
insulin resistance.  Moreover, there appears to be a preferential uptake of chylomicrons-
derived FFA compared to circulating FFA (Bickerton et al., 2007).  In general it is estimated 
that LPL releases FFA from TG-chylomicrons into splanchenic bed at a rate of 50-60% in 
overweight and obesity, a phenomena termed the spill-over effect (Nelson et al., 2007).  
These TG-rich chylomicrons contribute to 12-13% of systemic FFA and account for one-
third of the rise in portal veins FFA following a mixed meal (Nelson et al., 2007). 
 
Regardless of the source of FFA, enhanced availability of plasma circulating FFA can either 
directly impair insulin-induced capillary recruitment, leading to microvascular dysfunction 
(De Jongh et al., 2004a), or promote FFA accumulation (Stannard et al., 2002) in skeletal 
muscle, liver and pancreas and reactive oxygen species (ROS) generation leading to insulin 
resistance and impaired insulin-signalling (Hulver and Dohm, 2004), as discussed in the 
following section.   
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1.7.2 The role of intracellular free fatty acids  accumulation 
The relation between intracellular FFA accumulation and insulin resistance have been 
recognized for decades. Randle et al. (1963) was the first to hypothesis that enhanced 
intracellular FFA deposition and oxidation inhibits glucose uptake, phosphorylation and 
glycolysis.  This hypothesis was based on the substrate competition between FFA and 
glucose for mitochondrial oxidation.   As summarised in Figure 1.7, enhanced FFA oxidation 
increases acetyl-CoA/CoA, NADH/NAD and ATP/ADP ratios.  This metabolic milieu 
favours β-oxidation and inhibits the activity of several glycolytic enzymes leading to 
enhanced gluconeogenesis and reduced peripheral glucose uptake, hence insulin resistance.  
However, the initial Randle‘s hypothesis possessed several limitations mainly because it was 
based on studies on rat diaphragm and cardiac muscle (Randle et al., 1963). Moreover 
observations that in obesity, FFA oxidation is decreased, as demonstrated by enhanced 
respiratory quotient, led most authors to argue against Randle‘s hypothesis (Kelley et al., 
1999; Kim et al., 2000).  Since then numerous other paradigms have emerged each 
attempting to explore the relation between intracellular FFA accumulation and insulin 
resistance in line with their own strengths and weaknesses. These hypotheses have been 
extensively reviewed and include the portal hypothesis (Bjorntorp, 1990; Bergman, 2000; 
Bergman and Ader, 2000), ectopic fat storage syndrome (Montani, 2004; Rasouli et al., 
2007; Weiss, 2007; Lara-Castro and Garvey, 2008 ; Blüher, 2009; Szendroedi and Roden, 
2009) and adipocytes as an endocrine organ (Hutley and Prins, 2005; Fonseca-Alaniz et al., 
2007).  The upcoming sections will not attempt to deal with these hypotheses in detail 
although reference will be made to them when appropriate.   
 
 36 
 
 
 
 
Figure 1.7 Molecular basis of Randle’s hypothesis (Randle et al., 1963).  Enhanced free 
fatty acids (FFA)s oxidation creates a metabolic milieu of raised Acetyl-CoA, NADH 
and ATP.  This metabolic milieu leads to inhibition of pyruvate dehydrogenase (PDH), 
phosphofructokinase (PFK) and hexokinase (HK) causing reduced peripheral glucose 
uptake.  
 
 
In general deposition of FFA or so-called ectopic FFA storage could occur in a variety of 
insulin-sensitive tissue such as liver, skeletal muscle and pancreas (Jensen, 2006).  The 
resulting biochemical disturbances contribute via different mechanisms to systemic insulin 
resistance (Figure 1.8).  For instance, in the pancreas, in which FFA account for 30-50% of 
insulin secretion, FFA stimulate β-cells to secrete insulin leading to hyperinsulinaemia 
(Boden, 1998; Jensen, 2006),  while in the liver FFA induce hyperglycaemia, 
hyperinsulinaemia and triglyceridaemia by increasing rate of gluconeogenesis and β-
oxidation and by attenuating glycogenesis and insulin clearance (Jensen, 2006). By contrast, 
in skeletal muscle, enhanced FFA deposition diminishes glucose uptake and IR 
phosphorylation via mechanisms detailed in Section 1.7.5. 
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Figure 1.8  Effect of increased adipose tissue mass and FFA accumulation on skeletal 
muscle, liver and pancreas (adapted from McTernan and Kumar, see Barnett and 
Kumar, 2004) 
 
1.7.3 Intra-myocellular free fatty acids accumulation  
Much debate exits as to the contribution of FFA accumulation in each of the afore-
mentioned tissues to systemic insulin resistance.  Some authors argue that skeletal muscle is 
the chief contributor to systemic insulin resistance because it is the major site of substrate 
oxidation (Jensen, 2006).  Others argue in favour of disturbances in FFA metabolism in the 
liver because the liver is the primary site of glucose and lipid metabolism (Yki-Jarvinen, 
2002).  Regardless of this, recent evidence has provided some explanation to the molecular 
basis of enhanced FFA storage in skeletal muscle as well as in the liver.  In relation to 
skeletal muscle, Simoneau and Kelley (1998) have argued that enhanced glucose oxidation 
in overweight and obese individuals, possibly as a result of hyperglycaemia, may decrease 
LPL activity leading to diminished TG uptake and oxidation in skeletal muscle.   The 
reduction in β-oxidation implies that TG that do enter skeletal muscle are diverted into 
storage (Simoneau and Kelley, 1998).  As with Randle's hypothesis, Simoneau and Kelley‘s 
explanation is based on the competition between FFA and glucose for mitochondrial 
oxidation.  However, unlike Randle‘s hypothesis, Simoneau and Kelley‘s concept agrees 
with studies demonstrating raised respiratory quotient in overweight and obese individuals 
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(Kelley et al., 1999; Kim et al., 2000).  Furthermore, it is consistent with Nisoli et al. (2003) 
who have observed that eNOS knock-out mice have defective biogenesis, possibly as a result 
of fewer and smaller mitochondria being expressed in insulin target tissues (Le Gouill et al., 
2007).  The latter is then reflected as diminished energy expenditure and defective 
mitochondrial ß-oxidation, which in turn is associated with increased TG accumulation in 
muscle (Le Gouill et al., 2007).  Since NO bioavailability is known to be reduced in 
overweight and obese individuals (Williams et al., 2002; Mather et al., 2004), it is likely that 
defects in mitochondrial biogenesis contribute to the rise in skeletal muscle TG accumulation 
in overweight and obesity.   
 
1.7.4 Intra-hepatic free fatty acids accumulation  
The liver constitutes one of the major sites of insulin‘s actions.  This suggests that deposition 
of FFA in the liver could have major implications on the activity of insulin, notably to its 
effect on glucose and lipid metabolism.  This is evident in the positive correlation between 
hepatic FFA deposition, hyperinsulinaemia, hypertriglyceridaemia, blood pressure and the 
inverse association between hepatic FFA and HDL (Seppälä-Lindroos et al., 2002) 
 
In obesity, particularly abdominal obesity, there is enhanced deposition of FFA in the liver, a 
condition now termed non-alcoholic steatohepatitis.  In fact according to Kotronen and Yki-
Järvinen (2008), non-alcoholic steatohepatitis is considered a novel component of the 
metabolic syndrome.  In general, the liver is exposed to higher levels of FFA than other 
tissues.  This occurs chiefly as a result of the anatomical arrangement of hepatic circulation 
wherein dietary and adipose-derived FFA are delivered to the liver through both the portal 
and hepatic circulations (Bradbury, 2006).  In relation to the portal circulation, the strong 
positive association between visceral adipose tissue and hepatic FFA delivery, which is 
particularly evident in women (Nielsen et al., 2004), led most earlier studies to hypothesise 
that visceral adipose tissue lipolysis accounts for the largest proportion of FFA delivered to 
the liver via the portal vein (Bjorntrop, 1990; Rebuffé-Scrive et al., 1990). This Portal 
hypothesis was based on the higher metabolic activity of visceral adipose tissue as compared 
to subcutaneous adipose tissue (see review by Wajchenberg, 2000) and the resistance of 
visceral depots to insulin‘s antilipolytic actions (Endresen et al., 1994).  However, more 
recent studies suggest that visceral adipose tissue lipolysis contributes to only one-third or 
one-fifth of upper-body FFA release (Jensen et al., 2003).  Conversely, subcutaneous (non-
visceral) adipose tissue supplies 70% of systemic FFA under basal and post-prandial 
conditions (Nielsen et al., 2004) and contributes to 75% of hepatic FFA delivery (Delarue 
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and Magnan, 2007).  Although much debate remains as to the source of FFA in non-
alcoholic steatohepatitis, it is generally agreed that when hepatic FFA influx exceeds the 
processing capacity of the liver and is combined with enhanced hepatic FFA extraction, the 
result is increased hepatic FFA storage with subsequent disturbances in insulin-mediated 
glucose and lipid metabolism (Pardina et al., 2009).   
 
1.7.5 Free fatty acids: effect on insulin and glucose metabolism 
It is often presumed that hyperinsulinaemia is ensued primarily by compensatory secretion of 
insulin by pancreatic β-cells in response to peripheral insulin resistance (Reaven, 1988; 
DeFronzo, 1992; Kahn et al., 2006). However, the liver can also contribute to 
hyperinsulinaemia
 
by decreasing first-pass hepatic insulin clearance (Duckworth and 
Kitabch, 1981; Kotronene et al., 2007). In this respect, Svedberg et al. (1991) demonstrated 
that in an in situ perfused rat liver model, portal FFAs act as important mediators of hepatic 
insulin clearance.  Accordingly, a dose-dependent association between FFA and hepatic 
insulin clearance is observed in both the post-absorptive and post-prandial states with higher 
FFA levels inhibiting insulin clearance to a greater extent, thereby triggering systemic 
insulin resistance via a rise in peripheral insulin concentrations (Svedberg et al., 1991). 
Indeed, reduced hepatic insulin extraction under basal conditions have been reported in 
conjunction with obesity and elevated plasma insulin levels in both humans (Rossell et al., 
1983) and animals  (Hansen et al., 1993) and is thought to contribute to hyperinsulinaemia, 
independently of pancreatic β-cells, in obese glucose-intolerant subjects (Bonora et al., 
1983).  Hepatic insulin clearance have also been documented to be negatively correlated 
with hepatic fat content (Kotronen et al., 2007, 2008) 
 
In relation to glucose metabolism, it is well recognised that under normal physiological 
conditions, insulin suppresses glucose production in the post-prandial state while eliciting 
glycogenolysis and gluconeogenesis in the absorptive state.  This ensures sufficient levels of 
glucose are available as an energy substrate for tissues, particularly the brain and red blood 
cells, under all physiological states while maintaining euglycaemia (Champe and Harvey, 
1994).  In obesity, there is diminished insulin-induced suppression of glucose production, 
probably as a result of elevated glucose-6-phophatase activity (Paquot et al., 2002).  The 
latter is likely to occur due to  increased hepatic FFA influx  that stimulates β-oxidation 
leading to the generation of acetyl-CoA, citrate and glucose-6-phosphate, substrates that 
downregulate insulin-induced inhibition of gluconeogenesis (Randle‘s effect) (Seppälä-
Lindroos et al., 2002, Beck-Nielsen et al., 2005) and glycogenolysis in the liver (Boden et 
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al., 2002).  This relation between elevated rates of gluconeogenesis, total body fat, 
abdominal obesity, plasma circulating FFA and glucose has equally been described by 
Gastaldelli  et al. (2000).  
 
1.7.6 Free fatty acids:  effect on insulin-mediated regulation of 
endothelium function and blood pressure 
FFA can influence insulin-mediated regulation of endothelium function and blood pressure 
homeostasis by affecting insulin‘s vascular actions (see Section 1.5.2; p. 22 and Figure 1.6; 
p. 24).  Herein, FFA promote serine phosphorylation of IR which leads to decreased tyrosine 
phosphorylation of IR by insulin (Morino et al., 2005) and subsequently reduced Akt and 
eNOS activation.   FFA also activate the renin-angiotensin-aldosterone system which 
increases angiotensin-II production (Jonk et al., 2007).  The latter induces a reciprocal rise in 
FFA while promoting serine phosphorylation of IR, independently of FFA, resulting again in 
decreased Akt and eNOS activation (Andreozzi et al., 2004). While decreased Akt activation 
leads to a decline in GLUT4 translocation, hence reduced glucose uptake and glycogen 
storage and subsequently insulin resistance (Morino et al., 2005), impaired eNOS activation, 
hence reduced NO production, induces endothelium dysfunction.  Activation of renin-
angiotensin-aldosterone system and angiotensin-II further exacerbate endothelium function 
by activating NADPH oxidase and ROS formation which then promote NO degradation to 
peroxynitrate (Doughan et al., 2007).  Angiotensin-II also activates MAPK pathway which 
results in raised endothelin-1 production (Mather et al., 2004).  This diminished NO 
bioavailability then leads to endothelium dysfunction and subsequently hypertension 
(Cleland and Connell, 2005). 
 
1.7.7 Free fatty acids:  effect on insulin-induced lipid metabolism 
In the case of dyslipidaemia, it is well recognised that the liver is the primary site of 
lipogenesis in the body and one of the main sources of lipids for adipocytes alongside dietary 
lipids (McTernan and Kumar, 2004).  Enhanced hepatic delivery of FFA results in increased 
generation of VLDL (Jensen, 2006). This situation is further exacerbated by excess synthesis 
of apolipoprotein B-100 in the liver, which stimulates the transfer of TG in exchange for 
cholesterol esters resulting in smaller and less dense HDL particles being produced 
(Lamarche et al., 1999; Rashid et al., 2002a; Jensen, 2006). These HDL particles are rapidly 
metabolised  leading to a drop in circulating HDL levels (Lamarche et al., 1999; Rashid et 
al., 2002b). Together these disturbances in lipid metabolism lead to the development of 
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dyslipidaemia characterised by elevated VLDL, LDL, and apolipoprotein B-100 and reduced 
HDL, and which acts as a major risk factor for development of CVD in overweight and 
obesity. 
 
1.8. Adipose tissue as an endocrine organ 
The concept of adipose tissue as a passive energy repertoire has long been debated  (Siiteri, 
1987) and it is now become increasingly recognised that adipose tissue is an active endocrine 
organ, that produces, and secrets a wide array of bioactive substances including 
inflammatory mediators (Tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6)) and 
adipokines (FFA, leptin, resistin, angiotensinogen, adiponectin) which act  as major 
pathophysiological determinants of insulin resistance (Trayhurn and Beattie, 2001; Kershaw 
and Flier, 2004; Trayhurn and Wood, 2004; Clarke and Mohamed-Ali, 2005; Trayhurn, 
2005; Trayhurn and Wood, 2005; Bastard et al., 2006). The role of FFA in obesity-induced 
insulin resistance has already been discussed while the association between TNF-α, IL-6, 
adiponectin, leptin and insulin resistance has been extensively reviewed (Trayhurn and 
Beattie, 2001; Kershaw and Flier, 2004; Trayhurn and Wood, 2004; Clarke and Mohamed-
Ali, 2005; Trayhurn, 2005; Trayhurn and Wood, 2005; Bastard et al., 2006).  Thus the 
present section focuses on evaluating the relation between cortisol metabolism and insulin 
resistance.  The focus on cortisol stems from the critical role played by this hormone in 
controlling short-term and long-term glucose metabolism, as well as in its potential role in 
regulating other inflammatory cytokines (DeRijk et al., 1997) and adipokines (Fallo et al., 
2004).  In vitro,  cortisol has been shown to reduce adipose tissue IL-6 release (Fried et al., 
1998), diminish adiponectin gene expression  (Degawa-Yamauchi et al., 2005) and secretion 
(Halleux et al., 2001) and, in conjunction with insulin, stimulate leptin release from 
adipocytes (Halleux et al., 1998; Kanu et al., 2003). Similar changes in circulating 
adiponectin levels have also been reported in vivo with endogenous cortisol overproduction 
or exogenous cortisol administration (Fallo et al., 2004). However, whether this effect occurs 
as a direct action of cortisol on adiponectin secretion remains to be clarified (Gavrila et al., 
2003).   Cortisol is also known to inhibit TNF-α release from macrophages (Swantek et al., 
1997) but not from adipose tissue (Sewter et al., 1999). The latter could carry important 
implications to obesity considering  that TNF-α is overexpressed in adipose tissue of obese 
insulin
 
resistant subjects (Kern et al., 2001) and is associated, alongside and other 
inflammatory mediators, with  enhanced adipose tissue inflammation (Wellen and 
Hotamisligil, 2003).  
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In recent years, the similarities between Cushing disease and abdominal obesity has opted 
several researchers to consider a role for excessive cortisol production in the pathogenesis of 
obesity and the metabolic syndrome (Andrews and Walker, 1999; Darmon et al., 2006). This 
subchapter summarises some of the key findings and provides evidence for considering 
attenuation of cortisol metabolism as a therapeutic target for treating obesity-related 
complications.  
 
1.8.1 Cortisol: role in insulin resistance and obesity related-
complications 
Cortisol is a hormone that is generally secreted from the adrenal cortex in response to 
hypothalamus-pituitary-adrenal axis (HPA) activation by inflammation, pain, infection and 
stress (Newton, 2000).  It is essential in the long-term maintenance of blood glucose, which 
is why it is often referred to as a glucocorticoid (Champe and Harvey, 1994).  Cortisol is also 
considered a counter-regulatory hormone because it opposes insulin‘s metabolic functions by 
decreasing glucose uptake and utilisation, reducing insulin secretion by β-cells, promoting 
gluconeogenesis in liver and increasing mobilisation of amino acids and fatty acids from 
skeletal muscle and adipose tissue (Rizza et al., 1982; Andrew and Walker, 1999; Newton, 
2000).  These counter-regulatory effects are very much characteristic of the changes in 
glucose metabolism observed in insulin-resistant states such as obesity (see Figure 1.8, p. 37 
and Section 1.4.4, p. 17) and which may explain why excess plasma cortisol is often 
associated with hyperinsulinaemia and hyperglycaemia (Rizza et al., 1982).  
 
In general, cortisol can induce insulin resistance by influencing both peripheral glucose 
metabolism and hepatic glucose production (Rizza et al., 1982) whereas withdrawal of 
cortisol, in humans, improves insulin sensitivity by raising glucose oxidation and reducing 
endogenous
 
glucose production (Christiansen et al., 2007).  In relation to peripheral glucose 
metabolism, cortisol can affect several stages of insulin-stimulated glucose uptake, including 
IR binding (Olefsky et al., 1975; Buren et al., 2002). In this respect, acute administration of 
dexamethasone, a cortisol analogue (Gotelli et al., 1981), in rats has been shown to attenuate 
insulin binding to its receptor in adipocytes and hepatocytes, with this inhibitory effect being 
maintained in hepatocytes but not in adipocytes with chronic dexamethasone administration 
(Olefsky et al., 1975).  However, according to Olefsky (1975), decreased IR binding is likely 
to occur secondary to corticosteroid-induced hyperinsulinaemia rather than as a direct 
consequence of corticosteroid administration.  Consistent with this, several authors have 
demonstrated that defects in post-receptor insulin signalling and GLUT4 translocation, and 
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not IR binding, constitute the most recognised abnormalities associated with excess cortisol 
(Rizza et al., 1982; Oda et al., 1995; Venkatesan et al., 1996). Consequently, in the 
hippocampus, cortisol prevents insulin-stimulated phosphorylation of the IR and reduces the 
expression of Akt and GLUT4 (Piroli et al., 2007).   Likewise, in adipose tissue, 
dexamethasone  impairs glucose uptake (Czech and Fain, 1972; Buren et al., 2002; Kawai et 
al., 2002; Ngo et al., 2009) possibly by reducing the levels of insulin signalling substrates 
IRS-1 and PKB and insulin-induced PKB activation (Buren et al., 2002; Buren et al., 2008).  
A 50% reduction in the phosphorylation of Akt substrate (AS160), responsible for 14-3-3 
recruitment and subsequent GLUT4 translocation, has also been reported with 
dexamethasone treatment of murine and human adipocytes (Ngo et al., 2009). This reduction 
occurs under both basal and insulin-stimulated conditions (Ngo et al., 2009) and is further 
reinforced by the observed decrement in the concentration of GLUT4 on plasma membrane 
of adipocytes following chronic dexamethasone administration (Oda et al., 1995). In 
contrast, administration of a glucocorticoid receptor antagonist, reverses dexamethasone-
induced alterations in AS160-T642 phosphorylation and restores glucose disposal by as 
much as 80% (Ngo et al., 2009).  Pre-incubation of adipocytes with dexamethasone can also 
promote the activity and membrane translocation of conventional PKC isozymes, PKCα and 
PKCβ, as well as the atypical PKC isozyme, PKCζ in adipose tissue (Ishizuka et al., 1995; 
Ishizuka et al., 1997; Kajita et al., 2000-2001; Kawai et al., 2002), all of which can promote 
ROS production which then enhances serine/threonine phosphorylation of IR leading to 
inactivation of IR (see Section 1.8.3 and Section 1.9.3). Importantly, parallel changes in PKC 
activity and translocation have been reported in skeletal muscle (Ishizuka et al., 1995; 
Ishizuka et al., 1997; Kajita et al., 2000-2001 ; Kawai et al., 2002) wherein dexamethasone 
have been shown to suppress basal, insulin- and IGF-stimulated glucose transport (Weinstein 
et al., 1995), despite unaltered (Oda et al., 1995; Venkatesan et al., 1996) or increased 
muscle GLUT4 concentrations (Coderre et al., 1996; Weinstein et al., 1998).  The 
consequence of such actions is then reflected in reduced ―sensitivity‖ of glycogenesis and 
glucose oxidation, but not glycolysis, to insulin (Dimitriadis et al., 1997).  Consistent with 
the latter, Buren et al. (2008) recently demonstrated that dexamethasone, in addition to 
reducing PKB expression and insulin-stimulated glucose uptake, can inhibit glycogenesis via 
downregulation of glycogen synthase activity.   
 
In the liver, excess cortisol abrogates insulin-stimulated suppression of glucose production 
(Rizza et al., 1982) possibly through upregulation of the activity of the rate limiting 
gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEP-CK).  Cortisol‘s lipolytic 
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(Buren et al., 2008) and proteolytic actions may also contribute to enhanced gluconeogenesis 
by increasing the supply of gluconeogenic substrates such as amino acids, non-esterified 
fatty acids (NEFA) and glycerol to the liver.  In this respect, cortisol has been shown to raise 
the concentration (Khani and Tayek, 2001) and plasma rate appearance of the amino acids: 
alanine, leucine and phenylalanine (Simmons et al., 1984; Brillon et al., 1995; Berneis et al., 
1997).  Likewise administration of cortisol have been reported to increase serum NEFA and 
glycerol concentrations in humans (Samra et al., 1998; Khani and Tayek, 2001) with  NEFA 
levels being positively correlated with the rate of gluconeogenesis in healthy subjects (Tayek 
and Katz, 1997; Katz and Tayek, 1998; Khani and Tayek, 2001)  and in diabetics (Tayek and 
Katz, 1996). 
 
 
 
Figure 1.9 Effects of glucocorticoids on peripheral glucose uptake and lipid metabolism 
(adapted from Andrews and Walker, 1999).  Note that cortisol increases lipolysis 
leading to enhanced availability of free fatty acids which then compete with pyruvate 
for mitochondrial oxidative metabolism (Randle’s effect).   Counter-regulatory actions 
of glucocorticoids are shown by grey arrows while insulin actions are shown by striped 
arrows.   
 
In addition to the above short-term regulatory functions of cortisol, cortisol can contribute to 
insulin resistance through its long-term regulation of energy intake and body weight.  
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Support for this concept could be derived from studies on adrenalectomized rats wherein, in 
contrast to insulin, glucocorticoids enhance the mRNA expression of neuropeptide Y in the 
hippocampus causing a subsequent rise in food intake and weight gain (Strack et al., 1995). 
In fact, the reciprocal actions of glucocorticoids and insulin were found to account for 50% 
of the variance in food intake and body weight (Strack et al., 1995). Chavez et al. (1997) 
have also observed that,  in adrenalectomized rats, the absence of circulating glucocorticoids 
increases the brain's sensitivity to insulin, and that insulin in the brain acts to lower food 
intake and body weight via a glucocorticoid receptor-dependent mechanism.   Similarly, 
Santana et al. (1995) documented that corticosteroids act to enhance energy acquisition 
through direct interaction with mineralocorticoid receptors and glucocorticoid receptors, and 
that insulin prevents this interaction.  Notably, dexamethasone or dexamethasone-stimulated 
insulin were shown to selectively maintain or increase body fat stores (Santana et al., 1995). 
This enhanced fat accumulation appears to affect visceral fat depots to a greater extent than 
peripheral fat depots (Burt et al., 2007; Seckl et al., 2004) which when considering the role 
of visceral fat in supplying hepatic FFA via the portal vein could have important 
implications to obesity-associated insulin resistance (Section 1.7.3).  Cortisol also increases 
protein catabolism and oxidation (Burt et al., 2007) which can result in an unfavourable 
body composition such as is observed in Cushing‘s disease (Burt et al., 2006) while 
treatment of cortisol excess reduces energy intake and reverses changes in body composition 
(Pirlich et al., 2002; Wang et al., 2006).   
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1.8.2 Regulation of cortisol activity: role of 11β-hydroxysteroid 
dehydrogenase type-1 and type II 
Several enzymes are involved in the metabolism of cortisol (Figure 1.10). In particular, the 
interconversion of active cortisol to inactive cortisone is regulated by two isozymes: 11β-
hydroxysteroid dehydrogenase type 1 (11βHSD1) and type 2 (11βHSD2). These isozymes 
are products of distinct genes and consequently they differ in their physiological functions 
and tissue distribution which has important implications to determining tissue cortisol 
metabolism and activity (Stewart and Krozowski, 1999).  11βHSD1 was the first of the two 
isoforms to be discovered by Amelung et al. (1953) who demonstrated that incubation of 
cortisone with liver homogenates, particularly liver microsomes, yields cortisol.  
Interestingly, Amelung et al. (1953) also observed that addition of cortisone to kidney 
produced negative values for cortisol.  This observation went on to be explained by the 
presence of another 11βHSD isozyme in the kidney: 11βHSD2.  This isozyme was first 
purified by Brown et al. (1993) from human placenta and subsequently its gene coding was 
isolated from kidney, placenta and other aldosterone target tissues including salivary glands 
and reproductive tissues (Agarwal et al., 1994; Albiston et al., 1994).  
 
 
Figure 1.10  Regulation of cortisol metabolism by various reductases and 
dehydrogenases (N’Gankam et al., 2002). 
 
 
As shown in Figure 1.10, 11βHSD1 is a bidirectional enzyme that acts predominantly as a 
reductase converting inactive cortisone to active cortisol.  It is found in the liver and adipose 
tissue although recent studies have also identified its presence in the endothelium, brain and 
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central nervous system (Seckl and Walker, 2001).  Selective inhibition of 11βHSD1 
produces knock-out mice that have reduced mRNA expression of PEP-CK and glucose-6-
phosphate and are subsequently protected against obesity- or stress-induced hyperglycaemia 
and hyperinsulinaemia (Kotelevtsev et al., 1997; Holmes et al., 2001; Alberts et al., 2002; 
Alberts et al., 2003).  These 11βHSD1 knock-out mice also show improved lipid and 
lipoprotein profile (Morton et al., 2001).  In general, the activity of 11βHSD1 is determined 
by the availability of the substrate: cortisone (Seckl and Walker, 2001; Seckl et al., 2004), 
which is supplied by the activity of 11βHSD2 in the kidney (Whitworth et al., 1989) (see 
Figure 1.11).  Unlike cortisol, cortisone does not show a diurnal rhythm and is mainly found 
in its free form (Dunn et al., 1981) in concentrations as high as 50-100nmol/l (Walker et al., 
1992; Seckl and Walker, 2001; Seckl et al., 2004).  In contrast, plasma cortisol 
concentrations fluctuate between 1nmol/l and 100nmol/l through the day (Seckl and Walker, 
2001) and although concentrations could reach 400-600nmol/l during diurnal peak (Seckl et 
al., 2004), this cortisol is physiologically inactive since 90-95% of it is bound to 
corticosteroid-binding globulin (Dunn et al., 1981; Mendel, 1989). 
 
 
 
  
 
Figure 1.11  Contrasting influence of 11β-hydorxysteroid dehydrogenase type 1 and 
type 2 (11βHSD1 and 11βHSD2) on cortisol sensitivity in liver and kidney (Andrews 
and Walker, 1999).  Note how the activity of 11βHSD2 in the kidney protects against 
the mineralocorticoid effects of cortisol and supplies cortisone for 11βHSD1 in the liver.  
 
 
In contrast, 11βHSD2 is a unidirectional enzyme that acts solely as a dehydrogenase.  It is 
mainly found in the placenta and kidney where it confers aldosterone-specificity to 
mineralocorticoid receptor by reducing intracellular cortisol concentrations (Funder, 2005) 
(Figure 1.11).  This inhibitory action is important when considering that cortisol has a higher 
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affinity to mineralocorticoid receptor than aldosterone (Funder, 2005) and that even 
following 90% inhibition by 11βHSD2, cortisol levels remain 10-fold higher than those of 
aldosterone, while mineralocorticoid receptor continues to be occupied but not necessarily 
activated by cortisol (Funder and Myles, 1996; Funder, 2005).  In general defects in 
11βHSD2 activity promote the formation of cortisol- mineralocorticoid receptor complexes 
which produces symptoms of mineralocorticoid excess characterised by hypertension, 
sodium retention and enhanced urinary potassium excretion (Holmes et al., 2001; Seckl et 
al., 2004).   
 
 
1.8.3 Cortisol metabolism in obesity 
 
In obesity, particularly abdominal obesity, several alterations in cortisol metabolism are 
observed (see Table 1.3).  For instance, abdominally obese women have lower awakening 
salivary cortisol compared to peripherally obese women (Duclos et al., 2005).  This 
association between morning salivary cortisol and WHR is solely attributed to fat 
distribution and not BMI or total fat mass (Duclos et al., 2005).  There is also evidence of 
increased peripheral metabolism of cortisol, as evident by increased urinary cortisone-to-
cortisol ratio in abdominally obese women (Duclos et al., 2005).  Moreover, obese women 
show greater postprandial hypercortisolism which according to Duclos et al. (2005) may 
exacerbate insulin resistance due to glucocorticoids‘ counter-regulatory actions.  This is 
evident in that obese women, particularly those with abdominal fat distribution, show higher 
fasting insulin and homeostasis-model assessment of insulin resistance (HOMA-IR) than 
lean women, with a significant correlation being present between cortisolAUC, fasting insulin 
and HOMA-IR (Vicennati and Pasquali, 2000).    
 
Although the basis of hypothalamic-pituitary-adrenal axis  hyperactivity in obesity remains 
unknown (Walker, 2006), some evidence exists from  cross-sectional studies conducted by 
Barker and colleagues which suggest that low birth weight  and intrauterine programming of 
HPA can predict fasting cortisol concentrations in adults (Phillips et al, 2000).  In fact, 
intrauterine programming have been hypothesised to be the underlying mechanism linking 
low birth weight with the insulin resistance syndrome (Phillips et al, 1998).   This is evident 
in that variations in fasting cortisol concentrations even within the normal range can strongly 
predict changes in blood pressure, fasting glucose, glucose tolerance, insulin resistance and 
TG levels (Phillips et al, 1998).   
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Numerous changes in the gene expression and activity of enzymes that control the inter-
conversion of active cortisol to inactive cortisone have also been reported in obesity.  These 
changes are tissue-specific and differ between adipose, renal and liver tissues.  For instance, 
11βHSD1 gene expression is increased in obese men and women‘s adipose tissue, suggesting 
increased conversion of cortisone to cortisol (Paulsen et al., 2007).  This abnormality is more 
prominent in women than in men indicating that obese women are at a higher risk of 
developing cardiovascular-related diseases than obese men (Paulsen et al., 2007).  
Subcutaneous adipose tissue 11βHSD1 mRNA levels are also significantly higher in subjects 
with metabolic syndrome and type II diabetes compared with non-obese subjects or those 
with impaired or normal glucose tolerance, this being related to increased fasting glucose, 
urinary free cortisol, adiponectin, TNF-α and decreased serum adiponectin levels (Alberti et 
al., 2007).  Increased 11βHSD1 activity is known to impair glucose-stimulated insulin 
secretion (Ortsater et al., 2005), all of which confirms cortisol‘s central role in the 
pathophysiology of insulin resistance in obesity.  It is noteworthy, however, that insulin, 
itself, could influence cortisol by inhibiting 11βHSD1 activity (Jamieson et al., 1995) at the 
level of 11βHSD1 gene transcription or by inhibiting TNF-α‘s stimulatory effects on 
11βHSD1 (Handoko et al., 2000). Moreover, several factors that are implicated in impairing 
insulin‘s metabolic functions in obesity are also involved in regulating cortisol actions.  This 
is evident in the afore-mentioned Randle‘s hypothesis wherein excess FFA and 
hyperglycaemia raise NADPH/NADP ratio and glucose-6-phosphate which can then 
stimulate 11βHSD1 activity via mechanism that will be described later (see Section 1.11.7, 
p. 98 and Figure 1.20, p. 101). 
 
Hypercortisolaemia carries several implications to obesity.  First, hypercortisolaemia in the 
presence of insulin resistance can promote TG accumulation in adipose tissue via 
enhancement of the expression of LPL which consequently leads to weight gain (Ottosson et 
al., 1994).  Second, cortisol can modulate the activity of several enzymes involved in lipid 
metabolism. As such, increased postprandial cortisol excretion in obesity is inversely 
associated with HDL (Duclos et al., 2005) whereas 11βHSD1‘s absence, hence reduced 
cortisol, is linked to increased HDL and reduced TG, an effect mediated by increased hepatic 
expression of carnitine palmitoyltransferase and acetyl-CoA (Morton et al., 2001).  Third, 
excess cortisol also influences blood pressure and obese hypertensives are often 
characterised by raised late-night and early morning salivary cortisol (Kidambi et al., 2007).  
Last, and as mentioned earlier, cortisol regulates glucose metabolism.  It is, thus, 
unsurprising why obesity and the metabolic syndrome are often associated with 
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hypercortisolaemia and hyperinsulinaemia (Bjorntorp, 1996; Björntorp and Rosmond, 2000; 
Ferrannini et al, 2007) and why several authors have placed defects in cortisol metabolism at 
the centre of obesity-related complications (Phillips et al, 1998, 2000).  This could be further 
exemplified when considering that some of the disturbances in lipid metabolism induced by 
cortisol form the basis for excess FFA generation which then affects insulin-mediated 
regulation of blood pressure, glucose and lipid profile.  Additional support could be gained 
from observations that demonstrate that when present in relatively high concentrations, 
cortisol induces hypertension, atherosclerosis and diabetes mellitus via enhanced ROS 
production (see Figure 1.12, p 54).  The excess ROS could be generated as a result of 
cortisol‘s ability to reduce the expression of guanidine triphosphate-cyclohydrolase, the rate 
limiting enzyme regulating tetrahydrobiopterin (BH4) production (Johns et al., 2001).  This 
results in diminished BH4 levels (Bjelaković et al., 2007) which causes a rise in superoxide 
generation by eNOS (Kawashima, 2004). Increased ROS production then leads to impaired 
endothelium function and subsequent deterioration in blood pressure (Johns et al., 2001) and 
insulin sensitivity (Houstis et al, 2006). Glucocorticoids can also affect endothelium function 
via modulation of the bioavailability of NO.  Herein, glucocorticoids have been shown to 
influence the activity of eNOS, the availability of the NO substrate, L-arginine, and the co-
factor NADP(H) (Whitworth et al., 2002).  Both glucocorticoid receptor protein and mRNA 
as well as the two 11βHSD(1-2) isozymes have been identified in endothelial and smooth 
muscle cells (Yang and Zhang, 2004) where they have been shown to regulate the degree of 
decrement in eNOS expression induced by cortisol (Liu et al., 2009).   
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Table 1.3 Summary of endocrinological disturbances in overweight and obesity 
 
Study Study population Disturbances in cortisol metabolism 
Pasquali 1993 Abdominally obese vs. 
Peripherally obese 
↑24-h urinary free cortisol 
Andrews et al 
1998 
Obese men and women ↑24-h cortisol 
↑11βHSD1 
↑5α-reductase 
↑THF/THE in obese men vs lean men and 
in women vs men 
=11βHSD2 
Rosmond 1998 Abdominally obese men ↓ diurnal cortisol variation   
   
   
Duclos 1999 Abdominally obese vs. 
Peripherally obese women 
=plasma cortisol 
↓salivary post- overnight dexamethasone 
cortisol 
=24-h urinary free cortisol 
↑Overnight urinary free cortisol 
Stewart 1999 Abdominally obese vs. 
Peripherally obese 
=morning cortisol and cortisone 
↓11 βHSD1 
↑5ß-reductase 
=11ßHSD2 
= urinary free cortisol-to-cortisone ratio 
= urinary free cortisol 
↑urinary cortisol metabolites 
↑cortisol clearance 
Impaired cortisol→cortiosne conversion 
Rask 2002 Overweight and obese vs. Lean 
females 
↑11βHSD1 in adipose tissue 
↓11βHSD1 in liver 
↑urinary cortisol metabolites 
↑ cortisol clearance 
Purnell 2004 Healthy men and women with a 
wide range of BMI 
↑24-h cortisol production 
↑24-h plasma free cortisol in obesity 
Duclos 2005 Abdominally obese vs. 
Peripherally obese 
↓morning salivary cortisol 
  ↑ 24-h plasma free cortisol  
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1.9. Oxidative stress, insulin resistance and obesity 
1.9.1 Obesity and oxidative stress 
 Obesity is characterised by systemic oxidative stress (Keaney et al., 2003) and increased 
plasma (Olusi, 2002) and intramuscular lipid peroxidation (Russell et al., 2003) with a direct 
correlation being present between excess body fat, as determined by BMI, WHR and WC, 
and markers of oxidative stress including plasma thio-barbituric acid-reactive 
substances (TBARS) and urinary 8-epi-prostaglandin F2α (Keaney et al., 2003; Furukawa et 
al., 2004).  Since oxidative stress is also commonly associated with other pathologies such as 
insulin resistance, hypertension and CVD, several researchers have hypothesised that 
oxidative stress might be the underlying mechanism linking obesity with insulin resistance 
and the cardinal features of the metabolic syndrome (Keaney et al., 2003; Furukawa et al., 
2004).   However, before proceeding to discussing the relation between obesity and oxidative 
stress, it is necessary to define oxidative stress. 
 
Oxidative stress is a condition arising from an imbalance between oxidant and antioxidants 
leading to excess production of ROS. ROS are natural by-products of mitochondrial 
electron-transport chain reactions. They can be classified into six species: Superoxide anion 
(O2.-), hydrogen peroxide (H2O2), peroxyl radical (ROO.), hydroxyl radical (HO.), singlet 
oxygen (1O2) and peroxynitrite (ONOO-) (Huang et al., 2005).   The presence of an unpaired 
electron in the structure of ROS renders them highly unstable (Baskin and Salem, 1997).  In 
an attempt to stabilise this odd electron, ROS react readily with other adjoining substances 
such as nucleic acids, proteins and lipids, by abstracting a hydrogen atom from these  
molecules (Baskin and Salem, 1997).  ROS can also react with oxygen to form a peroxyl 
radical (Baskin and Salem, 1997).  In the case of membrane lipids, ROS can abstract a 
proton from a polyunsaturated fatty acid molecule which produces an unstable lipid radical  
that reacts with oxygen forming a lipid peroxyl radical (Biesalski and Grimm, 2005).  
Because this radical is equally unstable, it can propagate a chain of  reactions which if not 
terminated can lead to cellular damage (Biesalski and Grimm, 2005).  Under normal 
physiological conditions, the body can control the production  of ROS through a variety of 
mechanisms that involve both endogenous and exogenous antioxidants (Biesalski and 
Grimm, 2005).  However under pathological conditions, excess production of ROS 
overcomes the body‘s natural defence mechanisms leading to oxidative stress. 
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Much remains to be elucidated as to whether obesity per se causes oxidative stress.  
Although the work of Keaney et al. (2003) and others demonstrates a strong independent 
correlation between markers of adiposity, BMI and WHR and oxidative stress, Higdon and 
Frei (2003) argue that the presence of other metabolic risk factors alongside obesity can 
confound any true effect of obesity.   Similar inferences could be made in  relation to the 
association between obesity, oxidative stress and insulin resistance.   Herein, oxidative stress 
has been found to predict insulin resistance independently of BMI, suggesting that oxidative 
stress might act through mechanisms other than those related to excess body fat to promote 
insulin resistance  (Meigs et al., 2007).  Nonetheless,  the combination of obesity and 
oxidative stress was found to correlate with the highest levels of insulin resistance implying 
that certain features of the obese state could have a cumulative effect on ROS-induced 
insulin resistance (Meigs et al., 2007).  Indeed in obesity several factors could interact to 
promote ROS overproduction.  For instance, angiotensin-II and TNF-α stimulate the activity 
of NADPH oxidase in the vascular endothelium which can enhance the formation of 
superoxide anion and H2O2 (Griendling et al., 1994; Frey et al., 2002; Li and Shah, 2003).  
Angiotensin-II can also promote lipid peroxidation within macrophages by increasing 
oxidised-LDL uptake by macrophages (Keidar et al., 2001).  Likewise, hyperinsulinaemia 
which is characteristic of the first stages of insulin resistance can increase H2O2  generation 
in adipocytes via a G-protein coupled mechanism involving NADPH oxidase (Krieger-Bauer 
et al., 1997), while hyperglycaemia which precedes the  pre-diabetic state upregulates 
NADPH-dependent H2O2  production in adipocytes via a PKC dependent mechanism (Talior  
et al., 2005).  The impact of FFAs and cortisol on ROS production has already been 
discussed in Sections1.7.6 and 1.8.3.  
 
1.9.2 Oxidative stress as the cause of insulin resistance  
Each of the above factors can, in turn, induce insulin resistance via excessive ROS 
production as summarised in Figure 1.12.  It could thus be postulated that oxidative stress is 
one of the underlying and unifying pathologies linking obesity with insulin resistance and 
other metabolic risk factors. This hypothesis has been proposed by numerous reviewers 
including Eriksson (2007)  and Grattagliano et al. (2008)  who have argued that 
hyperglycaemia, inflammation and other endocrine determinants such as angiotensin-II and 
adipokines share ROS production as a common pathway propelling insulin resistance.  
However, what could be the primary source of oxidative stress in obesity? 
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Figure 1.12 Oxidative stress as a unifying pathway leading to insulin resistance and 
endothelium dysfunction (Eriksson, 2007). 
 
 
Some evidence exists to suggest that in obesity dysregulation of the redox state at the level 
of adipocytes lies at the heart of systemic oxidative stress. This entails that local impairments 
in adipose tissue can progress to cause systemic effects.  Support for this hypothesis stems 
from findings showing that overexpression of NADPH oxidase in adipocytes is accompanied 
with elevated plasma markers of lipid peroxidation (Furukawa et al., 2004). Furukawa et al. 
(2004) explained this link by suggesting that excess ROS from fat cells can be secreted into 
blood circulation triggering a systemic rise in ROS levels which, in turn, induces insulin 
resistance in skeletal muscle, liver, pancreas and adipose tissue itself.  These organ-specific 
dysregulations in insulin reactivity then manifest as systemic insulin resistance, a mechanism 
consistent with the well-established effects of increased adipose tissue mass, summarised 
earlier in Figure 1.8.  Interestingly, it is this exact increase in adipose tissue mass that  is 
thought to activate the over-expressed NADPH oxidase causing ROS overproduction  
(Furukawa et al., 2004).  The latter could, in turn, promote NADPH oxidase expression 
through a positive feedback mechanism (Dana et al., 1998; Levy et al., 2000).  In addition to 
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NADPH expression, macrophage infiltration into the stromavascular region of white adipose 
tissue has been implicated in the loss of redox balance in adipocytes (Weisberg et al., 2003, 
Xu et al., 2003).  Here, accumulated macrophages have been shown to activate a number of 
inflammatory pathways in adipose tissue leading to excess ROS production and the loss of 
adipose tissue endocrine function (Weisberg et al., 2003).  Importantly, the loss of endocrine 
function presented as adipokine dysregulation and reduced adiponectin expression in 
adipocytes, appears to, in turn,  promote  macrophage infiltration, thereby creating a vicious 
cycle of raised ROS production (Xu et al., 2003; Cancello et al., 2006).  It is important to 
note that macrophage infiltration occurs only after the expansion of adipose tissue suggesting 
that adipose tissue mass is an important determinant of the degree of macrophage influx 
(Weisberg et al., 2003).  Accordingly, adipose tissue from obese humans has been estimated 
to contain up to 5 times more macrophages than adipose tissue from lean individuals 
(Weisberg et al., 2003).   This might also imply that an initial trigger in adipose tissue might 
induce ROS production which in themselves can attract  macrophage into the adipocytes 
(Furukawa et al., 2004).  In this perspective, overfeeding and excess influx of energy 
substrates such as glucose and FFA  might play an important role since both these 
mechanisms are known to activate NADPH oxidase and increase ROS via the mitochondria 
chain reaction (Ceriello and Motz, 2004;  Ceriello, 2006). The molecular mechanism by 
which glucose in particular upregulates NADPH oxidase has been identified and appears to 
involve a PKCδ-dependent pathway (Talior et al., 2005).  Regardless, of the cause of 
oxidative stress in adipose tissue, consistent evidence from cross-sectional studies is 
emerging which suggests a strong correlation being present between excess fat mass, 
especially visceral fat, and systemic oxidative stress as measured by plasma  and urinary 
isoprostane concentrations, as well as systemic stress and insulin resistance(Keaney et al., 
2003, Urakawa et al., 2003, Pou et al., 2007).
   
 
1.9.3 Mechanisms of oxidative stress-induced insulin resistance and 
obesity-related complications 
Eriksson (2007) summarises the mechanism by which ROS induces insulin resistance to 
include: activation of stress kinases, injury to cellular proteins, lipid membranes, 
endoplasmic reticulum and DNA.  With the former, serine/threonine phosphorylation of IRS 
proteins is increased leading to diminished insulin signalling (Xu et al., 2003, Eriksson, 
2007). When this effect occurs at the level of adipose tissue, lipolysis could be induced 
resulting in excess FFA efflux into the circulation (Xu et al., 2003). The latter could then 
trigger systemic insulin resistance through mechanism described in Section 1.7.2. 
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Importantly, in obesity adipose tissue appear to be more susceptible to H2O2-induced 
impairment in insulin signalling compared to skeletal muscle, an effect attributed to the rapid 
removal of ADP from adipocytes, which seems to amplify the effect of H2O2- (Schmitt et al., 
2005).  Interestingly, the loss of adipose tissue redox balance and endocrine function as a 
result of macrophages infiltration could also lead to a similar impairment in insulin 
signalling  in adipocytes (Xu et al., 2003) implying again that dysregulation at the level of 
adipocytes could induce systemic insulin resistance, which in turn  explains why Xu et al. 
(2003) observed that  macrophage infiltration is closely correlated with insulin resistance.  
Since adiponectin also controls some of the gene involved in FFA oxidation (Yamauchi et 
al., 2001, Thamer et al., 2002), dysregulation of adipose tissue endocrine function by 
oxidative stress  can  promote intramyocellular lipid accumulation and subsequent insulin 
resistance as well as promote  macrophage-to-foam cell transformation, hence 
atherosclerosis (Ouchi et al., 2001).  These direct and indirect mechanisms of ROS action 
make it  unsurprising why ROS have been implicated in the development of multiple forms 
of insulin resistance (Houstis et al., 2006) and in the pathogenesis of hypertension and CVD 
(Ohara et al., 1993; Ceriello and Motz, 2004; De Champlain et al., 2004).   
 
In addition to this, ROS have been implicated in impaired insulin secretion from pancreatic 
β-cells (Piro et al., 2002; Newsholme et al., 2009) and glucose transport and uptake into 
skeletal muscle (Bitar et al., 2005) and adipose tissue (Rudich et al., 1998; Tirosh et al., 
1999).  ROS are also though to induce vascular damage via increased lipid peroxidation in 
macrophages, lipoproteins and cell walls leading to endothelium dysfunction, hypertension 
and CVD (see Keidar et al., 2004), a mechanism that could in turn affect insulin‘s 
glucoregulatory functions by opposing the latter‘s vascular action.  This latter mechanism, in 
particular, has led to the development of the common soil hypothesis which places oxidative 
stress at the centre of the insulin resistance-endothelium dysfunction link (Ceriello and Motz, 
2004).   
 
Oxidative stress can also influence insulin actions indirectly via its effects on lipid 
metabolism.  To illustrate, apolipoprotein-E is a protein expressed in a variety of tissues 
involved in lipid metabolism such as  macrophages, liver, muscle and adipose tissue.  Its 
function consists of promoting the uptake of lipids from TG-rich lipoproteins and their 
subsequent influx into the above mentioned cells.  In obesity, there appears to be a reduction 
in adipocytes apolipoprotein-E expression (Espiritu and Mazzone, 2008).  This reduction 
hinders the adipocytes‘ buffering capacity leading to a shift in lipid storage from adipocytes 
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to the liver and skeletal muscle.  Interestingly, antioxidants have been shown to reverse this 
effect by upregulating adipocyte apolipoprotein-E expression (Espiritu and Mazzne, 2008).  
Moreover, antioxidants that act via blockade of angiotensin-II and NADPH oxidase in 
adipose tissue have been shown to reduce ROS generation from fat-overloaded adipose 
tissue, implying an important role for antioxidants and angiotensin-II inhibitors in the 
prevention of atherosclerosis and CVD in the metabolic syndrome (Kurata et al., 2006).  
Likewise, treatment with NADPH oxidase inhibitors has been demonstrated to diminish 
TNFα expression, improve adiponectin expression in white adipose tissue, and reduce 
subsequent hyperinsulinaemia, hyperglycaemia, hypertriglyceridaemia and hepatic steatosis 
(Furukawa et al., 2004).  Dietary approaches aimed at increasing antioxidant intake in the 
overweight and obese population have also been shown to successfully lower blood pressure 
by counteracting  dyslipidaemia –induced oxidative stress (Lopes et al., 2003).  Together the 
above evidence, confirms the importance of maintaining redox balance in overweight and 
obesity and the need for adequate antioxidant intake to prevent oxidative stress-induced 
complications.     
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1.10. Polyphenols 
1.10.1 Definition 
Polyphenols are a group of antioxidants characterised by the presence of several hydroxyl 
groups on an aromatic ring (Manach et al., 2004).  Their importance stems from their 
abundance in the diet, their antioxidant properties and ability to regulate various 
biological/biochemical processes (Manach et al., 2004).  Over the last decade, polyphenols 
have been implicated in the prevention of a number of oxidative-related diseases including 
CVD, hypertension and diabetes. These antioxidants occur largely in plant and plant-derived 
products and are extensively involved in plant defence mechanisms (Manach et al., 2004).  
They are often categorized into 4 groups depending on the number of phenol rings embodied 
in their structure and the elements that bind these rings together (Manach et al., 2004).  
Distinction is hence made between phenolic acids, flavonoids, stilbenes and lignans (Scalbert 
and Williamson, 2000, Manach et al., 2004).  So far, thousands of polyphenols have been 
identified in the diet (DeLogeril and Salen, 2007) and the average dietary intake of these 
plant-products is estimated to be in the range of 1g/ d (Scalbert and Williamson, 2000; 
Saura-Calixto and Goñi, 2006). Nevertheless, the maximum plasma concentration of 
polyphenols  rarely exceeds 1μM following ingestion of 10-100 mg of a single phenolic 
compound (Scalbert and Williamson, 2000).  As a consequence, only a minority of these 
compounds are of therapeutical value. In fact, the  structural diversity of polyphenols implies 
differences in bioavailability and subsequent biological activity of these compounds which 
means that the most abundant polyphenols in the diet are not in effect the most biologically 
active (Scalbert and Williamson, 2000, Manach e al, 2004).  It is, thus,  empirical to 
differentiate between the different structures, bioavailabilities and consequent biological 
activities of these compounds in order to identify the most relevant polyphenols to health.  
 
1.10.2 Main classes 
1.10.2.a Phenolic acid 
Phenolic acids are deemed to be the most basic class of polyphenols because they only 
contain one phenol ring (Bagchi and Preuss, 2007).  Phenolic acids could be classified into 
derivatives of hydroxybenzoic acid and hydroxycinnamic acids (Manach et al., 2004) as a 
function of the degree of hydroxylation and methylation of the phenol ring (Bagchi and 
Preuss, 2007) (see, Figure 1.13).   
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Hydroxybenzoic acids 
 
 
Hydroxycinnamic acids 
 
Figure 1.13 Basic chemical structure of hydroxybenzoic and hydoxycinnamic acids 
showing the single phenol ring and different degrees of methylation (Manach et al., 
2004). 
 
 
Hydroxybenzoic acids are less commonly found in the diet than hydroxycinnamic acids, 
although both phenolic acids can exist in a free or an esterified form in the diet (Manach et 
al., 2004).  The most representative monomer of the hydroxybenzoic acid class is gallic acid 
(GA) (Manach et al., 2004).  Other examples include ellagic acid, ellagitannins; which are 
dimers or polymers of GA, respectively (Manach et al., 2004), and gallotannins.  
Ellagitannins and gallotannins are also called hydrolysable tannins (Manach et al., 2004).  
GA is found predominantly in tea (Tomas-Barberan and Clifford, 2000) while ellagic acid is 
present in pomegranate and certain varieties of berries (Amakura et al., 2000).  Cloudberry, 
raspberry, rose hip, strawberry, and sea buckthorn, on the other hand, are important dietary 
sources of ellagitannins (Koponen et al., 2007).  In general, hydroxybenzoic acids, with the 
exception of GA and ellagic acid (Tomas-Barberan and Clifford, 2000), do not contribute 
largely to total polyphenol intake and their dietary burden does not exceed 5mg/d (Clifford 
and Scalbert, 2000).    
 
Hydroxycinnamic acids include caffeic, ferulic, sinapic and p-coumaric acids (Clifford, 
2000).  These hydroxycinnamic acids rarely exist in their free form and are almost always 
esterified with other compounds yielding a range of caffeoyl, feruloyl and other trans-
cinnamic esters (Scalbert and Williamson, 2000).  When the latter esters combine with 
quinic acids, they produce caffeoylquinic (CQA), feruloylquinic or coumaroylquinic acids, 
which collectively are known as chlorogenic acids (Clifford, 1999).   5-O-CQA is the most 
renowned caffeoylquinic ester found in the diet (Clifford, 1999).  It is present in high 
concentrations in green coffee beans (Suzuki et al., 2002) and other food products (see Table 
7.6, p. 305) and is thus often referred to in the literature as chlorogenic acid (CGA).  To 
avoid confusion, the term chlorogenic acid will be used in the present thesis as synonymous 
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to the total CGA isomers found in a food product while the most predominant CGA will be 
referred to by its chemical  name; 5-O-caffeoylquinic acid.  CGA, particularly 5-CQAs, are 
predominantly present in coffee, blueberries, apples and ciders (Clifford, 1999) with coffee 
being  the chief dietary source of 5-CQA supplying 50-150mg 5-CQA per 200ml instant 
brew (2% w/v) (Clifford, 1999).   Based on the dietary consumption patterns from British 
National Diet and Nutrition Survey (NDNS) (2002), coffee alongside apples and pears could 
be considered amongst the most important sources of hydroxycinnamates in the average 
British diet. 
 
 
 
Figure 1.14 Chemical structure of 5-O-caffeoylquinic acid (Scalbert and Williamson, 
2000). 
 
 
 
1.10.2.b Flavonoids 
Flavonoids are phenolic compounds with 2 aromatic rings (A and B) that are linked together 
by an oxygenated heterocycle consisting of 3 carbon atoms (ring C) (Manach et al., 2004).  
They could be classified into 6 subclasses; flavonols, flavones, isoflavones, flavanones, 
anthocyanidins and flavanols (catechins and proanthocyanidins), depending on the 
characteristics of ring C (Manach et al., 2004).  Flavan-3-ols are found primarily in cocoa, 
dark chocolate, green tea, apricots, black and red grapes and their products (USDA, 2007a). 
They exist as monomers (Catechin, epicatechin, epicatechin gallate, gallocatechin and 
epigallocatechin) or proanthocyanidins (Figure 1.15).  Catechin and epicatechin are the main 
monomers found in cocoa and dark chocolate, while epicatechin gallate, gallocatechin, 
epigallocatechin are the main monomers in grapes and tea (Arts et al., 2000).   
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epicatechin 
 
 
catechin 
 
Procyanidin dimer (4β-6) 
 
Procyanidin dimer (4β-6) 
 
Procyanidin trimer (4β-8) 
 
Figure 1.15 Chemical structure of epicatechin, catechin and procyanidin dimers and 
trimers (Hammerstone, 2000; Scalbert and Williamson, 2000; Ariefdjohan and 
Savaiano, 2005). 
 
 
Proanthocyanidins are dimers, oligomers and polymers of catechins (Bagchi and Preuss, 
2007) bound together by links between C4 and C8 (or C6) (Hammerstone et al., 2000, 
Manach et al., 2004) (Figure 1.15).  They are also referred to as condensed tannins because 
they possess the ability to precipitate proteins from aqueous solution (Bagchi and Preuss, 
2007).  More precisely, proanthocyanidins form complexes with salivary protein which then 
account for the astringent taste of chocolate and certain fruits (grapes, peaches, kakis, apples, 
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pears, berries) and beverages (Manach et al., 2004).  Chocolate constitutes the major source 
of proanthocyanidins, although the proanthocyanidins content of certain varieties of apples, 
including Granny Smith and Red Delicious apples could exceed that of chocolate on mg per 
portion basis (Hammerstone et al., 2000). 
 
1.10.2.c Lignans 
Lignans are dimeric compounds consisting of two phenylpropane units (Manach et al., 2004, 
D‘Archivo et al., 2007) bound by the central carbon (C8) of their side chains (Umezawa, 
2003) (Figure 1.16).  They are found in lignified tissues, seeds and roots (Lamblin et al., 
2008).  The main source includes flaxseed and flaxseed oils, although other dietary sources 
such as cereals, oilseeds and nuts have recently been identified (Smeds et al., 2007).   They 
are transformed in the intestines to mammalian lignans (Smeds et al., 2007) which posses 
oestrogen agonist and antagonist properties (Scalbert and Williamson, 2000).  Lignans have 
thus recently been implicated in cancer prevention (Lamblin et al., 2008). 
 
1.10.2.d Stilbenes 
Stilbenes are the least common polyphenols in the diet.  The main representative is 
resveratrol, a stilbene found in wine (Figure 1.16). 
 
 
lignan 
 
 
resveratrol 
 
 
Figure 1.16 Chemical structure of lignans showing the two phenylpropane units and 
the main stilbene, resveratrol (Manach et al., 2004). 
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1.10.3 Importance of studying hydroxycinnamic acid and flavonoids 
The nutritional/biological importance of hydroxybenzoic acids, lignans and stilbenes is 
restricted by the relatively low prevalence of these compounds in the diet. Consequently 
protective effects cannot be achieved though dietary intake (Manach et al., 2004).  Phenolic 
acids (hydroxycinnamic acids) (Manach et al., 2004) and flavonoids, on the other hand, are 
widely distributed in the diet (Scalbert and Williamson, 2000) and could, hence, play an 
important role in preventive nutrition which aims at promoting health and preventing 
diseases. 
 
1.10.3.a Chocolate and coffee: Contribution to polyphenol and antioxidant intake in the 
western diet  
Cocoa and coffee are examples of food products rich in flavonoids and hydroxycinnamic 
acids, respectively.   They are also amongst the most widely consumed food commodities 
worldwide.  In the past few years, world cocoa consumption has witnessed a continuous 
annual growth of 2.9% (ICCO, 2008), while the average per capita world consumption of 
coffee has increased from 66153 in 1980s to 81003 in 2000-2003 (ICO, 2004) with  more 
than two-thirds of the world‘s population consuming coffee (ICO, 2006).  Because of their 
popularity, both cocoa and coffee possess the potential to play a central role in promoting 
health.  Consequently minor changes in their processing methods could have major health 
implications.   
 
Chocolate is an important purveyor of dietary antioxidants both in Europe and US.  In the 
US, chocolate is estimated to be the third dietary source of polyphenols after coffee and tea 
providing on average 100mg phenolics per day (Vinson et al., 2006).  In the Dutch 
population, on the other hand, chocolate has been shown to supply 20% of total catechin 
intake compared to tea which provides 55% of dietary catechins (Arts et al., 1999).  In the 
UK, no studies have as yet estimated the average polyphenol intake in the British diet 
making it difficult to elaborate on the potential contribution of these products to polyphenol 
intake.  Nonetheless, as the annual UK and world consumption of chocolate continues to rise 
steadily (DEFRA, 2010, ICCO, 2007) and with increased consumer concern over health and 
nutrition and higher demand for high quality chocolate (ICCO, 2007), the need for 
improving current commercial processing methods is becoming ever more important.  In a 
survey commissioned by Barry Callebaut and conducted by IPSOS in 2006, 1 in 3 European 
consumers expressed their wishes for healthy chocolate to become commercially more 
available (Barry Callebaut, 2007). This when combined with chocolate‘s potential effects on 
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health highlights a wide market for functional chocolate products with important 
implications to public health. 
 
Depending on consumption levels, coffee could also act as a key contributor to total 
antioxidant intake. In fact, in the Spanish and Mediterranean diet, coffee has been estimated 
to provide up to 66% of total antioxidants intake, followed by red wine (16%), fruit juices 
(6%), beer (4%) and finally tea (3%) (Pulido et al., 2003, Svilaas et al., 2004).  In the UK, 
coffee is the second most widely consumed beverage after tea.  Coffee is produced from 
green coffee beans that are subjected to different degrees of roasting.   Since green coffee 
beans are rich in CGA, suggestions have been  made to extend the use of GCBE  from the 
more traditional cosmetic products market (Farah et al., 2008a) to new coffee formulations 
with functional properties (Oka, 2007).    In fact, Nestlé have recently launched a new coffee 
formulation, the Nescafé Green Blend, which is made out of 35% unroasted coffee beans and 
which is claimed to provide 160mg polyphenols per 200ml.   
 
1.10.4 Polyphenols in cocoa and dark chocolate 
The most ubiquitous subclass of polyphenols found in cocoa and DC are the flavonoids.  
These compounds are present in cocoa and chocolate in a unique combination of monomeric 
catechins and epicatechins, on the one hand, and polymeric procyanidins, on the other hand 
(Hammerstone et al., 1999).  This combination of low and high molecular weight 
polyphenols confers several advantages to cocoa and DC. These advantages arise from the 
varying degree of absorption and metabolism, hence bioavailability, of these flavonoids 
which subsequently determines their in vivo biological activities, as will be discussed later.   
 
Overall, the most prevalent low molecular weight flavonoids in cocoa and DC are (-)-
epicatechin and (+)-catechin (Osakabe et al., 1998) which alongside other low molecular 
dimers and trimers form 30% of total procyanidins in chocolate (Gu et al., 2006).  Cocoa and 
DC also contain high levels of dimer to hexamer procyanidins, these procyanidins being 
characteristic of cocoa and chocolate products (Adamson et al., 1999, Natsume et al., 2000).  
Surprisingly, cocoa have also been shown to contain more polyphenols and flavonoids per 
serving than red wine, green tea or black tea (see Figure 1.17).   
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Figure 1.17  Total phenolic content and flavonoid content of cocoa, red wine, green and 
black tea expressed as milligrams of gallic acid equivalents  and epicatechin equivalents 
per serving, respectively. (Lee et al., 2003). GAE, gallic acid equivalents; ECE, 
epicatechin equivalents. 
 
1.10.4.a Effect of processing on polyphenol content 
Generally, the polyphenol content of cocoa or DC differs depending on environmental 
factors and processing methods. For instance, the procyanidin content of cacao liquors 
depends largely on cacao liquor variety and tends to decrease with increased fermentation 
time (Counet et al., 2004).  The degree of fermentation also appears to be an important 
determinant of procyanidin content, with fine varieties of cocoa beans with short 
fermentation time exhibiting the highest procyanidin content (Counet et al., 2004). This is in 
contrast to the aromatic compounds which tend to correlate positively with the length of 
bean fermentation and are thus inversely related to procyanidin content (Counet et al., 2004).  
In addition to fermentation, roasting have been implicated in the epimerization of (-)-
epicatechin to (+)-catechin (Caligiani et al., 2007) and the loss of up to 90% of phenolic 
content (Jalil and Ismail, 2008).   
 
Differences in the proportion of polyphenols between various cocoa products have also been 
attributed to variation in the manufacturing processes of these products.  Chocolate is 
generally produced from a combination of cocoa liquor, sugar and cocoa butter. 
Consequently, chocolate has similar proportions of catechins and proanthocyanidins to cacao 
liquor (Natsume et al., 2000).  Conversely, cocoa powder undergoes alkalisation or dutching, 
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a process known to alter the antioxidant properties and procyanidin content of cocoa (Gu et 
al., 2006).  As a result cocoa powder differs in its composition to chocolate and cocoa liquor, 
with the former containing a higher ratio of flavan-3-ols to total monomer and oligomer 
polyphenols (Natsume et al., 2000).  The implications of such differences in the quantity and 
proportion of polyphenols amongst these products remains elusive.  Nevertheless, it is 
generally agreed that the quantity of procyanidins is directly related to the non-fat cocoa 
solid content, antioxidant activity and total polyphenol content (Adamson et al., 1999, Gu et 
al., 2006, Miller et al., 2006).  As a result, products which contain the highest non-fat cocoa 
solids like cocoa powder have the highest procyanidin content and total antioxidant capacity 
while products with the lowest non-fat cocoa solids like milk chocolate demonstrate the 
lowest procyanidin content and total antioxidant capacity (Gu et al., 2006).  In fact, 
according to Arts et al. (2000) milk chocolate contains negligible quantities of catechin, 
hence the escalating interest in investigating the health properties of solid DC which contains 
more non-fat cocoa solids than other varieties of chocolate (Jalil and Ismail, 2008). 
 
1.10.5 Polyphenols in green coffee beans 
Green coffee beans contain 6-10% CGA on a dry matter basis (Clifford, 1999) with CQA, 
dicaffeoylquinic and feruloylquinic acids forming 98% of total CGA content of green coffee 
beans (Clifford and Staniforth, 1977 see Noirot et al., 2003).  Of these, the 5-CQA isomer 
contributes to 85% of total CGA content of green coffee beans (Clifford et al., 1989, see 
Noirot et al., 2003).  The 5-CQA isomer is also the component with the highest in vitro and 
ex vivo anti-hydroxyl radical activity in both green and roasted coffee (Daglia et al., 2004).  
In general, CGA content varies between and within coffee species (Noirot et al., 2003).  This 
is then reflected in the antioxidant activity of coffee species with Robusta green coffee beans 
having twice the antioxidant activity of Arabica green coffee beans (Richelle et al., 2001). 
 
1.10.5.a Effect of manufacturing processes on chlorogenic acid content 
Roasting results in gradual reduction in CGA (DelCastillo et al., 2002) and formation of 
chlorogenic lactones (Clifford, 2000) alongside other Maillard reaction compounds (Daglia 
et al., 2004).  In fact, for every 1% reduction in dry matter, 8-10% of CGA is lost (Clifford, 
2000).  Subsequently, green coffee beans have a higher CGA content than roasted beans 
which is then reflected in higher antioxidant activity of green coffee beans as compared to 
roasted coffee beans (Daglia et al., 2000). 
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1.10.6 Bioavailability 
Bioavailability is key to understanding the functions and actions of biological compounds as 
chemical compounds may have potent antioxidant properties in vitro but their biological 
effects in vivo may be restricted by poor bioavailability, including poor gut absorption or 
rapid metabolism (Manach et al., 2004).   
 
1.10.6.a Bioavailability of cocoa polyphenols 
Cocoa and DC are rich in low molecular weight phenols like (-)-epicatechin and (+)-
catechin, compounds that are considered to be highly bioactive because of their high 
bioavailability.  The latter could be illustrated by the kinetics of (-)-epicatechin which is 
considered the main predictor of total polyphenol content and especially the content of 
procyanidin B2 and C1 (Cooper et al., 2007).  Epicatechin diffuses rapidly through intestinal 
epithelium where it forms several conjugates (Baba et al., 2000) and reaches its maximum 
concentration in blood 2h post DC consumption (Richelle et al., 1999, Rein et al., 2000, 
Wang et al., 2000) where it increases plasma antioxidant capacity (Wang et al., 2000) and 
decreases plasma TBARS (Rein et al., 2000).  However, because of its basic structure, 
epicatechin is also rapidly eliminated and by 6h, its concentration returns to baseline 
alongside plasma antioxidant capacity (Wang et al., 2000).  Subsequently, this compound 
produces only a transient effect on plasma total antioxidant capacity and repeated ingestions 
are required to maintain its plasma levels.   
 
Conversely, the large polymeric procyanidins are more resistant to metabolic degradation 
than the simpler phenols. Although the long polymeric structure and high molecular weight 
of procyanidins generally compromises their intestinal absorption and bioavailability 
(Scalbert and Williamson, 2000), cocoa and DC are unique in that they contain high levels of 
dimer to hexamer procyanidins (Adamson et al., 1999, Natsume et al., 2000).  These 
procyanidins are more resistant to metabolic degradation and excretion than epicatechin 
(Rios et al., 2002), but are nonetheless more readily absorbed than the high polymers of 10 
catechin units (Weisburger, 2005).  Subsequently, high levels of these compounds reach the 
intestines where they are converted by microbial flora to various metabolites including m-
hydroxyphenylpropionic acid, ferulic acid, 3,4-dihydroxyphenylacetic acid, m-
hydroxyphenylacetic acid, vanillic acid, and m-hydroxybenzoic acid (Rios et al., 2003).   
Although, the exact advantage of these metabolite formation have not yet been identified, 
Rios et al. (2003) argues that they are likely to protect the gastrointestinal tract from 
oxidative damage and thus contribute to the antioxidant properties of cocoa and DC.  
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In addition to molecular weight and structure, bioavailability is also influenced by other 
macronutrients and food products.  To illustrate, simultaneous carbohydrate ingestion has 
been shown to increase the bioavailability of cocoa flavanols (Schramm et al., 2003).  
Conversely, certain studies indicate that the addition of milk to chocolate reduces its 
antioxidant capacity compared to DC (Serafini et al., 2003), others, however, do not confirm 
these findings (Schroeter et al., 2003).  In their review, Keen et al. (2005) explained the 
latter controversies by arguing that the reduction in antioxidant capacity seen in Serafini et 
al.‘s study could be due to the overall food matrix, rather than milk proteins alone.   
 
Regardless of the role of macronutrients and milk as determinants of the bioavailability of 
DC polyphenols, ingestion of 80g of polyphenol-rich DC containing 164 mg epicatechin 
have been reported to increase plasma epicatechin concentrations to 0.7mmol/L (Richelle et 
al., 1999) which according to Richelle et al. (1999) and Rice-Evans (1996) is close to the 
1mmol/L range required to produce biological effects in vivo.   
 
Table 1.4 provides a summary of peak plasma epicatechin concentrations achieved 2h 
following ingestion of different doses of polyphenol-rich DC.  As observed from this table, 
there are large variations in maximum plasma epicatechin concentrations between the 
different studies.  These variations possibly reflect large inter-subject variations in the 
metabolism of DC polyphenols. 
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Table 1.4  Peak plasma concentrations of epicatechin at 2h following ingestion of 
polyphenol-rich dark chocolate or cocoa.   
 
Study Phenolic 
compound 
Number of 
participants 
Ingested dose Baseline 
epicatechin 
Maximum 
concentration 
Richelle 
1999 
epicatechin 8 40g DC 
(892mg 
polyphenols 
82mg 
epicatechin) 
80g DC 
(1783 mg 
polyphenols 
164 mg 
epicatechin) 
undetectable 300nmol/L 
700nmol/L 
Rein 
2000 
epicatechin 10 (4 males 
and 6 
females) 
80g DC 
557 mg 
procyanidins, 
137 mg 
epicatechin 
22± 4 
nmol/L) 
257 ± 66 
nmol/L 
Wang 
2000 
epicatechin 13 
13 
10 
27g DC 
(186 mg 
procyanidins 46 
mg epicatechin)  
53g DC 
80g DC 
2±2 
 
 
 
4±2 
4±3 
133 ± 27 
 
 
 
258 ± 29 
355 ± 49 
Wan 
2001 
epicatechin 6
 
(3 males and 
3 females 
22 g cocoa 
powder and 16 g 
dark chocolate 
466 mg 
procyanidins 
3.3 ± 0.1 
nmol/L 
36.2 ± 8.2 
nmol/L 
Engler 
2004 
epicatechin 11 
2 
46g DC 
120g DC 
undetectable 200- 227 
nmol/L 
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1.10.6.b Bioavailability of green coffee beans polyphenols 
The majority of the studies relating to CGA metabolism have examined the bioavailability of 
CGA from pure CGA supplements or coffee.  These studies however do not provide a true 
reflection of the bioavailability of CGA from GCBE, since they do not take in account the 
effect of food matrices or differences in composition between GCBE and roasted coffee 
(Olthof et al., 2001a-b).  Only two studies have directly examined the bioavailability of CGA 
from GCBE.  According to these studies, CGA is highly bioavailable with 24-33% of CGA 
or its related metabolites being recovered in plasma following ingestion of 0.4g GCBE 
(170mg (451µmol) CGAs) (Farah et al., 2008a-b).  CGA was also found to persist in plasma 
for up to 8h following ingestion of GCBE (Farah et al. 2008a).  In fact, CGA has even been 
identified intact in urine, saliva, digestive fluids and plasma of fasting subjects (Farah et al., 
2006).  All of this evidence is consistent with a slow elimination of CGA and could also 
possibly imply that storage and recycling of CGA might occur through digestive fluids 
(Farah et al., 2008a-b).  This could be further illustrated in the unique pharmacokinetic 
properties of CGA.  Compared to other polyphenols, consumption of CGA from GCBE has 
been shown to produce two chromatogram peaks, one achieved between 0.5-1h and the other 
at 8h (Farah et al., 2008b).  Farah et al. (2008a) explained the presence of these two 
maximum concentration values by arguing that the first peak is an indication of early 
absorption of CGA from the stomach and jejunum while the second peak suggest a late 
absorption through the colon.  Farah et al. (2008a) also observed a preferential absorption of 
5-CQA as reflected by the higher plasma levels of this isomer compared to other CGA 
isomers. In fact, 5-CQA exhibited an apparent bioavailability of 33±17% which is similar to 
the bioavailability of 5-CQA from pure 5-CQA supplements (Olthof et al., 2001a).  In 
addition to this, Farah et al. (2008a) detected a number of metabolites that were unique to the 
consumption of GCBE but not roasted coffee and which include: ferulic, isoferulic and p-
coumaric (Figure 1.18). A large inter-subject variability in the bioavailability of CGA was 
also observed, with plasma CGA recovery ranging from 7.8-72.1% (Farah et al., 2008a). 
According to Farah et al. (2008a), such differences in bioavailability are likely to be the 
product of genetic polymorphisms in CGA metabolism and may subsequently result in 
differences in biological outcome of GCBE consumption.    
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Figure 1.18 The metabolism of 5-Caffeoylquinic acid (Farah et al., 2008a).  Note the metabolites: ferulic, isoferulic and p-coumaric which 
are specific to chlorogenic acid-rich green coffee bean extract.   Also note the metabolites: ferulic acid, isoferulic acid and gallic acid which 
potentially can contribute to the antioxidant properties of green coffee bean extract
 72 
1.11. Actions of polyphenols 
1.11.1 Polyphenols as antioxidants 
1.11.1.a Antioxidants properties of cocoa and dark chocolate  
Cocoa was first shown to produce less H2O2 than tea and coffee (Long et al., 1999).  This 
ability to resist oxidation led some other to suggest that cocoa and DC may contain certain 
compounds that prevented them from being oxidised (Osakabe et al., 1998, long et al., 
1999). As mentioned earlier, cocoa contains more polyphenols and flavonoids per serving 
than red wine, green tea or black tea (Lee et al., 2003). These polyphenols confer potent 
antioxidant properties to cocoa and DC with cocoa possessing the highest antioxidant 
activity amongst red wine, green, black (Lee et al., 2003) and herbal tea (Richelle et al., 
2001). In fact to quote Lee et al. (2003): ― on a per-serving basis, [the antioxidant capacity of 
cocoa is] 4-5 times stronger than that of black tea, 2-3 times stronger than green tea, and 
almost 2 times stronger than red wine‖.  
 
In a study conducted by Record et al. (2003), consumption of high procyanidin chocolate 
containing 200mg of flavanols and related procyanidins was shown to reduce ROS 
production in faecal water.  However, faecal water antioxidant capacity as measured by 
Trolox equivalent antioxidant capacity (TOC) and ferric-reducing capacity of plasma 
(FRAP) was not altered significantly (Record et al., 2003). Moreover, Record et al. (2003) 
observed a reduction in free radical production in faecal water even with the low-procyanidin 
chocolate (<10mg polyphenols), which possibly indicated that components, other than 
chocolate procyanidins accounted for chocolate‘s inhibitory effect on ROS generation.  
Despite these findings, several researchers who have used more robust methods for 
measuring antioxidant capacity, i.e oxygen radical absorbance capacity (ORAC) and total 
antioxidant capacity assays (AOC), have demonstrated that the procyanidin content of cocoa 
and chocolate is strongly and positively correlated with total antioxidant capacity of these 
products (Adamson et al., 1999, Gu et al., 2006, Miller et al., 2006).  In particular, 
epicatechin oligomers, especially tetramers, have been shown to be more powerful inhibitors 
of oxidation and nitration reactions than the monomeric epicatechin (Arteel and Sies, 1999, 
Arteel et al., 2000).  In fact even when expressed in relative monomeric efficiency units, 
oligomers, especially those with three or more epicatechin or catechin units, appear to inhibit 
oxidation reactions to a greater extent than monomers (Counet and Collin, 2003).  
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In addition to inhibiting peroxynitrite reactions, cocoa and cocoa liquor can enhance 
antioxidant capacity by inhibiting H2O2  and O2.  production (Sanbongi et al., 1997) possibly 
via upregulation of the activity of superoxide dismutase and catalase (Ramiro-Puig et al., 
2007). Cacao liquor polyphenols have also been reported to inhibit the formation of lipid 
peroxides in plasma independently of their effect on α-tocopherol levels (Yamagishi et al., 
2001), although a sparring effect on α-tocopherol as well as β-carotene have also been 
reported (Baba et al., 2000; Lotito and Fraga, 2000).  
 
In humans, consumption of polyphenol-rich cocoa and chocolate raises plasma antioxidant 
capacity, as measured by ORAC (Wan et al., 2001), antioxidant chain-breaking (TRAP) and 
FRAP assays (Flammer et al., 2007). Prevention of lipid peroxidation, as evident by the fall 
in plasma TBARS and isoprostanes levels and urinary isoprostanes, have also been observed 
following ingestion of cocoa and DC by some authors (Wang et al.,2000, Flammer et al., 
2007) but not others (Engler et al., 2004).  It, thus, follows that cocoa and DC possess 
powerful antioxidants properties in vitro and in vivo.  These antioxidants properties have 
been attributed mainly to the procyanidins content of cocoa and DC (Counet et al., 2004).  
However, recent evidence appears to suggest that as well as possessing antioxidant 
properties, procyanidins could equally act as pro-oxidants when present in their purified 
form.  Accordingly, procyanidin B2 (epicatechin-(4β8)-epicatechin), have been shown to 
protect DNA against oxidative damage caused by H2O2 but to induce H2O2 production at 
high concentrations (Sakano et al., 2005).   Similar findings have been made in relation to 
cocoa butter (Vinson et al., 2006).  When found on its own, cocoa butter acts as a mild pro-
oxidant both ex vivo and in vivo because of its high unsaturated fatty acids content (Vinson et 
al., 2006).  However, once combined with polyphenols, as is the case in a chocolate bar, this 
pro-oxidant effect appears to be attenuated to a certain extent by the presence of polyphenols 
(Vinson et al., 2006).  This explains why when comparing defatted cocoa to non-defatted 
cocoa with a similar polyphenol content, defatted cocoa presents with a higher antioxidant 
activity because it lacks the pro-oxidant properties of cocoa butter (Vinson et al., 2006). 
Since cocoa also contains compounds other than polyphenols which express antioxidant 
properties including: N-phenylpropenoyl-L-amino acids; N-[3‘4-dihydroxy-(E)-cinnamoyl]-
L-tryptophan, N-[4-hydroxy-(E)-cinnamoyl]-L-tryptophan and N-[4‘hydroxy-3‘-methoxy-
(E)-cinnamoyl]-L-tyrosine (Stark et al., 2006), it could be postulated that the antioxidant 
properties of cocoa and DC arise as a result of a complex interplay between the various 
constituents of these food products.  Consequently, consumption of food products naturally 
rich in polyphenols, such as cocoa or DC, is likely to confer greater health benefits than the 
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use of purified procyanidin supplements, whose metabolic efficacy and safety remains 
questionable. 
 
1.11.1.b Antioxidants properties of chlorogenic acid and green coffee beans 
Several studies have reported in vitro antioxidant activity of CGA.  Accordingly, CGA and 
its precursors, caffeic and ferulic acid, have been shown to increase LDL resistance to lipid 
peroxidation (Castelluccio et al., 1995; Chen and Ho, 1997) and to prevent oxidative damage 
of apolipoprotein-B100 (Castelluccio et al., 1995).  CGA has also been reported to possess 
greater 1,1 –diphenyl-2-picilhydrazyl (DPPH) scavenging activity than α-tocopherol (Chen 
and Ho, 1997). However, as yet, no study has reported in vivo antioxidant activity of CGA 
from CGBE.  According to Olthof et al. (2003), in vivo antioxidant activity of CGA could be 
restricted by the relative high metabolic degradation of this compound in liver and colon.  
Furthermore, hippuric acid, the main metabolite of CGA, lacks antioxidant activity because 
of the absence of a hydroxyl group in its structure (Olthof et al., 2003).  However, absorption 
of intact CGA has been reported by Olthof et al. (2001a), Monteiro et al. (2007) and Farah et 
al. (2008a-b).  In fact according to Olthof et al. (2001a) 33% of CGA is absorbed while only 
a minor fraction is hydrolysed in the digestive tract to caffeic acid, the latter being a potent 
antioxidant. The remaining two-thirds reaches the colon where it is extensively metabolised 
by the microflora (Olthof et al., 2003) to yield different microbial metabolites such as: m-
coumaric acid and derivatives of phenylpropionic, benzoic and hippuric acids, which 
together total for over 57% of CGA intake (Gonthier et al., 2003).  Generally, the advantage 
of metabolite formation lays in their long half-lives (Setchell et al., 2002), hence their ability 
to maintain plasma antioxidant capacity over prolonged periods.  Moreover, certain 
metabolites exert more potent biological effects compared to their parent compounds, as 
observed with equol, the main microbial metabolite formed from the isoflavones diadzin and 
diadzein (Setchell et al., 2002).  Although the antioxidant contribution of CGA metabolites 
remains to be elucidated, it could be postulated that the antioxidant properties of GCBE rich 
in CGA are likely to arise from a combination of the pharmacokinetical properties  of CGA 
(Section 1.10.6.b) and possibly its microbial metabolites (refer again to Figure 1.18).  
 
1.11.2 Polyphenols, carbohydrate metabolism and diabetes 
1.11.2.a Effect of cocoa and dark chocolate  
Cocoa and DC flavonoids act on different stages of carbohydrate metabolism.  For example 
in the gastrointestinal tract, cocoa polyphenols have been shown to downregulate α-amylase, 
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an enzyme involved in the breakdown of carbohydrate, with the larger polymers being more 
potent than the simpler phenols (Quesada et al., 1996).  These findings are consistent with 
the findings of McDougall et al. (2005) who identified proanthocyanidins as the strongest in 
vitro inhibitors of salivary and pancreatic α-amylase activity.  Other mechanisms that affect 
carbohydrate metabolism involve inhibition of facilitated intestinal glucose transporter,  
GLUT2 (Chen et al., 2007) and sodium-dependent glucose transporters namely GLUT1 and 
sodium-dependent glucose transporter-1 (Cermak et al., 2004). Both these inhibitory actions 
occur  via direct interactions between polyphenols such as epicatechin gallate or quercetin-3-
O-glucoside and the respective  transporters, which results in slower carbohydrate 
breakdown and delayed absorption, hence improved glycaemic response (Cermak et al., 
2004; Chen et al., 2007). 
 
In diabetic rats, consumption of a cocoa extract, containing 285.6mg polyphenols per gram, 
has been shown to reduce glucose concentrations in blood (Ruzaidi et al., 2005) while 
consumption of cacao liquor procyanidins have been reported to reduce both blood glucose 
and fructosamine levels in diabetic obese mice (Tomaru et al., 2007).  In humans, 
consumption of DC improves insulin resistance, insulin sensitivity and fasting glucose levels 
in healthy (Grassi et al., 2005a), hypertensives (Grassi et al., 2005b), glucose-intolerant 
hypertensives (Grassi et al., 2008), and obese subjects (Davison et al., 2008).  In particular, 
Grassi et al. (2005a) reported a significant improvement in HOMA-IR and quantitative 
insulin sensitivity check index (QUICKI) following consumption of 100g of DC containing 
500mg polyphenols by healthy normotensive volunteers for 15days, but not following intake 
of 100g of polyphenol-deficient white chocolate.  In a later study, Grassi et al. (2005b) 
observed a significant improvement in HOMA-IR, QUICKI, oral glucose tolerance test in 
patients with essential hypertension following 15days of 100g DC. Most recently, Grassi et 
al. (2008) reported improvement in HOMA-IR, QUICKI, insulin-sensitivity index (ISI) as 
well as β-cell function as calculated by corrected insulin response (CIR120) in hypertensive 
subjects with impaired glucose tolerance following 15days of 100g DC.  Most importantly in 
this study, changes in ISI, QUICKI, CIR120 were correlated with improvement in flow-
mediated dilation, thereby confirming previous observation that a relation exists between 
insulin resistance and endothelium function (see section 1.5).  Changes in ISI were also 
correlated with changes in blood pressure. 
 
Such improvements in glucose metabolism could be partially attributed to decreased 
carbohydrate digestion and delayed absorption.  However, improved vascular function is 
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possibly by far the main mechanism by which DC flavonoids exert their beneficial effect on 
glucose metabolism (Grassi et al., 2008), particularly when considering that improved 
endothelium function may increase substrate delivery to target tissue (Section 1.5.2).  
Flavonoids could also improve insulin resistance by preventing serine-phosphorylation 
associated with increased circulating FFA levels as discussed earlier. 
 
Currently, inconsistencies still exist regarding the treatment duration and dose required to 
achieve a glucose-lowering effect (see Table 1.5).  For example in their pilot study Stote and 
colleagues (2007) failed to show any significant improvement in glucose, HOMA-IR and ISI 
following 5days of twice daily consumption of procyanidin-rich cocoa beverage containing 
22 to 900mg procyanidins by insulin-resistant men and women.  In contrast, Davison et al. 
(2008) showed reduced insulin resistance following consumption of a cocoa beverage 
containing 902mg flavanols twice daily for 12 weeks in overweight and obese subjects.  
Taubert et al. (2007), on the other hand, failed to show any improvement in glucose or 
insulin levels following 18 weeks of daily ingestion of 6.3g of DC with 30mg polyphenols.   
Together these studies might suggest that a longer duration and a higher dose of polyphenols 
could be required to achieve a significant reduction in glucose levels.  It can also be 
postulated that improvement in glycaemic regulation can occur without a detectable 
reduction in fasting glucose.  This is evident in a study by Balzer et al. (2008) that 
investigated the effect of regular cocoa intake on diabetics. This study demonstrated that 
despite not having any effect on fasting glucose, consumption of cocoa containing 963mg 
and 75mg flavonols for 30 days significantly reduces the levels of  haemoglobin Alc,  
implying improved glycaemic control (Balzer et al., 2008).  In the latter study, flavonoid-
rich cocoa was given to patients undergoing either oral or insulin anti-diabetic therapy 
(Balzer et al., 2008).   As such, it might be possible that the effect of cocoa  on fasting 
glucose would not be detected due to the effect of treatment on fasting glucose.  It could also 
imply that cocoa intake might be more essential in terms of reducing diabetes-related 
complication in this population subgroup, as evident by the improvement in endothelium 
function following cocoa consumption (Balzer et al., 2008) and the reduction in cataract 
formation in diabetic rats (Osakabe et al., 2004).  Additionally it could be argued that Balzer 
et al. (2008) used a cocoa beverage containing 27g of carbohydrates of which 15g was sugar.  
Since the latter is known to induce hyperglycaemic, replacing sugared-cocoa with sugar-free 
cocoa might have yielded more prominent results.   
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Table 1.5  Summary of studies investigating the effect of polyphenol-rich dark chocolate and cocoa on glucoregulatory biomarkers.  Note 
the overall large quantities of DC used and the great variation in polyphenols doses and treatment duration.  
Study Study Design Population Number of 
participants 
Dose Placebo Glucoregulatory 
parameter 
Change 
significant? 
Mathur 
2002 
Non-randomised 
trial, subjects 
studied at the 
end of  6 weeks 
DC and at the 
end of 6weeks 
follow-up period 
Healthy 25 (12 females 
and 13 males) 
36.9 g DC and 30.95 
g cocoa drink 
651mg procyanidins 
Habitual diet Fasting glucose No 
Grassi 
2005a 
Randomised, 
crossover, 15 
days 
Healthy  15 (7 males and 8 
females 
100g DC 
500mg polyphenols 
88mg flavanols 
90g white 
chocolate 
OGTT, HOMA-IR, 
QUICKI, fasting 
insulin 
Yes 
Grassi 
2005b 
Randomised, 
crossover, 15 
days 
never-treated, grade I
 
patients with essential 
hypertension 
20 (10 males and 
10 females) 
100g DC 
500mg polyphenols 
88mg flavanols 
90g white 
chocolate 
OGTT, HOMA-IR, 
QUICKI, ISI, fasting 
insulin 
Yes 
Stote 
2007 
Randomised, 
parallel-group, 5 
days 
12 insulin resistant, 1 
diabetic, 7 healthy 
20 subjects (10 
men, 10 women) 
3 cocoa procyanidin 
doses 900, 400 and 
200mg procyanidins 
taken twice daily 
Control beverage 
22mg 
procyanidins 
OGTT, HOMA-IR No 
Taubert 
2007 
Randomised, 
parallel control, 
18 weeks 
upper-range
 
prehypertension or 
stage 1 hypertension 
44 (24 females, 
20 males) 
6.3g DC 30mg 
polyphenols 
30g white 
chocolate 
Fasting glucose No 
Balzer 
2008 
Randomised, 
parallel control, 
30 days 
Type-II diabetics 44 of which 3 
dropped-out  (29 
females and 12 
males) 
18g cocoa 321 mg
 
flavanols taken thrice 
daily (Total 963mg 
flavanols) 
18g cocoa 25 mg 
flavanols
 
taken 
thrice daily 
(Total 75mg 
flavanols) 
Fasting glucose , 
haemoglobin  A1C 
Significant 
reduction in  
HBA1C after 
both doses 
Davison 
2008 
Randomised, 
parallel control, 
12 weeks 
Overweight and 
obese 
49  (31 females 
and 18 males) 
cocoa drink 
902 mg flavanols 
Low flavanol 
cocoa drink 
HOMA-IR No 
Grassi 
2008 
Randomised, 
crossover, 15 
days 
hypertensives with 
impaired glucose 
tolerance 
19 (11 males, 8 
females) 
100g DC 
500mg polyphenols 
90g white 
chocolate 
OGTT, HOMA-IR, 
QUICKI, ISI, 
CIR120, fasting 
insulin 
Yes 
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1.11.2.b Effect of green coffee bean extract 
CGA is unique in its ability to regulate glucose homeostasis since it acts on different stages 
of glucose metabolism (Figure 1.19). In the intestine, CGA can either delay (Johnston et al., 
2003, Bassoli et al., 2007) or inhibit (Welsch et al., 1989) intestinal glucose uptake.  In the 
first instance, CGA has been shown to modulate the secretion of gastrointestinal hormones 
such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-I 
(GLP-1) secretion (Johnston et al., 2003).  GIP is generally secreted in response to active 
glucose absorption through sodium-dependent glucose transporter-1 (Sirinek et al., 1983).  A 
reduction in its level implies reduced sodium-dependent glucose uptake (Sirinek et al., 
1983). GLP-1, on the other hand, is secreted in response to carbohydrates‘ presence in the 
distal portion of the small intestine (Enc et al., 2001).   It, thus, acts as an indicator of 
delayed carbohydrate and glucose uptake (Enc et al., 2001).   GLP-1 also functions as a 
stimulator of β-cell insulin secretion, in response to increased plasma glucose (McCullough 
et al., 1983, McCarty, 2005) and a rise in its production levels have been postulated to  
counteract the adverse effect of chronic FFA exposure on β-cells in overweight and insulin 
resistant subjects (McCarty, 2005).     
 
 
Figure 1.19  A summary of the mechanisms by which GCBE improves glycaemia 
(Blum et al., 2007) 
↓ Na-dependent intestinal 
glucose uptake 
↓ insulinaemia 
Inhibition of glucose-6-
phosphotase 
Postprandial state Fasting state 
↓ hepatic glucose release including 
glycogenolysis   
gluconeogenesis 
Improved glycaemia 
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As for inhibition of glucose absorption, CGA have been demonstrated to reduce sodium-
dependent glucose transport by 80% (Welsch et al., 1989).  This effect being induced by 
evoking the dissipation of the Na+ electrochemical gradient, which provides the driving 
force for active glucose uptake (Welsch et al., 1989).  According to McCarty (2005), these 
combined mechanisms of delayed and reduced glucose absorption serve to preserve  
pancreatic β-cells function by reducing postprandial hyperglycaemia.   
 
In addition to its actions on the intestine, CGA can also dose-dependently inhibit 
gluconeogenesis and glycogenolysis in the liver by inhibiting the glucose-6-phosphate 
translocase system (Hemmerle et al.,1997; Bassoli et al., 2008).  Finally, in the pancreas, 
CGA diminishes insulin secretion from pancreatic β-cells, as demonstrated by a reduction in 
plasma C-peptide following consumption of CGA-rich coffee (Wu et al., 2005).  According 
to Wu et al. (2005), changes in C-peptide are a better indicator of insulin secretion because 
as well as being released from proinsulin into blood in equimolar amounts as insulin 
(Wahren et al., 2000), C-peptide has a longer  half-life than insulin (Hovorka et al., 1998).  
This, in conjunction with the afore-mentioned evidence, confirms CGA‘s ability to influence 
glucose metabolism and improve glycaemia. 
 
 
1.11.3 Polyphenols and blood pressure  
1.11.3.a Effect of cocoa and dark chocolate  
The first observations of an association between cocoa consumption and blood pressure 
came from studies on the Kuna population of Panama.  The Kuna Indians were found to have 
low rates of CVD and hypertension despite consuming large quantities of salt (McCullough 
et al., 2006), an effect that was explained by the large quantities of cocoa, 5 cups per day, 
consumed by this population (Hollenberg, 2006) and which provide over 900mg polyphenols 
(Bayard et al., 2007).  This high cocoa consumption was found to be associated with a 3-fold 
higher urinary nitrate: nitrite excretion in Kuna Indians compared to mainland dwellers who 
did not consume flavonoid-rich cocoa (Hollenberg, 2006).  This led authors to suggest that 
activation of NO system was the underlying mechanism by which cocoa consumption 
reduced blood pressure (Hollenberg, 2006).  This was confirmed by a later observational 
study that showed low mortality rates from NO-dependent conditions like CVD, cancer and 
diabetes among the Kuna Indians (Bayard et al., 2007).   
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Reductions in blood pressure were also reported by short-term randomised-controlled trials.  
Here, Taubert et al. (2003) reported a 5.1mmHg and a 1.8mmHg reduction in both SBP and 
DBP, respectively, following consumption of 100g DC containing 500mg polyphenols by 
elderly patients with untreated stage-1 mild isolated systolic hypertension.  This effect was 
achieved within 10days of DC consumption but was not sustained 2days after 
discontinuation (Taubert et al., 2003).  Reductions in SBP (Grassi et al., 2005a) and DBP 
(Grassi et al., 2005b, Grassi et al., 2008, Faridi et al., 2008) have also been demonstrated by 
other short-term studies using similar research protocol.  However, these reductions differed 
depending on the instruments used to monitor blood pressure and the population studied.  
For instance, in their first study, Grassi et al. (2005a) observed a significant 6.4mmHg fall in 
SBP, but not DBP, after ingestion of 100g DC by healthy volunteers.  In a later study on 
patients with essential hypertension, Grassi et al. (2005b) used a 24h-ambulatory blood 
pressure monitor, a more robust method of measuring blood pressure.  Here both 24h SBP 
and DBP were reduced by –11.9±7.7 mm Hg and –8.5±5.0 mm Hg, respectively.  In their 
latest study, Grassi et al. (2008) also reported a reduction in 24h SBP and DBP in glucose-
intolerant hypertensive patients.  However, in this study the reduction was lower than the one 
reported with patients suffering from hypertension only (24-h
 
SBP, –4.52mm Hg; 24-h DBP, 
–4.17 mm Hg) (Grassi et al., 2008).   This may suggest that DC varies in its effect on 
different populations probably due to differences in the severity of disease and possibly due 
to the involvement of other pathophysiological factors in these conditions. 
 
Differences between the effect of solid versus liquid cocoa and sugared versus sugar-free 
cocoa have also been reported.  For instance, acute consumption of DC and sugar-free cocoa 
by overweight and obese individuals have been shown to reduce SBP and DBP by 3.2mmHg 
or 1.2mmHg and 1.4mmHg or 1.2mmHg, respectively (Faridi et al., 2008).  In contrast, 
sugared-cocoa has not been shown to reduce blood pressure (Faridi et al., 2008).   
 
Long-term randomised-controlled trials have also reported improvement in blood pressure 
following flavonoid-rich cocoa or DC.  Here, reductions of 1.6 and 1.2mmHg in DBP and 
arterial blood pressure, respectively, have been observed in overweight and obese subjects 
following 12 weeks of twice daily consumption of cocoa containing 902mg flavanols 
(Davison et al., 2008).  The reduction in DBP (-1.3mmHg) is similar to the one seen in 
Taubert et al.‘s (2007) study following 12 weeks ingestion of 6.3g of DC with 30mg 
polyphenols by patients with untreated upper-range pre-hypertension and stage-1 
hypertension.  However, in the latter study, SBP and DBP continued to decrease further to -
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2.9mmHg and -1.9mmHg following 18 weeks of DC consumption (Taubert et al., 2007).  
This effect was correlated with an increase in S-nitrosoglutathione, thereby confirming 
previous observational studies‘ findings of the relation between cocoa consumption, NO 
system and blood pressure.      
 
It is worthy of attention that Taubert et al. (2007) stated that although the reduction in blood 
pressure was significant, none of their participants attained lower-range pre-hypertension 
(130/85) or an optimal blood pressure (120-80).  This statement is important since it suggests 
that statistical significance does not necessarily imply clinical relevance.  Nonetheless and as 
cited by Taubert et al. (2007), in the Zutphen Elderly Study, similar reductions in blood 
pressure related to cocoa ingestion have been correlated with a 50% reduction in 
cardiovascular and all-cause mortality (Buijsse et al., 2006).  This suggests that introducing 
cocoa or DC to the diet of hypertensive subjects or those at risk of hypertension such as the 
overweight and obese population may be more important in the long-term reduction of 
hypertension-related complications rather than in controlling hypertension itself.  This is 
similar to what have been discussed earlier in relation to treated diabetics, where cocoa and 
DC might be more essential in terms of preventing diabetes-associated complication rather 
than in improving glycaemic control.  Another question that arises is whether recommending 
DC and cocoa to patients who are already on antihypertensive treatment is of any benefit to 
them. Taubert et al. (2007) has also reported that the reduction in blood pressure seen in their 
long-term study is similar to the reduction seen in their short-term study using a larger dose 
of DC.  This led Taubert et al. (2007) to state that ‗the cumulative phenol dose may 
determine the magnitude of transcriptional NO synthase activation and subsequent fall in 
blood pressure‘.  This statement is important since most studies which have observed 
significant reduction in blood pressure have focused on providing DC in the form of a 100g 
bar which in the long-term might adversely affect body weight given the high-fat content of 
DC (Desch et al., 2009).   
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Table 1.6 Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) reported by previous studies (adapted from Desch et 
al., 2009).   
 
Study Study Design Population Number of 
participants 
Dose Reduction in SBP Reduction in 
DBP 
Taubert 
2003  
Crossover, 1 week Healthy elderly 13 100g DC 
500mg polyphenols 
-5.1[-6.40, -3.80] -1.80[-2.89, -0.71] 
Murphy 
2003 
Parallel-group, 
28days 
Healthy Cocoa: 13; Control: 
15 
Tablets 234 mg 
cocoa flavanols and 
procyanidins 
1.00 [-6.43, 8.43] -1.00 [-6.94, 4.94] 
Engler 2004 Parallel-group, 2 
weeks 
Healthy Cocoa: 11; Control: 
10 
46g DC 213 mg 
procyanidins, 46 mg 
epicatechin 
-1.80[-4.37, 0.77] 1.00[-0.71, 2.71] 
Grassi 2005a Crossover, 15 
days 
Healthy 15 100g DC  
500mg polyphenols 
-6.20[-7.41, -4.99] -3.50[-4.51, -2.49] 
Fraga 2005 Crossover, 2 
weeks 
Soccer players 27 105g DC 
168mg of flavanols; 39 
mg catechin and 
epicatechin 
-4.00[-4.59, -3.41] -4.00[-4.59, -3.41] 
Grassi 
2005b 
Crossover, 15 
days 
never-treated, grade I
 
patients with essential 
hypertension 
20 100g DC 
500mg polyphenols 
-11.00[-13.02, -8.98] -8.30[-10.10, -6.50] 
Taubert 
2007 
Parallel-group, 18 
weeks 
upper-range
 
prehypertension or 
Cocoa: 22; Control: 
22 
6.3g DC 
30mg polyphenols 
-3.00[-3.50, -2.50] -1.90[-2.70, -1.10] 
Grassi 2008 Crossover, 15 
days 
hypertensives with 
impaired glucose 
tolerance 
19 100g DC 
500mg polyphenols 
-4.60[-6.26, -2.94] -4.20[-6.00, -2.40] 
Crews 2008 Parallel-group, 6 
weeks 
Healthy elderly Cocoa: 45; Control: 
45 
37g DC and 237
 
ml 
cocoa  
754.71mg 
procyanidins 
-0.53[-5.69, 4.63] 0.07[-1.72, 3.72] 
Muniyappa 
2008 
Crossover, 2 
weeks 
Essential hypertension 20 150mg cocoa 
900mg flavanols 
-1.00[-6.82, 4.82] 1.00[-1.72, 3.72] 
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It is important to note that several studies have failed to report any significant changes in 
blood pressure following cocoa or DC ingestion (Fisher et al., 2003, Murphy et al., 2003, 
Heiss et al., 2007).  For instance, no significant change in blood pressure was observed 
following 2 weeks of 46g DC (213mg procyanidins) in healthy subjects (Engler et al., 2004).  
This occurred irrespective of the improvement in endothelium function (Engler et al., 2004).  
Similar findings were reported by Crews et al. (2008).  In both these studies, participants had 
normal baseline blood pressure levels.  Crews et al. (2008) thus attributed the lack of 
significant findings to these normal baseline blood pressure levels.  However, in Grassi et 
al.‘s (2005a) study, subjects also had a mean SBP of 113.9mmHg yet a significant 6.4mmHg 
reduction in SBP levels was observed.  This suggests that differences in these studies could 
be related to other factors like the duration of intervention, time point at which blood 
pressure was measured, dose of flavonoids used and the instruments used to monitor blood 
pressure.  Baseline differences in blood pressure levels among participants should also be 
taken in account, as those with lower baseline blood pressure levels may experience an 
increase in blood pressure leading to insignificant findings.     
 
1.11.3.b Effect of green coffee bean extract 
The ability of GCBE and CGA to improve blood pressure have been demonstrated in both 
spontaneously hypertensive rats and in humans (Kozuma et al., 2005; Suzuki et al. 2002; 
Chikama et al., 2006; Suzuki et al., 2006; Watanabe et al., 2006).  In humans, CGA-rich 
GCBE has been documented to reduce blood pressure in patients with mild hypertension in 
small scale (Watanabe et al., 2006) as well as large-scale interventions (Kozuma et al., 2005) 
(Table 1.7). These hypotensive properties were shown to be dose-dependent with GCBE 
containing 93mg and 185mg CGA being more effective than GCBE with a 46mg CGA 
content (Kozuma et al., 2005). Moreover, the antioxidant properties of GCBE and its ability 
to modulate endothelium function appear to lie at the centre of GCBE blood pressure-
lowering effects.   
 
It is important to note that so far the effect of GCBE on blood pressure is consistent in the 
literature whilst the role of coffee remains unconceivable (Suzuki et al., 2008).  It seems that 
in relation to blood pressure, consumption of GCBE has certain advantages over ingestion of 
coffee.  This is because GCBE contains high levels of CGA whilst in coffee the presence of 
some pro-oxidant compounds such as benzenetriols, including hydroxyhydroquinone can 
interfere with CGA‘s hypotensive properties by counteracting CGA‘s actions on ROS 
generation, NO bioavailability and subsequently endothelium function and blood pressure 
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(Suzuki et al., 2008).  This together suggests that the composition of GCBE and the balance 
between the pro-oxidant and oxidant compounds can have a profound effect on determining 
the biological actions of this polyphenol-rich product. 
 
 
Table 1.7 Summary of studies investigating the blood-pressure lowering effects of green 
coffee bean extract.  Note the limited amount of research. 
 
 
1.11.4 Polyphenols, nitric oxide and endothelium function 
1.11.4.a Effect of cocoa and dark chocolate  
DC flavonoids have been shown to improve NO bioavailability through a variety of 
mechanisms.  To illustrate, quercetin increases eNOS activity, while epicatechin decreases 
superoxide levels by directly scavenging it (Sanchez et al., 2006).  Conversely, epicatechin 
metabolites reduce superoxide generation by inhibiting NADPH oxidase (Sanchez et al., 
2006, Steffen et al., 2007) while the dimer procyanidin B2 and (-)-epicatechin glucuronide 
could both scavenge superoxide and inhibit NADPH oxidase (Steffen et al., 2008).  In 
relation to eNOS, polyphenols have also been shown to prevent eNOS uncoupling due to 
decreased BH4, an eNOS co-factor (Kawashima et al., 2004).  The clinical relevance of this 
mechanism could be viewed in that under pathological conditions when BH4 levels are 
reduced and dihydrobiopterin (BH2) levels are increased, eNOS becomes dysfunctional and 
produces superoxide rather than NO (Kawashima et al., 2004). As for NADPH oxidase, its 
inhibition is of particular relevance to diabetes, since increased glucose levels have been 
reported to increase NADPH oxidase activity leading to increased ROS production (Akbari 
et al., 1998, Title et al., 2000).  It is also of relevance to the metabolic syndrome where 
upregulation of NADPH oxidase and downregulation of dismutase, glutathione, peroxidase, 
heme-oxygenase has been reported, resulting in increased ROS production and oxidative 
stress (Roberts et al., 2006). 
Study Study Design Population Number of 
participants 
Dose Change from 
baseline 
(mmHg) 
Kozuma 
2005  
Randomised 
placebo-
controlled, 
28days 
Mild 
hypertension 
117 males  
  
Three GCBE doses  
46 mg GCBE 25mg 
CGA 
93 mg GCBE 50mg 
CGA 
185 mg GCBE 100mg 
CGA 
 
-3.2±4.6  
-4.7±4.5  
 -5.6±4.2  
Watanabe 
2006 
Randomised 
placebo-
controlled, 15 
days 
Mild 
hypertension 
28  GCBE 140mg 
CGA 
-4 
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DC flavonoids could also improve NO bioavailability by modulating the activity of arginase, 
an enzyme in the urea cycle.  Here, (-)-epicatechin and its metabolites have been shown to 
lower arginase-2 mRNA expression and activity in human endothelial cells in vitro (Schnorr 
et al., 2008).  This is essential since arginase competes with eNOS for arginine and increased 
arginase activity leads to decreased NO generation since arginine is converted to ornithine.  
This reduction in arginase activity is also seen in vivo in both rat kidney and human 
erythrocytes following consumption of cocoa (Schnorr et al., 2008).   
 
All of the above mechanisms explain the direct mechanism by which DC flavonoids increase 
NO bioavailability.  There is, however, an additional indirect mechanism by which DC 
flavonoids could promote NO bioavailability and which involves angiotensin-II, which is 
summarised below.  
 
Angiotensin-II is produced through the conversion of angiotensin-I by the enzyme 
angiotensin-converting enzyme.  Procyanidins (dimer to hexamers) and epigallocatechin, but 
not (+)-catechin, (-)-epicatechin, GA, CGA, caffeic acid, quercetin, kaempferol or 
resveratrol, have been shown to be effective inhibitors of angiotensin-converting enzyme 
(Actis-Goretta et al., 2003).  In relation to procyanidins, this effect is dependent on the 
number of flavanol units within the procyanidin (Actis-Goretta et al., 2003).  Chocolate 
extracts have also been shown to inhibit this enzyme in rat kidney membrane, the effect 
being related to the concentration of flavanols within the chocolate extract (Actis-Goretta et 
al., 2006).  Additionally, cocoa flavonoids have been reported to attenuate angiotensin-II-
induced activation of MAPK-dependent pathway (Lee et al., 2006) which is likely to lead to 
decreased endothelin-1 and ROS production, and subsequently improved NO bioavailability. 
However, in vivo inhibition of angiotensin-converting enzyme by chocolate or cocoa has not 
yet been reported. This area deserves further investigation since the renin-angiotensin-
aldosterone system is known to be an important regulator of blood pressure homeostasis.  
Moreover, in vivo inhibition of angiotensin-converting enzyme in humans following 
ingestion of polyphenol-rich pomegranate juice has been reported providing further evidence 
for the need to investigate potential in vivo inhibition of this enzyme by polyphenols 
(Avriam and Dornfeld, 2001).   
 
What is most important about the above mechanisms is that they suggest that cocoa and DC 
polyphenols have the potential to improve endothelium function as a result of their ability to 
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modulate NO, as highlighted below, with major consequences to glucose utilisation, blood 
pressure regulation and FFA oxidation. 
 
Initial reports of improved endothelium function following treatment with cocoa flavonoids 
came from a study on rabbit aortic rings (Karim et al., 2000). Here, polymeric procyanidins 
(tetramer through decamer
 
of catechin) induced dose-dependent endothelium-dependent 
vasodilation. This effect was attributed to the ability of these procyanidins, with the 
exception of monomers, to improve eNOS activity. 
 
Ever since, several studies have been published which explored both the acute and chronic 
effects of cocoa and DC on endothelium function in vivo.  To illustrate, in a short-term study 
by Heiss et al. (2003), consumption of 100ml flavanol-rich cocoa (containing 176mg flavan-
3-ols) by patients with at least 1 cardiovascular risk factor (coronary artery disease, 
hypertension, hyperlipidaemia, diabetes or smoking) for 2 consecutive days increased flow-
mediated dilation maximally at 2h, an effect that was correlated with increased nitrosylated 
and nitrosated species.  Brachial artery diameter, endothelium-independent dilation of 
brachial artery diameter, nitrite or nitrate levels remained unaltered.  In another short-term 
study, consumption of a flavanol-rich beverage for 5 days (containing 821mg flavanol/day) 
produced vasodilation and improved vasodilator response to ischemia in finger arteries 
(Fisher et al., 2003).  This effect was reversed following an intravenous infusion of the NOS- 
inhibitor L-NMMA suggesting that flavanols exert their effect via activation of NO system 
(Fisher et al., 2003).  Similar observations were made in smokers following consumption of 
100ml cocoa drink containing 176-185mg flavanols (Heiss et al., 2005).   
 
With regard to DC, acute consumption of 100g DC has been shown to increase both resting 
and hyperaemic brachial artery diameter in healthy subjects (Vlachopoulos et al., 2005), an 
effect that was not observed in Heiss et al. (2003) study.  Flow-mediated dilation also 
increased significantly 60min after DC consumption.  This effect occurred irrespective from 
significant changes in oxidant status (Vlachopoulos et al., 2005).  In another study, the 
increase in flow-mediated dilation reached its maximum at 2h and was then maintained to up 
to 8h following consumption of 40g DC (Hermann et al., 2006), consistent with the kinetics 
of (-)-epicatechin.  Indeed, Schroeter et al. (2006) identified (-)-epicatechin and its 
metabolite epicatechin-7-O-glucuronide as independent predictors of vascular effects of 
flavanol-rich cocoa and their effect on NO as the main mechanism by which these 
compounds improve endothelium function.  Improvement in flow-mediated dilation have 
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also been reported following consumption of 46g of DC containing 213mg procyanidins for 
2 weeks in healthy subjects (Engler et al., 2004) and 100g DC containing 500mg 
polyphenols for 2 weeks in patients with essential hypertension (Grassi et al., 2005b).  
Interestingly, in both these studies improvements in flow-mediated dilation were of similar 
magnitude as to the one observed by Vlachopoulos et al. (2005) following acute 
consumption of DC (1.43%, 1.5% vs. 1.3%).  This probably suggests that the effect of DC 
on endothelium function could be sustained with regular consumption of this flavonoid-rich 
product and that desensitization does not occur.  Indeed, consumption of a cocoa beverage 
containing 446mg flavanols for 6 weeks by hypercholesterolaemic women have been 
demonstrated to improve hyperaemic brachial artery blood flow, an effect that was correlated 
with a decrease in vascular adhesion molecule-1 (Wang-polagruto et al., 2006).  Similarly 
Heiss et al. (2007) have reported that continual improvement in flow-mediated dilation and 
sustained augmentation at 2h could be achieved with regular consumption of cocoa.  Most 
importantly, Heiss et al. (2007) identified the dose that achieves half-maximal flow-mediated 
dilation, which was 616mg flavanols. 
 
In the most recent trial, sugar-free cocoa has been shown to ameliorate flow-mediated 
dilation to a better extent than sugared-cocoa (5.7% vs. 2.0%).  This effect was even greater 
than the one observed with DC containing a similar quantity of cocoa (4.3%) (Faridi et al., 
2008).  This led Faridi et al. (2008) to conclude that while polyphenols improve endothelium 
function, the sugar fraction attenuates it.  This finding is particularly relevant to diabetic 
patients in whom increased glucose levels promote ROS production leading to decreased NO 
bioavailability.  Reducing the sugar content of the cocoa beverage could thus augment the 
improvement in endothelium function seen after acute and chronic consumption of cocoa in 
medicated diabetic patients, particularly that sugared flavanol-rich cocoa, on its own, is able 
to increase flow-mediated dilation by 30% (Balzer et al., 2008).  The use of sugar-free cocoa 
could also be of relevance to obese patients or those with the metabolic syndrome, since 
decreasing the sugar content will ultimately allow the delivery of higher quantities of 
flavanols in a less energy-dense form.  Reducing the sugar content is also likely to improve 
flow-mediated dilation further.  To illustrate, Davison et al. (2008) observed a 2.4% increase 
in flow-mediated dilation following acute consumption of sugared-cocoa and a 1.6% 
increase following 12 weeks of sugared-cocoa.  Faridi et al. (2008) also observed a similar 
increase using sugared-cocoa in overweight individuals but when the sugared-cocoa was 
replaced by a sugar-free version flow-mediated dilation increased strikingly by an additional 
2.1%. 
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All of the above evidence suggests that cocoa and DC could be used to promote vascular 
health in the overweight and obese population since their beneficial effects on vascular 
function extends from healthy individuals to those with cardiovascular risk factors, diabetes 
and the metabolic syndrome.   
 
1.11.4.b Effect of green coffee bean extract on nitric oxide  and endothelium function 
Improvements in endothelium function following GCBE or CGA consumption have been 
documented in humans as well as in animals (Ochiai et al., 2004; Chikama et al., 2006; 
Suzuki et al., 2006).  In general, these effects are attributed to both CGA and its metabolites, 
in particular ferulic acid.  Ferulic acid is a recognised NO-donor that has been shown to 
improve endothelium function (Suzuki et al., 2002; Suzuki et al., 2007).  CGA, on the other 
hand, can improve NO bioavailability by modulating oxidative stress via inhibition of 
NADPH oxidase activity and subsequent superoxide generation (Suzuki et al., 2006). 
Consumption of CGA has also been shown to reduce urinary H2O2  excretion in 
spontaneously hypertensive rats (Suzuki et al., 2006).  Additionally, CGA has been shown to 
ameliorate acetylcholine-induced endothelium-dependent vasodilation (Suzuki et al., 2006).   
Overall, these improvements in endothelium function might have potential implications for 
the regulation of blood pressure, glucose and lipid metabolism by GCBE.  
 
1.11.5 Polyphenols, Fat metabolism and obesity 
1.11.5.a Effect of cocoa and dark chocolate  
As discussed in previous sections, NO regulates flow-mediated dilation resulting in 
improved perfusion of skeletal muscle and substrate delivery and oxidation.  Accordingly, 
Davison et al. (2008) hypothesised that cocoa may reduce fat mass and increase fat oxidation 
in overweight and obese individuals via improvement in NO bioavailability. 
 
Support for this hypothesis stemmed mainly from studies on L-arginine, the precursor of 
NO.  According to these studies L-arginine supplementation decreases fat mass in Zucker-
diabetic rat (Fu et al., 2005) while in obese type II diabetes patients consuming 8.3g/day of 
L-arginine decreases both fat mass  and WC while maintaining lean muscle mass (Lucotti et 
al., 2006).  L-arginine supplementation was also shown to improve endothelium function by 
increasing the levels of NO second messenger, cGMP, while decreasing endothelin-1 levels, 
an effect that was correlated with improved SBP (Lucotti et al., 2006).  According to Lucotti 
et al. (2006), L-arginine supplementation in conjunction with exercise reduces atherogenesis, 
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as indicated by decreased leptin-to-adiponectin ratio, while producing an additive 
improvement on glucose metabolism, insulin sensitivity, adiponectin and antioxidant 
capacity, the latter being indicated by increased superoxide dismutase levels.  All of these 
findings led Davison et al. (2008) to investigate the effect of cocoa consumption, on its own 
or in combination with exercise, on body composition, endothelium function, insulin 
resistance and blood pressure in obese individuals.  Based on the findings of Davison et al. 
(2008), only exercise is capable of raising fat oxidation and reducing abdominal fat mass.  
High-flavanol cocoa on its own did not improve fat oxidation or decrease abdominal fat 
mass.  However, when comparing the data from the combined low-flavanol and exercise 
group and the high-flavanol and exercise group, it appears that within the high-flavanol 
group, fat oxidation was increased and abdominal fat was decreased to a greater extent.  Fat 
oxidation in high-flavanol group was greater by 0.140gmin-1 from baseline versus the 
0.064gmin-1 increase from baseline in low-flavanol group.  Percentage abdominal fat was 
lower by 1.31% from baseline in high-flavanol group versus the 0.52% reduction in low-
flavanol group.  Unfortunately, Davison et al. (2008) did not report the p-values or effect 
size of these results. 
 
Nonetheless, decreased visceral adipose tissue weight has been reported in rats following 
ingestion of cocoa (Matsui et al., 2005).  Ingested cocoa has also been shown to prevent 
high-fat diet-induced obesity by decreasing the gene expression of the enzymes that regulate 
fatty acid synthesis in liver and white adipose tissue as well as decreasing the gene 
expression of fatty acid transport systems in white adipose tissue (Matsui et al., 2005). 
Enhancement of the gene expression for uncoupling protein-2, which regulates 
thermogenesis, has also been reported (Matsui et al., 2005). 
 
All of this suggests the need for further research into the effects of different polyphenol 
compounds on substrate utilisation and thermogenesis, since some polyphenols have been 
demonstrated to increase fat oxidation (Boschmann and Thielecke, 2007).  This also 
highlights the need to monitor body composition and to obtain anthropometrical data to 
observe if any changes in these parameters occur in overweight and obese individuals during 
cocoa or DC consumption.  Understanding structure-activity relation is important in 
elucidating the mechanisms by which diet could prevent obesity, particularly that FFA 
accumulation in muscle is known to induce insulin resistance.  The effect of DC on 
pancreatic lipase activity should also be investigated since NO modulates its activity. This 
 90 
could carry important implication to improving lipid profile and post-prandial lipaemia in the 
overweight and obese population. 
 
1.11.5.b Effect of green coffee bean extract 
Blum et al. (2007) were the first to report that consumption of decaffeinated GCBE is 
associated with weight loss in a prospective preliminary study. These findings were 
subsequently confirmed by Dellalibera et al. (2006) in a larger placebo-controlled trial 
compromising 50 overweight volunteers.  In here, consumption of 400mg of decaffeinated 
GCBE in conjunction with caloric restriction  for 60 days was shown to induce a 4.97± 0.32 
(mean±SEM) kg reduction in weight.  Moreover, a significant elevation of muscle mass-to-
fat mass (mean± SEM= 4.1±0.7)  following decaffeinated GCBE consumption was observed 
compared to control which had a minimal effect on body composition (mean± SEM= 1.6± 
0.6) (Dellalibera et al., 2006).  These findings were postulated to be modulated by GCBE‘s 
ability to improve glycaemic control which arguably leads to a rise in fat utilisation and 
reduced fat storage, a hypothesis based on the close association between glucose and lipid 
metabolism (Blum et al., 2007).  This hypothesis was partially supported by a study on mice 
wherein consumption of GCBE evoked a reduction in fat absorption and hepatic TG 
accumulation which was accompanied by a reduction in body weight and visceral fat 
(Shimoda et al., 2006).  However, in contrast to the studies on human volunteers, the GCBE 
used by Shimoda et al. (2006) contained both caffeine (10%) and CGA (27%). Caffeine was 
identified as the chief component responsible for GCBE‘s inhibitory effect on fat absorption 
while CGA was shown to be effective in reducing hepatic TG accumulation (Shimoda et al., 
2006).  Importantly, though GCBE demonstrated dose-dependent attenuation of hepatic 
carnitine-palmitoyltransferase activity, this effect was not accounted by CGA. Instead other 
GCBE components such as neochlorogenic acid and feruloylquinic acid proved to contribute 
to GCBE-induced inhibition of carnitine-palmitoyltransferase (Shimoda et al., 2006).   
 
1.11.6 Polyphenols, lipid profile and lipid peroxidation  
1.11.6.a Effect of cocoa and dark chocolate  
DC could improve lipid profile by both decreasing LDL levels and decreasing its 
susceptibility to oxidation by increasing plasma antioxidant capacity and decreasing ROS 
formation.   
 
 91 
To illustrate, consumption of 22g cocoa and 16g DC, containing 446mg procyanidins, for 4 
weeks by healthy subjects have been shown to increase total antioxidant capacity, an effect 
that was correlated with an 8% increase in LDL oxidation lag time (Wan et al., 2001).  HDL 
cholesterol, but not HDL: LDL ratio, was also found to be increased by 4% (0.05mmol/l) 
(Wan et al., 2001). Indeed, prolongation of LDL oxidation lag time and improvements in 
lipid profile have been reported by numerous studies (Table 1.8).  In one study, increased 
LDL oxidation lag time was reported following 1 and 2 weeks of 36g of sugared cocoa 
powder with a 2610mg polyphenol content, an effect that occurred alongside increased 
epicatechin excretion in urine (Osakabe et al., 2001). In another study, 
normocholesterolaemic and mildly hypercholesterolaemic subjects who consumed 26 g 
cocoa powder and 12 g sugar/d, providing 41.08mg procyanidins and 98.02mg epicatechin, 
for 12weeks compared to a control of 12 g sugar/d, exhibited a 9% or a 13% prolongation of 
lag time of LDL oxidation compared to baseline or the control group, respectively, and a 
24% increase in plasma HDL cholesterol (Baba et al., 2007a).  Improvement in lipid profile 
have also been reported by Grassi et al. (2005b, 2008) who showed that 100g DC with 
500mg polyphenols decreases total cholesterol by 7.4% or 6.5% and LDL cholesterol by 
11.8% or 7.5% in hypertensive subjects and hypertensive subjects with glucose intolerance, 
respectively; by Fraga et al. (2005) who showed that flavanol-rich milk chocolate reduces 
total cholesterol by 11% and LDL-cholesterol by 15%, and by Balzer et al. (2008) who 
demonstrated that sugared-cocoa could reduce LDL levels in medicated diabetic patients. 
Reductions in total cholesterol, TG and LDL-cholesterol following supplementation with 
cocoa have also been reported in animal models of diabetes (Ruzaidi et al., 2005) and 
obesity (Jalil et al., 2009).  Jalil et al., (2009) attributed these effects to the potential ability 
of polyphenols to inhibit pancreatic lipase, promote cholesterol excretion in faeces and 
reduce hepatic lipid accumulation through activation of adenosine monophosphate (AMP)-
activated protein kinase, attenuation of hepatic secretion of apolipoprotein-B100 and 
stimulation of hepatic LDL receptors expressions.   Indirect mechanisms involving insulin‘s 
regulatory actions on lipid metabolism have also been implicated (Ruzaidi et al., 2005). 
 
However, not all cocoa and DC components affect LDL oxidation and lipid profile 
positively. For instance, in an ex vivo study by Vinson et al. (2006), it was demonstrated that 
while cocoa polyphenols prolong lag time of LDL+VLDL oxidation, cocoa butter decreases 
it resulting in increased LDL oxidation.  This was evident in that defatted cocoa powder and 
DC increased the lag time of LDL+VLDL oxidation to a greater extent than normal cocoa 
and DC (Vinson et al., 2006).  In relation to LDL+VLDL oxidation, similar observations 
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were made in humans following consumption of muffins containing 22g DC and 12g cocoa 
versus muffins with cocoa butter only (Vinson et al., 2006).    
 
It is well acknowledged that the composition of LDL or atherosclerotic plaque, as well as 
lipid membranes is largely influenced by the composition of dietary fats as evident in that 
dietary fats are rapidly incorporated into atherosclerotic plaque which then influences plaque 
composition, hence plaque formation and rupture (Felton et al., 1994).  Cocoa butter is rich 
in monounsaturated oleic acid and polyunsaturated fatty acids (Hannum et al., 2002).  The 
fact that cocoa butter increases LDL oxidation suggest that though oleic acids decreases LDL 
susceptibility to oxidation (Nicolosi et al., 2004), the polyunsaturated fatty acids in cocoa 
butter with their large numbers of unsaturated fatty acids bonds appear to override the 
beneficial effects of oleic acid rendering cocoa butter atherogenic (Vinson et al., 2006).   
 
Nonetheless, such findings may also suggest that the anti-atherosclerotic properties of cocoa 
or DC could be enhanced by reducing the cocoa butter content of cocoa or DC.  It also 
suggests that the use of cocoa instead of DC may be more appropriate in conditions of 
increased oxidative stress wherein maximal inhibition of LDL oxidation is required.  It is 
notable that in contrast to Wan et al. (2001) and Osakabe et al. (2001), Vinson et al. (2006) 
failed to show any correlation between plasma epicatechin and LDL+VLDL oxidation lag 
time.  This led Vinson et al. (2006) to suggest that while polyphenols could reduce LDL 
oxidation through interaction with the LDL particle, this interaction requires time to occur, 
hence the lack of correlation.  Most importantly, this study showed that low-dose cocoa, 
which corresponded to two 40g DC bars per day, and high dose cocoa prevent the 
development of early-stage atherosclerosis by 40% and 36%, respectively, in  Syrian Golden 
hamsters (Vinson et al., 2006).  The similarity in results between the low and high 
polyphenols possibly implied that a saturation effect occurs with increasing polyphenols 
concentration, an effect that was also noted in relation to cholesterol, TG and LDL oxidation 
(Vinson et al., 2006).  
  
In general, the lag time of LDL oxidation serves as an index of the quantity and quality of 
antioxidants within LDL particles.  Prolongation of LDL oxidation lag time following cocoa 
or DC consumption suggests that the levels and quality of antioxidant within LDL is 
increased, which as stated by Vinson et al. (2006) is the result of incorporation of cocoa 
polyphenols into the LDL molecule. Indeed, red wine polyphenols have been shown to bind 
to human LDL and HDL particles (Ivanov et al., 2001). In relation to quercetin, this effect is 
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attributed to its ability to form glycosidic ether bonds with the LDL molecule resulting in 
decreased metal-ion induced LDL oxidation and aggregation, hence decreased lesion size 
(Aviram and Fuhrman, 2002).  Increased paraoxonase activity and flavonoid accumulation in 
macrophages is another mechanism by which quercetin reduces LDL oxidation and uptake 
(Aviram and Fuhrman, 2002).  It is likely that cocoa polyphenols act via similar mechanisms 
to inhibit LDL oxidation.  This is evident in that consumption of cocoa results in reduced 
atherosclerotic lesion size in animal models of atherosclerosis (Kurosawa et al., 2005). 
Cocoa consumption have also been reported to reduce wall thickness and cholesterol content 
of aorta, although the change in the latter was not significant (Kurosawa et al., 2005). 
 
In addition to the above findings, acute reduction in F-2 isoprostane levels, which according 
to Wan et al. (2001) are a more direct measure of lipid peroxidation,  have been reported 
following ingestion of cocoa (Wiswedel et al., 2004).  Such findings were, however, not 
observed following 6 weeks consumption of a combination of 36.9g DC and 30.95g cocoa 
by healthy volunteers, despite that lag time of LDL oxidation was prolonged by 9.8% 
reflecting a reduction in copper-induced LDL oxidisation (Mathur et al., 2002). Mathur et al. 
(2002) explained the lack of significant change in F2-isoprostane to be the result of the use 
of a single morning urine sample rather than a 24h urine sample. Mathur et al. (2002) also 
failed to report any significant changes in plasma total antioxidant capacity or plasma 
polyphenols levels.  Mathur et al. (2002) argued that this effect was due to blood samples 
having been taken after an overnight fast rather 2h following cocoa ingestion when 
epicatechin levels are at their highest.  However, since reduced LDL oxidation was still 
observed 12h following DC consumption, this suggests that polyphenols affect LDL 
oxidation via mechanisms other than their antioxidant activity. For instance, via their 
sparring effects on α-tocopherol (see studies by Baba et al. (2000) and Lotito et al. (2000) p. 
67 and p. 908). 
 
In Baba et al.‘s (2007a) study, a negative correlation was observed between plasma 
concentrations of HDL, but not LDL cholesterol, and oxidized LDL.  Baba et al. (2007a) 
suggested that HDL could influence LDL oxidation through inhibition of monocyte 
chemotaxis, breakdown of lipid peroxide via paraoxonase, reverse cholesterol transporter via 
lecithin-cholesterol transferase and inhibition of vascular endothelium activation via 
apolipoproteinA1.  Indeed, the ability of HDL to prevent LDL oxidation have been reviewed 
by Mackness and Durrington  (1995) who argued that enzymes like paraoxonase, lecithin: 
cholesterol acyl transferase, platelet activating factor acetylhydrolase, phospholipase D and 
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protease, which are present on the surface of HDL may influence LDL oxidation (Mackness 
and  Durrington, 1995). In addition to these enzymes, apolipoprotein AI has been shown to 
reduce LDL oxidation by increasing HDL‘s anti-inflammatory action and by enhancing 
macrophage reverse cholesterol transport (Moore et al., 2005).   
 
It is important to note that some studies failed to report any significant change in lipid profile 
(Mathur et al., 2002, Engler et al., 2004, Grassi et al., 2005a, Taubert et al., 2007) or in LDL 
oxidation (Engler et al., 2004) following DC (see Table 1.8).  In relation to lipid profile, 
cocoa polyphenols could prevent atherosclerosis development without significantly altering 
lipid profile.  For instance, consumption of a diet containing 1% cacao liquor polyphenols 
for 10days by hypercholesterolaemic rabbits have been reported to increase lag time of LDL 
oxidation and to decrease TBARS without significantly affecting lipid profile (Osakabe et 
al., 2000). Based on the results of this study, Kurosawa et al. (2005) investigated the effect 
of a similar diet containing 1% cacao liquor polyphenols on atherosclerosis development in 
rabbits.  As with Osakabe et al. (2000), Kurosawa et al. (2005) demonstrated that cocoa 
increased resistance against LDL oxidation and decreased TBARS significantly at the end of 
the first 2 and 3months of the 6 month trial without significantly altering plasma cholesterol, 
TG or phospholipids  (Kurosawa et al., 2005). They argued that the decrement in LDL 
oxidation will lead to decreased foam cell formation, which was confirmed by the observed 
reduction in the area of atherosclerotic lesion following cocoa consumption (Kurosawa et al., 
2005). The importance of this study lies in that Kusagni rabbits reflect a more advanced and 
severe model of atherosclerosis (Vinson et al., 2006) which suggests that cocoa and DC 
polyphenols can act at different stages of atherosclerosis.  In rats, consumption of cocoa have 
also been reported to attenuate the accumulation of lipid peroxides in plasma and to spare 
plasma α-tocopherol from oxidation by the water-soluble free radical generator 2, 2‘-azobis-
(2-amidinopropane) dihydrochloride (AAPH) or copper sulphate, with an inverse correlation 
being observed between plasma epicatechin and lipid peroxides and a positive association 
between plasma epicatechin and α-tocopherol (Baba et al., 2000).  Attenuation of lipid 
peroxidation as measured by TBARS have also been documented ex-vivo (Lotito and Fraga, 
2000) 
 
Cocoa is also rich in fiber.  In a study by Lecumberri et al. (2007), supplementing the diet of 
rats with 165 g of cocoa fiber per kilogram reduced TG, total cholesterol and LDL-
cholesterol, though the latter two did not reach baseline values.  Decreased lipid peroxidation 
in serum and liver was also observed in both hypercholesterolaemic and 
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normocholesterolaemic rats, although no significant changes in total antioxidant capacity or 
the activity of antioxidant enzymes and glutathione levels in liver were seen (Lecumberri et 
al., 2007).  In another study, cocoa fiber obtained from cocoa husks was found to counteract 
the effects of lipid-rich diet by preventing fat-induced decline in HDL-cholesterol and fat-
induced rise in total cholesterol (TC), LDL-cholesterol and lipid peroxidation (Ramos et al., 
2008).  Cocoa fiber also reduced food intake, body weight gain and TG levels to values 
lower than those in the group fed the cholesterol-free diet (Ramos et al., 2008). 
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Table 1.8 Summary of studies investigating the effect of polyphenol-rich dark chocolate and cocoa on lipid profile. 
Study Study Design Population Number of 
participants 
Dose Placebo/Control Assessed 
parameter 
Change 
significant? 
Wan 
2001 
Randomised, parallel-
group, 4 weeks 
healthy  23 (10 men, 13 
women) 
22 g cocoa powder and 
16 g DC 
466 mg procyanidins 
Average American 
Diet 
LDL 
oxidation, lipid 
profile 
LDL oxidation lag 
time  and HDL 
increased  
Mathur 
2002 
Non-randomised trial, 
subjects studied at the 
end of  6 weeks DC and 
at the end of 6weeks 
follow-up period 
Healthy 25 (12 females, 
13 males) 
36.9 g DC and 30.95 g 
cocoa drink 
651mg procyanidins 
Habitual diet LDL 
oxidation, lipid 
profile 
LDL oxidation lag 
time  
 
Engler 
2004  
14days healthy adults 21 46g DC  
213 mg procyanidins, 
46 mg epicatechin 
Low-flavonoid DC LDL 
oxidation, lipid 
profile 
No 
Fraga 
2005 
Crossover, 2 weeks Soccer players 27 males 105g DC 
168mg of flavanols; 39 
mg catechin and 
epicatechin 
105g white 
chocolate 
Lipid profile TC -0.47mmol/L 
LDL - 0.4mmol/L 
Grassi 
2005a 
Randomised, crossover, 
15 days 
Healthy  15 (7 males, 8 
females 
100g DC 
500mg polyphenols 
88mg flavanols 
90g white chocolate Lipid profile No 
Grassi 
2005b 
Randomised, crossover, 
15 days 
never-treated, 
grade I
 
patients 
with essential 
hypertension 
20 (10 males, 10 
females) 
100g DC 
500mg polyphenols 
88mg flavanols 
90g white chocolate Lipid profile TC -0.4mmol/L 
LDL -0.4 mmol/L 
 
Continued... 
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Table 1.7...  Continued 
Study Study Design Population Number of 
participants 
Dose Placebo/Control Assessed 
parameter 
Change 
significant? 
Baba 
2007a 
Randomised, 
parallel-group, 12 
weeks 
normocholesterolaemic 
and mildly 
hypercholesterolaemic 
humans 
25 12g sugar and 26g 
cocoa 
41.08mg 
procyanidins; 
98.02mg 
epicatechin 
12 g sugar LDL 
oxidation, 
lipid profile 
HDL rose by 
24% 
Baba 
2007b 
Parallel-group, acute normocholesterolaemic 
and mildly 
hypercholesterolaemic 
humans 
160 3 polyphenol-rich 
cocoa drinks  
13, 19.5, and 26 g 
cocoa (65, 97 and 
129mg epicatechin) 
Low-polyphenol 
cocoa 
Lipid profile 
and oxidised-
LDL 
LDL, oxidized 
LDL, and
 
apolipoprotein B 
decreased 
HDL increased 
in subjects with 
LDL 3.23 
mmol/L 
Balzer 
2008 
Randomised, parallel 
control, 30 days 
Type-II diabetics 44 of which 3 
dropped-out  
(29 females and 
12 males) 
18g cocoa 321 mg
 
flavanols taken 
thrice daily (Total 
963mg flavanols) 
18g cocoa 25 mg 
flavanols
 
taken 
thrice daily 
(Total 75mg 
flavanols) 
Lipid profile LDL decreased 
by 0.02mmol/L 
Grassi 
2008 
Randomised, 
crossover, 15 days 
hypertensives with 
impaired glucose 
tolerance 
19 (11 males, 8 
females) 
100g DC 
500mg polyphenols 
90g white chocolate Lipid profile No 
Hamed 
2008 
 Open-label trial,  
7 days 
Healthy 28 700mg flavonoids Baseline  Lipid profile LDL fell by 6% 
and HDL rose by 
9%  
Nanetti 
2008 
Open label, 3 weeks Healthy 10 50g DC Baseline Lipid profile, 
lipid 
peroxidation 
HDL increased 
Conjugate 
formation in 
HDL and in LDL 
decreased 
Al-Faris 
2009 
Parallel-group 
15days 
Healthy 89 females 100g DC  
500mg polyphenols 
90g white chocolate 
or habitual diet 
Lipid profile No 
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1.11.6.b Effect of green coffee bean extract 
Coffee prolongs lag time of LDL oxidation (292-948min) to a greater extent than a serving 
of cocoa (217-444min), green tea (186-338min) or black tea (67-277min) (Richelle et al., 
2001) and its individual components particularly CGA possess the ability to inhibit lipid 
peroxidation (Kono et al., 1997).  However certain components present in unfiltered coffee 
such as diterpenes can increases
 
serum levels of total and LDL cholesterol (Jee et al., 2001) 
via  activation of CETP and inhibition of lecithin-cholesterol acyltransferase
 
 (De Roos et al., 
2000).  Diterpenes are also present in green coffee beans in the following concentrations: 
1.3% w: w in coffea Arabica and 0.2% w: w in coffea robusta (Urgert et al., 1995).    
Because of the diversity of GCBE components it is important to monitor the effect of CGA-
rich GCBE on lipid profile.  So far in one study in  obese, hyperlipidaemic, and insulin 
resistant (fa/fa) Zucker rats, treatment with CGA was shown to  reduce fasting plasma 
cholesterol and TG by 44% and 58%, respectively (Rodriguez et al., 2002).  These results 
were not replicated in humans wherein ingestion of GCBE supplying 140mg CGA for 4 
months failed to produce any significant changes in lipid profile (Ochiai et al., 2004).   It is 
likely that the effect of CGA in rats was exaggerated since CGA was administered via 
intravenous infusion which does not take into account metabolism by the liver.  In humans, 
the lack of an effect of CGA-rich GCBE on lipid profile could be explained by the method of 
GCBE administration.  Ochiai et al. (2004) provided GCBE in the form of a drink (125 ml), 
and it is well recognised that the food matrix and even fluid volume in which a 
pharmaceutical compound is administered could influence the bioavailability of the active 
components (Toothaker and Welling, 1980).  In fact some phenolic compounds are more 
bioavailable in fluid forms (Chen et al., 1997) while others require encapsulation to protect 
the active components in the digestive track (Parada and Aguilera, 2007). As such the effect 
of CGA-rich GCBE on TC, TG, HDL and LDL levels remains unclear. 
 
1.11.7 Polyphenols and glucocorticoid metabolism 
Polyphenols could influence cortisol and corticosteroid metabolism in several ways (see 
Table 1.9).  For instance, ingestion of liquorice and grapefruit juice polyphenols have been 
reported to increase plasma cortisol causing severe hypokalaemia and hypertension (Sardi et 
al., 2002).  Similarly, drinking grapefruit juice, rich in the flavonoids naringenin, quercetin 
and hesperetin, have been shown to decrease urinary cortisone-to-cortisol ratio (Lee et al., 
1996).  These effects occur through inhibition of 11βHSD2 (Song et al., 1992, Lee et al., 
1996, Guo et al., 1998, Sardi et al., 2002).   
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Table 1.9  Summary of the endocrine actions  and the metabolic sequelae of 
antioxidants and polyphenol-rich products. 
 
 
By contrast, extracts of freshly ground roasted Coffea Arabica L have been shown to inhibit 
11βHSD1 activity and to prevent glucocorticoid-receptor translocation, glucocorticoid-
induced expression of PEP-CK and gluconeogenesis (Atanasov et al., 2006).  These effects 
were observed even following removal of caffeine suggesting that compounds other than 
caffeine were responsible for coffee‘s dose-dependent inhibitory action against 11βHSD1 
(Atanasov et al., 2006).  Although Atanasov et al. (2006) were unable to identify the 
compound responsible for coffee‘s inhibitory activity, they characterised the compound as 
being highly polar and thermo-stable which is consistent with the chemical properties of 
CGA (see Figure 1.14; note the polar OH groups). CGA has consistently been reported to 
reduce cortisol concentrations by inhibiting glucose-6-phosphate transport into the lumen of 
Study Antioxidant or 
polyphenol-rich food 
Model Endocrine action/ physiological effects 
Song 1992 Gossypol 
glycyrrhetinic acid 
Kidney ↓ 11βHSD2 
Lee 1996 Grapefruit  Kidney 
microsomes, 
Humans 
↓11βHSD2 
↓ urinary cortisone/cortisol ratio 
Arion 1997; 
1998 
Chlorogenic acid and 
Chlorogenic Acid 
Analogue S 3483 
 
Liver 
microsomes 
↓glucose 6-phosphatase 
Hemmerle 
1997 
Chlorogenic acid Liver 
microsomes 
↓ glucose-6-phosphate translocase 
↓gluconeogenesis and glycogenolysis 
 
Guo 1998 quercetin, tea 
polyphenols, 
furosemide, and 
gossypol 
Cortex 
microsomes 
↓11βHSD2 
Ohtsuka 
1998 
Vitamin E Sprague-
Dawley rats 
↓lipid peroxidation and skeletal muscle 
oxidative stress 
Sardi 2002 Liquorice 
Grapefruit 
humans ↓11βHSD2 
Hypertension, hyperkalaemia 
Eid 2003 Dietary polyphenols Broiler chicken ↓ corticosterone and corticosterone-
induced oxidative stress, hyperlipidaemia, 
abdominal fat content, liver weight, lipid 
peroxidation 
Schweizer 
2003 
Flavanone from stably 
transfected cells 
Selective inhibition of 11βHSD1 but not 
11βHSD2  
Atanasov 
2006 
Caffeinated/ 
Decaffeinated coffee 
HEK-293 cells ↓11βHSD1 
Miguet 
2006 
Flavonone in silico 
screening 
↓11βHSD1 
Ajd anovi  
2009 
Genistein Wistar rats ↑DHEA secretion  
↓ corticosterone and aldosterone secretion 
Gumy 2009 Extract of Eriobotrya 
japonica 
Roasted coffee 
HEK-293 cells Selective inhibition of 11βHSD1 but not 
11βHSD2 
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endoplasmic reticulum (Arion et al., 1997, Hemmerle et al., 1997) (Figure 1.20).  In general, 
glucose-6-phosphate acts as a substrate for hexose-6-phosphate dehydrogenase, an enzyme 
that generates NADPH (Banhegyi et al., 2004).   Because NADPH is necessary for 
maintaining 11βHSD1‘s reductase activity (Banhegyi et al., 2004), inhibition of glucose-6-
phophate translocase causes a reduction in microsomal glucose-6-phosphate levels leading to 
diminished NADPH generation, impaired 11βHSD1 reductase activity, hence reduced 
cortisol generation.  Glucose-6-phophatase is also central to the regulation of 
gluconeogenesis and glycogenolysis (Hemmerle et al., 1997) and inhibition of glucose-6-
phosphate translocase have been shown to reduce plasma glucose concentrations in rats and 
mice (Parker et al., 1998). Treatments with dietary polyphenols and vitamin-E have also 
been demonstrated to reverse corticosterone-induced oxidative stress, lipid peroxidation, 
hyperlipidaemia and abdominal fat accumulation in animals (Ohtsuka  et al., 1998; Eid et al., 
2003).  More recently, the composition of dietary macronutrients have been shown to 
produce both acute and chronic effects on cortisol metabolism (Basu et al., 2006; Wake et 
al., 2006; Stimson et al., 2007).  In fact, consumption of dietary fat or high-fat low-
carbohydrate diets have been documented to replicate the changes in cortisol metabolism and 
11βHSD1 activity that are seen in obesity and the metabolic syndrome (Morton et al., 2004a; 
Drake et al., 2005; Stimson et al., 2007).    
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Figure 1.20 Inhibition of glucose-6-phosphate by CGA (Kenyon, see Dickinson, 2007). 
 
 
 
However given the limited studies conducted in humans and the growing evidence 
suggesting a potential role of diet and nutrition in regulating glucocorticoid metabolism and 
the ability of polyphenols to both adversely and positively affect cortisol metabolism (see 
Table 1.9 and London and Castonguay, 2009), investigating the effect of phenolic 
compounds, such as CGA in GCBE and DC polyphenols, on cortisol metabolism in 
overweight and obese individuals and assessing for a correlation between cortisol, glucose, 
insulin, and blood pressure and lipid profile might be essential to elucidating the mechanisms 
by which these phenolic compounds influence the above metabolic parameters.  This is 
particularly true when considering that currently efforts are being made to identify selective 
11βHSD1 inhibitors as novel treatments for obesity and the metabolic syndrome (Seckl et 
al., 2004). 
 
  
Glucose-6-phosphate 
6-phosphoglucono-δ-
lactone 
Glucose-6-phosphate 
dehydrogenase 
Hexose phosphate 
dehydrogenase 
Glucose-6-phosphate 
6-phosphoglucono-δ-
lactone 
 
NADP NADPH 
NADP NADPH 
11-dehydrocortisosterone corticosterone 
11βHSD1 
 
Lumen of endoplasmic reticulum 
Glucose-6-phosphate 
transporter 
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1.12. Overview and rationale for Thesis 
The following statements summarise the key themes discussed in Chapter 1: 
 
 Overweight and obesity are complex multi-factorial conditions that are associated 
with a wide array of metabolic sequelae including insulin resistance, hypertension 
and dyslipidaemia. 
 Insulin resistance lies at the centre of obesity-related complications with this 
pathophysiological feature being influenced by excess adiposity and defects in 
glucocorticoid metabolism and oxidative stress. 
 Polyphenols are a large and diverse group of antioxidants whose clinical importance 
arises from their wide distribution in the diet and their ability to regulate various 
physiological, endocrinological and antioxidant processes.   
 Hydroxycinnamic acids and flavonoids are the two main classes of polyphenols that 
can act as potential therapeutic compounds. 
 GCBE and DC are key dietary sources of hydroxycinnamic acids and flavonoids, 
respectively, and considerable evidence exists to suggest a role for these 
polyphenols-rich products in modulating glucose metabolism, blood pressure and 
lipid profile. 
 
Against this background, it could be hypothesised that polyphenol-rich products such as 
GCBE and DC, with their antioxidant properties and ability to regulate glucose, lipid and 
blood pressure homeostasis via various biochemical and endocrinological mechanisms 
(discussed in Section-1.10 to section 1.11.7) may be critical to modulating insulin resistance, 
hypertension and dyslipidaemia in overweight and obesity.  This is particularly evident when 
considering that these metabolic abnormalities are closely linked to increased risk of type II 
diabetes, hypertension and CVD.  The clinical relevance of polyphenols could also be 
derived from their potential ability to counteract the endocrinological imbalance and 
oxidative stress that often underlie overweight and obese-related insulin resistance.  Notably, 
the role of polyphenols in glucocorticoid metabolism emerges as a promising field of 
research as few studies exit in this area despite the established role of glucocorticoid in the 
regulation of glucose metabolism, body weight and oxidative stress and the mounting 
evidence concerning the involvement of HPA hyperactivity in the pathogenesis of obesity-
related complications.  Moreover, it remains unknown whether polyphenols can selectively 
and differentially target defects in glucocorticoid metabolism in liver, kidney and adipose 
tissue, which could have important implication to the treatment of overweight and obesity 
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and prevention of hepatic FFA accumulation. The diversity and complexity of polyphenols 
also implies that differences may exist between the mechanisms of action of the various 
polyphenolic groups.   As such improving our understanding of basis of the health-
promoting properties of polyphenols is central to identifying the most relevant polyphenolic 
classes to overweight and obesity and towards designing effective dietary strategy aimed at 
preventing or reducing the occurrence of chronic conditions.  Finally, it remains to be stated 
that at the time this thesis was first initiated only one randomised-controlled trial had 
examined the effect of GCBE on weight management in overweight an obese individuals 
(Dellalibera et al., 2006) and almost none have investigated the potential therapeutic 
properties of GCBE and DC in counteracting overweight and obesity-related complications.  
 
1.13. Aim of the Thesis 
This PhD research aims to investigate the effect of polyphenol-rich GCBE and DC on 
glucoregulatory biomarkers, blood pressure and lipid profile in overweight and obese 
individuals, the hypothesis being that polyphenol-rich GCBE and DC may improve 
glucoregulatory biomarkers, blood pressure and lipid profile in overweight and obese 
individuals.  To test this hypothesis and to achieve this overall aim, a series of in vitro, 
animal and human studies were conducted, the aims of which are described below.   
 
Objective 1: In vitro studies 
The in vitro work consisted of two studies, which aimed: 
1. To test the antioxidant properties and free-radical scavenging capacity of green 
coffee and Theobroma cacao bean extracts using three different extraction methods 
and  a panel of in vitro antioxidant assays including Folin-Ciocalteu, FRAP, ORAC 
and DPPH.   
2. To explore the potential inhibitory properties of green coffee and Theobroma cacao 
bean extracts on pancreatic lipase with a view of elucidating the mechanisms for the 
lipid-lowering effects of green coffee and Theobroma cacao bean extracts described 
in the literature. 
 
Objective 2: Animal studies 
1. To examine the effect of chlorogenic acid on tissue glucocorticoid levels in mice and 
to assess for tissue-specific differences in the effect of chlorogenic acid on 
glucocorticoid metabolism.  
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Objective 3: Human studies  
The human studies consisted of two preliminary studies and one main trial with the 
following aims: 
 
Green coffee bean extract: Preliminary study 
1. To examine the effect of GCBE on fasting glucose, blood pressure, total cholesterol, 
urinary cortisol, cortisone and cortisone-to-cortisol ratio in overweight and obese 
subjects 
 
Dark chocolate: Preliminary study 
1. To examine the effect of different doses of polyphenol DC on fasting glucose, blood 
pressure, total cholesterol, urinary cortisol, cortisone and cortisone-to-cortisol ratio 
in overweight and obese subjects and to identify minimum DC dose capable of 
inducing a significant reduction in fasting glucose. 
2. To determine whether the outcome of the preliminary study necessitates the need to 
conduct a large-scale, long-term study. 
 
Main dark chocolate study 
1. To elaborate further on the effect of polyphenol-rich DC on glucoregulatory biomarkers, 
blood pressure and lipid profile in overweight and obese females. 
 
Specific rationales for conducting in vitro, animal and humans studies and the significance of 
these studies are also provided below. 
 
1.13.1 Rationale for investigating antioxidant properties of green coffee 
and Theobroma cacao bean extracts 
Oxidative stress is one of the underlying and key factors involved in the pathogenesis of 
chronic diseases (Brownlee, 2001, 2005). Understanding the antioxidant properties of dietary 
compounds is particularly important in relation to overweight and obesity, since these 
conditions are characterised by a state of systemic and adipose-tissue oxidative stress 
(Keaney et al., 2003, Furukawa et al., 2004).   Moreover, in recent years multiple forms of 
insulin resistance have been linked to ROS overproduction (Houstis et al., 2006).  Since 
insulin resistance is central to the pathogenesis of overweight and obesity-related 
complications (see Section 1.3), examining the potential antioxidant properties of GCBE and 
Theobroma cacao bean extract (TCBE) could be pivotal to elucidating the molecular 
mechanisms by which these antioxidant-rich products may protect against disturbances in 
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insulin sensitivity and glucose homeostasis.  The rationale behind selecting various 
extraction methods and antioxidant assays was to give insight into the variability of 
extraction methods and to provide a detailed antioxidant profile for both GCBE and TCBE 
(Ou et al., 2001, Huang et al., 2005; Prior et al., 2005).   In relation to the latter, the diversity 
of ROS, the complexity of the antioxidant mixtures present in food products and variations 
in their mechanisms of action imply that no standard assay is capable of measuring the 
ability of antioxidants to scavenge all of the different ROS (i.e. total antioxidant activity) in a 
single reaction medium (Huang et al., 2005, Prior et al., 2005).  As a result, both electron 
transport (ET)-based antioxidant assays such as Folin-Ciocalteu (FC), FRAP and DPPH and 
hydrogen atom transfer (HAT)-based assays such as ORAC need to be employed if a 
comprehensive antioxidant profile is to be gained (Huang et al., 2005, Prior et al., 2005).   
 
Data from this experiment was subsequently used to estimate the potential contribution of 
GCBE, TCBE and Theobroma cacao‘s products such as polyphenol-rich DC to the total 
antioxidant intake in the UK adult population.  The data obtained from this study also served 
as the basis for examining GCBE and TCBE‘s potential inhibitory activities on pancreatic 
lipase. 
 
1.13.2 Rationale for investigating the effect of green coffee and 
Theobroma cacao bean extracts on pancreatic lipase 
It is increasingly recognised that polyphenols can affect the activity of numerous enzymes 
that regulate glucose, protein and lipid metabolism.  Consistent with this several studies have 
shown that extracts of Salacia reticulate (Yoshikawa et al., 2002), grape seed (Moreno et al., 
2003), berries (McDougall et al., 2005, McDougall and Stewart, 2005), oolong tea (Nakai et 
al., 2005) and green tea (Koo and Noh, 2007) inhibit α-amylase, α-glucosidase, trypsin and 
pancreatic lipase.  Inhibition of pancreatic lipase, in particular, by polyphenolic-rich plant 
extracts offers a natural dietary approach to preventing obesity.  This if combined with the 
ability of polyphenols to improve antioxidant status and reduce risk of diabetes, hypertension 
and coronary heart disease will result in additional benefits to obesity, the reduction of 
obesity-related complications 
 
Obesity is characterised by an imbalance between energy intake and energy expenditure.  
Strategies aimed at preventing or treating obesity often focus on blocking fat absorption and 
enhancing thermogenesis, amongst others (see review by Bray and  Tartaglia, 2000).  Both 
GCBE and cocoa reportably affect various pathways involved in lipid metabolism.   In 
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relation to GCBE, Shimoda et al. (2006) has demonstrated that GCBE reduces hepatic TG 
and visceral fat accumulation while enhancing the activity of carnitine-palmitoyltransferase.  
Cocoa, on the other hand, has been shown to reduce serum TG, downregulate fatty acid 
synthesis and transport in liver and adipose in addition to stimulating thermogenesis (Matsui 
et al., 2005).  All of the above evidence highlights the need for investigating the effect of 
GCBE and TCBE  on pancreatic lipase. 
 
1.13.3 Rationale for preliminary green coffee bean extract study 
Several studies have linked consumption of GCBE rich in CGA with reduced blood pressure 
(Suzuki et al., 2002; Kozuma et al., 2005, Suzuki et al., 2006; Watanabe et al., 2006).  
GCBE have also been shown to regulate glucose metabolism and improve glycaemic control 
in a range of in vitro, animal and human trials (Sirinek et al., 1983; Welsch et al., 1989; 
Hemmerle et al., 1997; Johnston et al., 2003; Wu et al., 2005; Blum et al., 2007; Bassoli et 
al., 2008). However, the relevance of these findings to overweight and obese population 
remains unknown.  To date no study has investigated the effect of GCBE consumption on 
blood pressure regulation in overweight and obesity despite excess body weight being the 
most common cause of essential hypertension (Fletcher et al., 1999).  Moreover data on the 
blood pressure-lowering effects of GCBE in healthy normotensives subjects are conflicting 
(Ochiai et al., 2004).  In relation to glycaemic control, although Blum et al. (2007) has 
reported improved glucose tolerance in individuals with BMI> 25kg/m
2
 following 40 days 
consumption of 200mg GCBE three times a day, the mechanism concerning this glucose-
lowering effect remains speculative.  The present open-label prospective non-blinded 
preliminary trial was based on the hypothesis that GCBE may reduce the above 
cardiometabolic risk factors in overweight and obese individuals through its potent 
antioxidant properties (see Section 3.1) and its potential inhibitory activity against pancreatic 
lipase (Section 3.2) and possibly 11βHSD1 (Section 1.11.7). 
 
1.13.4 Rationale for animal study 
Increased 11βHSD1 activity is implicated in the development of the metabolic syndrome 
(Lindsay et al., 2003, Seckl et al., 2004). Identifying natural compounds that influence 11 
βHSD1 activity could lead to novel methods of treating obesity, CVD and diabetes.  To 
elaborate further on the findings of the preliminary GCBE study and to establish the 
implications of the observed changes in glucocorticoid levels to overweight and obesity, the 
animal study was conducted to examine the effect of CGA on tissue corticosterone levels in 
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mice, corticosterone being the analogous of cortisol in humans.  This study was part of a 
larger trial investigating CGA‘s potential therapeutic effects against the metabolic syndrome, 
especially in relation to glucose and lipid metabolism (Dickinson, 2007).  Examining CGA 
effects on tissue glucocorticoid metabolism is particularly important considering that the 
main component of GCBE, CGA, can regulate hepatic FFA accumulation (Dickinson, 2007), 
an important factor contributing to the development of systemic insulin resistance (see 
Section 1.7.3).  Moreover, emerging findings suggest potential storage of CGA and its 
metabolite ferulic acid in the liver (Farah, 2009). Consequently, if CGA is proven to 
influence glucocorticoid metabolism in the liver, this may have important metabolic 
consequences to overweight and obesity since defects in hepatic 11βHSD1 are closely 
implicated in the development of obesity-related co-morbidities. 
 
1.13.5 Rationale for preliminary dark chocolate study 
Epidemiological studies link high polyphenol intake with reduced risk of oxidative stress-
related diseases like diabetes, hypertension and CVD (Buijsse et al., 2006; Pereira et al., 
2006; McCullough et al., 2006).  In particular consumption of cocoa and DC has been shown 
to improve endothelium function, insulin sensitivity, blood pressure in healthy individuals, 
hypertensives with or without glucose intolerance (Grassi et al., 2005a-b, 2008)   and obese 
subjects (Davison et al., 2008).  Cocoa and DC are rich sources of polyphenols providing on 
average more polyphenols per serving than red wine, green tea or black tea (Lee et al., 
2003).  These polyphenols confer potent antioxidant properties to cocoa and DC (Richelle et 
al., 2001; Lee et al., 2003) in addition to their ability to regulate NO (Grassi et al., 2005b, 
2008).   
 
Obesity is known to be associated with insulin resistance and elevated blood pressure 
(Section 1.2.3). One of the underlying factors linked to these cardiovascular risk factors is 
abnormal cortisol metabolism (Section 1.8.3).  Cortisol is a counter-regulatory hormone that 
is essential in the long-term maintenance of blood glucose and which could also 
unfavourably influence blood pressure (BP) and lipid profile (Section 1.8.1).   When present 
in excess, cortisol induces overproduction of ROS (Iuchi et al., 2003; Bjelaković et al., 
2007) leading to reduced endothelial NO synthase expression (Liu et al., 2009).  In obesity, 
particularly abdominal obesity, postprandial hypercortisolism and enhanced peripheral 
metabolism of cortisol, characterised by increased urinary cortisone-to-cortisol ratio, are 
observed which are linked to insulin resistance and increased fasting insulin (Vicennati and 
Pasquali, 2000).  Increased expression of subcutaneous adipose tissue 11βHSD1 has also 
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been reported which is known to impair glucose-stimulated insulin secretion (Alberti et al., 
2007).  Since improved NO bioavailability is the main mechanism by which DC polyphenols 
reduce endothelium dysfunction, insulin resistance and hypertension (Grassi et al., 2005a-b, 
Grassi et al., 2008), this preliminary DC study aimed to assess and compare the effect of DC 
containing two different doses of polyphenols on fasting capillary whole blood glucose 
levels, total cholesterol, BP, urinary free cortisol and cortisone excretion in healthy 
overweight and obese subjects.  The other objective was to observe whether improvements 
in fasting blood glucose, total cholesterol and BP could be correlated with changes in urinary 
free cortisol or cortisone excretion.  A secondary objective was to monitor magnesium intake 
and excretion since DC is known to contain large quantities of magnesium, which, in turn, 
could influence BP, insulin action and metabolic syndrome (Meisel, 2005; Song et al., 2005; 
Song et al., 2007). 
 
 
1.13.6 Rationale for main dark chocolate study 
Given the positive results of the preliminary study and the inheretent weaknesses of using 
capillary whole blood for measurements of glucose and total cholesterol, the main DC study 
was designed to elaborate further on the long-term effect of consumption of 500mg 
polyphenols DC on glucose, BP, lipid and glucocorticoid metabolism using more robust 
techniques.  The objective being to monitor several biomarkers of glucose metabolism 
including fasting glucose, fasting insulin, HOMA-IR, QUICKI, revised-QUICKI and 
HOMA-β alongside obtaining a detailed lipid and glucocorticoid profile.  In relation to 
glucocorticoids, this was achieved by quantifying urinary, salivary as well as serum cortisol 
and cortisone levels.  A secondary objective was to assess for differences in response to 
polyphenol-rich DC between lean females and overweight and obese females and to monitor 
for any changes in body composition in the overweight and obese group.   
 
Establishing the long-term benefits of consumption of 500mg polyphenols DC is important 
since it will provide information over the sustainability of the effect of polyphenols on 
glucose metabolism and BP.  Moreover, monitoring body composition is essential in the 
overweight and obese group given that 20g of DC provided an additional 100kcal and 7.34g 
of fat per day.  If proven to be effective, the advantage of using 500mg polyphenols as 
opposed to 1000mg could be seen in the potential greater palatability and acceptability of 
500mg DC to consumers, as a reduction in the polyphenol content also implies a reduction in 
the bitterness of chocolate. 
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2. General Materials and Methods 
2.1. In vitro studies 
2.1.1 Chemicals and validation of antioxidant assays 
Ascorbic acid, gallic acid and chlorogenic acid were from Sigma-Aldrich.  Folin-Ciocalteu, 
sodium carbonate, formic acid, ferrous sulphate, sodium acetate, 2,4,6-tris(2-pyridyl)-S-
triazine, ferric chloride, fluorescein, 2, 2‘-azobis-(2-amidinopropane) dihydrochloride 
(AAPH), 1, 1 –diphenyl-2-picilhydrazyl, , p-nitrophenyl laurate, Trition X-100 were 
obtained from Sigma (Poole, Dorset, UK).  Lipase was from porcine pancreas Type II 
(Sigma product L3126).  Acetonitrile, ethanol, glacial acetic acid, hydrochloric acid, sodium 
hydroxide, trolox were from Fisher Scientific (Loughborough, Leicestershire, UK).  All 
other chemicals and reagents were obtained from Sigma-Alrdich (Poole, Dorset, UK) unless 
otherwise stated. 
 
All antioxidant assays were validated by replicate analyses of known concentrations of 
standards as summarised in Appendix 1.  Accuracy was estimated by calculating the 
percentage deviation of measured standard from its expected concentration (Medina-Remon 
et al., 2009).  Precision was calculated by dividing the S.D. by the mean measured 
concentration to obtain the coefficient of variation (CV), which when conveyed as a 
percentage gives the relative standard deviation (R.S.D.) (Medina-Remon et al., 2009). 
 
2.1.2 Folin-Ciocalteu method 
2.1.2.a Principle of method 
The Folin-Ciocalteu (FC) method is a colorimetric assay which was adapted by Singleton 
and Rossi (1965) from an earlier method using Folin-Denis reagent.  It measures the ability 
of a sample to reduce yellow heteropoly phosphomolybdate-tungstate anions in the FC 
reagent to blue using GA as a standard (Singleton and Rossi, 1965).  The extensive use of 
GA as a standard in FC method is explained by the fact that GA represents the mean reaction 
between FC reagent and phenol aglycones and conjugates such as quercetin, catechin, 
procyanidins, caffeic and CGA (Singleton and Rossi, 1965).  Albeit non-specific, the 
simplicity and reproducibility of the FC method has permitted its extensive use in the 
literature for the quantification of total phenolic compounds in plant extracts and biological 
samples(Brat et al. 2006, McDougall et al., 2005; Roura et al., 2006). 
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2.1.2.b Preparation of extracts  
GCBE tablets were weighed to the nearest 0.0001g, grinded to a fine powder using a mortar 
and pestle, then dissolved in 20ml ethanol (EtOH) to give ethanol extract, in 20ml of 
acidified water (0.2% v/v formic acid/ water) to give acidified-water extract or in 20ml 
acetonitrile-water-formic acid solution  (50:50:2 v/v/v) to give acetonitrile extract.  The 
resulting mixtures were then extracted at room temperature at 200rpm for 30min on a 
Luckham, Model R100/TW rotatest shaker and centrifuged at 4000rpm for 15 min at 4
o
C to 
remove any solid material.  After centrifugation, the sample was run through porous-free 
filter using vacuum and the resulting solution collected in a Schlenk flask.  
 
For TCBE, 20g of Theobroma Cacao bean was dissolved in 200ml of acetonitrile-water-
formic acid solution  (50:50:2 v/v/v), homogenised 3 times to remove fat materials using 
Ultra-Turrax homogenizer (Rose Sci Ltd) and then extracted on a rotatest shaker, as 
described above.  Samples were treated with rotary evaporation to remove acetonitrile then 
loaded onto a 12-ml bed volume C18-E Giga Tube (Strata, Phenomenex, UK) previously 
conditioned and equilibrated with 98% methanol (MeOH) and acetone, respectively. Loaded 
samples were then washed with acidified water to obtain the unbound fraction. The bound 
fraction, rich in proanthocyanidins, was eluted with 2x 12ml acetonitrile.  To extract the 
polyphenols further, solid-phase extraction was repeated 3 times using the unbound fraction 
instead of sample.  
 
All extractions were carried out in triplicates and the coefficient of variation for each 
extraction was calculated (Hammerstone et al., 2000).  This was to examine whether any 
differences in procyanidin content were related to variation in the samples or extraction 
method (Hammerstone et al., 2000). 
 
2.1.2.c Standards 
A 50mg/L GA stock standard was prepared and serially diluted in water to give the 
following concentrations: 5, 10, 20, 30, 40, 50mg/L GA. 
 
2.1.2.d Measurement of total phenolic content 
Total phenol content of extracts was determined using a modification of the method of 
Singleton and Rossi (1965).  Briefly, 250µl of half-strength FC reagent (FC diluted 1:1 in 
distilled water) was added to a 1.6ml cuvette (Fisher Scientific, Leicestershire, UK) 
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containing 250µl of standard or diluted sample (1% dilution).  Following a 3-min incubation, 
500µl sodium carbonate (130g sodium carbonate in 1L water) was added and the samples 
were left to stand in darkness for 1h.  Absorbance was read at 750nm against a water blank 
using an Ultraspec II spectrophotometer (LKB Biochrom Ltd, UK).  A standard curve was 
constructed by plotting absorbance (nm) against known concentrations of GA standards and 
results were expressed as mmol gallic acid equivalents (GAE) per litre.  All test samples 
were analysed in triplicates. 
 
2.1.3 Ferric-reducing capacity of plasma 
2.1.3.a Principle of the method 
The use of the FRAP assay as a measure of total antioxidants was first described by Benzie 
and Strain (1996).  The FRAP assay is a colorimetric  assay used to measure the ability of a 
sample to reduce the straw-coloured ferric-2, 4, 6-tri-2pyridyl-s-triazine (TPTZ-Fe
3+
) 
complex to the blue-coloured ferrous-2, 4, 6-tri-2-pyridyl-s-triazine (TPTZ-Fe
2+
) form under 
acidic conditions (Benzie and Strain, 1996).  Compared to ORAC and DPPH, the FRAP 
assay has the advantage of directly measuring the concentration of reductants in any given 
sample (Halvorsen et al., 2002).   
 
2.1.3.b Preparation of extracts 
Extracts were prepared as for FC method. 
 
2.1.3.c Standards 
Ferrous sulphate (0.278g) was weighed and dissolved in 1 L of distilled water to give a 1mM 
stock solution.  The stock was serially diluted in phosphate buffer saline (PBS) to give the 
following standard concentrations:  0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mM Fe
2+
. 
 
2.1.3.d Acetate buffer 
A 300mM acetate buffer solution (pH 3.6) was prepared by dissolving 3.1g sodium acetate 
and 16ml of glacial acetic acid in 1 L of distilled water.   
2.1.3.e Ferric-2, 4, 6-tri-2-pyridyl-s-triazine  
A 10mM TPTZ solution was prepared by dissolving 0.031g TPTZ in 10ml of 40mM 
hydrochloric acid (HCL). 
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2.1.3.f Ferric chloride 
A 20mM ferric chloride solution was prepared by adding 0.054g of ferric chloride in 10ml 
distilled water. 
 
2.1.3.g Working ferric-reducing capacity of plasma solution 
The working FRAP solution was prepared by combining 100ml of 300mM actetate buffer 
(pH 3.6) with 10ml ferric chloride, 12ml distilled water followed by 10ml of TPTZ.  The 
TPTZ solution was added drop-wise giving a straw coloured working FRAP solution. Any 
traces of a blue colour were suggestive of contamination with a reducing compound 
indicating the need to discard the solution.  The working FRAP solution was kept in a water 
bath at 37
o
C. 
 
2.1.3.h Measurement of ferric-reducing capacity of plasma 
To a 96-well microplate, 6μl of standard or diluted sample was added, followed by 200μl of 
FRAP reagent.  The plate was left to incubate in an oven at 37
o
C for 4min and absorbance 
read at 600nm using a Dynex Technologies MRX microplate reader (Dynex Technologies 
Ltd, Worthing, UK). Results were expressed in mmol Fe
2+
 per litre.  
 
2.1.4 Oxygen radical absorbance capacity 
2.1.4.a Principle of method 
The ORAC method was initially developed by Cao et al. (1993, 1995, and 1999), adapted by 
Ou et al. (2001) and subsequently optimised by Girard-Lalancette et al. (2009).   Its principal 
is based on the oxidation of a fluorescent probe by peroxyl radicals generated by AAPH (Ou 
et al., 2001).   This oxidation (decay) results in a decline in fluorescence intensity that could 
be captured over time using a fluorometer (Huang et al., 2005).  Since Antioxidants could 
delay peroxyl-radical induced  fluorescence decay, the antioxidant capacity of a compound 
or biological sample could  quantified by comparing the area under the fluorescence decay 
curve (AUC) of the sample against the AUC of the blank (Ou et al., 2001, Huang et al., 
2005).   
 
Unlike most antioxidant assays the ORAC assay has the advantage of measuring the rate and 
the degree of free-radical inhibition by an antioxidant based on the HAT mechanism (Cao et 
al., 1998).  Most other antioxidant assays like FC and FRAP use a single ET reaction (Prior 
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et al., 2005).  This led a number of authors to suggest that the ORAC assay is 
physiologically more relevant since it is capable of directly  measuring the chain-breaking 
(free-radical scavenging) activity of a sample as opposed to simply providing a measure of 
the potential reducing-capacity of a sample (Ou et al., 2001, Huang et al., 2005, Prior et al., 
2005).  Moreover, ORAC can quantify the ability of an antioxidant to scavenge the peroxyl 
radical involved in lipid peroxidation (Prior et al., 2005).   This could be best illustrated by 
Equation 1 and Equation 2. Equation 1 shows the underlying principal of HAT reaction 
wherein the antioxidant inhibits free-radicals by directly donating a hydrogen atom.  
Conversely, Equation 2 shows the principal of the ET reaction wherein an  antioxidant could 
potentially inhibit free-radicals by initially donating an electron to the free radical and 
subsequently reacting with H2O to produce H3O which then inhibits the free-radical by 
donating a hydrogen atom (Pior et al, 2005).   
 
Equation 1   X. + AH → XH + A. 
 
 
Equation 2   X. + AH → X- + AH.+ (1) 
AH.+ H2O → A. + H3O+ (2) 
X- + H3O+  →XH + H2O (3) 
M(III) + AH → AH+ + M(II) (4)   (Prior et al., 2005). 
 
The use of fluorescein probe also renders the ORAC method  more robust and cost-effective 
because of the photostability of fluorescien, which permits the use of 96-well microplate (Ou 
et al, 2001).  As a result, the ORAC assay is considered the gold standard  method for the 
determination of the antioxidant capacity of biological samples (Cao et al, 1998). 
 
2.1.4.b Preparation of extracts 
Extracts were initially prepared in acetonitrile as for FC method and then diluted 1:1000 in 
(75mM, pH 7.4) phosphate buffer. 
 
2.1.4.c Standards 
A 10mM stock solution was prepared by dissolving 0.025g trolox in 10ml (75mM, pH 7.4) 
phosphate buffer saline (PBS).  The stock was serially diluted in PBS to give the following 
standard concentrations: 0, 6.25, 12.5, 25, 50 and 100 µM trolox equivalents. 
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2.1.4.d Fluorescein 
A 40mM stock solution was prepared by dissolving 0.1505g fluorescein in 10ml (75mM, pH 
7.4) PBS and stored at 4
o
C until required.  Prior to use, the stock was diluted in (75mM, pH 
7.4) PBS to give a 400nM fluorescein solution. 
 
2.1.4.e 2,2'-azobis-(2-amidinopropane) dihydrochloride 
A 375mM solution was prepared daily by dissolving 1.017g AAPH in 10ml (75mM, pH 7.4) 
phosphate buffer. 
 
2.1.4.f Measurement of oxygen radical absorbance capacity 
To a 96-well fluorescein reading  microplate (Wallac, Finland), 25μl of standard or diluted 
sample was added, followed by 150μl of 400nM fluorescein.  The plate was then incubated 
at 37
oC for 15min.  Next, 25μl of 375mM AAPH was added and the decay in fluorescein 
intensity was measured  kinetically over 35 min using a Fluoroskan Ascent plate reader 
(Thermo Scientific, USA) equipped with a 488nm excitation filter and a 515 nm emission 
filter.   Results were expressed in μmol trolox equivalents per litre.  
 
2.1.5 2,2-diphenyl-1-picrylhydrazyl radical 
2.1.5.a Principal of method 
Unlike the FRAP assay, the DPPH assay serves as an indirect measure of reductants in a 
sample since it measures the inhibition of ROS in the reaction medium (Halvorsen et al., 
2002). The purple DPPH radical has an absorbance wavelength of 515 nm.  When an 
antiradical compound donates H
+
 to the DPPH molecule, DPPH is reduced forming a 
colourless compound (Brand-Williams et al., 1995; Molyneux, 2004), as illustrated in the 
following equation: 
 
 
Purple diphenylpicrylhydrazyl radical Colourless diphenylpicrylhydrazine non-radical 
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The main limitations of DPPH assay is that colour interferences from samples containing 
anthocyanidins could lead to underestimation of antioxidant activity (Teow et al., 2007). 
This could be overcome by preparing extracts in colourless solvents such as EtOH or MeOH 
(Molyneux, 2004). Measuring the absorbance of samples without DPPH and subtracting 
from the absorbance of sample with DPPH could also help overcome this limitation. Another 
limitation of DPPH assay is that DPPH could take up to several hours to react with certain 
compounds (Teow et al., 2007).  
 
2.1.5.b Preparation of extracts 
GCBE and Theobroma cacao were ground using a mortar and pestle and dissolved in EtOH 
to give a 60μM GAE stock solution which was serially diluted to obtain the following 
concentrations: 3, 6, 15, 30, 60 µM GAE. 
2.1.5.c Standards 
DPPH standards were prepared in the following concentrations 0, 5, 10, 20, 40 and 60μM.  
These standards were used to construct a standard curve of DPPH concentrations against 
absorbance, which permitted the calculation of DPPH concentration in the reaction medium.   
 
2.1.5.d Positive controls 
Ascorbic acid, GA and CGA were dissolved in EtOH  to give a 60μM stock solution of each 
antioxidant.  These stock solutions were serially diluted to give 3, 6, 15, 30 and 60μM 
dilutions of each antioxidant. 
 
2.1.5.e Measurement of 2,2-diphenyl-1-picrylhydrazyl radical scavenging 
The effect of GCBE and TCBE on DPPH radical was determined using an adaptation of the 
method described by Blois (1958).  Briefly, a 100μl of each GCBE, TCBE and positive 
control dilutions were incubated with an equal volume of  DPPH in a 96-well microplate.  A 
solution of 95% EtOH acted as a blank.  The test samples were left to stand in the dark at 
room temperature and absorbance was read at 500 nm using a Dynex Technologies MRX 
microplate reader (Dynex Technologies Ltd, Worthing, UK).  All solutions were made up in 
duplicates.  Percentage of remaining DPPH was calculated using the following equation.     
% remaining DPPH= [DPPH]t / [DPPH]t=0 
 
Percentage DPPH inhibition was estimated: 
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%inhibition=((blank-test sample)/blank) x 100  (Ayoola et al., 2008). 
The inhibitory concentration 50 (IC50), defined as the concentration of antioxidant required 
to reduce the initial concentration of DPPH by 50%, was determined by plotting the 
percentage of remaining DPPH against increasing concentrations of GCBE, TCBE, GA, 
ascorbic acid and CGA using a non-linear regression model (GraphPad Prism 5, USA).    A 
linear regression model was used for estimating IC50 of CGA since the non-linear regression 
model did not generate the best-fit curve for the data. 
 
2.1.5.f Statistical analysis 
Differences in IC50 between the 5 different extracts and controls were analysed using a one-
way analysis of variance (ANOVA) (GraphPad Prism 5, USA). 
 
2.1.6 Pancreatic lipase: Preparation of extracts  
GCBE and TCBE were prepared in acetonitrile as described for FC assay (Section 2.1.2.b). 
 
2.1.7 Lipase assay 
Pancreatic lipase activity was measured according to the method described by Lin et al. 
(1996) and Gilham et al. (2003), with some modification, using p-nitrophenyl laurate (pNP) 
(10mg/ml) as the substrate. Briefly, 50µl of varying concentration of GCBE or bound TCBE 
fraction (5, 10, 25 and 50µg total polyphenols (GAE)) were added to a mixture containing 
350µl 100mM Tris buffer (pH 8.2) and 150µl of porcine lipase solution (10mg/ml). The 
reaction was started by adding the substrate solution. The latter was prepared by dissolving 
8mg pNP in 10ml of 5 mM sodium acetate (pH 5.0) containing 1% Trition X-100, which 
was subsequently heated in boiling water for 1 min to aid dissolution, mixed and cooled to 
room temperature.   The samples were then incubated for 2h at 37
o
C.  Following incubation, 
all samples were centrifuged at 16000rpm for 5 min, transferred to cuvettes and read at 400 
nm in a UV spectrophotometer.  Samples were assayed in triplicates and appropriate sample 
controls were prepared for each sample concentration to account for interference from 
GCBE or TCBE.  The percentage inhibitory activity of each sample was calculated using the 
following equation: 
 
% inhibitory activity = 100
)(
)()(
1
abscontrol
absrolsamplecontabssample
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2.2. Animals and Metabolic cage study 
Seven week old male C57BL6 mice were housed at a constant temperature (22
 o
C) and a 
12:12 h light/ dark cycle in metabolic cages at the Little France Biomedical Research 
Facility, Edinburgh, UK.  Animals were fed a standard rodent diet with free access to water 
for 7 days followed by 17 days of a diet containing 0.15% CGA (treatment group) or no 
CGA (control group).  At the end of the study period animals were decapitated, trunk blood 
samples were collected and organs and adipose tissue removed and weighed.   All 
procedures and experiments were conducted according to UK Animals (Scientific 
Procedures) Act, 1986.  Organs were kindly donated for corticosterone analysis by Dr Chris 
Kenyon from the Queen Medical Research Institute, Edinburgh, UK.  
 
2.2.1 Steroid Tissue Extraction 
Stock solutions of the homogenizing buffer (5mM potassium phosphate, pH 7) and 
extraction solvent (92.25ml EtOH + 4.75 H20 + 3ml glacial acetic acid) were prepared and 
stored overnight at 4
o
C and -80
o
C, respectively.  On the following day, kidney, liver, 
mesenteric and subcutaneous tissue were weighed (approximately 0.1g) and transferred to a 
2ml eppendorf placed on ice.  Each sample was subsequently homogenised in 1ml phosphate 
buffer (brief bursts with cooling), and then added dripwise using a glass Pasteur pipette with 
continuous stirring to a 20ml scintillation vial chilled on dry ice and acetone and which 
contained  5ml of the extraction solvent (Figure 2.1).  Samples were capped and frozen at -
80
o
C for 40h.  Next, samples were sonitanked for 2 min (15s bursts with cooling) and 
transferred to centrifuge tubes using an additional 1ml of extraction solvent in order to wash 
remnants.  Following 20min centrifugation at 4
o
C x14 000 rpm, the supernatant was 
collected, placed in Pyrex tubes and evaporated to dryness.  Samples were reconstituted in 
0.5ml 80% MeOH plus 0.5ml distilled water.  A 0.5ml aliquot was taken for corticosterone 
extraction using Sep-Pak C 18 cartridges (Waters Ltd, Elstree, Hertfordshire, UK) previously 
preconditioned and equilibrated with 5ml 100% MeOH and 2ml water.   The samples were 
first eluted with 1ml 40% MeOH, and then with 2ml 100% MeOH. This produced two 
fractions of corticosterone: sulphate and glucoronide-conjugated corticosterone and free 
corticosterone.  Both fraction were analysed for corticosterone using enzyme-linked 
immuno-sorbent assay (ELISA) according to the method described by Al-Dujaili et al. 
(2005, 2006) (see p. 146). 
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Figure 2.1 schematic showing drip-wise addition of the homogenate using a Pasteur 
pipette with continuous  stirring into a 20ml scintillation vial containing extraction 
solvent, placed in a bath of dry ice and acetone.  
 
  
Homogenate  
Extraction solvent 
Boat containing dry ice 
immersed in acetone 
Magnetic stir bar ‘flea’ 
Magnetic stirrer 
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2.3. Human studies 
2.3.1 Rational for study design: Preliminary green coffee bean extract 
study 
A self-controlled open-label single-subject experimental AB design was selected for the 
preliminary GCBE trial. Following an initial 7-day run-in phase, eligible volunteers were 
given 200mg GCBE twice daily for 14 days (Figure 2.2).   Capillary fasting glucose, BP and 
anthropometrical measurements were assessed at the end of the run-in phase (baseline) and 
after 1 week and 2 weeks of GCBE administration.  Capillary fasting total cholesterol was 
assessed at baseline at at the end of 2 weeks of each dietary intervention.  Likewise,  24h 
urine was collected at baseline and at the end of Week 2 to assess 24 urinary free cortisol, 
urinary free cortisone, cortisone-to-cortisol ratio and in order to monitor any changes in 
sodium, potassium and magnesium excretion.   Salivary cortisol and cortisone concentrations 
were also quantified in a sub-sample of the study population at baseline and at the end of the 
intervention (n=9).  
 
 
Day (-7)  Day (0) Baseline Day (7) Day (14) 
     
   
   
     
       ←    Run-in phase       → 
 
←                       GCBE                      → 
  
Figure 2.2 Summary of the study design 
 
The self-controlled open-label single-subject experimental AB study design was selected 
primarily due to the lack of appropriate placebo tablets matched for size, shape, colour, taste 
and smell of GCBE tablets.  Open-label trials are generally used for Phase I studies and serve 
as an initial investigation for new treatments (Mellis et al., 2002).  They are the opposite of 
double-blind studies in that both the investigator and the participant are aware of the 
treatment offered (Mellis et al., 2002).  As a result, they are likely to overestimate outcomes 
due to expectation bias (Mellis et al., 2002).  The single-subject AB design is also the most 
basic type of study designs (Satake et al., 2008).  It implies that the study consists of a pre-
treatment period and a post-treatment period.  Its main advantage lies in that subjects act as 
their own control which is particularly important when investigating a condition that shows 
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large inter-subject variations such as blood pressure (Cleophas, 1990).  However, the AB 
design has several limitations since it does not control for the effect of time.  To overcome 
this limitation, several baseline measurements need to be taken prior to intervention (Satake 
et al., 2008).   
 
In general, open-label single-subject trials are unlikely to prove the efficacy of treatment due 
to the inherent limitations associated with their design (Mellis et al., 2002).  Nonetheless, a 
number of studies have used this design to investigate the effect of new treatments on blood 
pressure and other parameters of the cardiovascular system (Shand et al., 2003, O‘Brien et 
al., 2007).  Investigators have also used this design to explore the potential in vivo activities 
of novel polyphenol-rich products (Blum et al., 2007). An open-label single-subject 
experimental AB design could thus be deemed ideal for feasibility studies that could then 
direct future research and justify the need for more rigorous research designs. 
 
2.3.2 Rational for study design: Preliminary dark chocolate study 
To assess the feasibility of the main study, the preliminary DC study used a randomised  
single-blind two-period two-treatment crossover design where each subject acted as his or 
her own control.  Following a 1-week run-in phase, eligible subjects were randomly assigned 
to one of the two polyphenol doses: 500 mg polyphenols DC or 1000 mg polyphenols DC.  
Participants followed each intervention for 2 weeks, after which they were crossed-over to 
the next intervention separated by a 1-week washout period (Figure 2.3).  As with 
preliminary GCBE study, capillary fasting glucose, BP and anthropometrical measurements 
were assessed at the end of the run-in phase (baseline) and after 1 week and 2 weeks of each 
of the dietary interventions.  Capillary fasting total cholesterol was assessed at baseline at at 
the end of 2 weeks of each dietary intervention.  Likewise, 24h urine was collected at 
baseline and at the end of Week2 to assess 24 urinary free cortisol, urinary free cortisone, 
cortisone-to-cortisol ratio and in order to monitor any changes in sodium, potassium and 
magnesium excretion.  
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Figure 2.3  Diagram showing random allocation of subjects into the different dietary 
interventions 
 
 
 
In general, the decision to use a parallel group or a cross over design depends on the balance 
between the merits and the weaknesses of each design given a specific condition or an 
outcome. In crossover studies, participants are randomly allocated to two or more sequences 
of treatment, each treatment period being separated by a washout period (Senn, 2002).  
Because each subject act as their own control, cross-over studies have the advantage of 
reducing systemic variations between groups and using a smaller number of participants to 
achieve a similar statistical power as parallel group designs (Prescott et al., 1999, Richens, 
2001, Grahame-Smith and Aronson, 2002).  As a result, several authors argue in favour of 
using crossover trials in cardiovascular and hypertension research, conditions characterised 
by large inter-subject variations (Sever et al., 1989, Cleophas, 1990).  There is also some 
evidence to suggest that cross-over trials are statistically more sensitive than parallel-group 
studies when comparing treatments with a similar biological action or chemical composition 
(Cleophas and De Vogel, 1998, Cleophas and Zwinderman, 2002), although this view is not 
21 individuals screened for fasting 
blood glucose, total cholesterol, BP, 
BMI 
14 selected and 
randomised 
500mg polyphenols DC 
1000mg polyphenols DC 
1-WEEK WASHOUT 
7-DAY RUN-IN 
500mg polyphenols DC 
1000mg polyphenols DC 
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held by some authors (Jackson and Yeo, 1997).  The main limitation with crossover trials 
lies in their duration, which could be inconvenient to subjects leading to high dropout rates 
(Sever et al., 1989).  Lack of knowledge of the pharmacokinetic properties of the compound 
under investigation might also lead to inappropriately designed crossover trials in which 
carry-over and order effects are not controlled for (Senn, 2002).  
 
Conversely, in parallel group studies participants are randomly allocated to receive treatment 
or control (Senn, 2002).  Parallel-group studies are consequently shorter, more convenient to 
participants and allow for multiple comparisons of treatments of varying chemical 
compositions (Cleophas, 2000). They are also not susceptible to carry-over and order effects 
and are ideal for examining both short-term and long-term effects of a treatment (Sever et 
al., 1989).  However, the time needed to recruit large numbers of participants is a 
disadvantage (Richens, 2001).     
 
Both cross-over and parallel group studies have the advantage of reducing selection bias as a 
result of random allocation of subjects to treatment groups (Edwards et al., 1998).  However 
this also implies that randomly allocated groups can differ in a number of baseline 
characteristics which according to Cleophas (1997) may or may not influence outcome.   
Parallel groups designs appear to be particularly susceptible to such an imbalance (Cleophas, 
1995) resulting in the need to use specialised randomisation softwares to ensure groups are 
matched for age, gender and other baseline variables.   This could be particularly difficult 
when recruitment rates are poor and when few eligible subjects are available.  As a result, 
the need to adopt a multi-centre approach is often inevitable with parallel group design 
(Richens, 2001).  Moreover, difficulties with obtaining consent might arise when patients 
have strong preferences for a specific treatment or when they refuse randomisation (Prescott 
et al., 1999, Cleophas et al., 1997).  Excluding participants, in this case, might result in a 
smaller sample, which might hinder the study‘s external validity (Cleophas et al., 1997) or 
render generation of matched-groups difficult.  There are thus several issues relating to 
randomisation, patient recruitment, informed consent and ethics that need to be considered 
before adopting a parallel-group design.    It is also important to note that in many cases, the 
decision to use parallel or crossover design largely depends on the number and duration of 
treatment periods (Prescott et al., 1999).  The risk of carry-over effects is also a determinant 
factor (Cleophas, 1990, Prescott et al., 1999; Senn, 2002).  In the present study the use of a 
cross-over design was deemed appropriate for both the preliminary and the main study since 
both consisted of two treatment periods each lasting for 2-4 weeks.  Risk of a carry-over 
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effect was minimal since epicatechin has a short half-life and is metabolised and excreted 
rapidly.  In fact, if using the criteria described by Graham-Smith and Aronson (2002) which 
suggests that a washout period should be equivalent to four to five half-lives of a compound, 
and assuming that the half-life of epicatechin is 2h (Richelle et al., 1999), then a minimum 
washout period of 8-10h should be sufficient for this study.  Nonetheless, because the effect 
of any chemical could persist beyond what is anticipated by its half-life (Grahame-Smith and 
Aronson, 2002), this study used a washout period of 1-2 weeks which is similar to the 
washout periods used by Taubert et al. (2003) and Grassi et al. (2005a-b).   
 
However, a major criticism of the crossover design, particularly the one used in the 
preliminary study, is its inability to control for the effect of time compared to a parallel-
group design (Richens, 2001).  This occurs when the severity of a disease or a parameter 
changes over time regardless of the intervention (i.e. BP) (Cleophas and Tavenier, 1995).  
Efforts were made to overcome this limitation, by randomising participants using a Latin 
square design such that one group received 500mg polyphenols DC followed by 1000mg 
polyphenols DC while the other group received 1000mg polyphenols DC followed by 
500mg polyphenols DC.  This randomisation reduces both order (Grahame-Smith and 
Aronson, 2002) and time effects (Senn, 2002).  Additional statistical analyses were also 
conducted to detect any carry-over effects in the preliminary DC study (see Section 2.18.2, 
p. 153) 
 
2.3.3 Rational for study design: Main study 
The main study adopted a placebo-controlled single-blind crossover design. Following a 1-
week run-in phase, eligible subjects were randomly assigned to receive 500mg polyphenols 
DC or placebo.  Participants followed each intervention for 4 weeks, after which they were 
crossed-over to the next intervention separated by a 2-week washout period (Figure 2.4).   
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Figure 2.4  Diagram showing random allocation of subjects into the different dietary 
interventions  
 
 
This design is generally used to measure the efficacy of a treatment under controlled 
conditions while controlling for placebo effects.  To overcome the limitations observed in 
the pilot study, baseline data were collected prior to each intervention period.  Given an 
adequate washout period, incorporating baseline measurements as covariates in statistical 
analysis has been suggested to improve data precision by reducing standard error (Senn, 
2002).   Additionally, the main study used a placebo to control for time effects and to asses 
for a causal relation.  Notably, the main study has the advantage of using a DC placebo as 
compared to a white chocolate which has been generally used in previous studies (see Table 
1.5, p. 77).  The lack of adequate blinding in previous research might have acted as a 
confounding factor increasing expectation bias since both the investigator and the participant 
were aware of the treatment received (Desch et al., 2009).   
 
Crossover studies are generally designed to measure the efficacy of a treatment while a 
parallel-group design measures a treatment‘s effectiveness.  Efficacy implies whether a 
treatment works under controlled conditions and effectiveness under less astringent 
conditions. The efficacy of a drug does not necessarily determine its effectiveness and 
broader long-term studies are needed to confirm the effectiveness of an intervention (Pittler 
and White, 1999). This suggests that regardless of the efficiency of cross-over trials, the use 
48 randomised 
Placebo 
500mg DC 
2-WEEK WASHOUT 
7-DAY RUN-IN 
Placebo 
500mg DC 
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of parallel-design studies remains indispensable for confirming the findings of cross-over 
trials and ensuring their generalisation (Sever et al., 1989, Cleophas and Tavenier, 1995).   
 
2.4. Ethical approval 
Ethical approval was gained from Queen Margaret University ethics committee and all 
interventions involving human volunteers were conducted according to the guidelines laid 
down in the Declaration of Helsinki. For studies involving human subjects, information 
sheets were provided to all potential volunteers and written informed consent was obtained 
prior to participation (Appendix 1).  All collected data was stored according to the Data 
Protection Act (1998). 
 
2.5. Subjects sources and selections 
For the pilot studies, volunteers were recruited via an email sent to all staff and students at 
Queen Margaret University and using fliers or word-of-mouth. 
 
For the main DC study, a detailed recruitment strategy was developed to ensure that the 
obtained study sample provided a good representation of the general population.  As a result, 
in addition to recruiting volunteers from various universities, colleagues and business parks 
across Edinburgh, advertisement using fliers and posters in newspapers, community centres 
and websites such as clinicaltrials.gov were used.  Websites yielded the least response but 
were nonetheless central to the success of newspaper and community centre advertisements 
as they permitted the general population to access detailed information on the study‘s 
objectives and design without necessitating the need for contacting the investigator.  This 
helped facilitate recruitment by concentrating the sample which permitted the focus on the 
target population.   
 
2.6. Inclusion and exclusion criteria  
2.6.1 Preliminary studies 
These studies included healthy volunteers aged 19-50years with a BMI ≥25kg/m2 and no 
history of diabetes, hypotension, hypertension or CVD (Table 2.1).  They, therefore, 
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included both overweight (BMI 25-29.99kg/m
2) and obese subjects (BMI ≥30kg/m2) as 
defined by the criteria set by WHO (2000).  
Table 2.1 Definition of diabetes, hypotension and hypertension 
Disease Definition Reference 
Diabetes  Diabetes symptoms (i.e. polyuria, polydipsia 
and unexplained weight loss) plus 
 fasting plasma glucose≥7.0mmol/l (whole blood 
≥6.1mmol/l) or 
  2-hour oral glucose tolerance test plasma 
glucose concentration ≥11.1mmol.l 2h after 75g 
anhydrous glucose. 
Diabetes UK, 
2006 
Hypotension BP<90/60mmHg  National Institute 
of Health, 2010 
Hypertension BP≥140/90mmHg on two or more seated BP readings 
on two or more visits 
Khatib and El-
Guindy, 2005 
 
Exclusion criteria consisted of smokers, people taking dietary supplements, BP or 
cholesterol-lowering drugs, and those with soy, nut and coffee allergies.  Smokers were 
excluded to minimise confounding factors since nicotine consumption is known to enhance 
HPA activity, hence resulting in elevated cortisol levels (Rohleder and Kirschbaum , 2006). 
Subjects who consume more than one portion of cocoa or DC a week (Taubert et al., 2007), 
one or more cup of green tea a week (Iso et al., 2006) and one or more cup of coffee a day 
were also excluded (Salazar-Martinez et al., 2004).  Exclusion criteria was based on that 
multivariate odds ratio for type II diabetes is highest for people who consume less than 1 cup 
of green tea per week compared to people who consume green tea 1 or more times per week 
(Iso et al, 2006).  Likewise, relative risk for type II diabetes is higher for coffee abstainers as 
compared to individuals who consume one or more cup of coffee per day (Salazar-Martinez, 
2004).  All potential participants were screened for fasting glucose, total cholesterol, BP, 
BMI, WHR prior to the intervention and completed a screening questionnaire to determine 
their eligibility (Appendix 3). 
 
2.6.2 Main study 
The afore-mentioned inclusion and exclusion criteria was applicable for the main study.  
Additionally, the main study included females with BMI between 18.5 and 24.99kg/m
2
 
(WHO, 2000), as to allow for comparison of the baseline characteristics between the two 
BMI categories.  This also permitted detection of differences in glucoregulatory biomarkers, 
BP, lipid profile, mineral, 24-h urinary cortisol or cortisol-to-cortisone ratio across the two 
BMI groups in response to polyphenol-rich DC or placebo. The choice of female volunteers 
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as opposed to both men and women was based on the wide variations in urinary cortisol and 
cortisone seen in the preliminary studies as well as available evidence in the literature 
suggesting differences in 11βHSD1 regulation and cortisol secretion between men and 
women (Andrew et al., 1998; Rask et al., 2002).   Consequently, only females were recruited 
for the main study as to minimise the confounding effect of gender. 
 
2.7. Sample size 
For DC pilot study, sample size was calculated to detect a 0.3mmol/l reduction in fasting 
glucose with a power of (1-β) =0.8, α=0.05 and an effect size of 0.6546537 (G-power 
software version 3.0.8, Dusseldorf, Germany).   This reduction was similar to the change in 
fasting glucose reported by Grassi et al. (2005b) in their study on polyphenols-rich DC 
[baseline mean±SD glucose =4.8±0.5mmol/l, post-DC mean±SD glucose=4.5±0.4]. 
Accordingly, a sample of 21 volunteers was identified as the minimum required to detect a 
significant reduction in fasting capillary glucose levels from baseline. 
 
For GCBE, the initial sample was selected to match the sample size of the DC pilot study.  
Once preliminary data was obtained, power analysis was conducted using the data from 
urinary glucocorticoid metabolism and sample size was adjusted accordingly in order to 
detect an effect on glucocorticoid metabolism.  Based on G-power, a sample size of 23 
volunteers was required to detect a significant change in urinary cortisone with a power (1-β) 
=0.80, alpha=0.05 and an effect size of effect size dz=0.7172830 [baseline mean±SD urinary 
cortisone =56.58±36.20 nmol/d, post-GCBE mean±SD urinary cortisone=37.26±15.79 
nmol/d]. 
 
For the main DC trial, a sample size of 22 subjects per group was required  to detect a 
reduction in fasting glucose of 0.5mmol/L with a power of (1-β) =0.8, alpha=0.05 and an 
effect size of effect size dz=0.6546537 (G-power software version 3.0.8, Dusseldorf, 
Germany). These Power calculations were based on the results of the pilot study, which 
showed that DC containing 500mg polyphenols reduces fasting glucose from 4.42±0.7 to 
3.92±0.86 mmol/l. 
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2.8. Diet and nutritional composition of green coffee bean extract 
Table 2.2 shows the nutritional composition of GCBE.  Following an initial 7-day run-in 
phase, participants were given 200mg GCBE containing 90mg CGA (Quest Vitamins Ltd, 
Birmingham, UK) twice daily for 14 days.  They were instructed to consume one tablet at 
breakfast between 8-10am with food or white bread and then another tablet 2 hours after the 
evening meal between 8-10pm. This was to ensure plasma concentrations of CGA were 
maintained throughout the study period.   
 
Most previous studies have incorporated GCBE or CGA supplements into drinks and foods 
like strawberry jam and soup bases, all of which contain little or no CGA (Olthof et al., 
2001b, Ochiai et al., 2004, Kozuma et al., 2005).  White bread is also a low source of 
polyphenols and CGA and it is therefore unlikely to interfere with the absorption of GCBE 
(Clifford, 1999).  In fact, two studies have indicated that carbohydrate-rich foods like bread 
could actually increase the bioavailability of polyphenols (Wang et al., 2000, Holt et al., 
2002).   
  
Table 2.2 The composition of green coffee bean extract 
Component content 
Green coffee bean extract (mg) 200 
Chlorogenic acid (mg) 90 
Caffeine (%) <2 
 
With regard to the dosages, although the manufacturer recommends up to 3 tablets of GCBE 
per day, only 2 tablets per day were used in the preliminary GCBE study.  This is because, 
consumption of 3 tablets of GCBE per day have been reported to produce side-effects 
including headaches, nausea and discomfort (Blum et al., 2007).  By contrast, the dose 
selected for use in the preliminary GCBE is in the range of doses used in previous studies on 
GCBE and CGA supplements, which showed no adverse effects (Olthof et al., 2001a-b, 
2003; Kozuma et al., 2005; Watanabe et al., 2006) but still reduced BP (Kozuma et al., 
2005; Watanabe et al., 2006).  It is noteworthy that one study did fail to show any significant 
reduction in BP following consumption of 140mg CGA for 4 months (Ochiai et al., 2004).  
However, the insignificant result seen in this study is likely to be attributed to the small 
sample size used (n=10).  This is confirmed by the fact that a later study with a larger sample 
size did demonstrate that 140mg CGA significantly reduces both SBP and DBP (Watanabe 
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et al., 2006).  Differences in the GCBE doses used in this preliminary study and previous 
studies are shown in Table 2.3.   
 
Table 2.3 Comparison of the dosages and compositions of green coffee bean extracts  
between the present study and previous studies 
Content per dose(g) GCBE
1
 (mg) Chlorogenic acid (mg) Caffeine% 
Kozuma et al. (2005) 46 
93 
185 
25 
50 
100 
12 
Ochiai et al., 2004 500 140 6 
Watanabe et al., 2006 - 140 - 
Present study  2 tablets 400 180 <2 
GCBE
1
, green coffee bean extract 
 
2.9. Diet and nutritional composition of dark chocolate 
Table 2.4 and Table 2.5provide a summary of the nutrient composition of the  DC  used as 
part of the preliminary DC (500mg and 1000mg polyphenols DC) and main study (placebo 
and 500mg polyphenols DC) alongside a comparison of the composition of these DC with 
DC from previous trials.   
NG, negligible. 
Table 2.4  Nutritional composition of 20 g of 500/1000 mg polyphenol dark chocolate and 
placebo.   
Component Placebo  500 mg 
DC
1
 
1000 mg DC
1
 
Polyphenols (mg) NG  500 1000 
Epicatechin and catechin (mg) NG  18.99 37.98 
Theobromine (mg) 160  160 160 
Energy (kJ) 425.8  425.8 425.8 
Fat (g) 7.34  7.34 7.34 
Protein (g) 1.34  1.34 1.34 
Carbohydrate (g) 7.44  7.44 7.44 
Magnesium (mg) 33.42  33.42 33.42 
Sodium (mg) 1.4  1.4 1.4 
Potassium (mg) 168.42  168.42 168.42 
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On average, DC was provided in the form of 20g containing negligible amount of 
polyphenols (placebo)  or 500mg polyphenols supplying 18.99mg of catechin and 
epicatechin or 1000mg polyphenols with 37.98mg of catechin and epicatechin (Barry 
Callebaut, Lebbeke, Belgium). The 500mg polyphenols dose was chosen to correspond to 
the total polyphenol content of DC used by Grassi et al. (2005a-b) and Taubert et al. (2003).  
However due to the great variation in the levels of epicatechin and catechin between the 
chocolate used in this study and the one used by Grassi et al. (2005a-b), and the importance 
of these monomers given their large bioavailability compared to other DC polyphenols 
(Manach et al., 2004), a higher DC dose was also chosen.  This 1000mg polyphenols dose 
was selected to provide similar quantities of polyphenol to what is consumed by the Kuna 
population (Bayard et al., 2007) and about 43.2% of the epicatechin and catechin dose used 
by Grassi et al. (2005a-b).  Overall, subjects were instructed to distribute DC doses 
throughout the day in order to achieve a high steady state concentration.  Additional data on 
the nutritional composition of DC is provided in Appendix 4.  In general, DC contained 
65.5% cocoa solids, and was found to be a rich source of magnesium and iron providing on 
average 11.14% recommended dietary allowance of magnesium and 27.52% recommended 
dietary allowance of iron per 20g. 
 
For the main DC study, the 500mg polyphenols DC was selected.  This choice was based on 
the results of the pilot study.   
 
It is noteworthy that the current trial possesses several advantages over previous studies.  
This is because most previous studies used DC doses of 100g providing 500mg polyphenols.  
Table 2.5 Comparison between the polyphenol composition of dark chocolate in the 
present study and previous studies 
Content per 
dose(g) 
Polyphenols 
(mg) 
Epicatechin 
(mg) 
Catechin 
(mg) 
Sum of 
epicatechin and 
catechin (mg) 
epicatechin-to-
catechin ratio 
Grassi et al. 
(2005b)  
100g DC 
500 65.97 21.91 87.88 1:3 
Taubert et 
al. (2007) 
6.3g DC 
30 5.1 1.7 6.8 1:3 
Engler et al. 
(2004) 
46g DC 
- 46 - - - 
Present 
study  
500-1000 - - 18.99-37.98 - 
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In a recent meta-analysis, Desch et al. (2009), has risen concern over the long-term use of 
100g polyphenol-rich DC.  This is because high doses of DC provide a substantial quantity 
of fat and sugar which in the long-term can counteract any beneficial effect of polyphenols 
by promoting weight gain (Desch et al., 2009).  By contrast, the current study uses 20g DC 
with 500-1000mg polyphenols, a product that delivers large quantities of polyphenols in a 
less energy-dense and more palatable form than common chocolate.  Moreover, in this study, 
the placebo was especially manufactured in the form of DC to ensure no differences in 
macronutrient or micronutrient composition exits.  This helped control for the confounding 
effects of varying fat, theobromine and magnesium content, all of which are likely to 
influence glucose, BP and lipid profile.  Earlier studies investigating the effect of 
polyphenols-rich DC on insulin sensitivity, BP and lipid profile used white chocolate as 
placebo (Table 1.5, p. 77 and Table 1.8, p. 96).  Apart from introducing bias due to 
differences in the nutritional composition, the use of white chocolate placebo would not have 
permitted effective blinding of volunteers to treatment which could have resulted in 
expectation bias.   As such, the present DC studies are likely to yield more reliable results 
because of the use of a more robust and a stronger study design. 
 
2.10. Compliance and validation of diet diaries 
Overall, all participants were instructed to maintain their usual diet throughout the study but 
to refrain from polyphenol-rich foods and beverages that supply 15 mg/kg epicatechin or 
CGA and 4 mg/l epicatechin or CGA, respectively (Olthof et al., 2001a-b, 2003) (see 
Appendix 1: Table 7.6, p. 305 and Table 7.7, p. 308). Subjects completed a 3-d (two 
weekdays and one weekend) diet and physical activity (Bouchard et al., 1983) diary during 
the run-in phase and at the end of each dietary intervention. The Photographic Atlas of Food 
Portion Sizes was used to assist subjects in describing their portion sizes (Nelson et al., 
2002). Diet diaries were analysed for energy, fat, protein, carbohydrate and mineral intake 
using Windiet software (Windiet Research, Univation Ltd, Robert Gordon University, 
Aberdeen, UK). Compliance with the study‘s protocol was assessed by direct interviewing, 
assessment of diet diaries and returning of empty chocolate foils or counting of GCBE 
tablets and measurement of total polyphenols excreted in urine  using FC, FRAP and ORAC, 
as described below (Khan et al., 2003, Taubert et al., 2007).   The validity of diet diaries was 
established by interviewing 13 volunteers using a validated questionnaire devised by 
Lindroos et al.  (1999).  Accordingly, energy (r=0.705; P=0.007), protein (r=607; P=0.028), 
carbohydrate (r=0.936; P=0.000), magnesium (r=0.731; P=0.004), sodium (r=0.735; 
P=0.004) and potassium intake (r=0.808; P=0.001) as estimated by the diet diaries were 
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found to be strongly and positively correlated with the corresponding reported intake from 
dietary questionnaire (Pearson‘s product-moment correlation).  A weak correlation was also 
observed for fat intake (r=0.103; P=0.737).    
 
2.11. Anthropometry  
For the preliminary studies, anthropometrical data was collected at baseline, Week 1 and at 
the end of each intervention period.  For the main DC, anthropometrical data was collected at 
baseline and at the end of each intervention period. 
 
2.11.1 Height 
Height was measured using a stadiometer. Participants were asked to stand barefoot with 
their knees straightened, their heels placed together against the backdrop and the head 
positioned such that the plane that passes between the upper margin of the ear canal and the 
lower border of the eye (Frankfurt Plane) was parallel to the floor (Figure 2.5). Height was 
recorded as the last completed millimetre.  
 
Figure 2.5 Positing of participant when measuring height. Note the of the placement of 
the head in the Frankfurt plane (Gibson, 2005). 
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2.11.2 Weight and body composition  
Body weight [recorded to the nearest 0.1kg] and body composition (water percentage and fat 
percentage) were quantified using BF681W Tanita scales with body fat monitor (Tanita, 
UK).  The scales were placed on a firm, flat surface and participants were asked to remove 
their shoes and any heavy clothing, to stand still with their arms on the side and to look 
forward (WHO, 2008).  
 
Tanita scales use the Bioelectrical Impedance Analysis technique to measure body 
composition.  This involves sending a low-grade electrical current through the body and 
measuring the speed at which this current travels from one foot electrode to the other foot 
electrode.  Because fat does not conduct electricity, the higher the percentage body fat, the 
lower is the speed and intensity of the electrical signal, hence the greater the impedance 
(Tanita, 2009a).    
 
The advantage of using Tanita scales to monitor weight and body composition is its relative 
low-cost and convenience to subjects compared to the conventional bioelectrical impedance 
analysis which require the subject to be placed in a supine position while several electrodes 
are being attached to specific anatomical sites on their skin (Jebb et al., 2000).  Moreover, 
according to Jebb et al. (2000) the estimates for body fat do not differ significantly between 
those obtained using the Tanita scales or the traditional bioelectrical impedance analysis. 
Tanita scales also permit the categorisation of body into underfat, healthy, overfat and obese 
on the basis of the National Institute of Health and WHO guidelines (Figure 2.6).   
 
 
 
Figure 2.6  Classification of body fat according to Tanita body fat monitors (Tanita, 
2009b)  
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2.11.3 Body mass index 
BMI was calculated as weight in kilograms divided by the square of height in meters. The 
WHO classification was subsequently adopted to categorise participants as lean (BMI<18.5 
kg/m
2
), overweight (BMI 18.5-24.99 kg/m
2) or obese (BMI≥25 kg/m2).  This BMI 
classification is based on the morbidity risk conveyed by each BMI category with the BMI 
categories ≥25 kg/m2 being associated with a progressive rise in risk of chronic diseases (see 
Table 2.6) (WHO, 2000; James et al., 2004).   
 
 Table 2.6 Risk of morbidity associated with different BMI categories (WHO, 2000)  
BMI category Value (kg/m
2
) Risk of associated morbidity 
Underweight <18.5 Low 
Normal weight 18.5-24.99 Moderate 
Overweight 25-29.99 increased 
Obesity Class I 30-34.99 High 
Obesity Class II 35-39.99 Very high 
Obesity Class III (morbidly obese) ≥ 40 Extremely high 
 
 
 
It is important to acknowledge that the WHO classification of BMI is based on the 
assumption that the association between BMI, morbidity and mortality follows a linear 
relation. However, on reviewing the literature it appears that although BMI is a strong 
predictor of metabolic risk factors, inconsistencies still remain with regard to the shape of the 
relation curve between this index of adiposity, morbidity and mortality.  This is because 
while some authors have reported a J- or U-shape relation between BMI, morbidity and 
mortality, with the lower and the highest BMI categories being associated with increased risk 
of morbidity and mortality (Manson et al., 1995; Allison et al., 1997; Calle et al., 1999; Jee 
et al., 2006), others have documented a linear association between BMI and mortality 
(Lindsted et al., 1991; Dorn et al., 1997).  This linear relation is particularly apparent after 
adjustment for smoking status (Manson et al., 1995) or fat free mass (Allison et al., 2002) 
and is clearly expressed in WHO BMI categorisation (Table 2.6).   
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Figure 2.7 Relative risk of death from cardiovascular disease, cancer and other diseases 
among men and women stratified according to Body-Mass Index.  Note, the J-shaped 
relation between BMI and relative risk of cardiovascular in both men and women. Also 
note, the U-shaped relation between relative risk of death from other causes and BMI 
in both men and women (Calle et al., 1995). 
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Overall, these inconsistencies could arise from the fact that despite its common use and 
simplicity, BMI remains a crude index of adiposity (WHO, 2000).  Consequently, the use of 
BMI as a measure of adiposity can pose limitations since it does not distinguish between fat 
mass and fat-free mass. To exemplify, consider Equation 3.  
 
Equation 3 
222)(
)(
height
sfatfreemas
height
fatmass
mheight
kgweight
BMI (Allison et al., 1997) 
 
This equation demonstrates that BMI consists of two main components: fat mass/height
2
 and 
fat free mass/height
2
 (Allison et al., 1997). This entails that under certain conditions when 
fat-free mass (i.e muscle mass) is high, such as in atheletes,  individuals could mistakenly be 
classified as overweight (WHO, 2000).  This also implies that individuals with an identical 
BMI do not necessarily have a similar quantity of body fat (WHO, 2000). All the more, it 
suggests that individuals with low or very low fat free mass (such as those with BMI< 25 
kg/m
2 
or <18 kg/m
2
) could be mistakenly classed at a low morbidity risk despite having a 
high fat mass: fat free mass ratio (Deurenberg-Yap et al., 2000; 2002), a phenomenon 
recently named by Professor Bell (2009) as TOFI (Thin on the Outside Fat on the Inside).   
 
Consequently, it could be argued that BMI could only provide a rough estimate of the 
relative risk of developing chronic diseases. Moreover, it appears that the current cut-offs for 
lean, overweight and obese are not optimal for defining metabolic risk factors in all 
populations (Deurenberg et al., 1999; 2000; WHO, 2000; Deurenberg-Yap et al., 2002; Lin 
et al., 2002; WHO, 2004). The latter is particularly evident in the Asia-Pacific Cohort 
Studies Collaboration study wherein increments in BMI above 21 kg/m
2
 were found to be 
associated with a raised risk of CVD in the Asian population (James et al., 2004). Regardless 
of these inconsistencies, a BMI> 30 kg/m
2
 remains a definite cut-off for excess fat (WHO, 
2000).   
 
Another main limitation of BMI is that it does not take in account the distribution of body fat 
and the subsequent risk conveyed to health.  As such BMI should be used in combination 
with other indices of adiposity such as WC and WHR in order to provide a clear picture of 
metabolic risk of developing overweight and obesity-related co-morbidities.  Moreover, the 
earlier evidence described above, argues for the need for recruiting individuals with normal 
physical activity and to exclude atheletes and for controlling for ethnicity when recruiting 
lean individuals.   
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2.11.4 Waist circumference, hip circumference and waist-to-hip ratio 
For waist and hip measurement, participants were asked to stand with their feet together and 
both arms relaxed at the sides.  Waist was measured in centimetres (cm) at the end of normal 
expiration half way between the lowest rib and the iliac crest  with the investigator standing 
at the side to ensure that the measuring tape is horizontal across the back and the front of the 
participant (National Institute of Health, 2000; WHO 2008) (Figure 2.8).  
 
 
 
The National Institute of Health 
recommends that the tape 
measure should be placed in 
horizontal plane round the 
abdomen, parallel to the floor and 
should be snug without 
compressing the skin  
 
Figure 2.8 Waist circumference measurement (National Institute of Health 2000) 
 
Hip circumference (HC) was measured at the maximum circumference over the buttocks 
(WHO 2008).  Data on waist and HC were then used to calculate WHR using the following 
equation: 
 
Equation 4 
)(
)(
cmerencehipcircumf
cmmferencewaistcircu
WHR  
 
As with BMI, WC serves as a good indicator of the degree of insulin resistance in 
overweight and obese individuals (Farin et al., 2006) and as shown in Table 2.7, WC ≥94cm 
in men and ≥80cm in women is generally associated with increased risk of metabolic 
complication (Table 2.7). By contrast, WHR is a strong predictor of the presence of 
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hypertension (Fuchs et al. 2005) and of HPA hyperactivity, characterised by high baseline 
plasma cortisol levels and low 24-h urinary cortisol excretion in obese women (Vicennati 
and Pasquali, 2000).  WHR also permits the classification of obesity as peripheral or 
abdominal obesity with WHR >1.0 in men and >0.85 in women being indicative of 
abdominal fat distribution (WHO, 2000).    
 
Table 2.7 Risk of metabolic complications as predicted by waist circumference (WHO, 
2000) 
Risk of metabolic complications Waist circumference (cm) 
 Men Women 
Increased ≥94 ≥80 
Markedly increased ≥102 ≥88 
 
The importance of differentiating between abdominal and peripheral fat distribution lies in 
that abdominal obesity is closely related to obesity-related co-morbidities and the metabolic 
syndrome than peripheral obesity (WHO, 2000; Grundy, 2004, 2005).  Moreover, abdominal 
obesity appears to be associated with a greater risk of hypertension, diabetes and CVD 
compared to peripheral obesity (Rosmond et al., 1998; WHO, 2000; Vicennati and Pasquali, 
2000; Grundy, 2004, 2005; Duclos et al., 2005; Wang et al., 2005).  This is particularly 
evident when considering that subjects with high WC are at a relatively higher risk of 
developing hypertension,
 
diabetes, dyslipidaemia, and the metabolic syndrome than 
individuals with normal WC in the same BMI category. In fact according to Janssen et al. 
(2002a), even within the lean BMI category, subjects with high WC show a greater risk of 
developing hypertension, diabetes, dyslipidaemia and the metabolic syndrome than 
individuals with normal WC.  This effect remains apparent even after adjustment for age, 
race, poverty-income ratio, physical activity, smoking,
 
and alcohol intake and is comparable 
to the health risk of overweight and obese individuals with an identical WC (Janssen et al., 
2004). By contrast, in the overweight category, individuals with high WC are twice more 
likely to exhibit elevated TG, insulin levels,
 
and the metabolic syndrome, compared to 
normal WC group (Janssen et al., 2005).  Accordingly, several authors have concluded that 
WC provides an estimation of disease risk similar to or above that explained by BMI 
(Janssen et al., 2004; Wildman et al., 2005; Farin et al., 2006), especially in relation to 
diabetes (Janiszweski et al., 2007). As a result, the US National Institute of Health (2000) 
recommends that abdominally-obese individuals should be placed at one health risk category 
above peripherally obese individuals with similar BMI (Table 2.8).  Moreover, Janssen et al. 
(2002b) have concluded that the current cut-off values
 
for WC are pivotal to identifying 
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individuals at increased disease risk within each of
 
the lean, overweight, and class I obese 
BMI categories.    
 
Table 2.8 
  Classification of overweight and obesity by BMI, waist circumference and associated 
health risk (adapted from National Institute of Health, 2000) 
 
 
Nonetheless, it is essential to recognise that BMI and WC may serve as independent and 
additive predictors
 
of total and regional fat distribution.  This could be illustrated in the work 
of Janssen et al. (2002b) who observed that BMI explains the greatest proportion of variance 
in nonabdominal and abdominal subcutaneous fat while WC is a stronger predictor of 
visceral fat accumulation than BMI.  Accordingly, within each of the 3 BMI categories, 
individuals with higher WC were shown to have more visceral fat than individuals from the 
same BMI category but with a lower WC.  Importantly, Janssen et al. (2002b) demonstrated 
that addition of WC to BMI increases the percentage variance accounted for in abdominal 
subcutaneous fat. This, according to Janssen et al. (2002b) could have important implications 
since  abdominal subcutaneous fat is closely related to insulin resistance (Goodpaster et al., 
1997).  Combining WC with BMI has also been shown to help explain a greater proportion 
of the variance in SBP (Janssen et al., 2005), which has led Janssen and colleagues (2002a, 
2004, 2005) to emphasise the need for monitoring both BMI and WC.  The National Institute 
of Health (2000) also suggests that monitoring WC may help detect changes in abdominal fat 
distribution in the absence of changes in weight or BMI. It is important to acknowledge that 
computed tomography (Jensen et al., 1995; Yoshizumi et al., 1999), dual-energy X-ray 
absorptiometry (Glickman et al., 2004; Lee et al., 2005) and magnetic resonance imaging 
(Thomas et al., 2000; Thomas and Bell, 2003) act as more accurate measurements of 
abdominal fat but that WC and WHR provide a more feasible approach to monitoring 
changes in abdominal fat accumulation (National Institute of Health, 2000). 
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2.12. Measurements (Preliminary studies) 
2.12.1 Capillary fasting glucose and total cholesterol 
To assess fasting glucose and total cholesterol in the preliminary GCBE and DC studies, a 
12-hour fasting finger-prick blood sample was taken using a calibrated AccutrendGC system 
(Roche diagnostics, Mannheim, Germany).  Quality controls were also run on the day of 
analyses and for each new batch of glucose or cholesterol strips.  The precision and accuracy 
of AccutrendGC system are shown in Table 2.9. Overall, normal fasting glucose was defined 
by values <6.1 mmol/l but ≥3.9 mmol/l (Roche Diagnostics, 2007a) while fasting plasma 
glucose 6.1-7.0 mmol/l were considered as impaired fasting glucose (Diabetes UK, 2006)).  
Total cholesterol values <5.2 mmol/l were deemed optimum (Roche Diagnostics, 2007b). 
Appropriate Health & Safety Risk assessment were undertaken for all sample collections and 
all samples were disposed off in accordance with the Health & Safety regulations.   
 
 
Table 2.9 Precision and accuracy of AccutrendGC system (Roche Diagnostics, 2007c) 
 Glucose Total cholesterol 
Measuring ranges 20 - 600 mg/dl  
(1.1 - 33.3 mmol/l) 
150 - 300 mg/dl  
(3.88 - 7.76 mmol/l) 
Accuracy  
(Mean systemic 
deviation) 
±5 % compared with a 
hexokinase protein free 
precipitate method 
±5% compared with the 
standard CHOD-PAP 
method 
Repeatability, within-run 
imprecision 
(Coefficient of variation) 
<5% ≤3.7% 
Reproducibility, between-
run imprecision: 
(Coefficient of variation) 
<5% ≤3.8% for concentration of 
191mg/dl (5mmol/l) 
≤5% for concentration 
between 270mg/dl (7mmol/l) 
 
 
All participants were instructed to consume the last dose of DC or GCBE 12hr prior to 
analysis (Taubert et al., 2007) and to avoid heavy physical activity and alcohol intake 24hr 
prior to testing.  They were also instructed to consume the same diet the day before each test 
for each of the interventions as to avoid additional confounding factors (Olthof et al., 2003).  
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2.12.2 Blood pressure 
Blood pressure (BP) was examined using an automated A&D Medical UA-767 Plus BP 
monitor (A&D Medical, San Jose, USA) according to the procedure described by Grassi et 
al. (2005b).  Accordingly, BP was measured following a 10 minutes rest in warm room with 
the cuff placed at the left upper arm of each subject, 2-3cm above the antecubital vein.  The 
investigator ensured that the arm rested on a flat surface so that BP-cuff was positioned in 
line with the heart and that the cuff size was appropriate for the volunteer, as shown below:  
 Small Cuff  6.3 - 9.4" (16-24cm)   
 Medium Cuff  9.4 - 14.2" (24 - 36cm)  
 Large Cuff  14.2 - 17.7" (26 - 45cm)  
 Extra Large Cuff  16.5-23.6" (42 - 60cm) 
 
To increase the reliability of the results three values were taken with 2 minutes intervals.  
According to Grassi et al. (2005b), such protocol increases the reliability of results and is 
likely to reduce white coat hypertension. The accuracy of the A&D Medical UA-767 BP 
monitor against the cuff/stethoscope auscultation method has been previously validated and 
has been shown to achieve grade A for both SBP and DBP according to the British 
Hypertension Society standard (Rogoza et al., 2000; Kobalava et al., 2003; Verdecchia et al., 
2004).  Mean difference in SBP and DBP reading between mercury sphygmomanometer and 
UA-767 BP monitor are in the range of –0.4±5.4 to -0.93±5.1 and -0.04±4.8 to –0,41±4,73 
mmHg, respectively (Rogoza et al., 2000; Kobalava et al., 2003).  Normal BP was defined as 
levels <120/80 mmHg (Khatib and El-Guindy, 2005) and hypotension and hypertension as in 
Table 2.1 (see, p. 127).   
 
Repeatability of A&D Medical UA-767 BP monitor was further  assessed in a sample of 10 
volunteers.  Three readings were taken 1 week apart according to the protocol described 
above and the average of the three readings obtained.  Bland-Altman plots were constructed 
using MedCalc software version 11.1  (Mariakerke, Belgium) to show inter-day variability in 
SBP and DBP and in order to obtain information on the limits of agreement and mean inter-
day differences  in SBP and DBP readings (see Appendix 5). The mean difference in SBP 
and DBP reading between Day 1 and Day2 were 0.17±2.17 and 0.33±2.19mmHg, 
respectively. Both differences and standard deviation fell within the American Association 
for the Advancement of Medical Instrumentation (AAMI) criteria for accuracy (mean(SD) = 
5(8)).  Repeatability was further confirmed by a paired sample t-test which demonstrated that 
inter-day differences in SBP (P=0.813) and DBP (P= 0.642) were not significant. 
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2.13. Urinary mineral excretion 
24-h urine samples were obtained for measurement of urinary magnesium, sodium and 
potassium levels using an automated platform (Olympus, UK) at the Clinical Biochemistry 
Laboratory, Royal Infirmary of Edinburgh, Scotland, UK.  Magnesium, sodium and 
potassium are primarily excreted through the kidneys (Eunsook and Willis, 2000; Tasevska 
et al., 2006) which implies that changes in their dietary intake could be directly reflected in 
their urinary levels. This is particularly important when considering that changes in dietary 
intake of magnesium, sodium and potassium may influence BP levels.  Urinary magnesium, 
sodium and potassium could also be viewed as biomarkers of micronutrient intake that can 
be used to validate the accuracy of the reported dietary intake (Eunsook and Willis, 2000).  
Additional reasons for monitoring the urinary excretion of these minerals in the present 
thesis are described below. 
 
2.13.1 Potassium and sodium 
Potassium is an important mineral that regulates insulin secretion by enhancing proinsulin‘s 
conversion to insulin (Dale and Haylett, 2004).  Its normal serum concentration range from 
3.5 to 5mmol/L (Kumar and Clark, 2005).  However, according to Zillich et al. (2006) 
maintaining serum potassium >3.9mmol/L is essential to prevent glucose intolerance.  This 
is because decreased dietary potassium intake is associated with increased fasting glucose 
levels (Gordon, see Zillich et al. 2006) while supplementation is linked to improved insulin 
sensitivity in obese individuals (Norbiato et al., 1984).   
 
Overweight and obese individuals exhibit several abnormalities in potassium metabolism.  
For instance, overweight and obese individuals excrete significantly more potassium than 
lean individuals, an effect thought to be caused by increased aldosterone secretion (Bentley-
Lewis et al., 2007).  Generally, aldosterone secretion is reduced in response to increased 
potassium secretion.  However, in obesity, increased angiotensin-II secretion counteracts the 
body‘s normal homeostatic mechanisms leading to enhanced aldosterone secretion, hence 
increased potassium losses (Bentley-Lewis et al., 2007).  Although such increased losses are 
not necessarily reflected in serum potassium levels, a reduction in intracellular potassium 
could still occur, as observed in obesity (Colt et al., 1981) which may then affect insulin 
secretion.  Obesity is also associated with decreased natriuretic peptide levels and increased 
sodium retention (Wang et al., 2004), which when combined with increased potassium 
losses, as reflected by high urinary sodium-to-potassium ratio
,
 is known to be associated with 
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hypertension (Langford, 1983).  Consequently, it is essential to monitor urinary sodium and 
potassium excretion in overweight and obese individuals, to compare their levels to the 
levels excreted by lean individuals, and to observe whether changes in insulin sensitivity or 
BP could be correlated with an improvement in urinary sodium-to-potassium ratio 
particularly that DC is rich in potassium.  
 
2.13.2 Magnesium 
Magnesium acts as a co-factor in the regulation of various ATP-requiring enzymes, many of 
which are implicated in glucose metabolism (Palanivel et al., 2005) and insulin‘s 
transduction pathways (Takaya et al., 2004).  It also regulates cholesterol synthesis and lipid 
homeostasis by controlling the activity of lecithin cholesterol acyltransferase and LPL both 
of which are required to increase HDL (Inoue, 2005) and TG‘s clearance (Rayssiguier, 
1984). Magnesium is also essential for maintaining vascular tone, BP (Barbagallo and 
Dominguez, 2007), calcium, sodium and potassium metabolism (Hordyjewska and 
Pasternak, 2004).  This implies that magnesium regulates virtually all intracellular reactions 
and that many of its metabolic effects are mediated through other ions‘ dependent pathways.  
It is therefore unsurprising why minor changes in magnesium, whether found on their own or 
accompanied by increased intracellular calcium, have been related to numerous metabolic 
abnormalities from insulin resistance, unfavourable lipid profile to hypertension (Barbagallo 
and Dominguez, 2007, Haglin et al., 2007, Schulze et al., 2007, Sharma et al., 2007). 
 
To illustrate, it has been shown repeatedly that hypomagnesaemia is associated with 
increased insulin resistance (Nadler et al., 1993), reduced insulin secretion (Paolisso et al., 
1989) and action (Paolisso et al., 1990) and impaired insulin binding with its receptor 
(Tonvai et al., see Paolisso et al., 1994). Conversely, correction of these deficiencies leads to 
reduced plasma glucose and increased insulin response (Paolisso et al., 1989).  Increased 
insulin response, particularly, is explained in terms of magnesium‘s ability to regulate 
potassium permeability, thereby increasing β-cell response to glucose (Paolisso et al., 1989).  
Similarly, magnesium supplementation has been shown to enhance insulin activity by 
increasing peripheral glucose uptake and glucose oxidation (Paolisso et al., 1992),  
 
With regard to lipid metabolism, animal models suggest that magnesium deficiency is 
associated with increased plasma TG, altered lipoprotein composition, increased 
susceptibility of lipoproteins and tissues to oxidative damage and raised apolipoprotein-B, 
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the latter being indicative of increased plasma TG-rich lipoproteins (Gueux et al., 1995). 
Conversely, high serum magnesium concentrations have been related to higher HDL 
(Guerrero-Romero and Rodríguez-Morán, 2000), while magnesium supplementation has 
been shown to lower LDL-cholesterol (Olatunji and Soladoye, 2007). Magnesium deficiency 
is also linked to increased oxidative stress and free radical generation (Bussière et al., 2002).  
This, as discussed earlier, diminishes NO bioavailability causing endothelium dysfunction 
and hypertension. 
 
Maintaining adequate magnesium intake in overweight and obese individuals could therefore 
be essential in reducing risk of insulin resistance, diabetes, dyslipidaemia and hypertension, 
especially that a direct association between low magnesium intake and increased prevalence 
of the metabolic syndrome exists (Ford et al., 2007).  A strong correlation between low 
magnesium intake and BMI in women also exists, suggesting that magnesium may help 
regulate women‘s body weight (Song et al., 2007). 
 
Both coffee and DC are rich in magnesium (Salmeron et al., 1997) providing on average 311 
and 100mg magnesium per 100g decaffeinated instant coffee or DC, respectively (Bruinsma 
and Taren, 1999; USDA, 2007b).  In fact, according to Bruinsma and Taren (1999), DC 
could be used to correct magnesium deficiencies.  Magnesium in DC is also thought to 
account for the reduction in BP and insulin resistance seen in Grassi et al.‘s studies (2005a-
b) (Meisel, 2005).  This indicates that foods like coffee and DC could contribute towards 
improving magnesium intake in overweight and obese subjects, thereby protecting them 
against insulin resistance, hypertension and dyslipidaemia.  Since, in the present thesis DC 
provided a daily intake of 33.42mg of magnesium, monitoring magnesium excretion could 
have been essential to explaining some of the mechanisms by which DC may affect glucose 
levels, BP, and lipid profile in overweight and obese subjects.   
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2.14. Urinary phenolic content, ferric-reducing capacity of plasma 
and oxygen radical absorbance capacity 
Urine samples were thawed at 4
o
C, centrifuged and subsequently diluted 1:10 for 
measurement of total phenolics and FRAP.  For ORAC, urine samples were diluted 1:100.  
Total polyphenol content, FRAP and ORAC were measured according to the methods 
described in section 2.1.2, section 2.1.3 and section 2.1.4. 
 
2.15. Validation of urine collection 
All 24-h urine collections were validated by measuring creatinine excretion (Eunsook and 
Willis, 2000, Rios et al., 2003, Roura et al., 2006) at the Clinical Biochemistry Laboratory at 
the Royal Infirmary, Edinburgh. According to Orth (1995), day-to-day variations in urinary 
creatinine concentration should not exceed 10%. 
 
 
2.16. Cortisol and Cortisone ELISA 
2.16.1 Principle of method 
Analyses of urinary free and salivary cortisol and cortisone levels were undertaken using an 
indirect competitive double-sandwich ELISA according to the protocol devised by Al-
Dujaili et al. (2005, 2006) (see below). In this assay, the microplate is coated with a constant 
amount of cortisol/ cortisone conjugate. This conjugate competes with the cortisol/cortisone 
in standards or samples for binding to a selective anti-sheep or anti-rabbit antibody.  Because 
the levels of the conjugate are held constant, the varying concentration of cortisol/cortisone 
in standard or sample can indirectly determine the amount of antibodies that bind to the 
conjugate.  An enzyme-linked antibody tracer is then added to the microplate which binds 
the conjugate-antibody complex. This double antibody sandwich produces a distinct yellow 
colour upon addition of the substrate and stop solution. The intensity of the colour, which is 
inversely proportionate to the concentration of cortisol/ cortisone in sample, is measured 
using an ELISA reader at 450nm and then compared to the absorbance of the cortisol/ 
cortisone standards. 
 
In general, measurements of 24-h urinary free cortisol and urinary free cortisone offers the 
advantage of obtaining a complete 24h glucocorticoid profile (Orth, 1995).  Although 
previously researchers used a single measurement of 24-h urinary free cortisol in diagnosing 
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imbalances in glucocorticoid metabolism, Remer and Maser-Gluth (2007) argue that the use 
of a combination of 24-h urinary free cortisol and urinary free cortisone ―provides more 
meaningful assessment of functional glucocorticoid activity‖ mainly because the 
concentrations of 24-urinary free cortisol could strongly be influenced by the activity of 
renal 11βHSD2 (Westerbacka et al., 2003).  Accordingly, several researchers have used both 
24-h urinary free cortisol and urinary free cortisone in assessing glucocorticoid metabolism 
in Cushing syndrome (Lin et al., 1997), apparent mineralcorticoid excess (Palermo et al., 
1996) and type-I diabetes (Remer et al., 2006).   
 
In the present thesis, urinary cortisone-to-cortisol ratio was also calculated because of the 
importance of this ratio as a marker of 11βHSD2 (Duclos et al., 2005). Moreover, 
monitoring the activity of this enzyme helps detect changes in peripheral metabolism of 
cortisol (Palermo et al., 1996).  Under normal physiological conditions,  24-h urinary free 
cortisone is present in concentrations two-fold higher than 24- urinary free cortisol (Lin et 
al., 1997; Taylor et al., 2002; Remer et al., 2006; Remer and Maser-Gluth, 2007)  with the 
urinary free cortisol-to-cortisone ratio being  equivalent to (mean± SE) 0.54±0.05 (Palermo 
et al., 1996).  However, in obesity, this ratio is elevated possibly due to increased cortisol 
metabolism, which according to Duclos et al. (2005) causes a reduction in plasma cortisol 
levels, and a subsequent increase in stress-induced cortisol secretion.  The 24h urinary free 
cortisol, on the other hand, serves as a measure of 24h free plasma cortisol (Vicennati and 
Pasquali, 2000).  In obesity decreased 24-h urinary free cortisol has been attributed to 
increased α-reductase activity, which catalyses the conversion of active cortisol to its 
metabolite 5α-THF (Andrew et al., 1998), as well as reduced cortisol generation from 
cortisone caused by 11βHSD1 inhibition (Stewart et al., 1999).   
 
The use of a combination of urinary, serum and salivary cortisol/ cortisone was deemed more 
appropriate for the main study given the wide variation observed in urinary free cortisol and 
urinary free cortisone excretion in the preliminary GCBE and DC studies.  Indeed, 
measurements of urinary cortisol and cortisone could be confounded by urine volume (Shi et 
al., 2008) and fluid intake (Fenske, 2006).  As with urine, salivary cortisol or cortisone 
permits the measurements of the biologically active free form of cortisol and cortisone.  In 
fact according to Viardot et al. (2005), salivary cortisol reflects 3-6% of the total serum 
cortisol concentrations.  Moreover, unlike urine, the concentration of cortisol and cortisone 
in saliva is not influenced by the rate of saliva
 
production (Guechot et al., 1982; Riad-Fahmy 
et al., 1982).  Moreover, collection of saliva is generally non-invasive and more convenient 
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since saliva is one of the most readily available body fluids and studies suggest that salivary 
glucocorticoids can remain stable at room temperature for up to 7d (Vining et al., 1987; 
Aardal et al., 1995, Aardal-Eriksson et al., 1998). This suggests that saliva could be 
collected at different time points during that day which could be important in monitoring 
changes in diurnal glucocorticoids production (Riad-Fahmy et al., 1982).  Finally, 
measurement of cortisol/ cortisone in saliva avoids interferences from renal 11βHSD2.    
 
It is important to note that the use of high-performance liquid chromatography (HPLC) 
(Weykamp et al., 1989; Lindsay et al., 2003), gas chromatography-mass spectrometry (GC-
MS) (Wudy and Hartmann, 2004), liquid chromatography- tandem mass spectrometry (LC-
MS/MS) (Taylor et al., 2002; Janzen et al., 2008; Soldin and Soldin, 2009) permits specific 
identification and quantification of urinary cortisol and cortisone metabolites which, in turn, 
enables more accurate determination of the activity of the different enzyme regulating 
glucocorticoid metabolism (see Figure 1.10; p. 46).  However, due to the expensive and 
time-consuming nature of such analyses, quantification of 24-h urinary free cortisol and 
urinary free cortisone was deemed more appropriate, particularly that most previous studies 
investigating the effect of polyphenols on glucocorticoid metabolism measured 24-h urinary 
free cortisol and urinary free cortisone rather than cortisol or cortisone metabolites (see 
Section1.11.7). 
 
2.16.2 Reagents and standards 
Dichloromethane, HCL, sodium hydroxide (NaOH), diethylether, disodium phosphate, 
dipotassium phosphate, sodium chloride, potassium chloride, bovine serum albumin (BSA), 
Tween 20, sodium acetate anhydrous, citric acid, 3,3,5,5 Tetramethyl-benzidine, dimethyl 
sulfoxide, H2O2  were obtained from Sigma-Aldrich (Poole, Dorset, UK).  Ultrapure water 
(Milli-Q) was obtained from Millipore System (Belford, MA). 
 
For the standards, a series of dilutions were prepared by diluting the stock cortisol standard 
in 0.05M PBS to give the following concentrations: 0, 2.5, 10, 50, 250 and 1000ng/ml. For 
cortisone, the following dilutions were prepared: 0, 0.5, 1.0, 2.5, 10 and 50ng/ml. 
 
2.16.2.a Phosphate buffer saline (0.05M, pH 7.4) 
PBS was prepared by adding 14.2g disodium phosphate, 3.4g dipotassium phosphate to a 
flask containing 1L distilled water. The solution was mixed on the bench and 10g of sodium 
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chloride and 1g of potassium chloride were added and the flask filled with distilled water to 
the 2.5L mark.  An iron flee was placed in the flask and the solution mixed on low heat on a 
magnetic stirrer and hotplate until the salts were completely dissolved.  PBS was stored at 
4
0
C until required 
 
2.16.2.b Assay buffer (0.025M) 
Assay buffer was prepared fresh on the day by diluting PBS 1:1 in distilled water.  BSA was 
then added, without stirring, to give a 0.1% BSA solution. 
 
2.16.2.c Coating buffer (0.02M) 
Coating buffer was prepared by diluting PBS1:1.5 in distilled water.  The buffer was stored 
at 4
0
C until required. 
 
2.16.2.d Block Buffer (0.25M)   
Block buffer was prepared fresh on the day by adding 0.2g BSA to 20ml PBS to give a 
solution with a final concentration of 0.5% BSA.   
 
2.16.2.e Wash buffer 
Wash buffer was prepared by adding 200ml PBS to 800ml distilled water (1:5 dilution) 
followed by 5ml Tween 20 (0.05% Tween 20 solution). 
 
2.16.2.f Substrate solution (pH 4-4.5) 
The substrate buffer was made by adding 8.2g sodium acetate anhydrous and 13g of citric 
acid to 0.5L distilled water and stored at 4
o
C until required. The stock substrate consisted of 
200mg 3,3,5,5 Tetramethyl-benzidine (TMB) dissolved in 20ml of dimethyl sulfoxide 
(DMSO).  This stock substrate was stored in an amber glass bottle and 1ml distilled water 
was added to prevent it from freezing upon storage at 4
o
C.  Overall, the substrate solution 
was prepared directly prior to use by combining 11ml of the prepared substrate buffer, 300µl 
stock substrate and 50µl H2O2. 
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2.16.2.g Preparation of plates 
For a 96-well plate, 20 ml of coating buffer was prepared by adding 50µl (0.5mg/ml) 
cortisol-conjugated to BSA or 30µl (0.5mg/ml) cortisone-conjugated to BSA. The solution 
was vortexed and a 200µl aliquot of the diluted cortisol-conjugate or 180µl of the diluted 
cortisone-conjugate was added to the plate using a multidispenser. The plate was covered 
with parafilm and a lid and left at 4
o
C overnight. 
 
2.16.2.h Preparation of antibodies 
A 60µl aliquot of cortisol/cortisone antibody was added to 11ml of assay buffer to give a 
1:1000 dilution prior to use.  
 
2.16.2.i Preparation of enzymes 
To prepare the cortisol enzyme, a 10µl cortisol anti-sheep enzyme was added to 10ml assay 
buffer (1:1000 dilutions).  For the cortisone enzyme, a 50µl cortisone anti-rabbit enzyme was 
added to 10ml assay buffer (1:200 dilution).  All enzymes were prepared directly prior to 
use. 
 
2.16.3 Preparation of urine samples 
Urine samples were initially defrosted and centrifuged at 6000rpm for 5minutes to remove 
any impurities. Glucocorticoids were subsequently extracted from urine samples according 
to the method described by Al-Dujaili et al. (2005, 2006). Briefly, 1ml urine was added to an 
extraction tube containing 8ml dichloromethane. The samples were vortexed for 10min and 
the resulting steroid-free urine was discarded using a Pasteur-pipette. Next, NaOH (0.05M) 
was added and the samples inverted gently 3 times. Then, using a Pasteur pipette, NaOH was 
discarded and HCL (0.05M) was added and the inverting and discarding procedures were 
repeated again. The same discarding and inverting procedure was repeated with water.  The 
obtained steroid-rich fraction was transferred to disposable Pyrex glass tubes and 
dichloromethane was evaporated in a water bath at 37
o
C.  The samples were then 
reconstituted in assay buffer and vortexed vigorously on V400 multi-tube vortexer (Alpha 
Laboratoiries, the Netherlands) before being stored overnight at 4
o
C.  The reconstituted 
samples were vortexed again prior to sampling. 
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2.16.4 Preparation of saliva samples 
As with urine, saliva samples were thawed and centrifuged at 6000rpm for 5 minutes to 
remove any impurities.  Next, a 500µl aliquot was pippetted to Fischer extraction tubes 
containing 4ml diethlyether, vortexed for 10 minutes on muti-tube vortexer, stored at -80°C 
for 10minutes.  Once, the aqueous phase was frozen, the remaining unfrozen steroid-rich 
fraction was decanted into disposable Pyrex glass tubes and diethylether was evaporated in a 
water bath at 37
o
C.  The samples were then reconstituted in assay buffer and vortexed 
vigorously on V400 multi-tube vortexer (Alpha Laboratoiries, the Netherlands) before being 
stored overnight at 4
o
C.  The reconstituted samples were vortexed again prior to sampling. 
 
2.16.5 Preparation of serum samples 
Serum samples were extracted according to the method described for urine.    
 
2.16.6 Assay 
A 96-well microplate was coated with cortisol/cortisone conjugate and incubated at 4
o
C 
overnight.  On the following morning, the fluid was discarded and the microplate was 
washed 3 times with 250µl wash buffer.  Next, 200µl blocking buffer was added and the 
plate was covered with parafilm and left to incubate for 1h at 37
o
C.  Following the 
incubation period, the fluid was discarded, and 50µl of standards and urine, saliva or serum 
samples were aliquoted in duplicates.  A 100µl of cortisol or cortisone antibody was added to 
all wells using a multi-channel pipette and the microplate mixed on the bench for 1 minute.  
After a 2h incubation in the dark at room temperature, the fluid was discarded and the plate 
washed 3 times with 250µl of wash buffer.  A 100µl of enzyme was added and the plate was 
left to incubate for 1h.  Following incubation, the discarding and washing procedures were 
repeated again and 100µl of freshly prepared substrate buffer was added to all wells and the 
plate was left in the dark for 15min to allow colour development.  Finally, 50µl of stop 
solution was dispensed into all wells using a multi-channel pipette and the absorbance read 
at 450nm using a Dynex Technologies MRX microplate reader (Dynex Technologies Ltd, 
Worthing, UK). 
 
Intra-assay precision for cortisol and cortisone ELISA ranged from 3.65% to 6.12% and 
5.5% to 11.7%, respectively while inter-assay precision ranged from 4.74% to 8.66% and 
from 8.7% to 12.8%, respectively (Al-Dujaili et al., 2007; 2009; Baghdadi et al., 2010).  
Additional validation data are provided in Appendix 1.  
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2.17. Measurements (Main study) 
2.17.1 Haematological, biochemical assessment and blood pressure 
Fasting glucose was measured using a commercial hexokinase assay (Sentinel, UK) while 
fasting insulin was measured using a commercial insulin ELISA kit (Mercodia, Sweden).  
Data on the precision and accuracy of the methods as determined by the manufacturers is 
provided in Appendix 1.  Assessment of the lipid profile was undertaken at the Clinical 
Biochemistry Laboratory, Royal Infirmary of Edinburgh, Scotland, UK, using an automated 
platform (Olympus, UK).  Serum NEFA were quantified using an automated enzymatic 
colorimetric method at the Rowett Institute of Nutrition and Health, Dundee, Scotland, UK 
(Wako, Germany). BP, 24-h urinary magnesium, sodium and potassium, urinary, salivary 
and serum cortisol and cortisone were measured as described for preliminary studies. The 
following equations were used to calculate HOMA-IR, HOMA-β, QUICKI and revised-
QUICKI. 
 
Equation 5 HOMA-IR= [fasting glucose (mmol/L) * fasting insulin (uLU/mL)]/22.5 
(Matthews et al., 1985) 
 
Equation 6 HOMA-β= 20* fasting insulin (mU/L)/ (fasting glucose (mmol/L) - 3.5) 
(Matthews et al., 1985) 
  
Equation 7 QUICKI= 1/[log (I0)+log (G0)], 
where I0= fasting insulin in (uLU/mL) and G0= fasting glucose in (mmol/L) (Wallace et al., 
2004) 
  
Equation 8 Revised-QUICKI= 1/[log (I0)+log (G0)+log (N0)], 
where I0= fasting insulin in (uLU/mL), G0= fasting glucose in (mmol/L) and N0= fasting 
NEFA in (mmol/L) (Perseghin et al., 2001) 
 
2.17.2 Serum phenolic content, ferric-reducing capacity of plasma and 
oxygen radical absorbance capacity 
To avoid interferences from proteins, serum samples were deproteinised according to the 
method of Cao et al. (1998).   Briefly, 500μl of 0.5M pechloric acid was added to a similar 
quantity of serum and the samples were left to cool for 15 min at 4
o
C.  Samples were then 
centrifuged for 30min at 13 000rpm and the resulting supernatant collected for estimation of 
total phenolics and FRAP. For ORAC, deproteinised serum samples were further diluted to 
give a final dilution factor of 1:100.  
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2.18. Statistical analyses 
2.18.1 Preliminary GCBE study 
All data are expressed as mean ± SDs unless otherwise stated. Changes in fasting capillary 
glucose, BP and anthropometrical measurements from baseline across Week1 and Week 2 of 
the intervention were compared using repeated measures ANOVA with Bonferroni post-hoc 
tests.  Differences in total cholesterol, urinary and salivary cortisone, cortisol and cortisone-
to-cortisol ratio, dietary intake and energy expenditure were analysed using a Paired sample 
t-test.  Significance was set at a p-value ≤0.05.  The relationship between capillary  fasting 
glucose levels, total cholesterol, SBP, DBP, BMI, weight, WC, HC, WHR, urinary 
magnesium, sodium and potassium levels, salivary and 24-h urinary free cortisol, cortisone, 
cortisol-to-cortisone ratio were assessed using Pearson product-moment correlation 
coefficient, r.  The coefficient of determination was estimated by obtaining r
2
.  All statistical
 
analyses were performed using SPSS for Windows version 16.0.0 (SPSS Inc, Chicago, IL, 
USA). 
 
2.18.2 Preliminary DC study 
All data are expressed as mean ± SDs unless otherwise stated. Mixed between-within 
subjects analysis of variance (SPANOVA) was performed for multiple comparison, where 
time (baseline, week 1, week 2) was the within-group variable and intervention group (500 
mg, 1000 mg DC) was the between-group variable and the continuous variable were glucose, 
SBP, DBP BMI, weight, WC, HC, WHR. A p-value ≤0.05 was deemed statistically 
significant. Within each intervention group (500 mg, 1000 mg DC) changes in fasting blood 
glucose levels, SBP and DBP were analysed using repeated measures ANOVA with 
Bonferroni post-hoc tests.  A separate SPANOVA was also performed to detect any carry-
over effects between the two interventions and to ensure changes in fasting glucose, SBP and 
DBP following each treatment were not affected by the sequence of DC administration 
(1000mg followed by 500mg vs. 500mg followed by 1000mg).  Two-tailed paired sample t-
tests were used to assess changes between baseline and post-intervention total cholesterol, 
urinary free cortisol or cortisone, urinary cortisol-to-cortisone ratio, mineral excretion, 
dietary intake and energy expenditure.  Similarly, differences in response to both DC doses 
amongst the various ethnic groups were assessed using one-way between-groups ANOVA 
with fasting glucose, SBP and DBP as the dependent variables and ethnicity as the Factor.  
An independent sample t-test was also used to compare the response to DC polyphenols 
between the abdominally obese individual and the peripherally obese individuals. The 
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relationship between fasting blood glucose levels, total cholesterol, SBP, DBP, BMI, weight, 
WC, HC, waist-to-hip circumference, urinary magnesium, sodium and potassium levels, 24-
h urinary free cortisol, cortisone, cortisol-to-cortisone ratio were assessed using Pearson 
product-moment correlation coefficient, r.  The coefficient of determination was estimated 
by obtaining r
2
.  All statistical
 
analysis was performed using SPSS for Windows version 
16.0.0 (SPSS Inc, Chicago, IL, USA). 
 
2.18.3 Main study 
Continuous normally distributed data are expressed as mean ± SD unless otherwise stated.  
Data distribution was assessed using the Explore function of the Descriptive Statistics in 
SPSS.  Differences in baseline characteristics between the two BMI categories (BMI< 
25kg/m
2
 and BMI≥ 25kg/m2) were examined using an independent sample t-test with BMI 
category placed as the grouping variable and age, BMI, WC, HC, WHR, fasting insulin, 
glucose, total cholesterol (TC), TG, HDL, LDL, TC: HDL ratio, SBP, DBP, urinary free 
cortisol, urinary free cortisone, urinary cortisone-to-cortisol ratio, urinary and serum FC, Fe
2+ 
, ORAC as the dependent variables.  For multiple comparisons, data were analysed with a 
three-factor repeated measures ANOVA with time (pre- and post-) and treatment (DC and 
placebo) as the 2 within-subject factors and BMI category as the between-subject factor.  
Post hoc comparisons of the main effects of time, treatment and BMI category were 
conducted using Bonferroni correction with significance level set at a P ≤ 0.05.  For 
statistically significant treatment-by-time interactions, differences from baseline for each of 
treatment and placebo group were obtained and compared using a paired-sample t-test.  
Analyses were also repeated using the split-file function in order to compare differences in 
response within each of the BMI categories.  If statistically significant treatment-by-time-by-
BMI category interactions were also observed, then differences from baseline were also used 
to compare the response between the two BMI categories using an independent sample t-test. 
Significance was set at a P≤ 0.05, unless otherwise stated.  Changes in physical activity, 
energy, macronutrient and micronutrient intake were assessed using SPANOVA with time as 
the within-subject factor and BMI as the between-subject factor.  Significant differences, if 
any, were tested by applying a Bonferroni correction. 
 
The relationship between all assessed variables was assessed using Pearson product-moment 
correlation coefficient, r.  The coefficient of determination was estimated by obtaining r
2
.  
All statistical
 
analyses were performed using SPSS for Windows version 16.0.0 (SPSS Inc, 
Chicago, IL, USA). 
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3. Results 
3.1. Antioxidant capacity of green coffee and Theobroma cacao 
bean extracts 
 
Table 3.1 shows mean polyphenol content of GCBE described as GAE per g extract.  As 
observed, the polyphenol content in the acidified water extract varied greatly amongst the 
triplicates as opposed to other extracts with a large variation being present between the 
polyphenol content of ethanol, acidified-water and acetonitrile extracts.  Similar findings 
were observed with the FRAP assay, wherein the acetonitrile extract exhibited a stronger 
ferric-reducing ability than the ethanolic extract and acidified-water extracts (Figure 3.1).  
With regard to TCBE, the bound fraction was found to contain the majority of phenolic 
compounds (2952.2±135.4μg GAE per ml bound fraction vs. 296.2±70.4μg GAE per ml 
unbound fraction).  
 
The ORAC values of GCBE and TCBE are shown in Figure 3.2. 
 
Figure 3.5  shows dose-dependent inhibition of DPPH-radical by each of the samples tested.  
One-way ANOVA revealed no significant difference in IC50 between the tested samples 
(P=0.097) although CGA was found to have the lowest DPPH-radical scavenging activity.   
The IC50 of different antioxidants and GCBE and TCBE are shown in Figure 3.4.  As 
observed, a high concentration of CGA was required to inhibit the DPPH-radical by 50%.  
Compared to CGA alone, GCBE rich in CGA had a lower IC50 value.  
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Table 3.1 Mean polyphenol content and coefficient of variation between triplicate analyses of the same sample and between different samples of green 
coffee bean extract 
 
Extraction solvent Mean (SD) of triplicates (mg/g extract) CV Mean (SD) of three different samples 
(mg/g extract)  
CV 
Acidified-water 130.91 (0.66) 0.50 116.47 (14.55) 12.49 
Ethanol 122.77 (0.23) 0.19 128.40 (5.76) 4.49 
acetonitrile 211.05 (0.51) 0.24 221.82 (8.63) 3.89 
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Figure 3.1  Ferric-reducing capacity of various extracts of green coffee bean.  Data are 
expressed as mmol Fe
2+
 per g extract. Data are expressed as mean of three different 
samples ±SEM.  
 
 
 
 
Figure 3.2 Antioxidant capacity of green coffee bean extract (GCBE) and Theobroma 
cacao bean extract (TCBE)  as measured by the Oxygen Radical Absorbance Capacity 
(ORAC) assay.  Data are represented as mean ±SEM (n=4).  Data are expressed in 
µmol trolox equivalents per g extract.  
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Figure 3.3The percentage remaining 2,2-diphenyl-1-picrylhydrazyl radical (DPPH)  against increasing concentrations of green coffee bean 
extract (GCBE), Theobroma cacao bean extract (TCBE), gallic acid (GA), ascorbic acid (AA) and chlorogenic acid (CGA).  Data are 
represented as mean of duplicates with standard deviations. 
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Figure 3.4  The inhibitory concentration (IC)50 of different phenolic compounds as 
measured by DPPH.  Data are represented as mean of duplicates. 
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3.2. Lipase assay 
 
Figure 3.5 shows the effect of GCBE and TCBE on pancreatic lipase activity.  GCBE 
showed a J-shaped dose-dependent inhibition of pancreatic lipase with the percentage 
inhibition ranging from 11.8 to 61.5%.  Similar concentrations of TCBE, on the other hand, 
had a negligible effect on lipase activity.  Non-linear regression analysis revealed that the 
concentration of GCBE required to elicit a 50% inhibition of pancreatic lipase activity 
(IC50) was 43.37µg. 
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Figure 3.5 percentage inhibition of pancreatic lipase by each of the green coffee bean 
extract (GCBE) and Theobroma cacao bean extract (TCBE).  Data are represented as 
mean of triplicates. 
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3.3. Preliminary green coffee bean extract study 
 
Table 3.2 shows baseline characteristics of the study population.  Overall, Twenty three 
healthy overweight or obese volunteers were recruited (9  males,  14 females).  Of these 
participants, twenty were peripherally obese and three were abdominally obese.  All subjects 
completed the trial with the exception of one volunteer who failed to complete the second 
urine (Week 2) collection.  Data from this subject for the remaining non-urinary tests was 
still included in the analyses.  Based on volunteers‘ reports and capsule counting, all GCBE 
tablets were ingested as directed in the subject information sheets. 
  
 
  Table 3.2  Baseline characteristics of the study population (n=23) 
Parameter  Values (mean ± SEM) 
Age (yr) 34.09 ± 11.27 
BMI (kg/m
2
) 27.79± 2.15 
WC (cm) 89.02± 9.91 
Waist-to-hip ratio 0.84 ± 0.08 
 
Repeated measures ANOVA revealed a significant reduction in SBP following consumption 
of GCBE (P=0.043).  This reduction as demonstrated by post-hoc Bonferroni test was 
present after 2 weeks of GCBE consumption (P=0.036) but not after 1 week (P=0.276) 
(Figure 3.6).  No significant changes in fasting glucose (Baseline 4.46±0.79, Week 1 
4.20±0.74, Post-GCBE 4.22±0.65; P=0.258), TC (Baseline 4.87±0.94, Post-GCBE 
4.90±0.81; P=0.694) or DBP (P=0.156; Figure 3.6) were seen. 
 
Paired sample t-test showed that 24h urinary free cortisone excretion significantly declined 
from 64.95± 34.47 to 42.61±24.47 nmol/d (P=0.0015) (Figure 3.7). A rise in urinary free 
cortisol from 21.47 ±50.55 to 42.61±24.47 nmol/d (p=0.279) and a fall in urinary cortisone-
to-cortisol ratio from 3.32 ±5.83 to 1.26±1.04 (p=0.085) were also observed but neither 
reached statistical significance (Figure 3.7). Reductions in urinary free cortisone remained 
significant even after adjustment for weight (Table 3.3).   In a subset sample of nine 
volunteers, salivary free cortisone was found to be significantly raised following 2-week 
consumption of GCBE while no significant changes in salivary cortisol or salivary cortisone-
to-cortisol ratio were detected (Figure 3.8).   
 
 162 
  
 
 
Figure 3.6  Effect of green coffee bean extract consumption for  14 days on systolic (SBP) and diastolic blood pressure (DBP) in healthy 
overweight subjects (n=13).  The asterisk indicates that there was a significant reduction in blood pressure following consumption of green 
coffee bean extract.  Data expressed as mean values  ± SEM 
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Figure 3.7  Effect of green coffee bean extract consumption for 14 days on urinary free 
cortisol, urinary free cortisone (a) and urinary cortisone-to-cortisol ratio (b) in healthy 
overweight subjects (n=22). Data expressed as mean ± SEM.  
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Table 3.3  Changes in  urinary glucocorticoids after adjustment for weight (n=22) 
variable Baseline Week 2 Paired Sample t-test 
mean SD mean  SD P-value 
Urinary free cortisol (nmol/kg/d/) 0.75 0.75 0.60 0.46 0.339 
Urinary free cortisone (nmol/kg/d) 0.86 0.46 0.55 0.32 0.0025 
Cortisone-to-cortisol ratio 3.46 5.94 1.29 1.06 0.083 
Magnesium (mmol/d) 3.27 2.23 3.23 2.13 0.934 
Sodium (mmol/d) 124.09 76.57 105.64 58.95 0.299 
Potassium (mmol/d) 94.14 83.28 77.29 79.42 0.227 
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Figure 3.8  Effect of green coffee bean extract consumption for 14 days on salivary free cortisone, salivary free cortisol and salivary 
cortisone-to-cortisol ratio in healthy overweight subjects (n=9). Data expressed as mean ± SEM. 
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3.3.1 Urinary total phenolics and ferric-reducing capacity of plasma 
In vivo antioxidant activity was determined using FC and FRAP.  There was a significant 
correlation between urinary polyphenols excretion as determined by FC and FRAP (0.637, 
p<0.0001).  However no significant increase in urinary antioxidant activity was observed 
(total phenolics: Pre-GCBE 126.89 (SD 100.76) mg/g GAE equivalents/creatinine vs. Post-
GCBE 135.81 (SD 130.77) mg/g GAE equivalents/creatinine, p>0.05; FRAP: Pre-GCBE 
1.77 (SD 1.29) mmol/g Fe
2+
/creatinine vs. Post-GCBE 1.49 (SD 0.78) mmol/g 
Fe
2+
/creatinine, p>0.05).   
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3.3.2 Weight and anthropometry 
No significant changes in weight, BMI, HC, percentage body water or fat were noted after 
consumption of GCBE (repeated measures ANOVA > 0.05).   
 
 
Table 3.4  Changes in  anthropometrical measurements(n=23) 
variable Baseline Week 1 Week 2 Repeated-ANOVA 
mean SD mean SD mean  SD Wilk‘s Lambda 
Weight(kg) 79.70 11.14 79.57 10.83 79.43 10.95 0.651 
BMI
1
 
(kg/m
2
) 
27.79 2.15 27.76 2.13 27.71 2.20 0.707 
HC
2
 (cm) 105.76 5.60 105.37 5.77 105.46 5.75 0.355 
WHR
3
 0.842 0.0797 0.840 0.083 0.837 0.084 0.086 
 BMI
1
bosy mass index; HC
2
hip circumference; WHR
3
waist-to-hip ratio 
 
However, a significant reduction in WC was observed (P=0.013) (Figure 3.9).  Post-hoc tests 
using Bonferroni further revealed that the reduction in WC was gradual and persisted from 
baseline (89.02±9.91) across Week 1 (88.50±9.69, P=0.055) and into Week 2 of GCBE 
ingestion (88.24±9.64; P=0.008). WHR was also decreased following GCBE by 0.004.  
However, this reduction did not reach statistical significance (P=0.086). 
 
 
 
Figure 3.9  Effect of green coffee bean extract consumption for 14 days on waist 
circumference (n=23). The asterisk indicates a significant reduction in waist 
circumference  following consumption of green coffee bean extract.  Data are expressed 
as mean  ± SEM 
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3.3.3 Energy intake and expenditure 
No significant changes in energy intake, energy expenditure or macronutrient, micronutrient 
intake were observed during the study (Paired sample t-test, P >0.05) (Figure 3.10).   
 
 
 
 
 
Figure 3.10 Energy, Macronutrient and mineral intake at baseline and at the end of 2-
week intervention (n=22). Values are mean, with standard errors represented by 
vertical bars. ( ) energy expenditure; ( ) energy intake; ( ) fat intake; ( ) protein 
intake; ( ) carbohydrate intake; ( ) magnesium intake; ( ) sodium intake; ( ) 
potassium intake). 
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3.4. Animal study 
 
Figure 3.11 shows free corticosterone levels in different tissues in both the control group and 
the treatment group.  Compared to control, mice receiving CGA showed a trend towards an 
increase in the concentration of free corticosterone in kidney.  Conversely in the liver, there 
was a trend towards a reduction in free corticosterone.  None of these values reached 
statistical significance (P= 0.108 and 0.219). However, calculation of Eta
2
 revealed a large 
effect of treatment on free corticosterone levels in kidney (Eta
2 
= 0.26) and liver (Eta
2 
=0.14).  
No differences in free corticosterone in mesenteric (P=0.521, Eta
2 
=0.05) or subcutaneous 
tissues (P=0.950 Eta
2 
< 0.001) were observed.   
 
 
  
 Figure 3.11 Tissue free corticosterone in control mice (n= 5) and in mice fed a diet 
containing 0.15% chlorogenic acid (n= 6). Data are expressed as mean ± SEM. 
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Figure 3.12 shows glucoronidated- and sulphated-corticosterone levels in different tissues in 
both the control group and the treatment group.  No significant changes in glucoronidated- or 
sulphated- corticosterone concentrations were observed in kidney, liver or mesenteric tissue.  
In subcutaneous tissue, mice receiving CGA showed a trend towards a reduction in 
glucoronidated- and sulphated-corticosterone as compared to mice receiving a control diet.  
However, this difference did not reach statistical significance.   
 
  
  
 
Figure 3.12 Tissue glucoronidated- and sulphated-corticosterone in control mice (n= 5) 
and in mice fed a diet containing 0.15% chlorogenic acid (n= 6). Data are expressed as 
mean ± SEM.  
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3.5. Preliminary dark chocolate study 
 
Figure 3.13 shows flow of volunteers through the preliminary DC study.  This study 
included fourteen healthy volunteers [eight males (five Caucasians, two Asians, one African) 
and six females (five Caucasians and one Hispanic], 21-50 years old, mean age 26.4± 11.5 
years) with a BMI of 27.7± 2.5 kg/ m
2
.  Of these participants, thirteen were peripherally 
obese and one was abdominally obese (African).  Based on volunteers‘ self-reports and 
returned empty bags, all volunteers were found to have ingested  the chocolate products 
provided.  
 
 
 
 
 
Figure 3.13 Flow of participants through the preliminary dark chocolate trial. 
 
 
Mixed between-within subjects analysis of variance revealed a significant reduction in 
fasting capillary blood glucose concentrations (P=0.002), SBP (P<0.0001) and DBP 
(P<0.0001) following DC consumption. These effects were independent of the sequence of 
DC administration and no significant interaction between time, intervention group and 
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sequence of DC administration was observed (fasting glucose F(2, 11)= 1.057, P =0.380; 
SBP F (2, 11)=0.431, P=0.660; DBP F (2, 11)=0.653, P=0.539) (Figure 3.14 and Figure 
3.15).  No significant differences between the effect of 1000mg and 500mg polyphenols DC 
on fasting capillary blood glucose (P > 0.05) and BP (P > 0.05) were observed indicating that 
both doses have a similar efficacy.   
 
To explore the results further, a one-way repeated measures ANOVA was conducted to 
compare fasting blood glucose levels, SBP and DBP at baseline, week 1 and week 2 for each 
of the two dietary interventions.  A significant effect of DC on fasting blood glucose levels 
(F(2, 12)=4.305, P=0.039), SBP (F(2,12)=12.330, P =0.001) and DBP (F(2,12)=13.937, P 
=0.001) was observed after consumption of 1000 mg DC.  Post-hoc comparisons using 
Bonferroni test indicated that mean fasting blood glucose levels and SBP at week 2 were 
significantly decreased after 1000mg DC ingestion (fasting glucose  3.97 (SD 0.54) vs. 
baseline 4.42 (SD 0.70)mmol/l; SBP 112.12 (SD 9.68) vs. baseline 119.38 (SD 10.51) 
mmHg).  Mean DBP levels were significantly lower at week 1 (74.45 (SD 7.17) mmHg) and 
week 2 (74.57 (SD 7.39)mmHg) compared to baseline (78.62 (SD 7.74)mmHg).   
 
A significant effect of 500mg DC on fasting glucose levels (F(2,12)=5.026, P=0.026), SBP 
(F(2,12)=11.971, P=0.001) and DBP (F(2,12)=7.709, P =0.007) was also observed.  Post-hoc 
comparisons indicated that the mean fasting glucose levels at week 2 were significantly 
different from baseline (3.92 (SD 0.86) vs. baseline 4.42 (SD 0.30) mmol/l).  Mean SBP was 
also reduced at the end of week 1 (114.24 (SD 9.53) mmHg) and week 2 (112.40 (SD 
9.51)mmHg) as compared to baseline (119.38 (SD 10.51)mmHg).  Similar findings were 
observed with DBP (Week 1= 74.62 (SD 4.27) and Week 2= 73.00 (SD 5.06) vs. baseline 
78.62 (SD 7.74) mmHg).   
 
Total cholesterol did not change significantly after 1000mg (4.98 (SD 0.90) mmol/l vs. 
baseline 5.21 (SD 1.01) mmol/l; P=0.191) or 500mg polyphenols DC (5.03 (SD 0.77) 
mmol/l vs. baseline 5.21 (SD 0.77) mmol/l; P=0.246).  There was a trend towards a 
reduction in 24h urinary free cortisone levels in both the 1000 mg and 500 mg DC groups, 
although this reduction did not reach statistical significance even after adjustment for weight.  
No changes in anthropometrical data (Table 3.5), 24h urinary free cortisol, cortisol-to-
cortisone ratio, 24h urinary magnesium, sodium, potassium were observed (Table 3.6).  
Likewise, one-way ANOVA revealed no significant effect of ethnicity on changes in fasting 
glucose, SBP, DBP in both DC groups, with the exception of one female subject (Hispanic) 
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who experienced a greater reduction in SBP following both polyphenol doses as compared to 
Caucasians (1000mg P =0.009; 500mg P <0.0001), Asians (1000mg P =0.014; 500mg P 
=0.003) and African (1000mg P =0.0001; 500mg P <0.009).  The subject with abdominal 
obesity showed an increase in urinary free cortisol following 1000mg polyphenols (+52.44 
nmol/d) compared to peripherally obese individuals who demonstrated a reduction (-11.05 
nmol/d; P=0.037).  This subject also had a greater reduction in DBP following 500mg DC 
compared to other individuals (-15.7 mmHg versus -3.10 mmHg; P=0.017). 
 
No significant changes in urinary total polyphenols were observed following consumption of 
either 500mg or 1000mg polyphenol-rich DC (total phenolics: Baseline 173.21 (SD 137.77) 
mg/g GAE equivalents/creatinine vs. Post-500mg polyphenols DC 160.81 (SD 74.37) mg/g 
GAE equivalents/creatinine and Post-1000mg polyphenols DC 207.61(SD 115.20) mg/g 
GAE equivalents/creatinine p>0.05; FRAP: Baseline 2.07 (SD 0.91) mmol/g Fe
2+
/creatinine 
vs. Post-500mg polyphenols 2.15 (SD 1.05) mmol/g Fe
2+
/creatinine and Post-1000mg 
polyphenols 3.01 (SD 1.57) mmol/g Fe
2+
/creatinine , p>0.05).  However, three subjects 
(Subject 5, 10 and 14) were found to have higher urinary FC and Fe
2+ 
values at baseline as 
compared to post-polyphenol-rich DC (Figure 3.16 and Figure 3.17).  These extreme values 
acted as outliers and following their exclusion a significant dose-dependent increase in 
urinary antioxidant capacity was observed  (total phenolics: Baseline 115.54 (SD 54.59) 
mg/g GAE equivalents/creatinine vs. Post-500mg polyphenols DC 166.21 (SD 82.22) mg/g 
GAE equivalents/creatinine, p=0.024 and Post-1000mg polyphenols DC 227.46(SD 122.28) 
mg/g GAE equivalents/creatinine p=0.007; FRAP: Baseline 1.76 (SD 0.67) mmol/g 
Fe
2+
/creatinine vs. Post-500mg polyphenols 2.36 (SD 1.09) mmol/g Fe
2+
/creatinine, p=0.033 
and Post-1000mg polyphenols 3.45 (SD 1.48) mmol/g Fe
2+
/creatinine , p=0.001).   
 
Pearson‘s product moment correlations revealed a significant correlation between changes in 
24h urinary free cortisol, cortisone and changes in 24h sodium excretion (Table 3.7).  There 
were no significant correlations between age and changes in fasting glucose, SBP, and DBP 
following both DC doses (P > 0.05).  Addition of DC to the diet did not affect magnesium 
intake or excretion significantly.  Moreover, no significant correlations were found between 
changes in magnesium intake or excretion and the reductions in fasting blood glucose and 
BP seen following DC consumption. Energy, macronutrient and mineral intake did not 
change significantly through the study period (Figure 3.18). Physical activity at the end of 
500mg DC (3572.40±933.90; Paired sample t-test, P=0.935) and 1000mg DC intervention 
(3589.39±949.69kcal/d; Paired sample t-test P=0.857) did not differ from baseline (Baseline: 
3561.17±813.25kcal/d). 
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Table 3.5  
Effect of either 500mg or 1000mg polyphenol dark chocolate on anthropometrical measurements (n= 14). 
 (Mean and standard deviations) 
DC
1
, dark chocolate; WC
2 
, waist circumference; HC
3
, hip circumference; WHR
4
, waist-to-hip ratio.  
 
 
 1000 mg  DC
1
 500 mg  DC
1
 
 baseline Week-1 Week-2   baseline Week-1 Week-2   
 Mean SD Mean SD Mean SD P Mean SD Mean SD Mean SD n P 
Weight (kg) 81.64 13.40 81.66 12.84 81.36 12.80 0.447 81.29 13.99 80.85 13.69 81.13 13.35 14 0.789 
BMI (kg/m
2
) 27.73 2.53 27.75 2.38 27.66 2.44 0.517 27.58 2.70 27.46 2.75 27.56 2.56 14 0.796 
WC
2 
(cm) 90.82 11.85 89.86 11.16 89.93 11.412 0.175 90.82 11.85 90.04 11.29 90.00 11.31 14 0.326 
HC
3
 (cm) 105.61 5.99 105.64 6.21 105.57 6.30 0.089 105.61 5.99 105.11 6.19 105.11 6.96 14 0.810 
WHR
4
 .86 .09357 .85 .09 .85 .10 0.165 .86 .09 .86 .11 .86 .11 14 0.992 
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Table 3.6 
Results for 24h urine collections. 
(Data are expressed as mean and standard deviations) 
 
 1000 mg DC
1
 500 mg DC
1
 
 baseline Week-2    baseline Week-2    
 Mean SD Mean SD n df P Mean SD Mean SD n df P 
Free cortisol (nmol/d) 77.33 27.09 71.16 38.90 13 12 0.477 86.83 44.05 78.58 47.28 14 13 0.620 
Free cortisone (nmol/d) 54.34 26.90 45.82 17.33 13 12 0.159 59.64 32.56 45.80 20.34 14 13 0.139 
Cortisol-to-cortisone ratio 1.6812 0.75 1.60 .63 13 12 0.664 1.68 0.72 1.77 0.62 14 13 0.682 
Cortisone-to-cortisol ratio 0.71 0.32 0.75 0.37 13 12 0.744 0.71 0.31 0.63 0.21 14 13 0.455 
Free cortisol (nmol/kg/d) 0.98 0.37 0.89 0.44 13 12 0.400 1.0529 0.43 0. 98 0.64 14 13 0.731 
Free cortisone (nmol/kg/d) 0.69 0.36 0.57 0.17 13 12 0.162 0.73 0.38 0.55 0.23 14 13 0.180 
Creatinine (mmol/d) 12.74 5.35 11.78 4.40 13 12 0.219 12.83 5.15 19.29 27.37 14 13 0.387 
Magnesium (mmol/d) 3.26 1.23 3.00 1.55 13 12 0.497 3.29 1.19 3.26 1.34 14 13 0.928 
Sodium (mmol/d) 122.07 57.90 114.63 48.71 13 12 0.802 124.35 56.28 132.69 54.44 14 13 0.644 
Potassium (mmol/d) 58.20 22.12 56.14 24.08 13 12 0.770 61.19 24.03 67.58 22.42 14 13 0.377 
DC
1
, dark chocolate. 
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Figure 3.14 
Capillary fasting glucose levels (FG) at baseline (Week 0), and at the end of 1 week and 
2 weeks of each of the polyphenol doses.   Group 1 received 1000mg polyphenols dark 
chocolate (Week 1-2) followed by 500mg polyphenols dark chocolate (Week 4-5). 
Group 2 received 500mg polyphenols dark chocolate (Week 1-2) followed by 1000mg 
polyphenols dark chocolate (Week 4-5).  Changes in fasting glucose were independent 
of the sequences of chocolate administration (p>0.05). Values are mean, with standard 
errors represented by vertical bars. 
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Figure 3.15 
Systolic (SBP) and diastolic blood pressure (DBP) at baseline (Week 0), and at the end 
of 1 week and 2 weeks of each of the polyphenols doses.  Group 1 received 1000mg 
polyphenols dark chocolate (Week 1-2) followed by 500mg polyphenols dark chocolate 
(Week 4-5). Group 2 received 500mg polyphenols dark chocolate (Week 1-2) followed 
by 1000mg polyphenols dark chocolate (Week 4-5).  Changes in SBP and DBP were 
independent of the sequences of chocolate administration (p>0.05). Values are mean, 
with standard errors represented by vertical bars. 
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Figure 3.16 
Total polyphenol concentration in urine at baseline and at the end of 2 weeks of 500mg and 1000mg polyphenols DC (n=14). Lines represent 
individual responses. Data are expressed in mmol GAE per gram creatinine.  Note the Outliers (Subjects 5, 10 and 14) 
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Figure 3.17 
Urinary ferric-reducing capcity (Fe 
2+
) at baseline and at the end of 2 weeks of 500mg and 1000mg polyphenols DC for each of 14 volunteers. Lines 
represent individual reponses. Data are expressed in mmol Fe 
2+
 per gram creatinine.  (Subjects 5, 10 and 14) 
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Figure 3.18  Energy (I), Macronutrient (II) and mineral intake (III) at baseline and at 
the end of each intervention: 20 g dark chocolate with 1000 mg polyphenols (a) and 20 
g dark chocolate with 500 mg polyphenols (b). Values are mean, with standard errors 
represented by vertical bars. ( ), Energy expenditure; ( ) energy intake; ( ) fat 
intake; ( ) protein intake; ( ) carbohydrate intake; ( ) magnesium intake; ( ) 
sodium intake; ( ) potassium intake. 
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Table 3.7 
Pearson product-moment correlations between changes in urinary glucocorticoids 
levels and changes in selected parameters 
Correlation pair n r P 
∆ Urinary free cortisol 
(nmol/kg/24h) 
∆Urinary free cortisone excretion 
(nmol/kg/24h) 
27 0.599 0.001 
∆ 24h urinary sodium (mmol/g 
creatinine) 
26 0.489 0.011 
∆ physical activity (kJ) 26 -0.384 0.053 
∆ Urinary free cortisone 
(nmol/kg/24h) 
∆ cortisol-to-cortisone ratio 27 -0.662 0.000 
∆ cortisone-to-cortisol ratio 27 0.628 0.000 
∆ 24 h urinary sodium  (mmol/g 
creatinine) 
26 0.478 0.014 
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3.6. Main study 
3.6.1 Study population: Baseline characteristics 
The study included 48 female volunteers (46 Caucasian, 1 Hispanic and 1 Asian).  All 
volunteers completed the trial with the exception of four volunteers who dropped-out 
following their first visit (Figure 3.19). Of these four volunteers, one was excluded on the 
basis of not consuming the specified polyphenol-rich DC on 7 consecutive occasions. An 
additional two volunteers (BMI <25kg/m
2
) also dropped-out after completing one part of the 
study for reasons unrelated to the study. Data from the latter two volunteers was not included 
in statistical analyses with the exception in baseline comparisons (Figure 3.20 and Figure 
3.21).  One subject also failed to return their 24h urine collections on 2 occasions.  Data from 
this subject for the remaining non-urinary tests was still included in the analyses.  On the 
basis of remaining volunteers‘ self-reports and returned empty bags, all chocolate portions 
were consumed.  However, 1 of 1176 polyphenol-rich DC portions and 6 of the 1176 
placebo portions were reported to be consumed upto 24h after the specified time-point.   
 
 
 
 
 
 
 
Figure 3.19 Flow of participants through the Main study.  
48 randomised 
Placebo 
500mg DC 
WASHOUT 
RUN-IN 
Placebo 
500mg DC 
4 dropped-out after 
first visit: 
1  Failed to consume 
specified dose 
2  Family reasons 
1  No reason 
specified 
 
2 dropped-out after 
completing first 
phase. 
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Baseline characteristics of the studied population are shown in Table 3.8.  Of the total 42 
female volunteers who completed the study, 21 had a BMI< 25kg/m
2
, 14 were overweight 
(BMI= 25-29.99 kg/m
2) and 7 were obese (BMI≥30 kg/m2).  Using WHO criteria for 
classifying fat distribution, it was observed that within the BMI ≥25kg/m2 group, 16 
participants had peripheral fat distribution (WHR≤ 0.85) and 5 had abdominal fat 
distribution (WHR> 0.85).  One subject from the normal weight group had abdominal fat 
distribution.  In order to assess the risk of metabolic complication, subjects from the 
overweight and obese group were also classified according to WC.  Accordingly, 6 subjects 
were identified to be at an increased risk of metabolic complications (WC≥ 80cm) while 
another 11 were deemed to be at a substantially increased risk (WC≥ 88cm).  Applying the 
same classification to the normal weight group showed that 4 subjects had a WC≥ 80cm 
indicating increased risk of metabolic complications.  
 
 
Table 3.8 Baseline characteristics of the study population 
Variable BMI < 25 kg/m
2
 (n=21) BMI ≥ 25 kg/m2 (n=21) Total ( n= 42) 
 Mean SD Mean SD Mean SD 
Age 30.71 9.80 35.38 11.43 33.05 10.78 
BMI 21.69 2.32 28.54 2.98 25.12 4.36 
WC 74.48 6.05 89.79 10.07 82.13 11.28 
WHR 0.77 0.05 0.81 0.07 0.79 0.06 
 
In contrast to individuals with BMI< 25kg/m
2
, overweight and obese subjects had marginally 
higher levels of fasting insulin (P= 0.053), and significantly greater TC: HDL ratio (P= 
0.043), SBP (P <0.0001) and DBP (P <0.0001) (Figure 3.20 and Figure 3.21).  Overweight 
and obese subjects also had significantly higher physical activity level (P <0.0001), WC (P 
<0.0001), HC (P <0.0001), WHR (P= 0.023) and percentage body fat (P <0.0001).  Subjects 
with BMI< 25kg/m
2 
had higher percentage body water than overweight and obese 
individuals (P <0.0001). No differences in other variables were observed.  
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Figure 3.20 Differences in baseline haematological values between the healthy BMI 
group and the overweight and obese group as tested by an independent sample t-test.  
Data expressed as mean± SEM. TC, total cholesterol; TG, triglycerides; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; TC:HDL, total cholesterol-to-high-
density lipoprotein ratio (n=44) 
 
 
 
Figure 3.21 Differences in baseline systolic (SBP) and diastolic blood pressure (DBP) 
between the healthy BMI group and the overweight and obese group as tested by an 
independent sample t-test.  Data expressed as mean± SEM (n=44). 
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3.6.2 Haematological, biochemical assessment and blood pressure 
Three-factor repeated measures ANOVA indicated that none of the variables violated the 
assumption of homogeneity, with the exception of TG (Leven‘s tests of equality of error 
variance P= 0.018). As a result, a more stringent P-value was set for testing differences in 
this variable (P≤ 0.01). 
 
Overall, three-factor repeated measures ANOVA demonstrated no significant effect of time 
or treatment on lipid profile (Table 3.9).  Serum NEFA concentrations were higher at the end 
of 4 weeks of placebo ingestion as compared to polyphenol-rich DC (Table 3.9).  However, 
this effect did not reach statistical significance (Treatment effect, Wilk‘s lambda =0.086).   
 
A significant effect of treatment on fasting glucose (P=0.028), fasting insulin (P= 0.030), 
HOMA-IR (P=0.005), QUICKI (P=0.04), revised-QUICKI (P=0.026), SBP (P= 0.020), DBP 
(P= 0.008) and salivary cortisol (P=0.006) was revealed.  A significant treatment-by-time 
interaction was also observed for these parameters suggesting that the change from baseline 
across the two treatment groups (polyphenol-rich DC vs. placebo) was not similar as seen in 
Figure 3.22 and Figure 3.23.  These results were further confirmed when differences from 
baseline between the DC and placebo group were assessed using a paired-sample t-test.   
Overall, values for polyphenol-rich DC fasting glucose (P=0.002), HOMA-IR (P=0.001), 
SBP (P=0.007) and DBP (P= 0.003) were found to be significantly lower after polyphenol-
rich DC as opposed to placebo, whereas values for QUICKI (P=0.002)  and revised-QUICKI 
(P=0.015) were significantly higher with polyphenol-rich DC compared to placebo (Figure 
3.23).  Interestingly, the placebo was found to raise fasting insulin, HOMA-IR and salivary 
cortisol from baseline by 1.36±4.29 mU/L (P=0.046), 0.37±1.06 (P=0.031) and 15.83±35.74 
nmol/l (P=0.007), respectively, as opposed to polyphenol-rich DC which reduced fasting 
glucose (P=0.012), HOMA-IR (P=0.004) and elevated QUICKI (P=0.042) and revised-
QUICKI (P=0.043) but had a negligible effect on fasting insulin (-0.56±2.62 mU/L from 
baseline) and salivary cortisol (+0.13±7.28 nmol/l from baseline).   The placebo also 
diminished insulin sensitivity from baseline as measured by QUICKI and revised-QUICKI, 
although the values did not reach statistical significance (P=0.055; p=0.157). 
 
No significant differences in urinary glucocorticoids or mineral excretion were observed 
through the study period (Table 3.10). 
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3.6.3 Differences between BMI categories 
The three-factor ANOVA demonstrated that participants from the two different BMI 
categories (BMI< 25 vs. BMI ≥25) differed in their fasting insulin (P=0.026), SBP (P=0.020) 
and DBP (P=0.001).  However, a significant treatment-by-time-by-BMI category interaction 
was only observed with fasting insulin levels suggesting that only the change in fasting 
insulin from baseline across the two treatment groups  was determined by the BMI category 
to which the participant belonged to (P=0.029).  Consequently, an independent sample t-test 
was performed to compare the fasting insulin response to treatment across the two BMI 
categories.  The independent sample t-test indicated that overweight and obese subjects 
responded less favourably to placebo and consequently had higher fasting insulin levels after 
consumption of placebo (+2.73±5.07 mU/L from baseline) compared to subjects with normal 
BMI (-0.01±2.82 mU/L from baseline) (P=0.021). 
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Table 3.9 Change from baseline in fasting insulin and lipid profile given for each of the two body mass index categories and for the total 
group (n=42) as shown by a three-factor ANOVA and confirmed by a paired-sample t-test.  Data are expressed as mean±SD.  
variable 
BMI 
category 
Baseline Post-treatment Three-factor ANOVA ∆ (Post-treatment - baseline) Paired-
sample t-test 
Pre-DC Pre-placebo Post-DC Post-placebo Wilk’s Lambda 
∆ (Post-DC – 
Pre-DC) 
∆ (Post-placebo – 
pre-placebo) 
mean SD mean SD mean SD mean SD 
treatment 
 
Treatment x 
time  
P 
TC 
(mmol/L) 
BMI <25 4.5714 1.07198 4.4810 .77564 4.5286 .81923 4.5619 .98716 
  
-0.04 0.54 0.08 0.81 0.624 
BMI ≥25 4.9000 1.19833 4.8571 1.03854 4.6810 .96572 4.8905 1.18908 -0.22 0.52 0.03 0.73 0.231 
Total 4.7357 1.13521 4.6690 .92512 4.6048 .88785 4.7262 1.09211 0.712 0.249 -0.14 0.53 0.06 0.76 0.244 
TG 
(mmol/L) 
BMI <25 .8857 .29204 .8143 .20319 .9333 .33066 .7857 .24349 
  
0.05 0.32 -0.03 0.22 0.411 
BMI ≥25 1.0333 .57562 1.0286 .51783 .9905 .58387 .9524 .43199 -0.04 0.34 -0.08 0.31 0.755 
Total .9595 .45696 .9214 .40336 .9619 .46954 .8690 .35647 0.051 0.436 0.00 0.33 -0.05 0.27 0.43 
HDL 
(mmol/L) 
BMI <25 1.6143 .30379 1.5810 .25420 1.6286 .26673 1.5952 .27473 
  
0.01 0.22 0.01 0.23 1 
BMI ≥25 1.5333 .31517 1.5476 .31562 1.5524 .30760 1.5762 .33302 0.02 0.25 0.03 0.23 0.895 
Total 1.5738 .30847 1.5643 .28355 1.5905 .28696 1.5857 .30168 0.737 0.929 0.02 0.24 0.02 0.23 0.928 
LDL 
(mmol/L) 
BMI <25 2.5571 .86636 2.5286 .69148 2.4667 .71438 2.6000 .79875 
  
-0.09 0.30 0.07 0.55 0.290 
BMI ≥25 2.8857 .92428 2.8476 .66153 2.6667 .69162 2.8762 .89213 -0.22 0.46 0.03 0.55 0.147 
Total 2.7214 .90028 2.6881 .68759 2.5667 .70180 2.7381 .84794 0.266 0.072 -0.15 0.39 0.05 0.54 0.069 
TC:HDL 
BMI <253 2.8619 .50048 2.8762 .53843 2.8238 .49589 2.8952 .50147 
  
-0.04 0.25 0.02 0.22 0.370 
BMI ≥25 3.2333 .72065 3.1571 .39188 3.0571 .59462 3.1429 .55459 -0.18 0.49 -0.01 0.39 0.212 
Total 3.0476 .64097 3.0167 .48636 2.9405 .55351 3.0190 .53704 0.596 0.126 -0.11 0.39 0.00 0.31 0.124 
 BMI <25 .4705 .16578 .4729 .23111 .4363 .22833 .5471 .26935   -0.03 0.20 0.07 0.27 0.169 
NEFA 
(mmol/L) 
BMI ≥25 .4481 .24064 .4973 .18320 .4430 .23106 .5395 .22262   -0.01 0.26 0.04 0.18 0.506 
 Total .4593 .20441 .4851 .20635 .4397 .22691 .5433 .24409 0.086 0.139 -0.02 0.23 0.06 0.22 0.136 
1. N= 21; N=21; total N= 42 
2. Significantly difference between the two BMI categories (Three-factor ANOVA and Bonferroni test): P=0.026 
3. Three-factor ANOVA and Bonferroni test: P=0.07 
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Figure 3.22 Changes in biomarkers of glucose metabolism following polyphenol-rich 
dark chocolate ( ) and placebo ( ) for each of the lean body mass index group and 
overweight and obese group.  Data are expressed as mean± SEM. 
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Figure 3.23 Change in systolic (SBP) and diastolic blood pressure (DBP) from baseline 
following polyphenol-rich DC ( ) and placebo ( ).  Data are expressed as mean± 
SEM. 
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Figure 3.24 Salivary glucocorticoid concentrations at baseline at the end of 4 weeks of polyphenol-rich dark chocolate (■) and placebo (♦) 
(n=42).  Data are expressed as mean of duplicates ± SEM.  Note that there was a significant effect of treatment (Wilks’ lambda=0.005) and a 
significant treatment-by-time interaction (Wilks’ lambda=0.03) on salivary cortisol with the paired sample t-test showing a greater increase 
in mean salivary cortisol from baseline within the placebo treatment group as compared to polyphenol-rich DC.  Data represents mean of 
three salivary collections obtained at 9.00-10.00am, 12.00-1.00pm and 4.00-5.00pm. 
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Figure 3.25 serum glucocorticoid concentrations at baseline at the end of 4 weeks of polyphenol-rich dark chocolate (■) and placebo (♦) 
(n=42).  Data are expressed as mean± SEM.  Note that there was a significant effect of time on cortisone-to-cortisol ratio (Wilks’ 
lambda=0.021) with the paired-sample t-test showing that the reduction in serum cortisone-to-cortisol ratio within the placebo treatment 
group was significant (P=0.039). 
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Table 3.10 
Results for 24h urine collections (n=41) 
(Data are expressed as mean and standard deviations) 
 
 Baseline Post-treatment Three-factor ANOVA 
 Pre-DC Pre-Placebo Post-DC Post-placebo Wilk’s Lambda 
 Mean SD Mean SD Mean SD Mean SD treatment 
 
Treatment 
x time  
Free cortisol (nmol/d) 35.32 24.86 40.95 36.95 40.20 32.24 42.16 33.75 0.454 0.504 
Free cortisone (nmol/d) 62.51 57.22 61.74 61.57 53.83 42.14 61.20 61.77 0.451 0.468 
Cortisol-to-cortisone ratio 2.55 2.55 2.51 2.78 2.34 2.69 2.33 3.27 0.922 0.925 
Free cortisol (nmol/kg/d) 0.53 0.40 0.60 0.55 0.60 0.51 0.64 0.55 0.468 0.630 
Free cortisone (nmol/kg/d) 1.02 1.10 0.98 1.10 0.84 0.71 0.97 1.22 0.502 0.458 
Creatinine (mmol/d) 13.27 10.94 14.58 11.20 12.02 9.22 11.63 8.23 0.556 0.240 
Magnesium (mmol/d) 3.23 3.40 3.24 3.52 3.25 2.58 4.17 3.97 0.242 0.246 
Sodium (mmol/d) 141.67 152.55 147.31 170.65 162.89 135.92 142.90 122.43 0.598 0.447 
Potassium (mmol/d) 76.33 105.83 82.61 114.60 92.27 94.18 93.83 82.26 0.683 0.832 
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3.6.4 Liver enzymes and troponin 
Three-factor ANOVA revealed a significant effect of treatment on serum creatine kinase 
concentration (P=0.023).  Accordingly, serum creatine kinase concentrations were found to 
be significantly higher at the end of 4-week treatment of polyphenol-rich DC as compared to 
placebo (P=0.023).  No changes in aspartate amino transferase or troponin were observed 
(P>0.05). 
 
 
 
Figure 3.26 Serum creatine kinase concentrations at the end of 4 weeks of 500mg 
polyphenols dark chocolate and placebo. Data are expressed as mean± SEM.  Asterisk 
denotes significance. 
 
  
0
10
20
30
40
50
60
70
80
90
100
Post- DC Post-placebo
C
K
 c
o
n
c
e
n
tr
a
ti
o
n
 (
U
/L
)
   *
 194 
3.6.5 Serum total phenolics content, ferric-reducing capacity of plasma 
and oxygen radical absorbance capacity 
No significant changes in serum phenolics, Fe
2+ 
or ORAC were found from baseline or 
between the placebo and DC group (Table 3.11). 
3.6.6 Urinary total phenolics content, ferric-reducing capacity of plasma 
and oxygen radical absorbance capacity 
As shown by the paired-sample t-test, urinary phenolic and Fe
2+
 content increased from 
baseline by 67.47±182.90 mg/d and 1.51±3.74 mmol/d, respectively, which was significantly 
different from placebo (FC: P=0.046; Fe
2+
: P=0.048) wherein a reduction of -
28.53±128.11mg/d in FC and of -0.27±0.32 mmol/d in Fe
2+
 was observed.  This was further 
indicated by the significant treatment effect and treatment-by-time interaction obtained by 
three-factor ANOVA (urinary total phenolics: treatment effect Wilk‘s lambda= 0.046, 
treatment-by-time interaction Wilk‘s lambda=0.005; Fe2+: treatment effect Wilk‘s lambda= 
0.048, treatment-by-time interaction Wilk‘s lambda= 0.006). No significant treatment-by-
time-by-BMI interaction was observed for both phenolic (P=0.815) and Fe
2+
 content 
(P=0.822) suggesting that changes in these variables were similar across the two BMI 
categories.  
 
A significant treatment effect (Wilk‘s lambda= 0.012) and treatment-by-time interaction 
(Wilk‘s lambda= 0.003) was also seen with ORAC of urine.   This was further confirmed by 
the paired-sample t-test which showed that the antioxidant capacity as measured by ORAC 
was increased by 4323.49± 12454.49µmol trolox equivalents/d following DC which was 
significantly different from the -3602.75±11076.35µmol trolox equivalents/d reduction in 
ORAC values seen following placebo (P=0.002). 
3.6.7 Weight and anthropometry 
No significant changes in WC, HC, WHR or percentage body water or fat were observed 
across the two BMI categories following either DC or placebo (Three-factor repeated 
measures ANOVA Wilk‘s lambda > 0.05).  However, a significant difference in body weight 
was detected between the placebo and the active polyphenol-rich DC group at the end of 4 
weeks treatment as demonstrated by the three-factor ANOVA (Post-Placebo body weight: 
69.93±13.28 kg; post-DC body weight: 69.45±13.01 kg; treatment effect Wilk‘s lambda = 
0.003; treatment-by-time interaction Wilk‘s lambda= 0.031).  Additional analyses using a 
paired-sample t-test further demonstrated that differences in body weight post-placebo and 
post-DC were greater within  the BMI≥ 25kg/m2 group (P=0.026) as compared to lean 
individuals (P=0.894) (Figure 3.29). 
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Table 3.11 
Plasma antioxidant capacity (n=42) 
(Data are expressed as mean and standard deviations) 
 
 Baseline Post-treatment Three-factor ANOVA 
 Pre-DC
1
 Pre-Placebo Post-DC Post-placebo Wilk’s Lambda 
 Mean SD treatment 
 
treatment 
 
Mean SD Mean SD treatment 
 
Treatment 
x time  
FRAP
2
 0.59 0.15 0.56 0.13 0.54 0.15 0.60 0.13 0.500 0.009 
FC
3
 15.23 3.77 16.09 4.30 14.57 4.77 15.78 3.72 0.069 0.787 
ORAC
4
 1699.89 773.99 1600.61 845.61 1474.57 930.80 1509.46 580.58 0.732 0.539 
DC
1, dark chocolate; FRAP2, ferric-reducing ability of plasma4;    FC3, Folin-Ciocalteu; ORAC4, oxygen radical absorbance capacity. 
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Figure 3.27 Changes in urinary total polyphenols content (a), ferric-reducing capacity 
(b) and oxygen radical absorbance capacity (c) from baseline across the two body mass 
index categories following polyphenol-rich dark chocolate and placebo (n=41). Asterisk 
denotes significance.  Data are expressed as means± SEM.  
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Figure 3.28 Change in body composition from baseline across the two body mass index 
categories following DC and placebo. Data are expressed as mean± SEM. 
  
Figure 3.29 Change in body weight from baseline across the two body mass index 
categories following polyphenol-rich dark chocolate and placebo. Data are expressed as 
mean± SEM.  
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3.6.8 Energy Intake and expenditure 
Physical activity did not alter significantly through the study period (SPANOVA Wilk‘s 
lambda =0.232) (Table 3.12).  No significant changes in energy or macronutrient, 
micronutrient intake were observed across the two BMI categories following either DC or 
placebo (SPANOVA Wilk‘s lambda > 0.05) (Figure 3.30).   
 
 
Table 3.12 Mean energy expenditure at baseline and post-intervention. 
 BMI.category Mean EE
1
 (kcal/d) SD 
Baseline BMI<25 2386.21 467.22 
BMI≥25 3381.37 564.10 
Total 2871.03 716.81 
DC
2
 BMI<25 2388.30 388.28 
BMI≥25 3244.60 410.27 
Total 2805.47 585.77 
Placebo BMI<25 2459.41 345.27 
BMI≥25 3378.74 560.38 
Total 2907.29 651.97 
EE
1
Energy expenditure 
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Figure 3.30 Energy (I), Macronutrient (II) and mineral intake (III) across the two body 
mass index categories: BMI< 25kg/m
2
 (a) and BMI≥25kg/m2 (b). Values are mean, with 
standard errors represented by vertical bars. ( ) energy intake; ( ) fat intake; ( ) 
protein intake; ( ) carbohydrate intake; ( ) magnesium intake; ( ) sodium intake; (
) potassium intake). 
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3.6.9 Correlation between assessed parameters 
Urinary cortisone concentrations were significantly correlated with improvements in several 
metabolic parameters linked to overweight and obesity (Table 3.13).  To illustrate, urinary 
cortisone was positively associated with HDL but negatively with LDL, TC:HDL and WHR.  
Additionally, urinary cortisone correlated positively with urinary and serum antioxidant 
capacity as measured by FC and FRAP.  Likewise, urinary cortisone-to-cortisol ratio 
correlated positively with HDL but inversely with LDL, TC: HDL, WHR, SBP and DBP.   
By contrast, urinary cortisol was related to higher DBP but surprisingly with lower WHR, 
HOMA-IR, urinary Fe, salivary cortisol and higher QUICKI and revised-QUICKI. 
 
In saliva (Table 3.14), cortisone was found to be again inversely correlated with LDL, 
TC:HDL and TC.  However, a positive correlation between salivary cortisone and HOMA-
IR was observed.  High salivary cortisol was marginally associated with lower revised-
QUICKI and higher NEFA. Salivary cortisone-to-cortisol ratio correlated negatively with 
TC, LDL and TC:HDL ratio. 
 
In serum (Table 3.15), cortisone correlated negatively with TC:HDL, SBP and DBP. 
Surprisingly, serum cortisol correlated negatively with WHR and positively with serum 
cortisone and urinary cortisone-to-cortisol ratio.  Similarly, serum cortisone-to-cortisol was 
found to be inversely correlated with urinary and serum FC and positively with both salivary 
cortisone and salivary cortisol.  
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Table 3.13 Pearson product-moment correlations between changes in urinary 
glucocorticoid levels and changes in selected metabolic risk factors  
Correlation Pair  R P 
Urinary cortisone (nmol/24h) HDL  0.165 0.046 
LDL -0.165 0.035 
 TC:HDL -2.53 0.001 
 WHR -0.331 0.000 
 SBP -0.166 0.034 
 Urinary FC 0.156 0.046 
 Urinary Fe 0.148 0.059 
 Serum FC 0.159 0.041 
 Serum Fe 0.146 0.062 
 Salivary cortisone (nmol/d) 0.252 0.001 
Urinary cortisol (nmol/24h) DBP 0.170 0.030 
HOMA-IR -0.147 0.061 
QUICKI 0.185 0.018 
Revised-QUICKI 0.142 0.069 
WHR -0.187 0.016 
 Urinary Fe 0.196 0.012 
 Salivary cortisol -0.113 0.154 
 Salivary cortisone -0.212 0.007 
 Serum cortisone -0.205 0.009 
urinary cortisone-to-cortisol ratio HDL 0.149 0.057 
 LDL -0.190 0.015 
 TC: HDL -0.237 0.002 
 WHR -0.159 0.043 
 SBP -0.215 0.006 
 DBP -0.159 0.042 
 Salivary cortisone (nmol/d) 0.316 0.000 
 
Table 3.14 Pearson product-moment correlations between changes in salivary 
glucocorticoid levels and changes in selected metabolic risk factors 
 
Correlation Pair r P 
Salivary cortisone (nmol/d) LDL -0.230 0.003 
 TC:HDL -0.230 0.003 
Salivary cortisol (nmol/d) Revised-QUICKI -0.144 0.067 
 NEFA 0.146 0.0.064 
Salivary cortisone-to-cortisol ratio TC -0.196 0.013 
 HDL -0.256 0.001 
 TC:HDL -0.263 0.001 
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Table 3.15 Pearson product-moment correlations between changes in serum 
glucocorticoid levels and changes in selected metabolic risk factors 
Correlation Pair  R P 
Serum cortisone (nmol/l) TC:HDL -0.191 0.013 
SBP -0.170 0.028 
DBP -0.190 0.013 
Urinary cortisol (nmol/24h) -0.205 0.009 
Serum cortisol (nmol/l) WHR -0.244 0.001 
 Serum cortisone 0.257 0.001 
 Urinary cortisone-to-cortisol ratio 0.187 0.017 
Serum cortisone-to-cortisol ratio SBP -0.154 0.046 
UFC -0.176 0.024 
FC -0.185 0.018 
 Salivary cortisol 0.145 0.065 
 Salivary cortisone 0.364 0.000 
 Urinary cortisone-to-cortisol ratio 0.206 0.017 
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4. General discussion 
4.1. In vitro studies: 
4.1.1 Variability of extraction methods and antioxidant activity of 
extracts 
The first objective of this thesis was to examine the antioxidant properties of GCBE and 
TCBE using a variety of extraction methods and a panel of antioxidant assays.  The 
emphasis on antioxidant properties was based on current evidence proposing a central role 
for oxidative stress in promoting insulin resistance and abnormalities of glucose metabolism.  
Accordingly, both GCBE and TCBE were found to be rich in phenolic compounds and to act 
as effective free-radical reducing compounds.   In particular, the acetonitrile extract was 
found to have the highest phenolic content as determined by the FC method as opposed to 
acidified-water or ethanolic extract. These findings persisted despite using different GCBE 
samples suggesting that the variation occurred as a result of differences in the ability of 
acetonitrile, acidified-water and ethanol to extract polyphenols.  Similar findings were 
observed with FRAP assay, wherein the acetonitrile extract exhibited a stronger ferric-
reducing ability than the ethanolic and acidified-water extracts.   
 
It is generally well acknowledged that the solvent used for extracting polyphenols 
determines the degree of polyphenol extraction.  Extraction of tea phenolics with ethanol 
gives a 60% higher phenol content than extraction with water (Gramza et al., 2005).  In the 
case of catechins, this could be explained by the higher solubility of catechins in ethanol than 
a 50% water-ethanol solvent (Nwuha et al., 1999).  In this study three solvents were used: 
ethanol, acidified water and acetonitrile.  The acidified water solvent was selected to reflect 
the acidic milieu of the stomach, which can affect the absorption and metabolism of 
polyphenols (G McDougall, personal communications, 2009). The more polar acetonitrile, 
on the other hand, was chosen because of its ability to dissolve a wide range of compounds 
as a result of its low acidity (G McDougall, personal communications, 2009).  As seen in 
Table 3.1, there was a large variation between the acidified water extract triplicates as 
compared to acetonitrile triplicates.  These variations could have been due to interferences 
from sacharrides.  Unlike acetonitrile, acidified-water does not remove sacharrides, which 
could then influence estimates of total phenol content by as much as 50% (Stratil et al., 
2007).  Generally, a correction value could be applied to account for any such interferences 
but in this case (Stratil et al., 2007); the acetonitrile extract was selected for the impendent 
ORAC analysis and for the pancreatic lipase experiment.   In relation to DPPH, the ethanolic 
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extract was chosen since it is known to produce minimal colour interferences (Molyneux, 
2004). As for TCBE, the bound fraction was found to contain the majority of phenolic 
compounds (2952.2μg GAE per ml bound fraction vs. 296.2μg GAE per ml unbound 
fraction) and was consequently used for lipase assay.  Based on the above results, it was also 
possible to estimate the average total polyphenol intake from GCBE in the preliminary 
GCBE human study to be 442 mg GAE per day. 
 
The potent reducing capacities of GCBE and TCBE were further reinforced by the DPPH 
assay.  Here data demonstrated that polyphenol-rich GCBE and TCBE possess similar 
DPPH-free radical scavenging activities to GA and ascorbic acid.  With regard to TCBE, 
such findings are consistent with the potent ROS scavenging activities of the major 
polyphenols found in TCBE: procyanidin B2, catechin and epicatechin (Yasuda et al, 2001).  
Surprisingly, CGA showed a low proton-donating ability (IC50=39.7μM) despite GCBE 
having a high DPPH-radical scavenging activity (IC50=2.56μM).  This might suggest that 
CGA may not be the main compound responsible for GCBE‘s free-radical scavenging 
activity.  The latter could be supported by the findings of Chen and Ho (1997) who have 
shown a higher DPPH-radical scavenging activity for caffeic acid compared to CGA.  
Regardless of this observation, the finding that GCBE could inhibit DPPH at concentration 
as low as 2.558μM is important since this value corresponds to the lower range of CGA 
found in plasma following consumption of GCBE (Farah et al., 2008a).  As a result, it could 
be argued that despite having a lower IC50 value than ascorbic acid, consumption of GCBE 
may still be crucial to preventing free radical-induced damage in plasma and tissues.   
 
In addition to their ability to act through the ET pathway, as demonstrated by the afore-
mentioned assays, both GCBE and TCBE exhibited potent free-radical scavenging activities 
via the HAT mechanism.  The latter was evident in the high ORAC values seen for these 
extracts.  As stated earlier, HAT-based assays serve as  direct measures of antioxidant 
capacity because they measure the ability of an  antioxidant to scavenge the peroxyl radical 
(Prior et al., 2005).  Since the latter is closely linked to lipid peroxidation, the HAT assays 
are also considered to be physiologically more relevant than ET-based assays (Prior et al., 
2005).  Nonetheless, Prior and colleagues (2005) argue that a high reducing capacity such as 
demonstrated by ET-based assays could be important in  halting the progression of radical 
chain reactions and might therefore reflect the ability of an antioxidant compound to 
maintain redox balance in plasma and tissue.  Thus, the combined evidence from both ET 
and HAT-based assays appear to confirm GCBE and TCBE as potent antioxidants.  The 
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latter will permit the differentiation between the various mechanisms of antioxidant activity 
(Ou et al., 2001, Prior et al., 2005).  Accordingly, the ability of GCBE and TCBE to act both 
through ET- as well as HAT-based mechanisms may imply that GCBE and TCBE can act as 
both reducing and free-radicals scavenging compounds.    The health implications of such 
findings lay in the potential contribution of these polyphenol-rich food products to overall 
antioxidant intake. 
 
To illustrate, analyses of ORAC showed that both GCBE and TCBE have potent antioxidant 
capacities.  In fact, when expressed per 100g, the ORAC values of GCBE and TCBE are 
found to be equivalent to 1187600µmol trolox equivalents/ 100g and 789100µmol trolox 
equivalents/100g, respectively.  These values rank GCBE and TCBE amongst USDA‘s 20th 
highest antioxidant-containing food products (Bhagwat et al., 2007).   
 
To put these figures further into perspective, consider the UK adult NDNS.  This survey 
indicates that on average, a British adult consumes 1073g of tea, 100g of bananas and 118g 
of apples or pears daily (Office for National Statistics, 2002).  When this data is combined 
with the ORAC values from the USDA database, it appears that compared to the most 
widely consumed fruits (bananas, apples and pears), a daily intake of one Theobroma cacao 
bean or one GCBE capsule could provide twice the amount of antioxidants in combined 
apples and pears and over 16 times more antioxidants than bananas (Figure 4.1).  
Furthermore, when considering that on average a British adult consumes 34g of chocolate 
daily (Office for National Statistics, 2002), replacing this chocolate with a polyphenol-rich 
alternative such as the one produced using unroasted Theobroma cacao beans, could increase 
the daily antioxidant intake by a substantial 1393543 μmol trolox equivalents.  This 
invariably suggests that GCBE, and TCBE can be important dietary sources of antioxidants 
and that due to their popularity and wide consumption, TCBE-derived products such as 
chocolate and cocoa could act as focal points for dietary intervention aimed at promoting 
health and increasing antioxidants intake in the population.  However, it is important to 
highlight the fact that the ORAC assay used in the present thesis has not be standardised 
according to the guidelines set by the international organisation for standardisation.  
Consequently, the values obtained in the present thesis might differ from the values obtained 
by USDA.  As such, no definite conclusions should be drawn from the above discussion and 
further studies using a standardised ORAC method will need to be conducted to confirm any 
statements mentioned herein. 
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Figure 4.1 Daily contribution of Theobroma cacao , Acticoa chocolate, green coffee bean 
extract in comparison to other polyphenol-rich products consumed in the UK to 
Oxygen Radical Absorbance Capacity (ORAC) (data adapted from USDA, 2007c). 
Data are expressed as TE trolox equivalents per day. 
 
4.1.2 Pancreatic lipase 
 
The second objective of the in vitro studies was to use the data on total phenol content 
obtained from the first in vitro study to examine the potential inhibitory activities of GCBE 
and TCBE against pancreatic lipase.  A key finding was that GCBE inhibits pancreatic lipase 
activity dose-dependently whereas similar concentrations of TCBE have a negligible effect 
on pancreatic lipase activity.  In fact, as seen in Figure 3.5, the inhibitory activity of GCBE 
produced a J-shaped curve of percentage inhibition over concentration of GCBE, with GCBE 
possessing a total phenolic content of 5mg and 50mg exerting stronger inhibitory activities 
against pancreatic lipase than GCBE concentrations of 10 and 25mg total phenolics.  These 
findings carry several implications since lipid hydrolysis by pancreatic lipase is a key step 
regulating dietary lipid absorption and inhibition of this process by pharmacological 
compounds such as Orlistat is known to reduce post-prandial plasma TG, remnant-like 
particles cholesterol and FFA (Tan et al., 2002).  This could be of particular relevance to 
obesity, wherein post-prandial lipaemia is associated with an array of obesity-associated 
complications including insulin resistance and dyslipidaemia.   
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GCBE is rich in CGA.  This phenolic acid has been shown to reach the intestines in high 
concentrations with only <1% of ingested CGA being hydrolysed in the stomach and the 
intestine (Lafay et al., 2006a).  The latter have been explained by the lack of an esterase 
enzyme capable of hydrolysing CGA in the stomach or the intestine (Plumb et al., 1999).  In 
fact in an in situ rat model of CGA perfusion onto upper intestinal tract (jejunum and ileum), 
90.8% of perfused CGA was found to reach the caecum intact (Lafay et al., 2006b).  
Similarly, Olthof et al. (2001a) demonstrated that following 1-4h incubation in duodenal  
fluids, 95-99% of CGA is recovered.  This poor absorption enhances the availability of CGA 
to intestinal mucosa, the site of pancreatic lipase action, a property exhibited by several 
known pancreatic lipase inhibitors including (−)-epigallocatechin gallate (Koo et al., 2007) 
and Orlistat (Zhi et al., 1995). Thus, CGA presents as an ideal candidate that may account 
for GCBE‘s inhibitory activity against pancreatic lipase, particularly when considering that 
caffeine, the second most prevalent constituent of GCBE, has been shown to be a poor 
inhibitor of pancreatic lipase (Nakai et al., 2005).  Moreover, CGA has other beneficial 
effects on the gastrointestinal tracts including its ability to increase NO bioavailability (Peri 
et al., 2005).  Nonetheless, further research is required to identify the active component of 
GCBE.  This could be achieved by fractionating GCBE constituents and assessing them 
individually for their inhibitory activity against pancreatic lipase. Synergism between the 
different constituents of GCBE remains a possibility. 
 
It is important to acknowledge that in vitro studies can often overestimate the biological 
effect of polyphenols since they do not take in account in vivo metabolism of polyphenols.  
As a result, in vitro suppression of pancreatic lipase activity does not necessarily imply an in 
vivo effect.  Moreover, even if pancreatic lipase activity is reduced, improvements in 
systemic lipid metabolism are not always observed (Shepard et al., 2000).  Nevertheless, it 
remains plausible that GCBE might exert an inhibitory activity against pancreatic lipase in 
vivo particularly that a recent study in mice has shown that consumption of GCBE reduces 
hepatic TG and visceral fat accumulation and enhances carnitine palmitoyl transferase 
activity, a rate-limiting enzyme that catalyses fatty acid transport to mitochondria for β-
oxidation (Shimoda et al., 2006).  In fact, reductions in hepatic TG content following 
ingestion of CGA have been observed in the other arm of the metabolic cage study reported 
in this thesis but conducted by Dickinson (2007) (data not shown).  Subsequently, further 
research is required to examine whether consumption of GCBE could improve post-prandial 
lipid metabolism or alter the activity of LPL and hepatic triglyceride lipase especially in 
obesity.   
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As for TCBE‘s lack of inhibitory activity against pancreatic lipase, it is consistent with the 
poor inhibitory potential of non-esterified flavan-3-ols like (-)-epicatechin and catechin 
(Nakai et al., 2005) which are likely to account for the major fraction of polyphenols in 
TCBE.  However, polyphenols from Theobroma cacao possess inhibitory activities against 
other digestive enzymes such as α-amylase (Queseda et al., 1996).  Subsequently, their role 
in glucose metabolism might be more important than their role in lipid metabolism.  The 
above results are, nonetheless, important since they demonstrate that inhibition of pancreatic 
lipase does not form one of the underlying mechanisms involved in the reduction of plasma 
total cholesterol, TG and LDL-cholesterol seen following long-term ingestion of cocoa by 
obese diabetic  mice (Jalil et al., 2009) 
 
Overall, the results from the pancreatic lipase study indicate that GCBE, but not TCBE, is an 
effective inhibitor of pancreatic lipase activity.   Hypothetically such data implies that 
consumption of GCBE could play a role in improving lipid profile or in attenuating post-
prandial dyslipidaemia, areas that deserve further investigation. 
 
4.2. Preliminary green coffee bean extract study 
The GCBE trial provided preliminary data on the potential role of GCBE in regulating 
glucocorticoid metabolism in overweight and obesity.  It demonstrated that GCBE  can raise 
cortisone levels in saliva while reducing WC and urinary cortisone production.  To our 
knowledge, few studies have reported such opposing effects with the exception of a recent 
study conducted by Tsang et al. (2009).  In the latter study, consumption of anthocyanidin-
rich pomegranate juice for 2 weeks yielded similar effects on glucocorticoid metabolism and 
WC.   
 
As stated earlier, defects in 11βHSD1 activity are closely associated with various features of 
the metabolic syndrome. In obesity, upregulation of 11βHSD1 enzyme in the liver and 
adipose tissue is thought to induce hypertension, insulin resistance, dyslipidaemia as well as 
abdominal fat accumulation (Masuzaki et al., 2001; Paterson  et al., 2004).   Such effects 
could invariably increase the risk of CVD and mortality.   
 
Recent studies have identified CGA as a potential therapeutic compound exhibiting strong 
antioxidant activities in vitro (Section 1.11.1.b) and capable of inhibiting 11βHSD1  in vitro 
(Arion  et al., 1997, Hemmerle  et al., 1997; Arion  et al., 1998; Atanasov  et al., 2006; 
Dickinson, 2007) and in animal models (Dickinson, 2007).  This study conveys some 
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evidence to support these reports by demonstrating that GCBE significantly increases 
salivary cortisone concentrations while exerting some beneficial effects on salivary 
cortisone-to-cortisol ratio.  Based on this data, it is reasonable to speculate the GCBE  
possesses potential inhibitory activity against 11βHSD1 in humans.  Hypothetically such 
effect should result in improved glucose, lipid and BP homeostasis. Nonetheless, no 
significant changes in fasting glucose or capillary total cholesterol were observed in this 
study following 2-week consumption of GCBE.  Although these findings are in agreement 
with previous studies demonstrating no significant effect of GCBE consumption on glucose 
metabolism in humans (Ochiai et al., 2004; Kozuma et al., 2005), they are in contrast to 
some of the animal and human studies which have reported beneficial effects of CGA on 
glucose regulation (Bassoli et al., 2007; Blum et al., 2007; Dickinson, 2007).  The lack of a 
significant effect could possibly be attributed to the presence of 2% of caffeine in the GCBE 
used in the current study.  According to Johnston et al. (2003), only the consumption of 
decaffeinated coffee, rich in CGA, improves glucose homeostasis. Acute ingestion of 
caffeinated coffee, on the other hand, even if rich in CGA, produces hyperinsulinaemic and 
hyperglycaemic effects (Johnston et al., 2003, Robinson et al., 2004, Moisey et al., 2008).   
 
In relation to total cholesterol, the lack of a significant effect was not consistent with the 
results from the in vitro study wherein GCBE inhibited pancreatic lipase by 61.5%.  This 
could be attributed to the short duration of the study since changes in total cholesterol can 
take up to 3 months to occur.  This can be partially supported by Kozuma et al. (2005) who 
demonstrated that consumption of GCBE supplying 93mg CGA for 28days reduces total 
cholesterol. Interestingly, in Kozuma et al.‘s study consumption of GCBE containing 185mg 
CGA produced a small yet statistically significant rise in total cholesterol (201.5±28.2mg/dl) 
as compared to placebo (201.3±31.0 mg/dl).  Consequently, it will be interesting to 
investigate whether different concentrations of GCBE affect total cholesterol in a pattern 
similar to their J-shaped effect on pancreatic lipase.   An alternative explanation for the lack 
of a significant finding might be attributed to the fact that only changes in total cholesterol 
were monitored whereas a complete lipid profile was not obtained. In this respect, 
consumption of GCBE containing 93 and 185mg has been shown to dose-dependently 
reduce LDL cholesterol without significantly affecting TG and HDL cholesterol (Kozuma et 
al., 2005).      
 
A significant reduction in WC in the absence of an effect on weight was observed in the 
preliminary GCBE study.  This finding is important since it may reflect an improvement in 
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body composition.  Recently, a double-blind randomized trial conducted by Dellalibera et al. 
(2006) revealed that 60-day consumption of decaffeinated GCBE  twice daily induced an 
increase in muscle mass-to-fat mass ratio. Dellalibera et al. (2006) explained their findings 
by arguing that increased fat utilisation and reduced fat accumulation due to improved 
glycaemic control might be the underlying mechanism responsible for such improvement in 
body composition.  In the latter study a significant 5.7 % reduction in weight was also 
observed.   No significant changes in percentage body fat were noted in the current study.  
However considering that no improvement in lipid or glucose metabolism were observed, 
these data appear to complement each other.  In relation to glucose metabolism, GCBE-
induced improvements in glucose handling as a result of either reduced glucose absorption or 
hepatic production are hypothesised to decrease the availability of glucose as an energy 
substrate, thereby forcing the body to rely on other energy substrates in particular FFA 
gained from lipolysis (Blum et al., 2007).  Such effects if proven to be correct might indicate 
that polyphenol-induced improvements in glucose regulation and subsequent weight loss 
could be central to reducing metabolic risk factors in overweight and obesity, particularly 
when considering that excess weight is known to be associated with insulin resistance, 
dyslipidaemia and hypertension.  The data from the preliminary GCBE study also adds to the 
body of evidence by providing an additional mechanism by which GCBE can improve body 
composition.  This is evident in the ability of GCBE to influence several parameters of 
glucocorticoid metabolism.  To our knowledge such changes in glucocorticoid metabolism in 
conjunction with reduced WC have not been reported previously by other studies on 
polyphenols.    These findings were further reinforced in the animal study wherein 
consumption of CGA for 17 days by mice was shown to influence glucocorticoids in a 
tissue-specific manner.   In the liver, mice given CGA showed a marginally significant 
reduction in corticosterone whereas corticosterone levels were increased, albeit, non-
significantly in the kidney.  This pattern was similar to what was observed in human subjects 
who experienced an increase in salivary cortisone implying possible inhibition of 11βHSD1, 
and a reduction in urinary cortisone and urinary cortisone-to-cortisol ratio highlighting 
possible inhibition of renal 11βHSD2.  The latter finding, in particular, adds to current 
controversies.  This is because renal 11βHSD2 is an enzyme that catalyzes the conversion of 
active cortisol to inactive cortisone thereby protecting the kidney against cortisol-induced 
mineralcorticoid effects (Whitworth et al., 2000).  Hypothetically, inhibition of 11βHSD2 
would result in increased cortisol concentrations in the kidney. Since cortisol is known to 
have a high affinity to the mineralcorticoid receptor, the presence of excess cortisol will 
prevent the binding of aldosterone to the mineralcorticoid receptor through competitive 
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binding which will then induce symptoms of apparent mineralcorticoid excess including 
hypertension, hypokalaemia and low aldosterone concentrations.  Such symptoms have been 
previously described in conjunction with the ingestion of liquorice rich in glycyrrhizic acid 
and grapefruit juice rich in naringenin and in relation to quercetin, tea polyphenols, 
furosemide and gossypol, all of these polyphenols being known to inhibit 11βHSD2 
(Mackenzie et al., 1990; Zhang et al., 1994; Lee et al., 1996; Guo and Reidenberg; 1998, 
Sardi et al., 2002).  In particular consumption of grapefruit juice has been shown to dose-
dependently reduce urinary cortisone-to-cortisol ratio in healthy volunteers (Lee et al., 1996) 
whilst consumption of glycyrrhetinic acid has been related to significant reductions in 
plasma and urinary cortisone concentrations (MackEnzie et al., 1990).  However, contrarily 
to the latter study, in the present intervention, salivary cortisone increased and was 
accompanied by a significant fall in BP as well as WC.  The design of the current study 
renders it difficult to elaborate on the mechanism involved in evoking such differential 
responses in saliva and urine.  As a result, further research is warranted to investigate the 
effect of GCBE or its active component CGA on tissue glucocorticoid metabolism.  In 
particular, the use of HPLC to separate cortisol and cortisone metabolites might provide a 
useful tool for identifying the specific location within the glucocorticoid pathway that is 
inhibited by GCBE.   This is because changes in cortisol and cortisone metabolite profile can 
strongly reflect specific changes in 11βHSD1 reductase or dehydrogenase activity as well as 
changes in 11βHSD2 or α-reductase activity (Please refer to Figure 1.10; p 37.). Although 
Palermo et al. (1996) has previously argued that the measurement of urinary free cortisone 
and the urinary free cortisol-to-cortisone ratio provides a more sensitive tool for analysing 
11βHSD2 activity in vivo than the ratio of cortisol-to-cortisone metabolites [(THF+allo-
THF)/THE ratio], with both urinary free cortisone and urinary free cortisone-to-cortisol ratio 
being extensively used in polyphenol research due to their feasibility (see Table 1.9, ; p 99.),  
Ferrari et al. (2001) has demonstrated that intra-individual variability of cortisol-to-cortisone 
metabolites is lower than that of urinary free cortisol-to-cortisone ratio rendering the former 
method more sensitive to the detection of changes in 11βHSD2.  Moreover, Stewart et al. 
(1999) has used cortisol-to-cortisone metabolites in detecting differences in the activity of 
11βHSD1, 11βHSD2 and α-reductase between lean, overweight and obese subjects.  
Likewise, Stimson et al. (2007) has employed urinary cortisol and cortisone metabolite 
analyses for testing the effect of dietary macronutrients on cortisol metabolism which 
enabled them to detect selective changes in 5α-reducatse, 5β-reductase, hepatic 11ß-HSD1 
and cortisol clearance. 
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In relation to BP, it is likely that mechanisms other than those involving glucocorticoids have 
contributed to the reduction in SBP seen following ingestion of GCBE.  In this respect, 
Ochiai et al. (2004) has shown that long-term consumption of GCBE improves endothelium 
function and vasoreactivity as assessed by post-ischemic vasodilator response to reactive 
hyperaemia  method.  They attributed these effects to one of the major metabolites of CGA, 
ferulic acid, a phenolic acid recognised for its strong antioxidant properties and which has 
been reported to enhance endothelium-dependent NO release in spontaneously hypertensive 
rats, a model of the metabolic syndrome (Suzuki et al., 2002).  In addition to endothelium 
function, the involvement of the renin-angiotensin-aldosterone system cannot be excluded.  
This is because like 11βHSD1, 5-α reductase, the enzyme responsible for aldosterone 
metabolism, requires NADPH, as a co-factor (Dickinson., 2007).  Since the inhibitory 
activity of CGA on cortisol is mediated by indirect inhibition of glucose-6-phospate 
transporter T1 which limits the availability of NADPH co-factor (Section 1.11.7), CGA 
might equally be capable of influencing aldosterone metabolism (Dickinson, 2007).   
 
The finding of a reduction in WC, in the absence of an effect on weight, is intriguing and 
emphasises, yet again, the need to examine the effect of GCBE on tissue glucocorticoid 
metabolism.  This is particularly true when considering that cortisol can increase abdominal 
fat depots in both men and women (Epel et al., 2000, Wallerius et al., 2003) and that 
attenuation of adipose tissue 11βHSD1 activity is critical to reducing abdominal fat 
accumulation and metabolic risk factors (Alberts et al., 2003; Morton et al., 2004b).  The 
effect of GCBE on fat oxidation and lipolysis also warrants further investigation. This could 
be achieved by measuring glycerol and NEFA or by collecting expiratory breath samples and 
subsequently calculating carbohydrate and fat oxidation using stoichiometric equations 
developed by Jeukendrup and Wallis (Venables et al., 2008).   
 
In contrast to the powerful antioxidant properties of GCBE observed in vitro (see section 
4.1.1) and extensively reported by other researchers (Castelluccio et al., 1995; Chen and Ho, 
1997; Olthof et al., 2003), no significant changes in urinary antioxidant capacity were 
observed in this preliminary study.  This could be attributed to the fact that hippuric acid, the 
major urinary metabolite of CGA has poor antioxidant properties (Olthof et al., 2003). 
Consequently, quantifying the antioxidant capacity of plasma, rather than urine, or 
measuring lipid peroxidation might have provided a better reflection of GCBE‘s in vivo 
antioxidant potential. Recently, Kurihara et al. (2003) have noted that polyphenol-rich 
oolong tea can act via mechanisms involving a reduction in cortisol concentrations and a rise 
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in antioxidant status to prevent lipid peroxidation.  Similar effects are likely to occur with 
GCBE consumption and merit investigation.   The lack of significant change in urinary 
polyphenol excretion might also indicate that in the case of GCBE, monitoring dietary 
compliance by measuring total phenolic compounds in urine using FC method might not be 
ideal. 
 
On the whole, this preliminary study demonstrates that GCBE rich in CGA could potentially 
be of therapeutical value in the treatment or prevention of the metabolic syndrome through 
its ability to improve glucocorticoid metabolism and attenuate BP and WC.  Consequently, 
further research using a randomised placebo-controlled design and a larger sample is 
warranted.   
 
4.3. Animal study 
The metabolic cage study was conducted to establish whether differences in the effect of 
GCBE rich in CGA on salivary and urinary glucocorticoid levels arose as a consequence of a 
differential effect of CGA on tissue glucocorticoid metabolism.  Obesity is known to be 
characterised by tissue-specific alteration in glucocorticoid metabolism.  Consequently 
investigating the effect of dietary polyphenols on tissue glucocorticoid levels is important in 
elucidating the mechanisms by which these compounds influence circulating and urinary 
cortisol and cortisone concentrations. Although the metabolic cage study demonstrated that 
CGA might influence corticosterone levels in a tissue-specific manner, the apparently 
insignificant results were somehow disappointing.  Moreover, due to lack of specific ELISA 
assay capable of quantifying the mice cortisone analogue, 11-dehydrocortisosterone, in our 
laboratory, it was not possible to collect data on the tissue activity of both 11 βHSD1 and 11 
βHSD2.   Nevertheless, the large effect size observed for both free corticosterone levels in 
kidney (Eta
2 
= 0.26) and liver (Eta
2 
=0.14) seems suggestive of a strong association between 
the changes in tissue corticosterone levels and CGA consumption.  Thus, the observed 
negative findings might be ascribed, in part, to the small sample size used in this study.  The 
later could be reinforced by the power calculations that were subsequently conducted using 
data from the kidney.  These showed that a sample of 13-21 animals was required to detect a 
significant difference in corticosterone levels using α =0.1 and power (1-β) =0.9 or α =0.05 
and power (1-β) =0.95, respectively. 
 
The lack of a significant effect could also be attributed to the use of normal mice which 
generally have low circulating and tissue glucocorticoid concentrations (Alberts et al., 2005).  
 214 
The use of obese KKA (y) or ob/ob mice might have been more appropriate in this case since 
these strains have up to 2.8-fold and 16-fold higher circulating corticosterone and up to 5.1 
and 8.1-fold higher liver corticosterone levels than normal mice (Alberts et al., 2005).  This 
would have rendered the detection of any changes in corticosterone concentrations more 
attainable.  
 
The mice study is, nonetheless, important since it demonstrates that CGA may potentially 
influence corticosterone metabolism differentially in various tissues.  In fact in the present 
study mean corticosterone concentrations in CGA group were found to be higher by 
24.8±11.9 mmol/ g tissue in the kidney and lower by 147.2± 170.8mmol/ g tissue in the liver 
as opposed to the control group.  These findings may also imply that apart from influencing 
11βHSD1 activity, CGA may affect the two other enzymes involved in glucocorticoid 
metabolism, 11βHSD2 and α-reductase.  However, no northern blotting was undertaken to 
assess mRNA expression of these enzymes making it difficult to elaborate on the results.  
Stewart et al., (2009), has recently argued that selective inhibition of hepatic 11βHSD1 may 
be more relevant to controlling obesity-related complication than inhibition of adipose tissue 
11βHSD1.  This is because according to Stewart et al. (2009), the liver consists the major 
site of cortisol production.  Indeed, systemic rise in corticosterone concentrations have been 
hypothesised to induce insulin resistance whilst on organ level; excess corticosterone in liver 
is thought to promote insulin resistance, non-alcohol liver steatosis and weight gain in 
omental tissue (Livingstone et al., 2000).   It thus follows that selective suppression of 
hepatic 11β-HSD1 could be pivotal to improving insulin sensitivity and reducing hepatic TG 
accumulation.  This could be further reinforced by the significant reduction in hepatic TG 
levels seen in the CGA-treated mice in the other arm of the present study and which was 
conducted by Dickinson (2007).  Previously, Shimoda et al. (2006) reported that mice who 
consumed 6mg/kg.day CGA for 14 days had more than two-fold reduction in hepatic TG 
accumulation, this effect being more prominent with CGA consumption than GCBE.  
Nevertheless, in the latter study only GCBE and not CGA was found to enhance carnitine-
palmitoyl transferase.  It could, thus, be postulated that the reduction in liver TG content 
seen by Shimoda et al. (2006) and Dickinson (2007) could be partially due to suppression of 
11β-HSD1 activity in liver.  This hypothesis is further supported by the finding that CGA 
can dose-dependently inhibit 11βHSD1 conversion of cortisone to cortisol in murine liver 
microsomes (Dickinson, 2007). However, given the results of the present in vivo trial, further 
research using a larger sample size and obese mice, will be required to confirm this 
hypothesis.   
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The present study also carries some implications to some of the current research being 
conducted on the effect of polyphenols on 11βHSD1 activity in humans (Song et al., 1992; 
Lee et al., 1996; Guo et al., 1998; Sardi et al., 2002).  This is because most of these studies 
rely on urinary cortisone-to-cortisol ratio as a measure of 11βHSD1 activity.  As argued by 
Hardy et al. (2008), urinary cortisol can reflect both systemic as well as kidney 
glucocorticoid metabolism, hence this measure does not offer a true reflection of tissue 
glucocorticoid concentrations, which is more relevant to obesity.  In fact, urinary free 
cortisol does not even reflect cortisol production rates since it accounts for less than 1% of 
total cortisol metabolites (Andrew et al., 1998).
 
 As a result, caution needs to be exercised 
when interpreting urinary cortisol results.  Moreover, if a better picture/profile of cortisol 
metabolism is to be gained from such studies, several measurements including saliva and 
blood might need to be employed.   
 
In summary, CGA might potentially influence tissue corticosterone concentrations 
differentially in kidney and liver.  However, due to the nature of the results, no direct 
conclusions could be drawn.  Further studies using a larger and more representative mice 
strain are needed to test this hypothesis. 
 
4.4. Preliminary dark chocolate study 
The preliminary DC study compared and contrasted the effect of two polyphenol-rich DC 
doses on capillary fasting glucose, total cholesterol, BP and urinary glucocorticoids.  The 
feasibility of conducting a long-term DC intervention was also determined.   Overall, this 
short-term trial demonstrated that polyphenol-rich DC reduces fasting blood glucose levels 
and BP in overweight and obese individuals.  These findings are consistent with previous 
observations that polyphenol-rich DC intake improves insulin resistance, insulin sensitivity, 
fasting glucose levels and BP in healthy individuals (Grassi et al., 2005a), hypertensives 
(Grassi et al., 2005b), glucose-intolerant hypertensives (Grassi et al., 2008), and obese 
subjects (Davison et al., 2008).  The results are also in agreement with studies on diabetic 
obese mice where reductions in blood glucose and fructosamine levels were reported 
following consumption of cacao liquor procyanidins (Tomaru et al., 2007).   
 
Enhanced vascular function is thought to be the main mechanism by which DC polyphenols 
improve glucose and BP homeostasis (Karim et al., 2000; Fisher et al., 2003; Taubert et al., 
2003; Grassi et al., 2005a-b, Taubert et al., 2007; Balzer et al., 2008; Faridi et al., 2008; 
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Grassi et al., 2008; Davison et al., 2008), although other mechanisms like decreased and 
delayed carbohydrate digestion and absorption might also be involved (Quesada et al., 1996; 
McDougall et al., 2005).  This study investigated whether polyphenol-rich DC could alter 
cortisol metabolism and whether improvements in glucose and BP seen in obese individuals 
following DC consumption are linked to improved cortisol metabolism.  The hypothesis was 
based on that cortisol plays an important role in glucose and BP homeostasis, probably 
through a mechanism involving increased ROS production and decreased NO bioavailability, 
and that in obesity several alteration in cortisol metabolism are observed which are, in turn, 
linked to increased insulin resistance and hypertension.  The study demonstrates that both 
500 mg and 1000 mg polyphenol DC decrease 24h urinary free cortisol and cortisone levels.  
However, these reductions were not significant and were not associated with reductions in 
fasting blood glucose or BP.  Such findings differ from previous findings wherein 
polyphenols increased (Song et al., 1992; Lee et al., 1996; Guo et al., 1998; Sardi et al., 
2002) or decreased  cortisol levels (Arion et al., 1997; Hemmerle et al., 1997).  The lack of 
significance could be related to a number of factors.  For instance, the sample size might 
have not been sufficiently large to detect a significant change.  In this case, using several 
parameters of cortisol metabolism including its measurement in urine, saliva and blood 
might have helped detect any such effect.  Additionally, the study population consisted 
mainly of subjects with peripheral obesity rather than those with abdominal obesity who 
exhibit more prominent abnormalities in cortisol metabolism as indicated by the association 
between high WC or WHR and high urinary cortisol or cortisone-to-cortisol ratio (Fraser et 
al., 1999; Vicennati and Pasquali, 2000).  Similarly, differences in sodium intake were not 
controlled for and could have acted as confounding factors (Chamarthi et al., 2007).  This 
could be observed in the association between changes in urinary free cortisol or cortisone 
and changes in sodium excretion, and the association between changes in sodium intake and 
changes in cortisol-to-cortisone ratio.  Dietary factors have been reported to influence 
cortisol metabolism.  High-fat low-carbohydrate diets stimulate cortisol regeneration by 
11βHSD1 while reducing cortisol inactivation in liver (Stimson et al., 2007). Sodium 
loading, on the other hand, decreases plasma cortisol levels by enhancing cortisol 
elimination (Litchfield et al., 1998) possibly via a mechanism involving increased hepatic 
blood flow (Kerstens et al., 2001).  The latter may explain the association between increased 
urinary free cortisol excretion and urinary sodium levels. However, subjects did not report 
significant changes in sodium intake during the study, which overall suggests that DC 
polyphenols influence glucose and BP homeostasis mainly via the NO pathway.   
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This study demonstrates that DC with 500 mg polyphenols is equally effective in reducing 
fasting blood glucose levels in overweight and obese individuals as 1000 mg polyphenol DC 
with a similar macronutrient composition.  Furthermore, the results indicate that DC 
polyphenols reduce blood glucose levels after 2 weeks of commencing a polyphenol-rich DC 
diet.  These findings are important since in relation to glucose metabolism, inconsistencies 
still exist regarding the treatment duration and dose required to achieve a glucose-lowering 
effect.  For example in their pilot study Stote et al. (2007) failed to show any significant 
improvement in glucose levels, insulin resistance, and insulin sensitivity following 5 d of 
twice daily consumption of procyanidin-rich cocoa beverage containing 22 to 900 mg 
procyanidins by insulin-resistant men and women.  Similarly, Taubert et al. (2007) failed to 
demonstrate any improvement in glucose or insulin levels following 18 weeks of daily 
ingestion of 6.3 g DC containing 30 mg polyphenols.  Conversely, Davison et al. (2008) 
showed reduced insulin resistance following consumption of a cocoa beverage containing 
902 mg flavanols twice daily for 12 weeks in overweight and obese subjects.  Together these 
findings suggest that a longer duration and a higher dose of polyphenols could be required to 
achieve a significant reduction in glucose levels.  This study reinforces this hypothesis while 
demonstrating that increasing polyphenol dose does not necessarily results in further 
reductions in glucose and BP level.  In relation to BP, 20 g DC with 500 mg polyphenols 
was found to reduce SBP and DBP to a similar extent as 20 g DC with 1000 mg polyphenol.  
Two explanations could be provided for the observed similarities in response to 500mg and 
1000mg polyphenols DC.  First, that increasing polyphenol dose does not necessarily confer 
additional benefits in relation to glucose metabolism or BP possibly because a plateau effect 
is reached with increasing polyphenol dose.  Second, that there exists a large inter-subject 
variations in the absorption and metabolism of polyphenols rendering certain subject more 
responsive to the actions of polyphenol-rich DC than others.  In agreement with the latter 
concept, differences in the ability to absorb or metabolise polyphenols have been reported by 
several studies (see review by Manach et al., 2004).  Procyanidins, in particular, have been 
shown to be differentially absorbed and metabolised by humans mainly because their large 
polymeric structure interferes with their absorption, thereby necessitating the hydrolysis of 
their polymeric structure into their respective trimers, dimers or monomers (Manach et al., 
2004). Since these processes are regulated by various enzymes, inter-individual variations in 
the expression and the activity of these enzymes may account for differences in polyphenol 
metabolism (Manach et al., 2004).   Even if procyanidins are effectively metabolised to the 
more absorbable dimers, the dimers, themselves, can undergo further hydrolysis into 
monomers or isomerisation under both acidic and alkaline conditions (Zhu et al., 2002a).  
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This has led Zhu et al. (2002a) to conclude that ‗the amount and type of flavanols and 
procyanidins in the gastrointestinal tract following the consumption of cocoa can be 
influenced by the stability of these compounds in both acidic and alkaline environments‘.  
The food matrix is another major determinant of polyphenols bioavailability and, concurrent 
ingestion of DC polyphenols and carbohydrates is known to enhance DC polyphenols‘ 
absorption (Schramm et al., 2003). This might indicate that subjects consuming greater 
quantities of carbohydrates could absorb DC polyphenols more effectively than subjects with 
lower carbohydrate intake, although such concept remains to be clarified. Regardless of the 
explanation, the pilot study provides interesting findings since few studies have compared 
the effect of different DC polyphenol doses on glucose, lipid and BP homeostasis for up to 2 
weeks.   As such the preliminary DC study highlights the need for a better understanding of 
the bioavailability of DC polyphenols since it will permit identifying and establishing 
maximum and minimum levels of DC polyphenol intake needed to exert a biological effect.  
This could be important since a reduction in the polyphenol-content of chocolate also implies 
reduced bitterness (Luna et al., 2002; Counet et al., 2004), which could render the chocolate 
more palatable and acceptable to the general population.   
 
It is noteworthy that one of the main strengths of the preliminary study was the use of 20g 
DC providing 500-1000mg polyphenols.  Most previous studies have been criticised for 
using large quantities of DC.   In fact, Grassi et al.(2005a-b) used a daily dose of 100g DC 
containing 500mg polyphenols.  According to Desch et al.(2009), long-term consumption of  
such large quantities of DC is likely to result in weight-gain, thereby  counteracting any 
beneficial effect of DC polyphenols on BP.    Since few studies have examined the short-
term effect of ingestion of small portions of polyphenol-rich DC, this study is amongst the 
first to demonstrate that consumption of 20 g DC (500 mg polyphenols) produces 
comparable reduction in BP to 100g DC with 500mg polyphenols (7 and 3 mmHg reduction 
in SBP and DBP, respectively) (Grassi et al., 2005a).  Such findings may suggest that 
reducing the portion of DC while maintaining a similar total phenolic content results in 
equivalent reductions in BP. This could provide several advantages since reducing the 
portion of DC would permit delivery of high quantity of polyphenols in a less energy dense 
form, which is essential if DC is to be included as part of a healthy balanced diet.     
  
In relation to total cholesterol, no significant changes in total cholesterol were observed 
following 2-week consumption of either 500mg or 1000mg polyphenols DC.  This is in 
contrast to Fraga et al (2005) and Grassi et al. (2005b).  However, such results are to be 
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expected since in the present study subjects had normal baseline total blood cholesterol 
levels as compared to Grassi et al. (2005b) (baseline total cholesterol in Grassi et al‘s study 
was 5.4±0.6 mmol/L).  Moreover, Grassi et al. (2005b) suggested that both the catechin and 
the fat component of DC account for its beneficial effect on total cholesterol.  Similar 
assumptions were made in relation to stearic acid in DC (Ding et al., 2006).  Since in the 
present study a lower DC portion was used, the lack of significant change in total blood 
cholesterol could be related to the lower levels of linoleic, oleic and stearic acids present in 
this DC.   
 
In the present preliminary study, no correlation between reported energy intake and physical 
activity was detected. This finding is similar to the findings of Davison et al. (2008) who 
argued that obese individuals can underreport energy intake and over-report physical 
activity.   Likewise, in the present study, no significant changes in urinary antioxidant 
capacity were observed.  This lack of significance could be attributed to the large inter-
individual differences in baseline urinary polyphenols excretion.  In fact, despite efforts to 
educate volunteers about the importance of excluding polyphenol-rich products during the 
run-in phase, three subjects were found to have higher polyphenol levels in urine at baseline 
as compared to post-500mg and post-1000mg polyphenols DC treatment. These outliers 
accounted for the initial lack of statistically significant changes in urinary antioxidant 
capacity.  Exclusion of these outliers produced a dose-dependent increase in urinary 
antioxidant capacity consistent with previous observations of a dose-dependent association 
between polyphenol intake and urinary antioxidant capacity (Richelle et al., 1999; Wang et 
al., 2001). 
 
Overall, the present short-term preliminary study confirms previous reports of improved 
fasting glucose levels and BP following DC consumption while demonstrating that these 
effects are unlikely to be mediated through changes in cortisol metabolism.  Nonetheless, 
further studies using cortisol measurements in urine, saliva and possibly blood might be 
necessitated.  Research aimed at identifying the optimal dose of polyphenols required to 
improve glucose metabolism and the mechanisms involved in such hypoglycaemic 
properties is also warranted.  
 
4.5. Main study 
As stated in section 1.13., one of the aims of the current thesis was to identify the minimum 
polyphenol dose capable of producing hypoglycaemic and hypotensive effects and to 
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subsequently investigate the long-term response of overweight and obese individuals to this 
polyphenol dose.  The importance of differentiating between the effects of 500mg and 
1000mg polyphenols was based on the emerging evidence relating possible pro-oxidant 
effects to intake of high doses of procyanidins (Sakano et al., 2005) and the controversial 
findings concerning the glucose-lowering effects of high cacao polyphenol intake (Stote et 
al., 2007; Balzer et al., 2008; Davison et al., 2008).  Overall, the main study demonstrated 
that 4-week consumption of 500mg polyphenols DC can improve BP and glucose 
metabolism as indicated by the reduction in fasting glucose, HOMA-IR and the rise in 
QUICKI and revised-QUICKI.  Such findings confirmed the observations of the short-term 
preliminary DC study and were consistent with previous studies on healthy individuals, 
hypertensives and glucose-intolerant hypertensives.  The data was also in accordance with 
the most recent findings of Davison et al. (2008) who reported beneficial effects of 
polyphenol-rich cocoa on cardiometabolic markers in subjects with BMI ≥25kg/m2.  Most 
importantly, the current study demonstrates that overweight and obese subjects respond more 
effectively to the hypoglycaemic and hypotensive properties of polyphenol-rich DC than 
their lean counterparts.  To our knowledge, this is the first study that allowed direct 
comparison of the effect of polyphenol-rich DC on glucose, lipid and BP across the two BMI 
categories.  Such differences in response may be attributed to the raised metabolic risk 
factors seen in individuals with BMI≥25kg/m2 and which were predicted in the current study 
by the higher baseline WHR, WC, TC: HDL ratio and BP compared to lean individuals.  
Support for this explanation could be gained from Grassi et al. (2005a-b, 2008) who 
documented greater reductions in SBP and DBP in hypertensive patients compared to 
healthy normotensive volunteers.   
 
By contrast to previous human studies (Grassi et al., 2005a-b; 2008), no significant changes 
in fasting insulin or insulin secretion (HOMA-β) were observed in this study.  This may be 
expected since in animals, some studies have failed to report any improvement in insulin in 
some models of obesity but not in others, which could indicate that the underlying cause of 
insulin resistance may dictate a subject‘s responsiveness to polyphenol-rich DC.  
Alternatively, the use of a more robust study design which included a DC placebo rather than 
a white chocolate placebo might have eliminated any possible effect of varying magnesium 
and theobromine content between the active DC and the placebo.   This implies that, unlike 
other studies which did not control for differences in macronutrient and micronutrient 
content, any changes in the assessed parameters in our study can be directly related to the 
presence of DC polyphenols rather than other DC components.  The strength of such design 
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could be further viewed in that DC placebo permits effective blinding of volunteers, which 
may minimise expectation bias.  
 
In the present intervention, reduction in SBP and DBP of 4.17mmHg and 2.29mmHg, 
respectively, were observed.   These values are consistent with a  recent meta-analysis of 10 
randomised controlled trials involving 297 volunteers  which demonstrated that, on average, 
polyphenol-rich DC and cocoa reduce SBP by 4.5mmHg and DBP by 2.5mmHg, 
respectively (Desch et al., 2009).     However, when comparing changes in BP in the main 
study to the preliminary DC study, it can be observed that the magnitude of reduction in SBP 
and DBP were lower at the end of the 4-week main DC intervention than at the end of the 2 
weeks of the preliminary study (SBP -6.98mmHg from baseline, DBP -5.62mmHg from 
baseline).  This is partially in agreement with the afore-mentioned meta-analysis wherein 
Desch et al. (2009) demonstrated greater reductions in SBP and DBP in short-term 2-week 
trials as opposed to long-term 4-18 week interventions suggesting a possible adaptation 
occurring to high doses of polyphenol over time.  The study by Taubert et al. (2007) is 
particularly interesting in this respect since it is the only study to have monitored BP at 
different time-point of the intervention (i.e. at baseline, 6, 12 and 18 weeks of polyphenol-
rich DC ingestion).  In that study no adaptation to polyphenols was observed and SBP and 
DBP continued to fall steadily from baseline through week 6 to week 12 and week 18 of the 
trial (Taubert et al., 2007).  However, the lack of adaptation could be attributed to the use of 
a small quantity of DC (6.3g) containing 30mg polyphenols which might indicate that with 
lower polyphenol doses a cumulative effect of dose on BP occurs over time (Taubert et al., 
2007).  By contrast, with larger doses such as used in the present study, maximum reduction 
in BP might be achieved rapidly after which the effect might begin to subside until the 
maximum possible long-term reduction is reached.   
 
Although, the lack of significant improvement in lipid profile is in contrast to previous 
studies (Mathur, 2002, Mursu et al., 2004, Grassi et al., 2005b, Baba et al., 2007a-b), these 
findings are consistent with other researchers who have failed to observe any changes in 
lipid profile after ingestion of polyphenol-rich DC (Taubert et al., 2003, Engler et al., 2004, 
Grassi et al., 2005a).  In general, studies that reported changes in lipid profile used 75-100g 
DC containing 500mg polyphenols (Mursu et al., 2004, Grassi et al., 2005b, 2008) which 
provided up to 5 times more cocoa butter than the present study.  It is, therefore, likely that 
cocoa butter, with its high monounsaturated fat content, accounted for some of the 
improvements in lipid profile.  Nonetheless, Baba et al. (2007a-b) and others (Mathur et al., 
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2002) have also reported a reduction in LDL concentrations and a rise in HDL levels after 
consumption of liquid cocoa, containing no cocoa butter, suggesting that polyphenols per se 
can influence lipid profile.  Hence, the lack of significant effect in this present study could 
only be attributed to the normal lipid levels of this study‘s population.  Genetic 
polymorphisms, likewise, cannot be excluded (Ordovas, 1999).   
 
It is important to stress that the present long-term dietary intervention adds to current 
research by indicating that overweight and obese individuals might be affected more 
adversely by the ingestion of polyphenol-poor DC.  This is observed in the significant rise in 
fasting insulin, HOMA-IR and the marginally significant decline in QUICKI following 
placebo, which could suggest that common chocolate might increase the risk of 
hyperinsulinaemia and insulin resistance in overweight and obese individuals.  In support of 
this finding, Brand-Miller et al. (2003) have shown that compared to alternate flavourings, 
the addition of common cocoa powder into foods increases postprandial insulin secretion. In 
fact, according to Brand-Miller et al. (2003), products containing commercially-available 
chocolate increase insulin secretion to a greater extent than products with a similar fat 
content like potato chips and croissants.  Likewise, Holt et al. (1997) have reported that 
chocolate confectionery (Mars Bar) and chocolate-flavoured breakfast cereal (Coco Pops) 
can have an insulin index 50-60% higher than their glycolic index. This led Brand-Miller et 
al. (2003) to argue that stearic acid in cocoa butter or amino acids in cocoa might account for 
the enhanced insulin response of cocoa products.  The current study provides some insight 
into the findings of the above studies as will be discussed later.   Regardless of mechanisms, 
the combination of hyperinsulinaemia and unfavourable lipid profile (raised TC: HDL) as 
seen in the overweight and obese group in the present study might render this population 
group more prone to the development of CVD.  It is noteworthy that the findings concerning 
the changes in HOMA-IR and QUICKI following placebo have not been reported by other 
studies.  Such discrepancies might be attributed to differences in the products used as most 
other studies that investigated the effect of DC polyphenols on glucoregulatory biomarkers 
used white chocolate containing milk powder and butyric fat as placebo (Grassi et al., 
2005a-b, 2008).    
 
Despite the negative correlations seen between urinary, salivary and serum cortisone as well 
as urinary cortisone-to-cortisol ratio and several parameters of the metabolic syndrome 
including LDL, TC: HDL, SBP, DBP and WHR, no significant changes in glucocorticoid 
metabolism were observed within the polyphenol-rich DC group.  This was consistent with 
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findings of the preliminary DC study.  However, a significant rise in salivary cortisol and a 
significant reduction in cortisone-to-cortisol ratio were observed following ingestion of 
placebo.  Although at present it is difficult to elaborate on the observed changes in 
glucocorticoid metabolism within the placebo group, a plausible explanation could be related 
to the placebo‘s effect on fasting insulin. Fasting insulin and HOMA-IR are known to be 
strongly and positively correlated with 5α-reducase activity (Tomlinson et al., 2008).  Under 
normal physiological conditions and those of insulin resistance, upregulation of this enzyme 
helps reduce cortisol availability in the liver, a mechanism aimed towards sustaining hepatic 
insulin sensitivity (Tomlinson et al., 2008).   However, in obesity, enhanced 5α-reductase 
activity stimulates hepatic clearance of cortisol causing a compensatory activation of HPA, 
which in turn leads to excess cortisol secretion (Livingstone et al., 2000; Westerbacka et al., 
2003).  As a result, it is possible to postulate that upregulation of 5α-reductase via insulin 
might be the underlying mechanism by which the placebo raised salivary cortisol secretion.  
Emerging evidence concerning the role of dietary macronutrients in regulating 5α-reductase 
and HPA activity could provide a further explanation for the effect of placebo on salivary 
cortisol and serum cortisone-to-cortisol ratio while supporting the involvement of 5α-
reductase.  Accordingly, several studies in mice and rats have shown that high-fat feeding 
stimulates basal and stress induced HPA activity (Morton et al., 2004a; Drake et al., 2005). 
This effect has also been observed in humans following infusions of insulin or lipid (Wake et 
al., 2006) and following ingestion of a mixed-meal (Basu et al., 2006) or a high-fat low-
carbohydrate diet (Basu et al., 2006; Wake et al., 2006; Stimson et al., 2007).  In the study 
by Stimson et al. (2007), healthy obese men were given a high-fat low-carbohydrate diet for 
4 weeks.  At the end of the study period, an increase in cortisol regeneration by 11βHSD1 
and a reduction in α- and β-reductase-induced cortisol inactivation was observed.  Although 
this evidence only provides preliminary data on the relation between macronutrients and 
cortisol metabolism, there is a possibility that a similar effect could have occurred in the 
current study wherein the placebo provided an additional 7.34g of fat to the diet per day 
which over 4 weeks and in the absence of adequate antioxidant intake might have resulted in 
enhanced cortisol secretion.  Biochemically, such response permits the shift in substrate 
oxidation towards enhanced fat utilisation and diminished glucose oxidation (Andrew and 
walker 1999).  Albeit a normal physiological response, in obesity, hypersensitivity of HPA 
axis means excess cortisol could be secreted which could have detrimental effects on the 
metabolic state, particularly when considering that raised cortisol levels induce oxidative 
stress (see section 1.8.3) and promote abdominal TG accumulation in the presence of 
hyperinsulinaemia via upregulation of LPL activity (Ottosson et al., 1994). The finding that 
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the placebo stimulated cortisol secretion whereas polyphenol-rich DC did not, could be 
important as it might suggest a potential role for polyphenols in counteracting the effect of 
high-fat diet-induced cortisol secretion.  Thus, improving processing methods of cocoa beans 
could be vital to the development of novel functional foods that can protect the population 
against overweight and obesity-related metabolic abnormalities. The above findings also 
highlight one major public health implication. That is if the consumption of placebo, which 
is equivalent to the polyphenol-poor chocolate products currently available on the market, 
increases cortisol generation and if the latter effect occurs via enhanced 5α-reductase 
activity, which in turn, may influence body composition and insulin resistance (see 
Tomlinson et al., 2008), then it could be hypothesised that the current commercially-
available chocolate products may act as part of the driving force that promote the current 
overweight and obesity epidemic both through their energy-density and detrimental impact 
on cortisol metabolism (Figure 4.2). This statement may also help explain the 
hyperinsulinaemic-effects of commercial chocolate and chocolate-products reported by Holt 
et al. (1997) and Brand-Miller et al. (2003) as the relation between 5α-reductase and insulin 
is reciprocal.  That is as well as being influenced by insulin, 5α-reductase might influence 
insulin levels (Tsilchorozidou et al., 2003). If this hypothesis is proven to be correct then it 
might provide a more perturbing picture considering the popularity of these food-products 
across various population subgroups.  However, further research will be required to elucidate 
the points mentioned above.  Moreover, the active component responsible for the placebo‘s 
stimulatory effect on cortisol will need to be identified since as yet it remains unclear 
whether the adverse response to polyphenol-poor DC is evoked as a consequence of its high 
fat content or due to the presence of specific hyperinsulinaemic and hypercortisolaemic 
compounds in placebo.  As such further studies that compare the effect of polyphenol-rich 
DC, polyphenol-deficient DC and a food product containing a similar fat content but an 
alternative fat to cocoa butter on fasting insulin and salivary cortisol levels may be required.  
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Figure 4.2 Proposed novel hypothesis by which the high energy density and potential 
hyperinsulinaemic, cortisolaemic effects and possibly gluconeogenic and oxidative 
stress-inducing properties of polyphenol-deficient DC may promote weight gain.   
 
 
In support of the hypothesis depicted in Figure 4.2, body weight was found to be 
significantly higher at the end of 4 weeks of placebo treatment as compared to polyphenol-
rich DC.  Similarly, the concentration of serum NEFA was increased, albeit marginally, 
following consumption of placebo but not polyphenol-rich DC.  Moreover, a significant 
positive correlation between serum NEFA and salivary cortisol concentrations was observed.  
In general, 70-75% of cortisol circulates in blood bound to corticosteroid-binding globulin 
with only 5–10% of cortisol being found in the active unbound while 15–20% is bound to 
albumin (Andrews and Walker, 1999).  When the levels of free cortisol increase, due to 
saturation of corticosteroid-binding globulin in the morning or during conditions of stress or 
abdominal obesity, two outcomes are to be expected (Andrews and Walker, 1999; Purnell et 
al., 2004).  First, fat is redistributed from peripheral to abdominal fat depots leading to a 
raised WHR (Pasquali et al., 1993; Westerbacka et al., 2003).  Second, hepatic 
gluconeogenesis is stimulated (Khani and Tayek, 2001). 
 
In the first instance, although no changes in fat distribution as measured by WC, HC and 
WHR were seen in this trial, body weight was significantly higher at the end of 4 weeks of 
placebo ingestion as compared to polyphenol-rich DC wherein a significant reduction from 
baseline was observed.   As with changes in salivary cortisol and fasting insulin, changes in 
body weight occurred selectively within the overweight and obese group. Such changes in 
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body weight have not been reported by previous studies which can be attributed to the use of 
lean individuals, the short duration of the former trials (see Table 1.5 to Table 1.8) and the 
use of tailored iso-caloric diets (Grassi et al., 2005a). Arguably, the changes in body weight 
within the overweight and obese group might have influenced the hemodynamic (BP) and 
metabolic variables (glucoregulatory biomarkers) assessed in this trial, thereby explaining 
the significant differences in these parameters between the placebo and polyphenol-rich DC 
groups.  This may suggest that despite the lack of significant changes in energy intake or 
physical activity as measured by the diet and physical activity diaries, and despite efforts to 
ensure that both treatment products provided similar amounts of energy, macronutrients and 
micronutrient, non-compliance, under-reporting and changes in dietary intake within the 
overweight and obese group cannot be excluded.  However, it is important to note that 
changes in body weight occurred selectively following administration of placebo or 
polyphenol-rich DC while no significant changes between the two baselines periods were 
detected. In animal models, ingestion of cocoa has been reported to increase thermogenesis 
(Matsui et al., 2005).   Improved glycaemic control has also been postulated to be one of the 
underlying mechanisms by which polyphenols promote weight reduction (Dellalibera et al. 
2006; Blum et al., 2007).  Based on these findings, it is not possible to elaborate on the 
direction of the cause-and-effect relation as changes in body weight can occur as both a 
cause and a consequence of changes in insulin sensitivity (Potenza et al., 2007).  In the 
present thesis, the application of dichloromethane extraction onto serum samples and the use 
of salivary cortisol permitted the quantification of the active free form of cortisol (Vining et 
al., 1983; Gozansky et al., 2005).  Hence, the combination of increased salivary cortisol, 
reduced serum cortisone-to-cortisol ratio and raised fasting insulin makes it tempting to 
speculate that these changes might have accounted for the rise in body weight within the 
placebo group.  Moreover, the fact that all of these changes were specific to the BMI 
≥25kg/m2, with the exception of serum cortisone-to-cortisol ratio which decreased across 
both BMI groups, and were not seen within the lean group supports such concept, although 
no definite conclusions should be drawn at present. 
 
The association between changes in body weight, fasting insulin and glucocorticoid 
metabolism could be further reinforced by the observed rise in serum NEFA concentrations 
in the placebo group.  Cortisol is known to stimulate NEFA release which is then correlated 
with enhanced gluconeogenesis (Khani and Tayek, 2001; Djurhuus et al., 2002).   This 
enhanced gluconeogenesis has been hypothesised to induce hyperglycaemia and 
hyperinsulinaemia leading to insulin resistance and eventually type II diabetes (Barthel and 
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Schmoll, 2003).  By contrast, inhibition of early morning
 
rise in cortisol using 
pharmacological compounds such as metyrapone reduces NEFA and glycerol concentrations 
(Samra et al., 1996). In the present trial, fasting glucose levels were not increased following 
ingestion of placebo.  However, fasting insulin and HOMA-IR were raised within the 
placebo group which is consistent with the metabolic effects of raised circulating NEFA 
(refer to Figure 1.8 in Introduction).  Moreover, salivary cortisol concentrations were found 
to correlate positively with serum NEFA concentrations and inversely with insulin sensitivity 
as measured by revised-QUICKI.  Thus, the combined evidence from the present long-term 
trial appears to favour the hypothesis concerning the detrimental effects of DC deficient in 
polyphenols and highlights the importance of elucidating the differential effects of 
polyphenol-rich DC and polyphenol-deficient DC on overweight and obese individuals.   
 
Although not investigated in the present trial, it is well recognised that DC and cocoa 
polyphenols exert their beneficial effect via modulation of NO bioavailability.  Accordingly, 
Schroeter et al. (2006) have demonstrated higher urinary nitrate+nitrite excretion among 
Kuna Indians consuming a flavanol-rich cocoa-based diet as compared to Kuna Indians 
consuming a western-diet.  Dose-dependent rise in the concentration of plasma nitros(yl)ated 
species (RNO), also referred to as the NO pool and which consists of S- and N-
nitrosoproteins and iron-nitrosyl complexes, have also been reported 2h following acute 
ingestion of 100ml cocoa drink containing 176–185mg flavanols (70-74mg monomers, 20-
22mg epicatechin, 106-111mg procyanidins) (Heiss et al., 2005).  Likewise, increased 
plasma S-nitrosoglutathione have been documented with chronic consumption of 
polyphenol-rich DC but not white chocolate (Taubert et al, 2007).    Recently, two isoforms 
of NOS have been identified in white adipose tissue: eNOS and inducible-NOS (iNOS) 
(Ribiere et al., 1996; Kapur et al., 2000).  This has led to a rise in the number of studies 
investigating the potential modulatory or regulatory activities of NO in adipose tissue.  
Accordingly, studies on isolated adipocytes have indicated that NO can modulate the 
processes of lipolysis and lipogenesis.  In fact, incubation of adipocytes, isolated from male 
Sprague-Dawley rats, with increasing concentrations of the NO donors, the nitrosothiols, has 
been shown to produce dose-dependent stimulation of basal lipolysis as indicated by the rise 
in glycerol release (Gaudiot et al., 1998).  NO has also been demonstrated to enhance 
differentiation of brown (Nisoli et al., 1998) as well as white adipose tissue (Yan et al., 
2002), although in the case of the latter this effect was only achieved in the presence of an 
adipocyte differentiation stimulus (Yan et al., 2002).  NO is also known to regulate the gene 
expression and activity of several enzymes involved in lipogenesis (glycerol-3-phosphate 
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acyltransferase, SREBP-1c and phosphoenolpyruvate carboxykinase) and lipolysis 
(hormone-sensitive lipase) (Jobgen et al., 2006).  This evidence in conjunction with the 
changes in body weight seen in the main DC study emphasise the need for elucidating the 
precise metabolic and biochemical pathways that can be modulated by polyphenols, 
specifically in relation to overweight and obesity.   Moreover, such evidence adds weight to 
the hypothesis that polyphenols, in particular cocoa and DC polyphenols, can act as 
important dietary targets for the prevention of obesity-associated chronic conditions (Figure 
4.3).   
 
 
Figure 4.3  Proposed mechanisms by which polyphenols from dark chocolate can 
protect against obesity-related complications.  Changes in thermogenesis and fat 
oxidation are areas that deserve further investigation given the findings of animal 
studies and the potential role of NO in modulating lipolysis and adipose tissue 
differentiation. 
 
Finally, it remains to be stated that although commonly-consumed chocolate may adversely 
affect body weight and other metabolic parameters in overweight and obese individuals, as 
observed in this thesis and previous studies, this does not argue against the use of small or 
moderate amounts of polyphenol-rich DC or cocoa as part of a healthy balanced diet in the 
prevention of obesity-related complications.  Nonetheless, it is important to highlight that in 
a recent study by Desch et al. (2010), consumption of polyphenol-rich DC by overweight 
and obese individuals over 3 months was shown to induce a significant rise in body weight.  
Although, in the latter study, patients did not receive a control diet, rendering comparisons 
between the effect of polyphenol-poor DC and the effect of polyphenol-rich DC difficult, 
such observations imply that research on the potential application of polyphenol-rich DC or 
cocoa in the context of overweight and obesity should be pursued further in order to establish 
the long-term metabolic effects of polyphenol-rich DC or cocoa consumption.  
↓ Oxidative stress 
↓ Blood pressure ↑Insulin sensitivity 
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In the present main DC study, no significant differences in plasma or urinary antioxidant 
capacities as measured by FC, FRAP and ORAC were observed between the lean and 
overweight/ obese group.  Similarly, no significant changes in plasma antioxidant capacity 
were detected during the intervention period which is in agreement with other studies 
(Vlachopoulos et al. 2005, Taubert et al., 2007).  Epicatechin, the main DC polyphenol, is 
known to be rapidly absorbed and metabolised in the body because of its basic structure.  As 
a result, its concentration in plasma alongside plasma antioxidant capacity usually return to 
baseline 6h following the consumption of polyphenol-rich DC (Richelle et al., 1999, Wang 
et al., 2000).   Since in the present study blood was drawn at fasting 12h following the 
ingestion of DC, it is unsurprising that no changes in plasma antioxidant capacity were 
detected.  Urine, on the other hand, was collected on the last day of DC consumption.  
Accordingly, an increase in urinary FC, FRAP and ORAC was found following consumption 
of polyphenol-rich DC but not placebo.  In fact using estimates from FC, urinary polyphenol 
levels were found to increase by 29.23% from baseline.  Likewise, based on the mean rise in 
urinary total polyphenol concentrations from baseline (64.11mg GAE/d), urinary recovery of 
polyphenols in the present study could be estimated to be 12.8%. In general, researchers 
have reported wide variations in urinary recovery of polyphenols.  For instance, Ito et al. 
(2005) has noted a 1.9% recovery of epicatechin following consumption of a cocoa beverage 
containing 289mg catechin and procyanidins. Baba et al. (2000) showed a 25-30% recovery 
of epicatechin following ingestion of cocoa or DC.  Most of these studies employed HPLC 
coupled with electrospray ionisation mass-MS or a combination of HPLC and LC-MS to 
detect phenolic compounds under controlled dietary conditions making it difficult to 
compare the data from these studies with the present study since HPLC and LC-MS permit 
more accurate quantification of polyphenols in urine than FC.  The only study that employed 
the FC method for polyphenol quantification demonstrated a 55% increase in urinary 
polyphenols levels from baseline and an average polyphenol recovery of 7.44% (Roura al., 
2006).  Assuming that in the present study, participants consumed half the polyphenol dose 
used in Roura et al.‘s study, these findings may reflect that a dose-dependent effect of 
increasing polyphenol intake on urinary polyphenol excretion exists, which is in agreement 
with former studies (Richelle et al., 1999; Wang et al., 2001) and the preliminary DC study.   
Unfortunately, due to limited resources no direct measurement of lipid peroxidation was 
undertaken in plasma or urine.  This would have provided additional support for the 
hypothesis summarised in Figure 4.2 if the placebo-DC was found to increase lipid 
peroxidation at the end of the placebo period.  Moreover, assessment of lipid peroxidation 
would have provided some insight as to whether the increase in cortisol and insulin 
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resistance seen following placebo was associated with elevated plasma or urinary lipid 
peroxides. This would have been particularly important considering that a positive 
correlation between urinary cortisone and serum and urinary antioxidant capacities were 
observed in this thesis, which is consistent with a role for glucocorticoids in inducing 
oxidative stress (see section 1.8.3).   In this respect, quantification of F2-isoprostanes in 
plasma or urine might have been useful but unfeasible.  F2-isoprostanes are compounds 
formed from ROS-induced peroxidation of arachidonic acid.  Because their levels in human 
biological fluids are considerably higher than other prostanoids (Morrow et al., 1995), they 
can be accurately and easily quantified in conditions of low as well as high oxidative stress 
(Young, 2005, Longmire et al., 1994). F2-isoprostanes are also directly involved in the 
pathologies of many diseases and consistent evidence exists to demonstrate a strong 
association between their levels in obesity and obesity-related co-morbidities including 
insulin resistance (Keaney et al., 2003, Urakawa et al., 2008).  As a result, F2-isoprostanes 
are considered by far the best marker of lipid peroxidation and are consequently deemed 
much superior to measurement of malondialdehyde using TBARS assay, another assay used 
for determination of lipid peroxidation but which is considered to reflect less accurately the 
process of lipid peroxidation
 
within biological fluids (Morrow et al., 1995).    Nevertheless, 
the results from the urinary antioxidant assays (Figure 3.27) seem suggestive of oxidative 
stress as the urinary values for total phenolics and FRAP appear to be lower at the end of 4 
weeks of placebo than at the end of 4 weeks of polyphenol-rich DC. Notably, urinary ORAC 
values were significantly reduced from baseline after placebo (Figure 3.27).   Added to this, 
is the evidence from the ex vivo and in vivo animal and human studies conducted by Vinson 
et al. (2006) which clearly demonstrate the pro-oxidant and pro-atherogenic properties of 
cocoa butter and which suggest that cocoa polyphenols can blunt the pro-oxidant properties 
of cocoa butter (see p 72. of Chapter 1).  A key question that arises from such results is the 
potential implications of such findings and the potential application of cocoa polyphenols in 
counteracting obesity-related and high-fat diet-induced oxidative stress? 
 
In conclusion, the above long-term DC study provides evidence for a potential role for 
moderate consumption of polyphenol-rich DC in improving glucose and blood pressure 
levels in overweight and obese females.  However, given the potential adverse metabolic 
effects observed with polyphenol-poor DC and the associated changes in weight, further 
research will be required to elaborate on the findings of this human trial. 
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4.6. Limitations 
There are several limitations to the human studies conducted as part of this thesis.  For 
instance in the pilot studies, capillary blood was used to measure glucose and total 
cholesterol. Although the use of either capillary blood or venous blood does not pose any 
issues in relation to total cholesterol (Warnick et al., 1994; Sblendorio et al., 2008), 
differences between capillary whole blood glucose and venous blood glucose are known to 
exit (Stahl et al., 2002; Colagiuri et al., 2003; Boyd et al., 2005). For instance, Colagiuri et 
al. (2003) has shown that fasting glucose concentrations can be higher if measured using 
venous plasma compared to capillary blood whereas 2h post glucose tolerance test glucose 
levels are lower when measured using venous plasma as opposed to capillary blood.  
Consequently, although a good correlation may exists between capillary blood glucose and 
venous blood (Boyd et al., 2005), caution needs to be exerted when comparing the results 
from the DC pilot study to the main DC study and other studies that used venous blood for 
measuring glucose.   
 
Additionally, a number of problems were observed with the study design.  For instance, 
baseline data were only obtained once in the pilot studies, thus failing to take in account day-
to-day fluctuations in glucose, cholesterol, BP and urinary glucocorticoids levels.  This 
proved to be particularly problematic in relation to BP, as certain subjects had low baseline 
BP and were therefore expected to increase regardless of the intervention.  Monitoring BP 
once during each treatment period also posed numerous difficulties as it only reflected BP 
levels at a particular period during the day, rather than the entire intervention period.  The 
latter could also explain why Taubert et al. (2003) and Grassi et al. (2005a-b) observed 
greater reductions in BP, as they used more reliable methods, including daily BP monitoring 
and 24-hour ambulatory sphygmomanometers.   
 
The lack of control or appropriate placebo in the pilot GCBE study also implies that no 
direct conclusions could be drawn from this intervention and that further studies using a 
placebo-controlled design or a parallel-group design are needed to confirm the results from 
the GCBE trial.   As indicated in section 1.13.3, an open-label single-subject experimental 
AB design is only ideal for feasibility studies that can then direct future research and justify 
the need for more rigorous research designs.  As such, conducting a bioavailability study 
using several DC and GCBE doses would have been probably more useful for calculating 
doses and designing dosage regimens.  Moreover, conducting a bioavailability study would 
have permitted examining the pharmacokinetics of epicatechin and CGA as well as assessing 
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for a correlation between the different metabolites and plasma oxidative capacity.  This, 
however, was not feasible. 
 
Another limitation to the current studies is the use of free-living volunteers whose diet was 
not closely controlled.  Although all volunteers were instructed to limit the intake of 
polyphenol-rich products and to consume a similar diet on the days prior to undertaking the 
measurements, large intra and inter-individual variations in urinary polyphenol excretion 
were seen in both the GCBE and DC interventions.  This was further exacerbated by the use 
of FC and FRAP assays for estimating polyphenols levels in plasma or urine as a method of 
measuring compliance. This is because both these assays lack specificity and the presence of 
any reducing compound could interfere with the readings produced by these tests.  As a 
result given adequate resources, it would have been best to quantify polyphenols in urine 
using HPLC or LC-MS.  Apart from permitting more precise monitoring of compliance, 
these methods can enable accurate measurement of the recovery of polyphenols which can in 
turn assist in studying inter-subject differences in polyphenol metabolism. 
 
In relation to the main study, a crossover design was used. As discussed earlier, cross-over 
studies are generally designed to measure the efficacy of a treatment under controlled 
conditions while a parallel-group design measures a treatment‘s effectiveness under less 
astringent conditions. As a result, the efficacy of a drug does not necessarily determine its 
effectiveness and broader long-term studies are needed to confirm the effectiveness of an 
intervention (Pittler and White, 1999). This suggests that regardless of the efficiency of 
cross-over trials, the use of parallel-design studies remains indispensable for confirming the 
findings of cross-over trials and ensuring their generalisation (Sever et al., 1989, Cleophas 
and Tavenier, 1995).  Cross-over designs are also susceptible to carry-over effects 
(Cleophas, 1993) and as such are likely to underestimate the effect of treatment (Cleophas, 
1990).  There are also issues with the use of placebo for blinding or for controlling for 
macronutrient and micronutrient differences between the active treatment period and non-
active treatment period.  This is because differences between treatment and placebo even if 
significant do not essentially imply clinical relevance (Cleophas, 1995).  In respect to the 
latter much remains to be understood with regard to the effect of the pattern of DC 
consumption on health.  This is because the therapeutic value of DC can be limited by the 
short-half lives and rapid elimination of DC polyphenols.  Hence the extent to which DC-
induced improvements in fasting glucose and BP are maintained beyond 12h following DC 
withdrawal need to be examined. A key question that remains to be elucidated is whether 
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non daily intermittent consumption of DC is of any therapeutical value to overweight and 
obesity?   
 
The use of Tanita scales for monitoring body composition also acted as a limitation. 
Although the manufacturer claims that the readings obtained using these scales for 
percentage body fat are within 5% of the gold standard, DEXA method (Tanita, 2009), 
Lazzer and colleagues (2003) have argued that foot-to-foot bioelectrical impedance and 
DEXA are two non-interchangeable methods and that despite showing great limits of 
agreement, Tanita scales can often underestimate fat mass.  Most importantly the use of foot-
to-foot bioelectrical impedance shows large inter-subject variability in fat mass estimates 
(Lazzer et al., 2003). Subsequently, future research aimed at investigating the effect of 
GCBE on body composition should focus on using more robust techniques for measuring 
body composition.  This is particularly important when considering some of the changes in 
anthropometrical indices seen in the preliminary GCBE and the main DC study. 
 
 
4.7. Implications 
The ability of GCBE to reduce WC in individuals with BMI ≥25kg/m2 while simultaneously 
increasing salivary cortisone concentrations and salivary cortisone-to-cortisol ratio has 
important implications to the prevention of obesity-related health risks and the treatment of 
obesity.  This is because WC is an important predictor of excess adiposity (Katzmarzyk et 
al., 2006), obesity-related complications (Zhu et al., 2002b; Janssen et al., 2004) and all-
cause mortality (Visscher et al., 2001; Bigaard et al., 2005; Katzmarzyk et al., 2006) whilst 
excessive cortisol regeneration by 11βHSD1 as indicated by a lower salivary cortisone-to-
cortisol ratio is known to be associated with abdominal fat accumulation, insulin resistance, 
hypertension and dyslipidaemia.  Conversely a smaller WC and inhibition of 11βHSD1 are 
often linked to improved metabolic profile and reduced metabolic risk factors.  This could be 
further reinforced by the findings from the main DC study wherein urinary cortisone 
correlated inversely with several parameters of the metabolic syndrome including LDL, 
TC:HDL, SBP and WHR  while a positive correlation was observed between urinary 
cortisone, HDL and serum and urinary antioxidant capacities (refer to Table 3.13).  As such, 
increasing polyphenol intake in the overweight and obese population in addition to 
conferring antioxidant protection against ROS might be pivotal to reducing metabolic risk 
factors in this population via modulation of WC and glucocorticoid metabolism.   
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Currently, most strategies aimed at reducing WC focus on caloric restriction and increasing 
physical activity (Dumesnil et al., 2001; Koh-Banerjee et al., 2003; Mayo et al., 2003; 
Valsamakis et al., 2004).  These strategies do not produce selective reduction in WC and any 
changes in WC generally result from an overall drop in body weight.  This is evident in that 
exercise although capable of evoking large reductions in weight which are preferentially 
linked to decreased WC (Mayo et al., 2003), is still not proven to produce a dose-dependent 
decrement in WC (Ross and Janssen, 2001).  In contrast, if dietary factors such as 
polyphenols are proven to selectively diminish WC and improve body composition 
independently of any effect on weight, then their use in weight loss programmes might 
confer additional health benefits.  In this respect, more recent data suggest that certain 
macronutrients have the capacity to modulate WC, in the absence of caloric restriction.  
Accordingly, an increment of 12g in fibre intake has been reported to be associated with a 
0.63cm reduction in WC while the intake of trans fats (2% of total energy intake) is linked to 
a 0.77-cm waist gain over 9 years (Koh-Banerjee et al., 2003).  Although the mechanism of 
such an effect has not been explored so far, it is likely to involve inhibition of 11βHSD1.  
Support for such concept arises from the preliminary findings of this thesis and from 
observations that, in women, cortisone is inversely related to WC (Cooper et al., 2004). 
 
It is important to note that consumption of GCBE in humans and of CGA in mice reduced 
cortisone levels in urine and the kidney, respectively.  Hypothetically such changes in 
cortisone concentrations could be reflective of 11βHSD2 inhibition.  Inhibition of 11βHSD2 
is known to be associated with increased kidney exposure to the mineralcorticoid effects of 
cortisol which causes hypertension.  However, since no rise in BP was observed in this 
study, it is difficult to elaborate on the implications of such tissue-specific effects of GCBE 
and CGA. Alternatively it could be speculated that inhibition of 11βHSD2 in the kidney will 
reduce the availability of the cortisone substrate, thereby abrogating hepatic 11βHSD1‘s 
ability to generate cortisol from cortisone (Seckl and Walker, 2001) (see section 1.8.2 and 
Figure 1.11; p. 47).  
 
As for the DC interventions, the hypoglycaemic and insulin sensitising properties of 
polyphenol-rich DC can be of relevance to conditions of impaired glycaemic control such as 
glucose intolerance and diabetes wherein the loss of glucose homeostasis is reflected in 
increased risk of vascular diseases.  In relation to diabetes, consistent evidence exists from 
animal research using different models of diabetes suggesting a potential role for cocoa in 
improving short-term and long-term glycaemic response (Ruzaidi et al., 2005, Tomaru et al., 
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2007, Jalil et al., 2008), diabetes-related cardiometabolic risk factors such as dyslipidaemia 
(Ruzaidi et al., 2005, Jalil et al., 2008) as well as diabetes-induced complications like 
cataracts (Osakabe et al., 2004).  Only two studies have so far examined the effect of 
chocolate or cocoa consumption on glycaemic control in diabetics. The first study was 
conducted on diabetic adolescents. It demonstrated that milk chocolate yields a lower 
glucose peak and glucose AUC than a conventional diabetes snack (Cedermark et al., 1993).  
The second study that was carried out on medicated type-II diabetics showed that daily 
intake of cocoa containing 963mg flavanols reversed vascular dysfunction in this population 
without adversely affecting their glycaemic control (Balzer et al., 2008).  Benefits to 
glucose-intolerant hypertensives have also been reported (Grassi et al., 2008).  In light of this 
evidence and the findings of the present study, it appears that further research is warranted in 
this field especially using sugar-free DC or cocoa, in which the effect of polyphenols would 
not be attenuated by the sugar content.  
 
The clinical importance of the hypotensive properties of DC can be viewed in 
epidemiological studies demonstrating that a 3.7mmHg decrement in SBP is linked to a 15-
year reduction in CVD and mortality (Buijsse et al., 2006) whereas, a 2mmHg reduction in 
DBP reduces the prevalence of hypertension by 17% and the risk of coronary artery disease 
and stroke by 6% and 15%, respectively (Cook et al. 1995).  Moreover, essential 
hypertension forms 90% of all hypertension cases (Kumar and Clarke, 2005), with weight 
gain being the most common cause of this disease (Fletcher et al., 1999).  Given the 
inadequacy of pharmacological strategies in such cases, the addition of food with 
hypotensive properties such as DC could help prevent or reduce the occurrence of 
hypertension in overweight individuals.  Such hypothesis is reinforced by the fact that 
chocolate decreases BP even in populations with high sodium intakes (McCullough et al., 
2006).   
 
Conversely, the lack of significant improvements in lipid profile in the main DC study, albeit 
disappointing, highlights an important observation and that is including a moderate portion 
of DC as part of a balanced diet does not adversely affect lipid metabolism, regardless of the 
fat content of DC.  However, long-term studies will be required to monitor the effect of long-
term consumption of DC on body composition and weight gain. 
 
To our knowledge, the findings of increased creatine kinase following 4-week consumption 
of polyphenol-rich DC but not placebo have not been reported by other studies. Although no 
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explanation could be provided at present, it is possible to speculate that because of the nature 
of polyphenols as plant toxins (Duthie et al., 2003); it is likely that the liver in its attempt to 
metabolise and eliminate these products raises serum creatine kinase.  However, skeletal 
muscle can also account for the raised serum creatine kinase (Apple et al., 1985) alongside 
other high energy demand tissues wherein creatine kinase helps regulate energy metabolism 
(Wallimann et al., 1992).  Consequently, the cause of the raised creatine kinase values and 
the implications of such rise should be investigated further and the major organ contributing 
to this effect identified.   
 
 
4.8. Directions for future research 
Data from in vitro antioxidant studies highlight the need for examining the contribution of 
various food products to polyphenol intake in the UK.  There is also a need for identifying 
major dietary sources of polyphenols in the average UK adult diet as these can reflect focal 
points for designing appropriate dietary strategies aimed at reducing the prevalence of 
chronic diseases.  Additionally, the in vitro studies revealed that GCBE possesses a strong 
antioxidant capacity and although no significant increase in urinary total phenolics was 
observed in the preliminary GCBE study, further research on the effect of GCBE on plasma 
antioxidant capacity is warranted.  Assessing the pharmacokinetics of CGA from GCBE and 
the impact of food matrix on the bioavailability of CGA from GCBE is also deserved as so 
far only one study has examined the bioavailability and metabolism of CGA from GCBE.  
Understanding the bioavailability of CGA and its metabolites is important in determining in 
vivo antioxidant properties of GCBE as well as in clarifying the contribution of each of CGA 
or its metabolites to the hypotensive properties of GCBE noted in the preliminary GCBE 
study.  The pros and cons of supplementing coffee formulations with GCBE as suggested by 
Oka (2007) need to be evaluated as well.  Similarly, the advantages of incorporating TCBE 
in the diet and identifying various nutritional application of this bean in addition to the well-
known uses in cocoa powder and chocolate production merits further exploration.    
 
Based on the pancreatic lipase experiment, attention should also be drawn to the potential 
role of GCBE in modulating the activity of pancreatic lipase and other lipases in humans and 
the possibility of improved lipid metabolism as a consequence of such actions.  However, 
more importantly, a large randomised placebo-controlled trial is warranted to investigate the 
effect of GCBE on body composition and glucocorticoid metabolism. It is well established 
that inhibition of 11βHSD1 lies at the centre of the current therapeutic targets aimed at 
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treating obesity and the metabolic syndrome (Wake and Walker, 2004; Anagnostis et al., 
2009) and in recent years several selective 11βHSD1 inhibitors have been developed (Wake 
and Walker, 2004; Anagnostis et al., 2009).  However, the role of diet in modulating 
glucocorticoid metabolism remains unclear. Similarly, in respect to the aetiology of HPA 
axis hyperactivity in obesity and the metabolic syndrome, although a role for chronic stress 
and low birth weight have been speculated (Wake et al., 2003), involvement of dietary 
factors have not been investigated.  In connection with diet, some data exists to suggest that 
dietary macronutrients can influence glucocorticoid metabolism in obesity independently of 
weight loss (Stimson et al., 2007). As such the role of dietary macronutrients and 
polyphenols in the aetiology and/or treatment of HPA hyperactivity emerge as an interesting 
field of future research.  In particular structure-activity relations should be clarified. If 
polyphenols are indeed proven to influence glucocorticoid metabolism, then their effect on 
growth hormone and testosterone will need to be examined as well.   This is because both 
these hormones are known to oppose the actions of cortisol on TG accumulation (see  
Bjorntorp,1998).  Moreover, administration of testosterone is reported to reduce fasting 
glucose, insulin resistance, total cholesterol and WC (Kapoor et al., 2006).  For future 
studies, the use of decaffeinated GCBE such as Le Svetol® is recommended as to exclude 
any potential interference from the caffeine component of GCBE (Dellalibera et al., 2006).    
 
In relation to DC, it is important to note that geographical origin can influence the 
composition of cocoa phenolics resulting in certain varieties of cocoa to contain up to 4 
times more polyphenols than other varieties.  Natsume et al. (2000) has even demonstrated 
that although the ratio of the various procyanidin components might not vary, the amount of 
procyanidins is markedly influenced by geographical origin. The concentration of 
epicatechin and catechin monomers is also affected by geographical origin. These 
differences could in turn account for some of the inconsistencies in the findings between 
different researchers.  As a result, it might be good practice in future for studies to state the 
origin of the cocoa beans used in their trials in an attempt to identify the factors that 
determine cocoa‘s and DC‘s health properties. 
 
It remains plausible that some of the health-promoting properties of cacao polyphenols may 
be concealed in the long-term by the energy density and high-fat content  of DC (Desch et 
al., 2009) and that, as a result, consumption of cocoa powder may incur greater benefits to 
overweight and obese individuals than ingestion of polyphenol-rich DC.  In this respect, it 
remains to be clarified whether minor differences in the polyphenol composition between 
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cocoa and DC products  affect their biochemical properties,  particularly that, to date, studies 
that have used polyphenol-rich cocoa as an alternative to DC have produced conflicting 
results on glycaemic control and BP. 
 
In addition to polyphenols, DC and cocoa also contain high concentrations of 
methylxanthines such as theobromine, caffeine, theophylline and paraxanthines (Eteng and 
Ettarah, 2000) and minerals like magnesium.  Theobromine, in particular, has been shown to 
improve lipid profile in rats (Eteng and Ettarah, 2000).  This may suggest that 
inconsistencies in the findings relating to lipid profile could be attributed to difference in 
theobromine content of the various DC and cocoa products used in research, since most 
previous studies have not controlled for theobromine content.  However, so far, little data 
exists concerning the contribution of methylxanthins to DC-induced improvements in lipid 
profile.  Since, theobromine and theophylline have half-lives of 6.2 and 7.2h, respectively 
(Lelo et al., 1986), which are considerably longer than the half-lives of epicatechin, the role 
of these compounds in cocoa and DC‘s hypolipidaemic, hypotensive and hypoglycaemic 
properties remains to be examined. 
 
As for minerals, it is well known that 100g DC can provide up to 300mg magnesium which 
is equivalent to 100% of recommended daily allowance of magnesium (Meisel, 2005).  As a 
result, previous studies demonstrating beneficial effects of polyphenol-rich DC consumption 
have been criticised for not controlling for magnesium intake (Meisel, 2005).   This is 
because previous researchers compared the effects of polyphenol- and magnesium-rich DC 
to a white chocolate placebo which is deficient in both polyphenols and magnesium (Grassi 
et al., 2005a-b; 2008).  Consequently, the beneficial properties of polyphenol-rich DC might 
have been exaggerated.  The present study has the advantage of using DC placebo which 
contained a similar magnesium content as the polyphenol-rich DC.  Consequently, any 
hypotensive or hypoglycaemic properties could be directly attributed to the polyphenols in 
DC and not magnesium.  Nonetheless, it remains to be clarified whether combining high 
polyphenol intake with a diet rich in magnesium could produce an accumulative or 
synergetic effect on BP and glucose levels (Meisel, 2005). 
 
The results of the main study in conjunction with the afore-mentioned in vitro and 
preliminary studies also highlight one major gap in the current scientific literature and that is 
the scarcity of studies that estimate total polyphenol intake in the general population and that 
assess differences in polyphenol intake amongst the different population subgroups.  
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Furthermore, it remains unclear whether there exists differences in the polyphenol intake and 
plasma antioxidant status between overweight and obese individuals and lean individuals 
which then predisposes the former group to oxidative stress.  Such investigations will be 
focal to identifying the pathophysiological link between oxidative stress and systemic 
inflammation in obesity since polyphenols in addition to possessing antioxidant properties, 
have the capacity to modulate several biomarkers of inflammation.  Indeed, emerging 
evidence suggests a central role for oxidative stress in the pathophysiology of chronic 
conditions like obesity, diabetes, hypertension and CVD while demonstrating that increased 
antioxidant intake can improve antioxidant status while reducing complications and 
mortality due to these conditions (Gey et al., 1993; Sundaram et al., 1996; Lopes et al., 
2003; Maxwell et al., 2003; Kashyap et al., 2005; Crujeira et al., 2006).  Overweight and 
obese individuals, in particular, exhibit a low antioxidant status  and dysfunctional 
antioxidant defence mechanism as observed in reduced plasma α-tocopherol and β-carotene 
levels and diminished superoxide dismutase and glutathione peroxidase activity (Beltowski 
et al., 2000; Ozata et al., 2002; Molnar et al., 2004)   making it a high priority to examine the 
polyphenol intake of this population subgroup.   However, according to Molnar et al. (2004), 
obese individuals are not likely to consume lower quantities of antioxidants; neither are they 
more predisposed to having defects in the absorption of antioxidants compared to lean 
individuals.  Nonetheless and as discussed throughout this thesis and suggested by Molnar et 
al. (2004), the presence of hypertriglyceridaemia, hyperinsulinaemia and subsequent 
oxidative stress are likely to exhaust the antioxidant reserves in overweight and obese 
individuals leading to lower antioxidant availability and a higher demand for antioxidants to 
preserve redox balance in these individuals. This once again confirms the need for 
maintaining adequate polyphenol and micronutrient intake in the overweight and obese 
population while possibly reducing the intake of pro-oxidant food products such as fat.   
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5. General conclusion 
 
This thesis embarked on exploring the potential role of polyphenols in preventing 
overweight and obesity-related complications.  It supports the hypothesis that polyphenols 
from GCBE and DC can differentially improve glucose and BP levels in overweight and 
obese individuals without significantly affecting lipid profile.  It also  provides insight into 
novel mechanistic pathways by which polyphenols can potentially protect against obesity 
and its associated complications and which involve inhibition of pancreatic lipase and 
possibly 11βHSD1.   
 
The following points outline the general conclusions and implications of this thesis:  
1. GCBE and TCBE are rich in polyphenols and possess strong antioxidant capacities.  
These products could act as focal points of intervention as both DC and coffee are 
widely consumed on a daily basis in the UK. 
2. GCBE, but not TCBE, can inhibit pancreatic lipase dose-dependently in vitro.  This 
is of particular relevance to overweight and obesity since reducing fat absorption 
constitutes a key target for counteracting overweight and obesity and their associated 
co-morbidities. 
3. In healthy overweight and obese individuals, short-term consumption of GCBE can 
improve BP and glucocorticoid regulation.  This effect is likely to be mediated via 
the differential effect of CGA on tissue corticosterone concentrations as 
demonstrated by the animal study.    
4. Short-term consumption of 20g DC containing 500mg or 1000mg polyphenols 
reduces fasting glucose and BP with both 500mg and 1000mg polyphenol DC 
yielding a similar effect on fasting glucose and BP. 
5. Long-term ingestion of 20g DC containing 500mg polyphenols improves 
glucoregulatory biomarkers and BP without significantly affecting lipid profile.  
These metabolic effects appear to be more prominent in overweight and obese 
females than lean females and could be related in part to improved antioxidant 
capacity.  The role of glucocorticoids as one of the underlying biochemical pathways 
by which polyphenol-rich DC exerts its beneficial metabolic effects remains to be 
clarified. 
6. Polyphenol-poor DC has the potential to adversely affect insulin, cortisol and body 
weight regulation in overweight and obese females.     
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Key research areas to be considered in future in relation to overweight and obesity include: 
1. Investigating in vivo effect of polyphenols, in particular GCBE, on fat absorption.  
Herein, the effect of polyphenols on pancreatic lipase could be examined.  
Measurement of time-course changes in total cholesterol or TG following acute 
consumption of a high-fat meal could also be used to assess the effect of GCBE on 
fat absorption.    
2. Identifying and examining the effect of polyphenols on 11βHSD1 activity.    To 
achieve this, a series of in vitro, animal and human studies can be conducted.  In 
vitro, inhibition of 11βHSD1 by polyphenols could be assessed in hepatic 
microsomes.  In animals, administration of a diet rich in a specific phenolic 
compound or a polyphenol-rich product followed by cortisone injection would 
permit accurate measurement of cortisone conversion to cortisol, hence 11βHSD1 
activity.  The use of mice strains such as KKA (y) or ob/ob mice is recommended.  
In humans, application of HPLC for accurate quantification of cortisol and cortisone 
metabolites is recommended.  This will enable identification of selective changes in 
the activity of the enzymes that regulate cortisol metabolism including 11βHSD1, 
11βHSD2 and α-reductase following consumption of a polyphenol-rich product 
such as GCBE. 
3. Investigating the effect of polyphenols on thermogenesis, substrate oxidation and 
lipolysis.  This could be attained using indirect colorimetry in combination with 
measurements of NEFA and glycerol. Quantification of TG in cultured adipocytes 
would also permit estimation of lipolytic activity. Lipoprotein lipase and hormone-
sensitive lipase activity could also be estimated by incubating polyphenol extracts 
with isolated adipocytes and subsequently measuring NEFA and glycerol.  
4. A potential role for polyphenols in regulating appetite and energy intake also 
warrants investigation.  
 
It remains to cite Duthie et al. (2003) that although deficiencies in polyphenol intake are not 
accompanied with any apparent symptoms of deficiency as is the case with the more 
traditional antioxidants, their ability to influence and prevent disease processes highlights the 
importance of ensuring adequate intake of these antioxidants amongst high risk populations 
such as the overweight and obese population.  Moreover, the fact that certain classes of 
polyphenols possess the potential to counteract some of the underlying endocrinological 
abnormalities characteristic of overweight and obesity provides novel insights into the 
relation between diet and health.  With the ever-increasing global burden of the overweight 
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and obesity epidemic, the need to prevent overweight and obesity-related chronic conditions 
through appropriate dietary strategies and public health strategies is becoming ever-more 
important.   However, the diversity and complexity of these compounds implies that much 
remains to be elucidated concerning the mechanisms by which these compounds influence 
health.   
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7. Appendices 
 
7.1. Appendix 1 Precision and accuracy of assays 
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7.1.1 Validation of Folin-Ciocalteu method 
7.1.1.a Standard curve for determination of total phenolic content 
Linear regression produced a calibration curve of Y =0.0343x + 0.0422, r
2
= 0.9975, where Y 
reflects abs in nm and X the concentration of GA.   
7.1.1.b Assay precision and accuracy 
Assay precision was determined replicate analysis (n=4) of six known concentrations of GA 
(Roura et al., 2006).  The limit of detection (LoD) and limit of quantification (LoQ) for the 
assay were 0.003 and 0.011mM, respectively. 
Table 7.1 Evaluation of precision and accuracy of Folin-Ciocalteu method 
Calibrator 
concentration mg/l 
Mean measured 
concentrations mg/l n(4) 
Precision, 
RSD
1
 (%) 
Predicted 
concentration (%) 
5 4.236152 4.248305 87.34694 
10 9.877551 1.476215 97.7551 
20 20.6793 3.420414 100.9548 
30 31.24781 1.339651 105.1555 
40 40.57726 2.166507 99.91254 
100 49.13411 0.168029 98.1516 
RSD
1
, relative standard deviation 
7.1.2 Validation of ferric-reducing capacity of plasma method 
7.1.2.a Standard curve for determination of ferric-reducing capacity of plasma 
Linear regression produced a calibration curve of Y =0.0343x + 0.0422, r
2
= 0.9977, where Y 
reflects abs in nm and X the concentration of Fe
2+
.   
7.1.2.a Assay precision and accuracy 
Assay precision was determined by replicate analysis (n=4) of five known concentrations of 
ferrous sulphate standards. The limit of detection (LoD) and limit of quantification (LoQ) for 
the assay were  0.003 and 0.011mM, respectively. 
Table 7.2 Evaluation of precision and accuracy of ferric-reducing capacity of plasma 
assay 
Calibrator 
concentration mg/l 
Mean measured 
concentrations mg/l n(4) 
Precision, 
RSD
1
 (%) 
Predicted 
concentration (%) 
1 1.101156 2.677926 110.1156 
2 1.973988 5.197011 98.69942 
4 3.971098 2.301195 99.27746 
6 6.306358 2.433795 105.106 
8 8.00289 1.839638 100.0361 
RSD
1
, relative standard deviation 
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7.1.3 Validation of oxygen radical absorbance capacity method 
7.1.3.a Standard curve for determination of ORAC 
Linear regression produced a calibration curve of Y =0.190x + 1.233, r2= 0.996, where Y 
reflects abs in nm and X the concentration of trolox.   
7.1.3.b Assay precision 
Assay precision was determined by replicate analysis (n=4) of five known concentrations of 
Trolox standards.  The limit of detection (LoD) and limit of quantification (LoQ) for the 
assay were 1.142 and 3.807 µM trolox equivalents, respectively. 
 
 
Table 7.3 Evaluation of precision and accuracy of oxygen radical absorbance capacity 
method 
Calibrator 
concentration mg/l 
Mean measured 
concentrations mg/l n(4) 
Precision, 
RSD
1
 (%) 
Predicted 
concentration (%) 
6.25 6.648198 2.573648 106.3712 
12.5 13.70795 1.853424 109.6636 
25 26.66962 0.463117 106.6785 
50 48.81343 0.21282 97.62685 
100 87.52354 0.21869 87.52354 
RSD
1
, relative standard deviation 
7.1.4 Validation of 2,2-diphenyl-1-picrylhydrazyl radical 
7.1.5 Standard curve for determination of 2,2-diphenyl-1-picrylhydrazyl radical 
Linear regression produced a calibration curve of Y =0.0048x + 0.0454, r
2
= 0.9988, where Y 
reflects abs in nm and X the concentration of DPPH in medium. 
7.1.5.a Assay precision 
Assay precision was determined by replicate analysis (n=4) of five known concentrations of 
DPPH. The limit of detection (LoD) and limit of quantification (LoQ) for the assay were  
0.003 and 0.011mM, respectively. 
 
Table 7.4 Evaluation of precision and accuracy of 2,2-diphenyl-1-picrylhydrazyl radical 
assay 
Calibrator 
concentration mg/l 
Mean measured 
concentrations mg/l n(4) 
Precision, 
RSD
1
 (%) 
Predicted 
concentration (%) 
5 4.395833 0.113744 87.91667 
10 11.16667 0.044776 111.6667 
20 20.85417 0.028771 104.2708 
40 40.22917 0.027343 100.5729 
60 59.70833 0.021773 99.51389 
RSD
1
, relative standard deviation 
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7.1.6 Cortisol ELISA validation data 
Cross-reactivity was not that significant with many interfering steroids: Cortisone=o.68%, 
Corticosterone= 0.06%, Deoxy-cortisol= 1.1%, Prednisolone=24%, Testosterone= 0.4%, 
other steroids were < 0.5%.  
  
Intra-assay precision  ranged from 3.65% to 6.12%, and Inter-assay precision data ranged 
from 4.74% to 8.66%. 
  
Recovery studies for a range of cortisol levels from 2.6 – 40.8 ng/ml were 89.8% to 107.7%. 
  
Sensitivity of the assay defined as the minimum detection limit was 0.1 ng/ml.(0.276 
nmol/L) 
  
  
7.1.7 Cortisone ELISA validation data 
Cross reactivity of our affinity purified cortisone antibody with cortisol was reduced to 
0.25% (see Table).  
 
The validity of cortisone ELISA was confirmed by the good correlation obtained before and 
after an HPLC fractionation step (Y= 1.09X - 0.21, R
2
=0.98).  
 
Intra and Inter-assay imprecision were 5.5 – 11.7% and 8.7 – 12.8% CV respectively.   
 
 Minimum detection limit of cortisone ELISA was 28 pg/mL (77.7pmole/L) 
 
Table 7.5: Cross-reactivity data for purified Anti-Cortisone antibody 
Steroid        % Cross-reactivity 
 Cortisone         100 
 Cortisol             0.252 
 11-Deoxycortisol             0.105 
 Aldosterone             0.011 
 17α OH-Progesterone             0.014 
 Progesterone             0.0002 
 Deoxycorticosterone             0.006 
 Corticosterone             0.0025 
 Testosterone             0.0005 
 DHEA             0.0004 
 DHEA sulphate             0.0002 
 Androstenedione             0.006 
 18-OH-deoxycorticosterone             0.0002 
 5β dihydroaldosterone             0.0003 
 5 β Tetrahydrocorticosterone             0.0004 
 Dihydropregnenolone             0.0005 
 5α Dihydroaldosterone             0.0003 
 Tetrahydrodeoxycorticosterone             0.0003 
 5 β Dihydrocortisol             0.004 
 5α Dihydrocorticosterone             0.002 
 Tetrahydroaldosterone             0.0005 
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7.1.8 Assays accuracy and precision 
 
7.1.8.a Glucose Liquid (Sentinel Diagnostics, UK) 
Measuring range: 2 - 400 mg/dL.  
Intra-Assay Precision: 338.2 mg/dL, SD 3.30, CV% 0.98. 
Inter-Assay Precision:  
 
 Mean 
mg/dl 
Within Run Run to Run Total  Total 
 SD CV% SD CV% SD CV% 
L1 102 1.10 1.07 2.11 2.07 2.38 2.33 
L2 198 1.26 0.64 1.44 0.73 1.92 0.97 
L3 245 2.25 0.92 1.96 0.80 2.98 1.22 
 
Sensitivity:  2 mg/dL.  
Accuracy:  N = 60, r = 0.99908, y = 0.9883 x - 0.30816 
 
 
 
 
7.1.8.b Insulin (Mercodia, Sweden) 
Sensitivity Detection limit is 1 mU/l (6 pmol/l) calculated as two standard 
deviations above Calibrator 0. 
Recovery Recovery upon addition is 94-113% (mean 104%). 
Precision Each sample was analyzed in six replicates on six different 
occasions. 
 
Sample Obtained value 
(mU/l) 
CV 
within assay % Between 
assay% 
Total assay% 
1 11 3.4 3.6 5.0 
2 36 4.0 2.6 4.7 
3 80 2.8 2.8 4.0 
4 154 3.2 2.9 4.4 
 
 
7.1.8.c NEFA (Wako Chemicals, Neuss, Germany) 
Accuracy ± 15% of the known concentration. 
 
Sensitivity When purified water is assayed, the absorbance is not more than 0.140. 
When a standard of given concentration (oleic acid 1 mEq/L) is assayed, the 
absorbance is 0.100 - 0.380. 
Precision When a sample is assayed not less than 5 times in a run, CV of absorbance is 
not more than 1.5%. 
Measurable range 0.01 - 4.00 mEq/L NEFA. (In the case of using the standard 
procedure) 
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7.2. Appendix 2 Consent form and information sheets 
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QMUC Research Ethics Sub-Committee 
Standard Consent Form 
Effect of polyphenols on glucoregulatory biomarkers, BP and lipid profile in overweight and 
obese subjects  
 
 
I agree to participate in this study. 
I have read and understood the subject information sheet and this consent form.  I have had 
an opportunity to ask questions about my participation. 
I understand that I am under no obligation to take part in this study. 
I understand that I have the right to withdraw from this study at any stage for no reason. 
 
Name of subject:                 ______________________________________________ 
Signature of subject:           ______________________________________________ 
Signature of investigator:    ______________________________________________ 
   Date:                                    ______________________________________________ 
 
 
Further information is available from: 
 
Name of Investigator:    Suzana Almoosawi 
Address:                         Postgraduate student 
                                       Public Health Nutrition 
                                       Department of Dietetics, Nutrition & Biological Sciences 
                                       Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU 
Email:                            03002888@student.qmu.ac.uk 
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Information sheet for potential subjects 
Effect of polyphenols on glucoregulatory biomarkers, BP and lipid profile in overweight and 
obese subjects (Pilot study)  
 
My name is Suzana Almoosawi and I am Public Health Nutrition PhD student currently 
undertaking my research project in the Department of Dietetics, Nutrition & Biological 
Sciences at Queen Margaret University.  In view of the current interest in the protective role 
of dark chocolate and green coffee extract against cardiovascular disease, I wish to carry out 
my research project in this area.  More precisely my research will examine the effect of 
green coffee extract intake on fasting glucose, blood pressure, total cholesterol and urinary 
mineral, cortisol and cortisone excretion in overweight and obese people. 
 
Green coffee extract are rich sources of antioxidants, known as polyphenols.  It has been 
shown to protect against hypertension and weight-gain.  Moreover, it possesses the potential 
to reduce risk of diabetes because it contains high levels of a polyphenol known as 
chlorogenic acid.  Though current manufacturing processes destroy much of coffee beans‘ 
antioxidants, a number of polyphenol-rich green coffee extracts are still available on the 
market, whose properties deserve to be investigated.  Indeed, if positive health attributes are 
to be found in these products, then their role in the primary prevention of hypertension, 
diabetes and cardiovascular diseases could be significant.  Such findings will be of particular 
relevance to populations at risk of these diseases, such as the overweight population. 
 
If you wish to take part in this study, you have to be healthy with a body mass index equal to 
or above 25, non-smoker, not currently taking any blood pressure or cholesterol-lowering 
drugs.   You should also have a normal physical activity level and your intake of cocoa, dark 
chocolate, green tea and coffee should be low.   
 
The study will consist of a baseline week + 2 weeks intervention.  You will have to be 
available on two days two weeks apart for an average of 15 minutes (see, timetable attached 
at the end of this document). 
 
You will be asked to follow your usual diet throughout the study, but to avoid consuming 
polyphenol-rich beverages and foods.  You will find a list of these products and a list of 
alternative products that you can consume at the back of this document (see Table-7.6). 
During the week before the intervention, you will be asked to avoid eating any type of 
chocolate, chocolate products and coffee.  During this baseline week you will also be 
required to complete a 3-day diet diary (two weekdays & one weekend), a physical activity 
questionnaire, a 24-urine collection (see timetable at the end of this document) and 3 saliva 
collections.   
 
Following the baseline week, you will be assigned to receive a green coffee bean extract.  
You will be asked to follow the diet for 14days.  You will be provided with FREE Quest‘s 
green coffee extract.  The doses will consist of 2 tablets of green coffee extract; one capsule 
to be taken in the morning between 8-10am with breakfast or preferably 200ml water and 
white bread and another capsule to be taken with your evening meal or preferably with 
200ml water and white bread between 8-10pm.  During the intervention week you will also 
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be asked to complete another diet diary and physical activity questionnaire, in addition to 
completing a 24-urine collection and 3 saliva samples at the end of 14 days period. 
 
The following measurements will also be assessed during the study: height, weight, body 
mass index, waist and hip circumferences, blood pressure, fasting glucose, total cholesterol, 
urinary magnesium, sodium, potassium, cortisol and cortisone (see, timetable attached at the 
end of this document ). 
 
Before, examining your blood pressure, you will be asked to sit comfortably for 15 minutes.  
Your blood pressure will then be measured three times with 5 minutes interval using an 
electronic sphygmomanometer.  This should therefore take approximately 15 minutes.  The 
12-hour fasting glucose and cholesterol measurements will be obtained by finger-prick blood 
samples.  This procedure should not cause any distress as finger prick samples are obtained 
quickly.   
 
You will be free to withdraw from the study at any stage for any reason.  All data collected 
will remain anonymous and your name will be replaced with an identification number that 
could only be identified by the researcher.  
 
If you would like to consult a person who is not involved in this research for independent 
advice, please contact Dr Jane McKenzie.  Her contact details are provided below. 
 
If you have any further queries concerning this research, please do not hesitate to ask.  
Alternatively, if you have read and understood the information provided in this document 
and you would like to participate in this study, please sign the attached consent form.  
 
Contact Details of the investigator 
Name of Investigator:    Suzana Almoosawi 
Address:                         Postgraduate student 
                                       Public Health Nutrition 
                                       Department of Dietetics, Nutrition & Biological Sciences 
                                       Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU 
Email:                            03002888@student.qmu.ac.uk 
 
 
Contact Details of the independent adviser 
Name of adviser:            Jane McKenzie 
Address:                         Lecturer in biochemistry and metabolism 
Programme leader for human biology  
                                       Department of Dietetics, Nutrition & Biological Sciences 
Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU                                       
Email:                             JMcKENZIE@qmu.ac.uk                    
Telephone:                     0131 474 0000  
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Table 7.6 List of polyphenol-rich foods and beverages to be avoided by the GCBE group 
(adapted from Clifford, 1999) 
 
Foods rich in polyphenols 
(chlorogenic acids) 
Chlorogenic acid content (mg)  per 
kg food 
Alternatives 
 Total CGAs 
 
Caffeoylquinic 
acids (CQA)* 
 
Apples, raw (per kg) 30-60 
 
62-385    
Artichoke  - 180-450   
Aubergines - 600   
Blackberries 70 - Raspberries 
Strawberries 
Redcurrants 
gooseberries 
Blackcurrants 140 -   
Blueberries - 500-2000  
Cherries - 150-600  
Pears, raw - 60-280  
 
 
    
Beverages rich in polyphenols 
(chlorogenic acids) 
Total chlorogenic acids or caffeoyl-
quinic acid content (mg)  per litre 
beverage or per 200ml coffee 
 
 Total CGAs Caffeoylquinic 
acids (CQA) 
 
Apple juice - Up to 208  
Bilbbery wine 50 -  
Cider - 11-480  
Coffee  
Instant brew 
Weak brew, very dark roast 
Strong brew, very pale roast 
robusta 
Arabica 
Robusta 
 
- 
20 
675 
 
70-200  
70-300 
 
50-150 
- 
- 
 
- 
- 
 
Pear juice - 240   
Tea 
Green 
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Information sheet for potential subjects 
Effect of polyphenols on glucoregulatory biomarkers, BP and lipid profile in overweight and 
obese subjects (Pilot study)  
 
My name is Suzana Almoosawi and I am Public Health Nutrition PhD student currently 
undertaking my research project in the Department of Dietetics, Nutrition & Biological 
Sciences at Queen Margaret University.  In view of the current interest in the protective role 
of dark chocolate against cardiovascular disease, I wish to carry out my research project in 
this area.  More precisely my research will examine the effect of dark chocolate on fasting 
glucose, blood pressure, total cholesterol and urinary mineral, cortisol and cortisone 
excretion in overweight and obese people. 
 
Dark chocolate is a rich source of antioxidants, known as polyphenols.  Recently, a number 
of studies have indicated that polyphenol-rich dark chocolate could reduce the risk of 
hypertension, diabetes and coronary artery disease.  Though current manufacturing processes 
destroy much of chocolate‘s antioxidants, some polyphenol-rich chocolate is still available 
on the market, whose properties deserve to be investigated.  Indeed, if positive health 
attributes are to be found in these products, then their role in the primary prevention of 
hypertension, diabetes and cardiovascular diseases could be significant.  Such findings will 
be of particular relevance to populations at risk of these diseases, such as the overweight 
population. 
If you wish to take part in this study, you have to be healthy with a body mass index equal to 
or above 25, non-smoker, not currently taking any blood pressure or cholesterol-lowering 
drugs.   You should also have a normal physical activity level and your intake of cocoa, dark 
chocolate and green tea should be low.   
 
The study will last approximately 6 weeks.  You will have to be available for an average of 
15 minutes once every week, except for Week-3 where no measurements will be taken (see, 
timetable attached at the end of this document). 
 
You will be asked to follow your usual diet throughout the study, but to avoid consuming 
polyphenol-rich beverages and foods.  You will find a list of these products and a list of 
alternative products that you can consume at the back of this document (see Table-7.7). 
During the week before the intervention, you will be asked to avoid eating any type of 
chocolate and chocolate products.  During this baseline week you will also be required to 
complete a 3-day diet diary (two weekdays & one weekend), a physical activity 
questionnaire and a 24-urine collection (see timetable at the end of this document).   
 
On Week-0, you will be randomly assigned to one of the two intervention groups: low dark 
chocolate or high dark chocolate.  You will be asked to follow each diet for 14days followed 
by 1-week washout period after which you will be asked to cross-over to the 2
nd
 diet and so 
on until you complete all four diets.  You will be provided with FREE dark chocolate for 
each of the intervention weeks.  The doses will be in the range of 20g of dark chocolate.  
During the dark chocolate diet, you will be asked to distribute the chocolate dose throughout 
the day.  For example, you could have some of the dark chocolate instead of your usual 
breakfast, and then eat the remaining chocolate every 2-3 hours.  You will be asked to 
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complete another diet diary and physical activity questionnaire during Week-1 and 4 in 
addition to completing 24-urine collection at the end of each of these weeks. 
 
The following measurements will also be assessed during the study: height, weight, body 
mass index, waist and hip circumferences, blood pressure, fasting glucose, total cholesterol, 
urinary magnesium, sodium, potassium, cortisol and cortisone (see, timetable attached at the 
end of this document ). 
 
Before, examining your blood pressure, you will be asked to sit comfortably for 10 minutes.  
Your blood pressure will then be measured three times with 2 minutes interval using an 
electronic sphygmomanometer.  This should therefore take approximately 6 minutes.  The 
12-hour fasting glucose and cholesterol measurements will be obtained by finger-prick blood 
samples.  This procedure should not cause any distress as finger prick samples are obtained 
quickly.   
 
You will be free to withdraw from the study at any stage for any reason.  All data collected 
will remain anonymous and your name will be replaced with an identification number that 
could only be identified by the researcher.  
 
If you would like to consult a person who is not involved in this research for independent 
advice, please contact Dr Jane McKenzie.  Her contact details are provided below. 
 
If you have any further queries concerning this research, please do not hesitate to ask.  
Alternatively, if you have read and understood the information provided in this document 
and you would like to participate in this study, please sign the attached consent form.  
 
Contact Details of the investigator 
Name of Investigator:    Suzana Almoosawi 
Address:                         Postgraduate student 
                                       Public Health Nutrition 
                                       Department of Dietetics, Nutrition & Biological Sciences 
                                       Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU 
Email:                            03002888@student.qmu.ac.uk 
 
 
Contact Details of the independent adviser 
Name of adviser:            Jane McKenzie 
Address:                         Lecturer in biochemistry and metabolism 
Programme leader for human biology  
                                       Department of Dietetics, Nutrition & Biological Sciences 
Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU                                       
Email:                             JMcKENZIE@qmu.ac.uk                    
Telephone:                     0131 474 0000  
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Table 7.7 List of polyphenol-rich foods and beverages to be avoided by the cocoa group 
(adapted from the USDA database for flavonoid content of foods, 2007a). 
 
Foods rich in polyphenols 
(epicatechin) 
Epicatechin content (mg) per 100g 
food product 
Alternatives 
Apples 
Fuji 
gala 
golden with peel 
granny smith 
 
5.21 
4.71 
3.79 
3.60 
Strawberries 
Quinces 
Apple sauce 5.41  
Apricots 5.47  
Blackberries 4.66  
Blueberries 13.69  
Broadbeans, boiled 7.82  
Cacao beans 99.18  
Cherries, canned 4.31  
Cherries, raw 6.97  
Chocolate, dark 
Chocolate, milk 
41.5 
10.45 
White 
chocolate 
Grapes, black 8.68 Grapes, red 
Grapes, white 
Nectarines, raw 2.54 Avocado 
Peaches, raw 2.34  
Pears 1.74  
Plums, raw 3.2  
Raspberries 4.07  
Soybeans 37.41  
   
Beverages rich in polyphenols 
(epicatechin) 
  
Red wine 3.28 White wine 
Green tea 8.29 Black tea  
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Information sheet for potential subjects 
Effect of polyphenols on glucoregulatory biomarkers, BP and lipid profile in overweight and 
obese subjects  
 
My name is Suzana Almoosawi and I am Public Health Nutrition PhD student currently 
undertaking my research project in the Department of Dietetics, Nutrition & Biological 
Sciences at Queen Margaret University.  In view of the current interest in the protective role 
of dark chocolate against cardiovascular disease, I wish to carry out my research project in 
this area.  More precisely my research will examine the effect of dark chocolate on fasting 
glucose, insulin, blood pressure, lipids, cortisol and cortisone levels on people with different 
body mass indexes (BMI). 
 
Dark chocolate is a rich source of antioxidants, known as polyphenols.  Recently, a number 
of studies have indicated that polyphenol-rich dark chocolate could reduce the risk of 
hypertension, diabetes and coronary artery disease.  Though current manufacturing processes 
destroy much of chocolate‘s‘ antioxidants, a number of polyphenol-rich chocolates are still 
available on the market, whose properties deserve to be investigated.  Indeed, if positive 
health attributes are to be found in these products, then their role in the primary prevention of 
hypertension, diabetes and cardiovascular diseases could be significant.  Such findings will 
be of particular relevance to populations at risk of these diseases, such as the overweight 
population. 
If you wish to take part in this study, you have to be healthy, non-smoker, not currently 
taking any blood pressure or cholesterol-lowering drugs.   You should also have a normal 
physical activity level and your intake of cocoa, dark chocolate and green tea should be low.   
 
The study will last approximately 11 weeks.  You will have to be available for an average of 
20 minutes once every 2 weeks (see, timetable attached at the end of this document). 
 
You will be asked to follow your usual diet throughout the study, but to avoid consuming 
polyphenol-rich beverages and foods.  You will find a list of these products and a list of 
alternative products that you can consume at the back of this document (see Table 7.8). 
During the week before the intervention, you will be asked to avoid eating any type of 
chocolate or chocolate products.  During this baseline week you will also be required to 
complete a 3-day diet and physical activity diary (two weekdays & one weekend), 3 saliva 
collection (one before breakfast, 1 before lunch, 1 before dinner) and one 24-urine collection 
(see timetable at the end of this document).   
 
On Week-0, you will be randomly assigned to one of the two intervention groups: placebo 
then polyphenol-rich dark chocolate, or polyphenol-rich dark chocolate then placebo.  You 
will be asked to follow each diet for 4 weeks followed by 2-week washout period after which 
you will be asked to cross-over to the 2
nd
 diet and so on until you complete both diets.  You 
will be provided with FREE Barry Callebaut dark chocolate for each of the intervention 
weeks.  The doses will be 20g for both intervention.  During the intervention, you will be 
asked to distribute the chocolate dose throughout the day.  For example, you could have 5g 
in the morning before breakfast, 5g before lunch, 5g before dinner and 5g at 8 or 10pm.  You 
will be asked to complete another a 3-day diet and physical activity diary and 3 saliva 
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collection (one before breakfast, 1 before lunch, 1 before dinner) during Week-2, and 8.  You 
will also be requested to complete 3 saliva collection (one before breakfast, 1 before lunch, 1 
before dinner) and a 24-urine collection at the end of each intervention. 
 
Overall, the following measurements will be assessed during the study: height, weight, body 
mass index, waist and hip circumferences, percentage body fat, blood pressure, fasting 
glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, 
salivary and urinary cortisol and cortisone.  Before taking your blood pressure, you will be 
asked to sit comfortably for 15 minutes.  Your blood pressure will then be measured three 
times with 5 minutes interval using an electronic sphygmomanometer.  This should therefore 
take approximately 15 minutes.  The 12-hour glucose, insulin and lipids measurements will 
be obtained using venous blood samples.  This procedure may cause some discomfort but 
you will only be required to undergo it 4 times within the 11 weeks.  You will also be paid 
5£ for each venous blood samples you will provide.  
 
You will be free to withdraw from the study at any stage for any reason.  All data collected 
will remain anonymous and your name will be replaced with an identification number that 
could only be identified by the researcher.  
 
If you would like to consult a person who is not involved in this research for independent 
advice, please contact Dr Jane McKenzie.  Her contact details are provided below. 
 
If you have any further queries concerning this research, please do not hesitate to ask.  
Alternatively, if you have read and understood the information provided in this document 
and you would like to participate in this study, please sign the attached consent form.  
 
Contact Details of the investigator 
Name of Investigator:    Suzana Almoosawi 
Address:                         Postgraduate student 
                                       Public Health Nutrition 
                                       Department of Dietetics, Nutrition & Biological Sciences 
                                       Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU 
Email:                            03002888@student.qmu.ac.uk 
 
 
Contact Details of the independent adviser 
Name of adviser:            Jane McKenzie 
Address:                         Lecturer in biochemistry and metabolism 
Programme leader for human biology  
                                       Department of Dietetics, Nutrition & Biological Sciences 
Queen Margaret University  
                                       Queen Margaret University Drive 
                                       Musselburgh 
                                       EH21 8UU                                       
Email:                             JMcKENZIE@qmu.ac.uk                    
Telephone:                     0131 474 0000  
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Table 7.8 List of polyphenol-rich foods and beverages to be avoided by the cocoa group 
(adapted from the USDA database for flavonoid content of foods, 2007a). 
 
Foods rich in polyphenols 
(epicatechin) 
Epicatechin content (mg) per 100g 
food product 
Alternatives 
Apples 
Fuji 
gala 
golden with peel 
granny smith 
 
5.21 
4.71 
3.79 
3.60 
Strawberries 
Quinces 
Apple sauce 5.41  
Apricots 5.47  
Blackberries 4.66  
Blueberries 13.69  
Broadbeans, boiled 7.82  
Cacao beans 99.18  
Cherries, canned 4.31  
Cherries, raw 6.97  
Chocolate, dark 
Chocolate, milk 
41.5 
10.45 
White 
chocolate 
Grapes, black 8.68 Grapes, red 
Grapes, white 
Nectarines, raw 2.54 Avocado 
Peaches, raw 2.34  
Pears 1.74  
Plums, raw 3.2  
Raspberries 4.07  
Soybeans 37.41  
   
Beverages rich in polyphenols 
(epicatechin) 
  
Red wine 3.28 White wine 
Green tea 8.29 Black tea  
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7.3. Appendix 3 Screening questionnaire 
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Screening questionnaire 
Effect of dark chocolate and green coffee bean extract on glucoregulatory biomarkers, BP 
and lipid profile in overweight and obese subjects 
____________________________________________________________________ 
Personal history 
 Male       Female  
1. Please tick the appropriate box 
 
Date of birth                             day…………..month…………..year………….. 
 
2. Please tick the appropriate box about your employment situation 
 In a full-time job 
 In a part-time job 
 Unemployed, seeking work 
 Unemployed because sick or disabled 
 Housewife 
 Full-time student 
 
  
Family history 
3. Did your mother or father have heart disease before they were 60 years old? 
      Yes                             No                         don‘t know 
4. How many brothers and sisters did you have in your family (not counting yourself)? 
……………………brothers and sisters 
5. Did any of your brothers or sisters have heart disease before they were 60 years old? 
      Yes                             No                         don‘t know 
 
 
Medical history 
6. Have you ever been told by a doctor that you have, or have had any of the following? 
Tick Yes or No for each condition. 
Yes No 
□ □ Angina 
□ □ Heart attack (coronary thrombosis, mycardial infarction) 
□ □ High blood pressure 
□ □ Stroke 
□ □ Diabetes 
□ □ High chloesterol 
 
7. Are you taking any medication for high blood pressure? 
      Yes                             No 
If yes, please write the names of the medicine(s) you are taking. 
…………………………………………………………………………………………. 
 
8. Are you taking any medication for high cholesterol? 
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      Yes                             No 
 
If yes, please write the names of the medicine(s) you are taking. 
………………………………………………………………………………………… 
 
9. Are you now taking aspirin regularly? 
      Yes                             No              if no, go to question 
If yes, is it for your heart 
 Yes                             No                         don’t know 
If it is for your heart, why did you start taking it? 
 The doctor told you to take it 
 Ou decided for yourself 
 Other reason, please give details……………………………………………… 
 
11. Are you taking an other medication at present? 
      Yes                             No 
If yes, write the name of the medicine(s) and what you are taking them for (if you know). 
………………………………………………………………………………………… 
12. Are you regularly taking any vitamins, mineral or food supplements at present? 
      Yes                             No 
 
If yes, give the type of supplement, brand name, and how often you take each one. 
Type Brand (and strength) Frequency 
   
   
13. Do you smoke cigarettes, now? 
 Yes, regularly 
 No 
 Ocassionally (usually less than one a day) 
 
 
Your diet 
1. How many cups of coffee do you drink?                              ……….cups per day 
                                                                                                    .……...cups per week 
Is this                                                                           ground coffee           instant 
coffee 
Is it decaffeinated?                                                                             Yes                             No 
 
2. How many cups of tea do you have?                                    ……….cups per day 
                                                                                                   .……...cups per week 
3. How many cups of green tea do you have?                          ……….cups per day 
                                                                                                    .……...cups per week                                
4. How many cups of cocoa or hot chocolate do you have?     ……….cups per day 
                                                                                                   .……...cups per week 
5. How often do you eat dark chocolate?                                  ……….cups per day 
                                                                                                    .……...cups per week 
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7.4. Appendix 4 Nutritional composition of dark chocolate 
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7.5. Appendix 5  Inter-day variability in blood pressure 
measurements 
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Figure 7.1 Bland-Altman plots for systolic (a) and diastolic blood pressure (b) showing 
limits of agreement and mean inter-day differences  between blood pressure measurements 
on two different occasions (Day 1 and Day 2) taken from the same group of subjects (n=10) 
1 week apart.  Values are mean of three readings. 
(a) 
 
(b) 
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Polyphenols and pancreatic lipase 
 
Summary 
The present study investigated the effect of green coffee bean extract and Theobroma cacao bean extract on pancreatic lipase 
activity in vitro.  Green coffee bean extract produced a J-shaped dose-dependent inhibition of pancreatic lipase with the 
percentage inhibition of pancreatic lipase ranging from 11.8 to 61.5%.  Similar concentrations of  Theobroma cacao failed to 
produce any effect on pancreatic lipase.  Non-linear regression analysis revealed that the concentration of green coffee bean 
extract required to elicit a 50% inhibition of pancreatic lipase activity (IC50) was ~ 43µM.  In conclusion, extracts of green 
coffee beans but not Theobroma cacao possess potent inhibitory activity against pancreatic lipase. 
 
Introduction 
 
It is increasingly recognised that polyphenols can affect the activity of numerous enzymes that regulate glucose, protein and 
lipid metabolism.  Consistent with this, several studies have shown that extracts of Salacia reticulata (Yoshikawa et al. 2002), 
grape seed (Moreno et al. 2003), berries (McDougall et al. 2005, McDougall and Stewart 2005), oolong tea (Nakai et al. 2005) 
and green tea (Koo and Noh 2007) inhibit α-amylase, α-glucosidase, trypsin and pancreatic lipase.  Inhibition of pancreatic 
lipase, in particular, by polyphenolic-rich plant extracts offers a natural dietary approach to preventing obesity (Kulkarni et al. 
2009).  This, if combined with the ability of polyphenols to improve antioxidant status and reduce risk of diabetes, hypertension 
and coronary heart disease (Fraga 2005; Manach et al. 2005; Scalbert et al. 2005) will result in additional benefits to obesity, 
the reduction of obesity-related complications 
 Obesity is characterised by an imbalance between energy intake and energy expenditure.  Strategies aimed at preventing 
or treating obesity often focus on blocking fat absorption and enhancing thermogenesis, amongst others (Bray and Tartaglia 
2000).  Both green coffee bean extracts (GCBE) and cocoa reportably affect various pathways involved in lipid metabolism.   
Shimoda et al. (2006) has demonstrated that GCBE reduces hepatic triglycerides and visceral fat accumulation while enhancing 
the activity of carnitine-palmitoyltransferase.  Cocoa, on the other hand, has been shown to reduce serum triglycerides, down-
regulate fatty acid synthesis and transport in liver and adipose in addition to stimulating thermogenesis (Matsui et al. 2004). The 
aim of this study was to investigate the effect of GCBE and Theobroma cacao bean extract (TCBE) on pancreatic lipase activity 
in vitro. 
 
Methodology 
Preparation of extracts  
GCBE tablets (Quest Vitamins, Birmingham, UK) were weighed to the nearest 0.0001g, ground to a fine powder using a mortar 
and pestle, then dissolved in 20mL of acidified water (0.2% v/v formic acid/ water) to give acidified-water extract or in 20ml 
acetonitrile-water-formic acid solution  (50:50:2 v/v/v) to give acetonitrile extract.  The resulting solutions were then extracted 
at room temperature at 200 rpm for 30 min on a Luckham, Model R100/TW rotatest shaker then centrifuged at 4000rpm for 15 
min at 4 °C to remove any solid material or soluble polysaccharides.  The sample was then filtered through Whatman filter 
paper under vacuum.  
For TCBE, 20g of Peruvian Theobroma cacao beans (Creative Nature, Surrey, UK) was dissolved in 200ml of 
acetonitrile-water-formic acid solution  (50:50:2 v/v/v), homogenised 3 times using Ultra-Turrax homogenizer (Rose Sci Ltd, ) 
and then extracted on a rotatest shaker, as described above.  Samples were treated with rotary evaporation to remove acetonitrile 
then loaded onto a 12-ml bed volume C18-E Giga solid phase extraction unit (Strata, Phenomenex, UK) previously conditioned 
with acetonitrile and equilibrated with acidified water respectively. Samples were loaded onto the unit then washed with 
acidified water to elute the unbound material. The bound fraction, rich in proanthocyanidins, was eluted with 2x 12ml 
acetonitrile whereas lipid-like material remained bound to the unit.   
 
Estimation of phenolic content 
The phenolic content of the diluted extracts was estimated using the Folin Ciocalteu method.  Briefly, 250 µl of 1% diluted 
sample or water (blank) was transferred into a cuvette and 250µl half strength Folin Ciocalteu reagent was added.  After 3min, 
500µl of saturated sodium carbonate solution (130g/L) was added to each cuvette and the samples were incubated in the dark 
for an hour.  Absorbance was read at 750nm and phenol content assessed against a standard curve of gallic acid (Singleton and 
Rossi 1965).  
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Lipase assay 
Pancreatic lipase activity was measured according to the method described by Gilham et al. (2003) and Lin et al. (1996), with 
some modifications. Briefly, 50µl of varying concentration of GCBE or TCBE (0, 5, 10, 25 and 50µM gallic acid equivalents; 
GAE) were added to an assay mixture containing 350µl 100 mM Tris buffer (pH 8.2) and 150µl of porcine lipase solution 
(10mg/ml). The reaction was started by adding 450 µl of the substrate solution (8 mg/ml p-nitrophenyl laurate in 5 mM sodium 
acetate pH 5.0 containing 1% Triton X-100). The samples were then incubated for 2h at 37oC.  Following incubation, all 
samples were centrifuged at 16000rpm for 2.5 min, transferred to cuvettes and read at 400 nm in a UV spectrophotometer.  
Samples were assayed in triplicates and appropriate sample controls were prepared for each sample concentration to account for 
interference from GCBE or TCBE.  The percentage inhibitory activity of each sample was calculated using the following 
equation: 
 
% inhibitory activity = 100
)(
)()(
1
abscontrol
absrolsamplecontabssample
  
 
Results 
Phenolic content 
The phenol content in the acidified water extract of green coffee beans varied widely between the triplicates compared to 
acetonitrile extract (Table 1).  This variation could have been due to interference from polysaccharides in the acidifed water 
extract, which are known to affect phenolic content measurement by as much as 50% (Stratil et al. 2007).  For the purpose of 
pancreatic lipase assay, the acetonitrile extract, which yielded a higher phenol content and lacked soluble polysaccharides, was 
selected for study. With regard to TCBE, the SPE-bound fraction contained the majority of phenolic compounds (2952.2μg 
GAE per ml bound fraction vs. 296.2μg GAE per ml unbound fraction) and was consequently used for lipase assay. Aliquots of 
these extracts containing known phenol contents were dried in a Speed-Vac to remove acetonitrile and acids then resuspended 
in ultra-pure water at the required concentrations. 
 
Lipase assay 
Fig. 1 shows the effect of GCBE and TCBE on pancreatic lipase activity.  GCBE showed a J-shaped dose-dependent inhibition 
of pancreatic lipase with the percentage inhibition ranging from 11.8 to 61.5%.  Similar concentrations of TCBE, on the other 
hand, had a negligible effect on lipase activity.  Non-linear regression analysis revealed that the concentration of GCBE 
required to elicit a 50% inhibition of pancreatic lipase activity (IC50) was ~ 43µg. 
 
Discussion 
This study investigated the inhibitory potential of GCBE and TCBE against pancreatic lipase activity.  The key finding of the 
present study is that GCBE inhibits pancreatic lipase activity dose-dependently whereas concentrations of TCBE up to 50 
negligible effect on activity.  These findings carry several implications since lipid hydrolysis by pancreatic lipase 
controls dietary lipid absorption and inhibition of this process by drugs such as Orlistat has been shown to improve post-
prandial concentrations of plasma triglycerides, remnant-like particles, cholesterol and free fatty acids (Tan et al. 2002).  This 
could be of particular relevance to obesity, as post-prandial lipaemia is associated with an array of obesity-associated 
complications including insulin resistance and dyslipdaemia (Kolovou  et al. 2004; Kolovou et al. 2005; Reaven 2005).   
 GCBE is rich in chlorogenic acid (CGA) and its derivatives (Fig. 2; Table 2).  CGA has been shown to reach the 
intestines in high concentrations with <1% of ingested CGA being hydrolysed in the stomach and the intestine (Lafay et al. 
2006a).  The low breakdown has been explained  by the lack of an esterase enzyme capable of hydrolysing CGA in the stomach 
or the intestine (Plump et al. 1999).  In fact, in an in-situ rat model of CGA perfusion onto upper intestinal tract (jejunum and 
ileum), 90.8 % of perfused CGA was found to reach the caecum intact (Lafay et al. 2006b), suggesting that CGA had 
considerable longevity once in the small intestine.  Similarly, Olthof et al. (2000) demonstrated that following 1-4h incubation 
in duodenal fluids, 95-99% of CGA is recovered.  This poor absorption enhances the availability of CGA to intestinal mucosa, 
the site of lipase action, a property exhibited by several known pancreatic lipase inhibitors including epigallocatechin gallate 
(Koo et al, 2007) and Orlistat (Zhi et al. 1995). Thus, CGA presents an ideal candidate, which might account for GCBE 
inhibitory activity particularly that caffeine, the other major constituent of GCBE, is known to be a poor inhibitor of pancreatic 
lipase (Nakai et al. 2005). Moreover, CGA has other beneficial effects on the gastrointestinal tract including increased nitric 
oxide bioavailability (Peri et al. 2005).  Nonetheless, further research is required to identify the active component of GCBE. 
This could be achieved by fractionating GCBE constituents and assessing them individually for their inhibitory activity against 
pancreatic lipase. Synergism between the different constituents of GCBE remains a possibility. 
 It is also important to acknowledge that in vitro studies can often overestimate the biological effect of polyphenols since 
they do not take in account in vivo metabolism of polyphenols.  As a result, in vitro inhibition of pancreatic lipase activity does 
not necessarily imply an in vivo effect.  Moreover, even if pancreatic lipase activity is reduced, improvements in systemic lipid 
metabolism are not always observed (Shepard et al. 2000).  Nevertheless, it remains plausible that GCBE might exert an 
inhibitory activity against pancreatic lipase in vivo particularly that a recent study in mice has shown that consumption of 
GCBE reduces hepatic triglycerides and visceral fat accumulation and enhances carnitine palmitoyl transferase activity, a rate-
limiting enzyme that catalyses fatty acid transport to mitochondria for β-oxidation (Shimoda et al. 2006).  Subsequently, further 
research is required to examine whether consumption of GCBE could improve post-prandial lipid metabolism or alter the 
activity of lipoprotein lipase and hepatic triglyceride lipase especially in obesity.   
 As for the lack of inhibitory activity on lipase shown by TCBE, it is consistent with the poor inhibitory potential of 
nonesterified flavan-3-ols like (-)-epicatechin and catechin (Nakai et al. 2005) which are likely to account for the major fraction 
of polyphenols in TCBE.  However, TC polyphenols have inhibitory actions against other digestive enzymes such as α-amylase 
(Queseda et al. 1996).  Subsequently, their role in glucose metabolism might be more important than their role in lipid 
metabolism. 
 In conclusion, this study demonstrates that GCBE, but not TCBE, is an effective inhibitor of pancreatic lipase activity.  
Further research is warranted to examine whether similar effects could be achieved in-vivo.   
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Table 1  Phenolic content of GCBE expressed as μg GAE/ml extract. Data presented as the mean 
(standard deviation) of triplicates. 
 
 Total phenolic content (μg/ml)  
Acidified water extract 1180.4 (111.53) 
Acetonitrile extract 1456.7 (61.9) 
 
 329 
 
Figure 2  LC-MS profile of green coffee bean extract.  Peaks refer to Table 2. Profile is obtained at 280 nm. Assignments 
supported by previous work (Clifford et al. 2003). 
 
Table 2  Retention times of the different LC-MS peaks    
Peak No. Retention Time PDA M/Z [M-H] MS2 Putative ID 
1 19.42 325 353.2, 191.3 191.2, 179.2 3-O-caffeolylquinic acid 
2 27.33 325 353.2, 191.3 191.2, 179.2 5-O-caffeolylquinic acid 
3 28.68 275 195.3+ ND Caffeine 
4 36.18 325 367.2, 191.2 191.2 3-O-feruloylquinic acid 
5 37.27 320 367.2, 191.2  191.2 5-O-feruloylquinic acid 
6 48.91 325 515.3, 353.3 353.1, 335.2 3, 4-O-dicaffeoyl quinic acid 
7 50.84 325 515.3, 353.3 353.1 3, 5-O-dicaffeoyl quinic acid 
8 54.02 325 515.3, 353.3 353.1, 179.3 4, 5-O-dicaffeoyl quinic acid 
9 56.92 325 529.3, 551.2 367.1, 335.2, 193.2 4, 5-O-feruloylcaffeoyl 
quinic acid 
10 59.58 325 529.3, 551.2 367.1, 335.2, 193.2 3, 5-O-feruloylcaffeoyl 
quinic acid 
11 62.39 325 529.3, 551.2 367.1, 335.2, 193.2 3, 4-O-feruloylcaffeoyl 
quinic acid 
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Polyphenol-rich dark chocolate: effect on fasting capillary glucose, total cholesterol, blood pressure 
and glucocorticoids in healthy overweight and obese subjects. By S. Almoosawi, E.A.S. Al-Dujaili and 
L. Fyfe, Department of Dietetics, Nutrition and Biological Sciences, Queen Margaret University, Queen 
Margaret Drive, Musselburgh EH21 6UU, UK 
 
Excess cortisol is associated with various variables of the metabolic syndrome including hypertension, 
insulin resistance and dyslipidaemia
(1)
. This relationship is likely to be mediated via cortisol‘s ability to 
regulate NO bioavailability
(2,3)
. Since increased NO bioavailability is considered the main mechanism by 
which polyphenols improve glucose, blood pressure and lipid homeostasis, the present study aimed to 
investigate the effect of two doses of polyphenol-rich dark chocolate on fasting capillary glucose (FG), total 
cholesterol (TC), systolic (SBP) and diastolic blood pressure (DBP) and urinary free cortisol (F), cortisone 
(E) and cortisone:cortisol (E:F) in a group of overweight and obese subjects. 
The study used a single-blind randomised cross-over design wherein fourteen subjects (eight males, six 
females; age 36 (SD 11) years; BMI 28 (SD 2.5) kg/m
2
) consumed 20 g dark chocolate containing 500 mg or 
1000 mg polyphenols for 2 weeks, separated by a 1-week washout period. This 20g portion corresponds to 
half a portion of habitual chocolate intake and provides similar concentrations of polyphenols as used in 
previous studies on healthy and hypertensive volunteers that have reported significant reductions in blood 
pressure following consumption of dark chocolate 
(4,5)
. 
Capillary FG and TC levels were measured using a calibrated Accutrend GC system (Roche 
Diagnostics, Burgess Hill, West Sussex, UK). Blood pressure was measured using an automated A&D 
Medical UA-767 BP monitor (A&D Medical, San Jose, CA, USA). Subjects also completed three 3 d diet 
and physical activity diaries at baseline and during each intervention. Compliance was measured by direct 
interviewing, returning of empty chocolate foils and assessment of diet diaries. 
Repeated-measures ANOVA revealed a significant reduction in capillary FG levels, SBP and DBP 
following both treatments. No significant differences were observed between dark chocolate containing 500 
mg and 1000 mg polyphenols, suggesting that both doses were equally effective in improving these 
variables (P>0.05). No changes in anthropometrical measurements, capillary TC and urinary free 
glucocorticoids levels were observed. 
In conclusion, the present study confirms previous findings of a reduction in blood pressure and fasting 
glucose following consumption of polyphenol-rich dark chocolate. This effect seems unlikely to be 
mediated through the glucocorticoid pathway, although involvement of the renin–angiotensin–aldosterone 
system cannot be excluded. Furthermore, it appears that increasing the polyphenol dose does not result in 
further improvement in the assessed variables, suggesting that a saturation effect may occur with increasing 
doses. 
 
1. Rosmond R & Björntorp P (2001) Endocrinologist 11, 491–497. 
2. Iuchi T, Akaike M, Mitsui T et al. (2003) Circ Res 92, 81–87. 
3. Liu Y, Mladinov D, Pietrusz JL et al. (2009) Cardiovasc Res 81, 140–147. 
4. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C (2005) Am J Clin Nutr 81, 611-614. 
5. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C 
(2005)  Hypertension 46, 398-405. 
 
 1000 mg polyphenols 500 mg polyphenols 
 Baseline Week 1 Week 2 Baseline Week 1 Week 2 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
FG 
(mmol/l) 
4.42 0.70 4.21 0.82 3.97* 0.54 4.42 0.70 3.94 0.72 3.92* 0.86 
TC 
(mmol/l) 
5.02 1.01 –  –  4.98 0.90 5.02 1.01 –  –  5.03 0.77 
SBP 
(mmHg) 
119 10.5 114 12.0 112** 9.68 119 10.5 114 9.53 112** 9.51 
DBP 
(mmHg) 
78.6 7.74 74.5 7.17 74.6** 7.39 78.6 7.74 74.6 4.27 73.0** 5.06 
F (nmol/d) 77.3 27.1 –  –  71.2 38.9 86.8 44.1 –  –  78.6 47.3 
E (nmol/d) 54.3 26.9 –  –  45.8 17.3 59.6 32.6 –  –  45.8 20.3 
E:F ratio 0.71 0.32 –  –  0.75 0.37 0.71 0.31 –  –  0.63 0.21 
Mean values were significantly different from those at baseline: *P<0.05, **P<0.01. 
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The effect of green-coffee-bean extract rich in chlorogenic acid on antioxidant status of healthy 
human volunteers. By S. Almoosawi, C. Tsang, I. Davidson, L. Fyfe and E.A.S Al-Dujaili, Department of 
Dietetics, Nutrition and Biological Sciences, Queen Margaret University, Queen Margaret Drive, 
Musselburgh EH21 6UU, UK 
 
Several studies have linked consumption of green-coffee-bean extract (GCBE) rich in chlorogenic acid 
(CGA) with reduced blood pressure
(1–3)
. It is hypothesised that increased antioxidant activity could be one 
of the underlying mechanisms by which GCBE reduces blood pressure.  To test this hypothesis a GCBE 
preparation rich in CGA was assessed by three extraction methods for antioxidant activity. In vivo 
antioxidant activity was also determined in a group of healthy volunteers. 
The phenolic content of GCBE, as determined by the Folin-Ciocalteu method, varied greatly between 
the ethanolic acidified water (0.2 % (v/v) formic acid) and acetonitrile extract (acetonitrile–water 
containing 0.2 % (v/v) formic acid; 50:50, v/v): 123 (SD 0.23), 131 (SD 0.66) and 211 (SD 0.51) mg gallic 
acid  equivalents (GAE)/g extract respectively. Similar findings were observed with the Fe
3+
-reducing 
ability of plasma (FRAP) assay, wherein the acetonitrile extract exhibited a stronger Fe
3+
-reducing ability 
than the ethanolic extract (0.067 mmol/g extract v. 0.048 mmol/g extract). The 2,2-di(4-tert-octylphenyl)-1-
picrylhydrazyl (DPPH) radical-scavenging activity of the ethanolic extract of GCBE was 70.4 % at 50 µM 
as compared with ascorbic acid (86.1 % inhibition at 50 µM) and GAE (82.2 % at 50 µM). 
 
 
 
To examine in vivo antioxidant properties of GCBE thirteen healthy volunteers (age 36 (SD 11) years, 
BMI 28 (SD 2.5) kg/m
2
) consumed 200 mg GCBE containing 90 mg CGA twice daily for 2 weeks. In vivo 
antioxidant activity was determined using the Folin-Ciocalteu method and FRAP. There was a significant 
correlation between urinary polyphenols excretion as determined by the Folin-Ciocalteu method and FRAP 
(0.664, P<0.0001). However no significant increase in urinary antioxidant activity was observed (total 
phenolics: 173.2 (SD 137.8) mg GAE/ g creatinine v. 175.20 (SD 115.7) mg GAE/ g creatinine, P>0.05; 
FRAP: 2.07 (SD 0.9) mmol Fe
2+
/ g creatinine v. 1.56 (SD 0.7) mmol Fe
2+
/ g creatinine, P>0.05). Systolic 
blood pressure decreased from 119 (SD 10.5) to 114 (SD 9.1) mmHg (P=0.05) following the 2-week 
treatment. 
In conclusion, green coffee bean extract has a high antioxidant activity. However, no changes in 
antioxidant activity are observed in urine. This finding is consistent with previous findings of poor 
antioxidant activity of hippuric acid, the main urinary metabolite of chlorogenic acid
(4)
. Further research is 
required to identify the mechanism(s) of reduction in blood pressure. The antioxidant activity of plasma 
should also be determined. 
 
1. Watanabe T, Arai Y, Mitsui Y et al. (2006) Clin Exp Hypertens 28, 439–449. 
2. Kozuma K, Tsuchiya S, Kohori J et al. (2005) Hypertens Res 28, 711–718. 
3. Ochiai R, Jokura H, Suzuki A et al. (2004) Hypertens Res 27, 731–737. 
4. Olthof MR, Hollman PC, Buijsman MN et al. (2003) J Nutr 133, 1806–1814. 
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Effect of green coffee bean extract and 
chlorogenic acid consumption on 11βHSD 
activity in humans and mice 
S Almoosawi1, A Dickinson2, L Fyfe1, CJ Kenyon2 & EAS Al-Dujaili1 
1Queen Margaret University, Edinburgh, UK; 2University of Edinburgh, Edinburgh, UK. 
 
Increased 11β hydroxysteroid dehydrogenase type 1 (11βHSD1) activity is implicated in the 
development of the metabolic syndrome. Identifying natural compounds that influence 11βHSD1 
activity could lead to novel methods of treating obesity, cardiovascular disease and diabetes. In 
the present study, we tested the effect of green coffee bean extract (GCBE), rich in chlorogenic 
acid (CGA), in human volunteers and of CGA in mice on blood pressure (BP), lipid and glucose 
metabolism. Our hypothesis was that CGA would improve these parameters, by blocking the 
uptake of microsomal glucose-6-phosphate which in turn would limit the production of co-factor 
for 11βHSD1 reductase activity. With local Ethics Committee approval, 13 healthy overweight 
subjects were given GCBE containing 90 mg CGA twice daily for 2 weeks. Urinary 24 h free 
cortisol was reduced from 1.0523±0.45 to 0.763±0.40 nmol/kg (P=0.07). Free cortisone excretion 
was reduced from 0.712±0.38 to 0.432±0.24 nmol/kg (P=0.007). Systolic BP decreased from 
119.4±10.5 to 113.8±9.1 mmHg (P=0.05). Fasting plasma glucose (P=0.101), diastolic BP 
(P=0.114), free cortisol:cortisone ratio (P=0.216) and anthropometrical measurement were not 
affected. In vitro, 11βHSD1 activity (conversion of added cortisone to cortisol) in isolated mouse 
microsomes was inhibited dose-dependently by CGA. The effects of feeding diet containing 
0.15% CGA for 17 days was tested in male C57BL6 mice. Adiposity was unaffected but liver 
(27.7±4.9 vs 15.5±2.2 mg/g, P<0.04) and plasma (1.24±0.18 vs 0.86±0.08 mg/ml, P<0.08) 
triglycerides tended to be reduced. Urinary 24 h cortisol excretion following IP injection of 20 
mg/kg cortisone was 30.1±4.1 vs 24.2±5.3 nmol/kg (P<0.4) for control and CGA-treated mice. 
Peak plasma glucose levels in tolerance tests were earlier with CGA treatment although, over a 
2 h period, glucose clearance was not affected. 
In conclusion, GCBE decreased urinary cortisol and cortisone excretion in overweight subjects 
but CGA did not significantly inhibit 11βHSD1 activity in mice in vivo. Treatments lowered blood 
pressure and triglyceride levels. Further research into the mechanism(s) of these beneficial 
effects is required. 
 
Endocrine Abstracts (2009) 19 P122  
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Effect of polyphenol-rich dark chocolate on cardiovascular risk factors and glucocorticoids in 
healthy overweight and obese subjects  Suzana Almoosawi; Catherine Tsang; Lorna Fyfe; Emad 
EAS Al-Dujaili and Davidson I. Department of Dietetics, Nutrition and Biological Sciences, 
Queen Margaret University, Edinburgh, UK 
 
The association between excess cortisol and various parameters of the metabolic syndrome including 
hypertension, insulin resistance and dyslipidemia is increasingly recognised.  The present single-blind 
randomised placebo-controlled cross-over study investigated the effect of polyphenol-rich dark 
chocolate (DC) on salivary free cortisol (F) and biomarkers of cardiovascular disease including 
glucose metabolism, lipid profile and  blood pressure (BP) in 21 females with BMI≥25 kg/m2 and a 
control group of 23 females with  BMI<25kg/m
2 
(n=42).  Volunteers consumed 20g of DC containing 
500mg polyphenols or placebo for 4 weeks, separated by a 2-week washout period.  
 
Paired sample t-tests revealed that the reductions in systolic BP (SBP) (-4.17±6.62mmHg from 
baseline) and diastolic BP (DBP) (-2.29±4.72mmHg from baseline) following polyphenol-rich DC 
were significantly greater (SBP: P=0.007; DBP: P=0.003) than the changes seen following placebo.  
Interestingly, the placebo raised fasting insulin, HOMA-IR and salivary F from baseline by 
1.36±4.29mU/L (P=0.008), 0.37±1.05 (P=0.001) and 13.02±38.38nmol/d (P=0.055), respectively, an 
effect that was significantly different from polyphenol-rich DC which had a negligible effect on 
fasting insulin (-0.56±2.62mU/L from baseline), HOMA-IR (-0.28±0.60 from baseline) and salivary F 
(+1.23±6.82nmol/d from baseline).  Overweight and obese females, in particular, were found to 
respond less favourably to placebo than the control group and consequently had higher fasting insulin 
(P=0.006) and HOMA-IR (P=0.004) and lower QUICKI (P=0.003) after ingestion of placebo 
compared to polyphenol-rich DC.   
 
In conclusion, this study provides evidence for the metabolic benefits of consuming polyphenol-rich 
dark chocolate by the overweight and obese group while demonstrating the possibility of adverse 
effects occurring with polyphenol-poor placebo.  The apparent susceptibility of overweight and obese 
females to insulin resistance following placebo could carry major public health implications and 
emphasises the need to improve our understating of the relation between polyphenols and health.   
 
 
